Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna

ABSTRACT

This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority to, and the benefit under 35 U.S.C. §119(e) of, the following applications: U.S. provisional patent application No. 61/166,559, filed Apr. 3, 2009; U.S. provisional patent application No. 61/166,578, filed Apr. 3, 2009; U.S. provisional patent application No. 61/174,279, filed Apr. 30, 2009; U.S. provisional patent application No. 61/174,306, filed Apr. 30, 2009; U.S. provisional patent application No. 61/257,810, filed Nov. 3, 2009; and U.S. provisional patent application No. 61/257,820, filed Nov. 3, 2009. The present application also claims priority to the following applications: U.S. patent application Ser. No. 12/704,256, filed Feb. 11, 2010; U.S. patent application Ser. No. 12/642,371, filed Dec. 18, 2009; U.S. patent application Ser. No. 12/646,404, filed Dec. 18, 2009; U.S. patent application Ser. No. 12/642,264, filed Dec. 18, 2009; and PCT application No. PCT/US2009/005214, filed Sep. 17, 2009. The present application claims priority to, and the benefit under 35 U.S.C. §119(e) of, the following applications: U.S. provisional patent application No. 61/183,815, filed Jun. 3, 2009; U.S. provisional patent application No. 61/183,818, filed Jun. 3, 2009; U.S. provisional patent application No. 61/184,735, filed Jun. 5, 2009; U.S. provisional patent application No. 61/285,925, filed Dec. 11, 2009; and U.S. provisional patent application No. 61/309,266, filed Mar. 1, 2010. The entire teachings of the above applications are incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of KRAS gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in KRAS gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions. Specifically, the invention relates to small nucleic acid molecules that are capable of being processed by the Dicer enzyme, such as Dicer substrate siRNAs (DsiRNAs) capable of mediating RNA interference (RNAi) against KRAS gene expression. Such anti-KRAS DsiRNAs are useful, for example, in providing compositions for treatment of traits, diseases and conditions that can respond to modulation of KRAS in a subject, such as cancer and/or other proliferative diseases, disorders, or conditions.

BACKGROUND OF THE INVENTION

Disregulated Ras signaling can lead to tumor growth and metastasis (Goodsell D S. Oncologist 4: 263-4). It is estimated that 20-25% of all human tumors contain activating mutations in Ras; and in specific tumor types, this figure can be as high as 90% (Downward J. Nat Rev Cancer, 3: 11-22). Accordingly, members of the Ras gene family are attractive molecular targets for cancer therapeutic design.

The three human RAS genes encode highly related 188 to 189 amino acid proteins, designated H-Ras, N-Ras and K-Ras4A (KRAS isoform a) and K-Ras4B (KRAS isoform b; the two KRas proteins arise from alternative gene splicing). Ras proteins function as binary molecular switches that control intracellular signaling networks. Ras-regulated signal pathways control such processes as actin cytoskeletal integrity, proliferation, differentiation, cell adhesion, apoptosis, and cell migration. Ras and Ras-related proteins are often deregulated in cancers, leading to increased invasion and metastasis, and decreased apoptosis. Ras activates a number of pathways but an especially important one for tumorigenesis appears to be the mitogen-activated protein (MAP) kinases, which themselves transmit signals downstream to other protein kinases and gene regulatory proteins (Lodish et al. Molecular Cell Biology (4th ed.). San Francisco: W.H. Freeman, Chapter 25, “Cancer”).

Double-stranded RNA (dsRNA) agents possessing strand lengths of 25 to 35 nucleotides have been described as effective inhibitors of target gene expression in mammalian cells (Rossi et al., U.S. Patent Application Nos. 2005/0244858 and US 2005/0277610). dsRNA agents of such length are believed to be processed by the Dicer enzyme of the RNA interference (RNAi) pathway, leading such agents to be termed “Dicer substrate siRNA” (“DsiRNA”) agents. Additional modified structures of DsiRNA agents were previously described (Rossi et al., U.S. Patent Application No. 2007/0265220).

BRIEF SUMMARY OF THE INVENTION

The present invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them. The dsRNAs of the invention are capable of reducing the expression of a target KRas gene in a cell, either in vitro or in a mammalian subject. More particularly, the invention is directed to preferred Dicer substrate siRNAs (“DsiRNAs”) with structures and modification patterns that are optimized to act as effective and highly potent KRAS inhibitory agents, optionally possessing extended duration of inhibitory effect. A majority of such DsiRNAs possess target-specific inhibitory potencies and efficacies that are surprisingly enhanced relative to 21 nucleotide siRNAs directed against the same target RNA. While not intending to be bound by theory, such enhanced activity likely reflects an advantage inherent in DsiRNA agents engaging the RNAi pathway at a point in the pathway that is upstream of the point at which shorter siRNA agents engage the RNAi pathway.

In one aspect, the invention provides an isolated double stranded ribonucleic acid (dsRNA) comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein the second strand of said dsRNA comprises 1-5 single-stranded nucleotides at its 3′ terminus, wherein the second oligonucleotide strand is sufficiently complementary to a target KRAS cDNA sequence selected from the group consisting of SEQ ID NOs: 141-186 along at least 19 nucleotides and at most 35 nucleotides of the second oligonucleotide strand length to reduce KRAS target gene expression when the double stranded nucleic acid is introduced into a mammalian cell.

In one embodiment, starting from the first nucleotide (position 1) at the 3′ terminus of the first oligonucleotide strand, position 1, 2 and/or 3 is substituted with a modified nucleotide. In certain embodiments, the modified nucleotide residue of the 3′ terminus of the first strand is a deoxyribonucleotide, an acyclonucleotide or a fluorescent molecule. In a related embodiment, position 1 of the 3′ terminus of the first oligonucleotide strand is a deoxyribonucleotide.

In an additional embodiment, the 3′ terminus of the first strand and the 5′ terminus of the second strand form a blunt end.

In another embodiment, the first strand is 25 nucleotides in length and the second strand is 27 nucleotides in length.

In one embodiment, the second strand includes a sequence of SEQ ID NOs: 11-50 and 135-140.

In another embodiment, the first strand includes a sequence of SEQ ID NOs: 5, 8 and 91-134.

In an additional embodiment, the dsRNA includes a pair of first strand/second strand sequences that is SEQ ID NO: 5/SEQ ID NO: 14, SEQ ID NO: 8/SEQ ID NO: 43, SEQ ID NO: 132/SEQ ID NO: 138, SEQ ID NO: 91/SEQ ID NO: 11, SEQ ID NO: 129/SEQ ID NO: 135, SEQ ID NO: 92/SEQ ID NO: 12, SEQ ID NO: 130/SEQ ID NO: 136, SEQ ID NO: 93/SEQ ID NO: 13, SEQ ID NO: 131/SEQ ID NO: 137, SEQ ID NO: 94/SEQ ID NO: 15, SEQ ID NO: 133/SEQ ID NO: 139, SEQ ID NO: 95/SEQ ID NO: 16, SEQ ID NO: 96/SEQ ID NO: 17, SEQ ID NO: 97/SEQ ID NO: 18, SEQ ID NO: 98/SEQ ID NO: 19, SEQ ID NO: 99/SEQ ID NO: 20, SEQ ID NO: 100/SEQ ID NO: 21, SEQ ID NO: 101/SEQ ID NO: 22, SEQ ID NO: 102/SEQ ID NO: 23, SEQ ID NO: 103/SEQ ID NO: 24, SEQ ID NO: 104/SEQ ID NO: 25, SEQ ID NO: 105/SEQ ID NO: 26, SEQ ID NO: 106/SEQ ID NO: 27, SEQ ID NO: 107/SEQ ID NO: 28, SEQ ID NO: 108/SEQ ID NO: 29, SEQ ID NO: 109/SEQ ID NO: 30, SEQ ID NO: 110/SEQ ID NO: 31, SEQ ID NO: 111/SEQ ID NO: 32, SEQ ID NO: 112/SEQ ID NO: 33, SEQ ID NO: 113/SEQ ID NO: 34, SEQ ID NO: 114/SEQ ID NO: 35, SEQ ID NO: 115/SEQ ID NO: 36, SEQ ID NO: 116/SEQ ID NO: 37, SEQ ID NO: 117/SEQ ID NO: 38, SEQ ID NO: 118/SEQ ID NO: 39, SEQ ID NO: 119/SEQ ID NO: 40, SEQ ID NO: 134/SEQ ID NO: 140, SEQ ID NO: 120/SEQ ID NO: 41, SEQ ID NO: 121/SEQ ID NO: 42, SEQ ID NO: 122/SEQ ID NO: 44, SEQ ID NO: 123/SEQ ID NO: 45, SEQ ID NO: 124/SEQ ID NO: 46, SEQ ID NO: 125/SEQ ID NO: 47, SEQ ID NO: 126/SEQ ID NO: 48, SEQ ID NO: 127/SEQ ID NO: 49 or SEQ ID NO: 128/SEQ ID NO: 50.

In one embodiment, each of the first and the second strands has a length which is at least 26 nucleotides.

In another embodiment, the nucleotides of the 3′ overhang include a modified nucleotide. Optionally, the modified nucleotide of the 3′ overhang is a 2′-O-methyl ribonucleotide. In a related embodiment, all nucleotides of the 3′ overhang are modified nucleotides.

In an additional embodiment, one or both of the first and second oligonucleotide strands includes a 5′ phosphate.

In another embodiment, the modified nucleotide residues of the dsRNA are 2′-O-methyl, 2′-methoxyethoxy, 2′-fluoro, 2′-allyl, 2′-O-[2-(methylamino)-2-oxoethyl], 4′-thio, 4′-CH2-O-2′-bridge, 4′-(CH2)2-O-2′-bridge, 2′-LNA, 2′-amino or 2′-O-(N-methlycarbamate).

In one embodiment, the 3′ overhang of the dsRNA is 1-3 nucleotides in length. Optionally, the 3′ overhang is 1-2 nucleotides in length. In a related embodiment, the 3′ overhang is two nucleotides in length and the modified nucleotide of the 3′ overhang is a 2′-O-methyl modified ribonucleotide.

In a further embodiment, the second oligonucleotide strand, starting from the nucleotide residue of the second strand that is complementary to the 5′ terminal nucleotide residue of the first oligonucleotide strand, includes alternating modified and unmodified nucleotide residues. In another embodiment, the second oligonucleotide strand, starting from the nucleotide residue of the second strand that is complementary to the 5′ terminal nucleotide residue of the first oligonucleotide strand, includes unmodified nucleotide residues at all positions from position 18 to the 5′ terminus of the second oligonucleotide strand.

In another embodiment, each of the first and the second strands has a length which is at least 26 and at most 30 nucleotides.

In one embodiment, the dsRNA is cleaved endogenously in the cell by Dicer.

In an additional embodiment, the amount of the isolated double stranded nucleic acid sufficient to reduce expression of the target gene is 1 nanomolar or less, 200 picomolar or less, 100 picomolar or less, 50 picomolar or less, 20 picomolar or less, 10 picomolar or less, 5 picomolar or less, 2 picomolar or less or 1 picomolar or less in the environment of the cell.

In a further embodiment, the isolated dsRNA possesses greater potency than isolated 21mer siRNAs directed to the identical at least 19 nucleotides of the target KRAS cDNA in reducing target KRAS gene expression when assayed in vitro in a mammalian cell at an effective concentration in the environment of a cell of 1 nanomolar or less, 200 picomolar or less, 100 picomolar or less, 50 picomolar or less, 20 picomolar or less, 10 picomolar or less, 5 picomolar or less, 2 picomolar or less or 1 picomolar or less.

In another embodiment, the isolated dsRNA is sufficiently complementary to the target KRAS cDNA sequence to reduce KRAS target gene expression by at least 10%, at least 50%, at least 80-90%, at least 95%, at least 98%, or at least 99% when the double stranded nucleic acid is introduced into a mammalian cell.

In a further embodiment, the first and second strands are joined by a chemical linker. In a related embodiment, the 3′ terminus of the first strand and the 5′ terminus of the second strand are joined by a chemical linker.

In one embodiment, a nucleotide of the second or first strand is substituted with a modified nucleotide that directs the orientation of Dicer cleavage.

In another embodiment, the dsRNA has a modified nucleotide that is a deoxyribonucleotide, a dideoxyribonucleotide, an acyclonucleotide, a 3′-deoxyadenosine (cordycepin), a 3′-azido-3′-deoxythymidine (AZT), a 2′,3′-dideoxyinosine (ddI), a 2′,3′-dideoxy-3′-thiacytidine (3TC), a 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), a monophosphate nucleotide of 3′-azido-3′-deoxythymidine (AZT), a 2′,3′-dideoxy-3′-thiacytidine (3TC) and a monophosphate nucleotide of 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), a 4-thiouracil, a 5-bromouracil, a 5-iodouracil, a 5-(3-aminoallyl)-uracil, a 2′-O-alkyl ribonucleotide, a 2′-O-methyl ribonucleotide, a 2′-amino ribonucleotide, a 2′-fluoro ribonucleotide, or a locked nucleic acid.

In an additional embodiment, the dsRNA has a phosphonate, a phosphorothioate or a phosphotriesterphosphate backbone modification.

In one embodiment, the invention provides a method for reducing expression of a target KRAS gene in a mammalian cell having contacting a mammalian cell in vitro with an isolated dsRNA as described in an amount sufficient to reduce expression of a target KRAS gene in the cell.

In one embodiment, target KRAS gene expression is reduced by at least 10%, at least 50%, or at least 80-90%. In another embodiment, target KRAS mRNA levels are reduced at least 90% at least 8 days after the cell is contacted with the dsRNA. In a further embodiment, KRAS mRNA levels are reduced by at least 70% at least 10 days after the cell is contacted with the dsRNA.

In a further embodiment, the invention provides a method for reducing expression of a target KRAS gene in a mammal by administering an isolated dsRNA as described to a mammal in an amount sufficient to reduce expression of a target KRAS gene in the mammal.

In one embodiment, the isolated dsRNA is administered at a dosage of 1 microgram to 5 milligrams per kilogram of the mammal per day, 100 micrograms to 0.5 milligrams per kilogram, 0.001 to 0.25 milligrams per kilogram, 0.01 to 20 micrograms per kilogram, 0.01 to 10 micrograms per kilogram, 0.10 to 5 micrograms per kilogram, or 0.1 to 2.5 micrograms per kilogram.

In another embodiment, the isolated dsRNA possesses greater potency than isolated 21 mer siRNAs directed to the identical at least 19 nucleotides of the target KRAS cDNA in reducing target KRAS gene expression when assayed in vitro in a mammalian cell at an effective concentration in the environment of a cell of 1 nanomolar or less.

In an additional embodiment, the administering step includes intravenous injection, intramuscular injection, intraperitoneal injection, infusion, subcutaneous injection, transdermal, aerosol, rectal, vaginal, topical, oral or inhaled delivery.

In a further embodiment, the invention provides a method for selectively inhibiting the growth of a cell by contacting a cell with an amount of an isolated dsRNA as described, in an amount sufficient to inhibit the growth of the cell.

In one embodiment, the cell is a tumor cell of a subject. Optionally, the cell is a tumor cell in vitro. In a related embodiment, the cell is a human cell.

In an additional embodiment, the invention provides a formulation which includes an isolated dsRNA as described, where the dsRNA is present in an amount effective to reduce target KRAS RNA levels when the dsRNA is introduced into a mammalian cell in vitro by at least 10%, at least 50% or at least 80-90%, and where the dsRNA possesses greater potency than isolated 21mer siRNAs directed to the identical at least 19 nucleotides of the target KRAS cDNA in reducing target KRAS RNA levels when assayed in vitro in a mammalian cell at an effective concentration in the environment of a cell of 1 nanomolar or less.

In one embodiment, the effective amount is 1 nanomolar or less, 200 picomolar or less, 100 picomolar or less, 50 picomolar or less, 20 picomolar or less, 10 picomolar or less, 5 picomolar or less, 2 picomolar or less or 1 picomolar or less in the environment of the cell.

In another embodiment, the invention provides a formulation which includes an isolated dsRNA as described, where the dsRNA is present in an amount effective to reduce target RNA levels when the dsRNA is introduced into a cell of a mammalian subject by at least 10%, at least 50% or at least 80-90%, and where the dsRNA possesses greater potency than isolated 21mer siRNAs directed to the identical at least 19 nucleotides of the target KRAS cDNA in reducing target KRAS RNA levels when assayed in vitro in a mammalian cell at an effective concentration in the environment of a cell of 1 nanomolar or less.

In one embodiment, the effective amount is a dosage of 1 microgram to 5 milligrams per kilogram of the subject per day, 100 micrograms to 0.5 milligrams per kilogram, 0.001 to 0.25 milligrams per kilogram, 0.01 to 20 micrograms per kilogram, 0.01 to 10 micrograms per kilogram, 0.10 to 5 micrograms per kilogram, or 0.1 to 2.5 micrograms per kilogram.

In an additional embodiment, the invention provides a mammalian cell containing an isolated dsRNA as described.

Another embodiment of the invention provides a pharmaceutical composition which includes an isolated dsRNA as described and a pharmaceutically acceptable carrier. A further embodiment of the invention provides a kit having an isolated dsRNA as described and instructions for its use.

In an additional aspect, the invention provides a composition possessing KRAS inhibitory activity consisting essentially of an isolated double stranded ribonucleic acid (dsRNA) comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein the second strand of said dsRNA comprises 1-5 single-stranded nucleotides at its 3′ terminus, wherein the second oligonucleotide strand is sufficiently complementary to a target KRAS cDNA sequence selected from the group consisting of SEQ ID NOs: 141-186 along at least 19 nucleotides and at most 35 nucleotides of the second oligonucleotide strand length to reduce KRAS target gene expression when the double stranded nucleic acid is introduced into a mammalian cell.

In another aspect, the invention provides an isolated double stranded ribonucleic acid (dsRNA) comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein the second strand of said dsRNA comprises 1-5 single-stranded nucleotides at its 3′ terminus, wherein the second oligonucleotide strand is sufficiently complementary to a target KRAS cDNA sequence selected from the group consisting of SEQ ID NOs: 1595-2297 and 3704-4406 along at least 19 nucleotides and at most 35 nucleotides of the second oligonucleotide strand length to reduce KRAS target gene expression when the double stranded nucleic acid is introduced into a mammalian cell.

In one embodiment, the second strand includes a sequence of SEQ ID NOs: 189-891 and 2298-3000.

In another embodiment, the first strand includes a sequence of SEQ ID NOs: 892-1594 and 3001-3703.

In an additional embodiment, the dsRNA includes a DsiRNA agent selected from the group consisting of DsiRNA agents shown in Tables 4-5.

In a further aspect, the invention provides a composition possessing KRAS inhibitory activity consisting essentially of an isolated double stranded ribonucleic acid (dsRNA) comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein the second strand of the dsRNA comprises 1-5 single-stranded nucleotides at its 3′ terminus, wherein the second oligonucleotide strand is sufficiently complementary to a target KRAS cDNA sequence selected from the group consisting of SEQ ID NOs: 1595-2297 and 3704-4406 along at least 19 nucleotides and at most 35 nucleotides of the second oligonucleotide strand length to reduce KRAS target gene expression when the double stranded nucleic acid is introduced into a mammalian cell.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the structures of exemplary DsiRNA agents targeting a site in the KRAS RNA referred to herein as the “KRAS-355” target site. The 25/27mer and 27/27mer DsiRNA agents (optionally, possessing a blunt/fray design) were tested for KRas inhibitory efficacy in comparison with the 21mer siRNA constructs shown. UPPER case=unmodified RNA, lower case=DNA, Bold=mismatch base pair nucleotides; arrowheads indicate projected Dicer enzyme cleavage sites; dashed line indicates sense strand (top strand) sequences corresponding to the projected Argonaute 2 (Ago2) cleavage site within the targeted KRas sequence.

FIG. 2 shows the anti-KRAS inhibitory efficacy of the agents depicted in FIG. 1, when transformed into cells in culture at 1 nanomolar concentration. “Optimized”=25/27mer DsiRNA and 21mer siRNA of FIG. 1; Blunt/Blunt and Blunt/Fray agents are as indicated in FIG. 1; “Veh”=vehicle-treated control; “Un”=untreated control.

FIG. 3 shows the anti-KRAS inhibitory efficacy of the agents depicted in FIG. 1, when transformed into cells in culture at 100 picomolar concentration. “Optimized”=25/27mer DsiRNA and 21mer siRNA of FIG. 1; Blunt/Blunt and Blunt/Fray agents are as indicated in FIG. 1; “Veh”=vehicle-treated control; “Un”=untreated control.

FIG. 4 shows the structures of exemplary DsiRNA agents targeting a site in the KRAS RNA referred to herein as the “KRAS-940” target site. The 25/27mer and 27/27mer DsiRNA agents (optionally, possessing a blunt/fray design) were tested for KRAS inhibitory efficacy in comparison with the 21mer siRNA constructs shown. UPPER case=unmodified RNA, lower case=DNA, Bold=mismatch base pair nucleotides; arrowheads indicate projected Dicer enzyme cleavage sites; dashed line indicates sense strand (top strand) sequences corresponding to the projected Argonaute 2 (Ago2) cleavage site within the targeted KRAS sequence.

FIG. 5 shows the anti-KRAS inhibitory efficacy of the agents depicted in FIG. 4, when transformed into cells in culture at 1 nanomolar concentration. “Optimized”=25/27mer DsiRNA and 21mer siRNA of FIG. 4; Blunt/Blunt and Blunt/Fray agents are as indicated in FIG. 4; “Veh”=vehicle-treated control; “Un”=untreated control.

FIG. 6 shows the anti-KRAS inhibitory efficacy of the agents depicted in FIG. 4, when transformed into cells in culture at 100 picomolar concentration. “Optimized”=25/27mer DsiRNA and 21mer siRNA of FIG. 4; Blunt/Blunt and Blunt/Fray agents are as indicated in FIG. 4; “Veh”=vehicle-treated control; “Un”=untreated control.

FIG. 7 shows a schematic comparison of tested DsiRNAs and their Dicer processing products, as compared to cognate 21 mer siRNAs directed against the same exact KRAS target sequence. 2′-O-methyl modifications are indicated by open circles; shaded circles indicate deoxyribonucleotides; shaded triangles indicate Dicer enzyme cleavage sites within a 25/27mer agent; open triangles indicate the position on the antisense strand corresponding to the Argonaute 2 (Ago2) cleavage sites within the target RNA. Such sites are identical between the 40 tested DsiRNA agents when compared to their cognate siRNA agents.

FIG. 8 shows a plot of comparative inhibitory efficacies between anti-KRAS DsiRNA 25/27mers and their cognate 21mer siRNAs. The plot is arranged in rank-order by % inhibition of KRAS target gene by the 25/27mer DsiRNA agent. Arrows indicate the difference in efficacy observed between DsiRNA agent and corresponding siRNA agent. Squares indicate siRNA inhibitory results; circles indicate DsiRNA inhibitory results.

FIG. 9 shows a graph of inhibitory results arranged in rank-order by amount of difference in inhibitory effect between DsiRNA agents and their cognate siRNAs. Both DsiRNAs and siRNAs were tested at 24 hours post-administration at both 5 nM (shaded squares) and 1 nM (shaded triangles), and at 48 hours post administration at both 5 nM (open squares) and 1 nM (open triangles). Shaded regions indicate agents for which a statistically significant difference was observed between DsiRNA and cognate siRNA. For 26 of the 40 tested anti-KRAS DsiRNA agents, statistically significant DsiRNA superiority was observed, as compared to only six of forty siRNA agents that outperformed DsiRNA agents.

FIGS. 10 and 11 show IC-50 curves observed for indicated human KRAS-targeting DsiRNAs.

FIGS. 12-21 show histograms of human KRAS inhibitory efficacies observed for indicated DsiRNAs. “P1” indicates phase 1, while “P2” indicates phase 2. In phase 1, DsiRNAs were tested at 1 nM in the environment of HeLa cells. In phase 2, DsiRNAs were tested at 1 nM and at 0.1 nM (with duplicate experiments run at 0.1 nM) in the environment of HeLa cells. Individual bars represent average human KRAS levels observed in triplicate, with standard errors shown. Human KRAS levels were normalized to HPRT and SFRS9 levels.

FIGS. 22-31 show histograms of mouse KRAS inhibitory efficacies observed for indicated DsiRNAs. “P1” indicates phase 1, while “P2” indicates phase 2. In phase 1, DsiRNAs were tested at 1 nM in the environment of mouse Hepa 1-6 cells. In phase 2, DsiRNAs were tested at 1 nM and at 0.1 nM (with duplicate experiments run at 0.1 nM) in the environment of mouse Hepa 1-6 cells. Individual bars represent average mouse KRAS levels observed in triplicate, with standard errors shown. Mouse KRAS levels were normalized to HPRT and Rp123 levels.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the level and/or expression of the KRAS gene in vivo or in vitro. One of the strands of the dsRNA contains a region of nucleotide sequence that has a length that ranges from 19 to 35 nucleotides that can direct the destruction and/or translational inhibition of the targeted KRAS transcript.

DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them below, unless specified otherwise.

The present invention features one or more DsiRNA molecules that can modulate (e.g., inhibit) KRAS expression. The DsiRNAs of the invention optionally can be used in combination with modulators of other genes and/or gene products associated with the maintenance or development of diseases or disorders associated with KRAS misregulation (e.g., tumor formation and/or growth, etc.). The DsiRNA agents of the invention modulate KRAS RNAs such as those corresponding to the cDNA sequences referred to by GenBank Accession Nos. NM_(—)033360 and NM_(—)004985, which are recited below and referred to herein generally as “KRAS.”

The below description of the various aspects and embodiments of the invention is provided with reference to exemplary KRAS RNAs, generally referred to herein as KRAS. However, such reference is meant to be exemplary only and the various aspects and embodiments of the invention are also directed to alternate KRAS RNAs, such as mutant KRAS RNAs or additional KRAS splice variants. Certain aspects and embodiments are also directed to other genes involved in KRAS pathways, including genes whose misregulation acts in association with that of KRAS (or is affected or affects KRAS regulation) to produce phenotypic effects that may be targeted for treatment (e.g., tumor formation and/or growth, etc.). Such additional genes can be targeted using DsiRNA and the methods described herein for use of KRAS targeting DsiRNAs. Thus, the inhibition and the effects of such inhibition of the other genes can be performed as described herein.

The term “KRAS” refers to nucleic acid sequences encoding a KRas protein, peptide, or polypeptide (e.g., KRAS transcripts, such as the sequences of KRAS Genbank Accession Nos. NM_(—)033360.2 and NM_(—)004985.3). In certain embodiments, the term “KRAS” is also meant to include other KRAS encoding sequence, such as other KRAS isoforms, mutant KRAS genes, splice variants of KRAS genes, and KRAS gene polymorphisms. The term “Kras” is used to refer to the polypeptide gene product of a KRAS gene/transript, e.g., a Kras protein, peptide, or polypeptide, such as those encoded by KRAS Genbank Accession Nos. NM_(—)033360.2 and NM_(—)004985.3.

As used herein, a “KRAS-associated disease or disorder” refers to a disease or disorder known in the art to be associated with altered KRAS expression, level and/or activity. Notably, a “KRAS-associated disease or disorder” includes cancer and/or proliferative diseases, conditions, or disorders.

By “proliferative disease” or “cancer” as used herein is meant, a disease, condition, trait, genotype or phenotype characterized by unregulated cell growth or replication as is known in the art; including leukemias, for example, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia, AIDS related cancers such as Kaposi's sarcoma; breast cancers; bone cancers such as Osteosarcoma, Chondrosarcomas, Ewing's sarcoma, Fibrosarcomas, Giant cell tumors, Adamantinomas, and Chordomas; Brain cancers such as Meningiomas, Glioblastomas, Lower-Grade Astrocytomas, Oligodendrocytomas, Pituitary Tumors, Schwannomas, and Metastatic brain cancers; cancers of the head and neck including various lymphomas such as mantle cell lymphdma, non-Hodgkins lymphoma, adenoma, squamous cell carcinoma, laryngeal carcinoma, gallbladder and bile duct cancers, cancers of the retina such as retinoblastoma, cancers of the esophagus, gastric cancers, multiple myeloma, ovarian cancer, uterine cancer, thyroid cancer, testicular cancer, endometrial cancer, melanoma, colorectal cancer, lung cancer, bladder cancer, prostate cancer, lung cancer (including non-small cell lung carcinoma), pancreatic cancer, sarcomas, Wilms' tumor, cervical cancer, head and neck cancer, skin cancers, nasopharyngeal carcinoma, liposarcoma, epithelial carcinoma, renal cell carcinoma, gallbladder adeno carcinoma, parotid adenocarcinoma, endometrial sarcoma, multidrug resistant cancers; and proliferative diseases and conditions, such as neovascularization associated with tumor angiogenesis, macular degeneration (e.g., wet/dry AMD), corneal neovascularization, diabetic retinopathy, neovascular glaucoma, myopic degeneration and other proliferative diseases and conditions such as restenosis and polycystic kidney disease, and other cancer or proliferative disease, condition, trait, genotype or phenotype that can respond to the modulation of disease related gene expression in a cell or tissue, alone or in combination with other therapies.

In certain embodiments, DsiRNA-mediated inhibition of a KRAS target sequence is assessed. In such embodiments, KRAS RNA levels can be assessed by art-recognized methods (e.g., RT-PCR, Northern blot, expression array, etc.), optionally via comparison of KRAS levels in the presence of an anti-KRAS DsiRNA of the invention relative to the absence of such an anti-KRAS DsiRNA. In certain embodiments, KRAS levels in the presence of an anti-KRAS DsiRNA are compared to those observed in the presence of vehicle alone, in the presence of a DsiRNA directed against an unrelated target RNA, or in the absence of any treatment. It is also recognized that levels of Kras protein can be assessed as indicative of KRAS RNA levels and/or the extent to which a DsiRNA inhibits KRAS expression, thus art-recognized methods of assessing KRAS protein levels (e.g., Western blot, immunoprecipitation, other antibody-based methods, etc.) can also be employed to examine the inhibitory effect of a DsiRNA of the invention. An anti-KRAS DsiRNA of the invention is deemed to possess “KRAS inhibitory activity” if a statistically significant reduction in KRAS RNA or protein levels is seen when an anti-KRAS DsiRNA of the invention is administered to a system (e.g., cell-free in vitro system), cell, tissue or organism, as compared to an appropriate control. The distribution of experimental values and the number of replicate assays performed will tend to dictate the parameters of what levels of reduction in KRAS RNA or protein (either as a % or in absolute terms) is deemed statistically significant (as assessed by standard methods of determining statistical significance known in the art). However, in certain embodiments, “KRAS inhibitory activity” is defined based upon a % or absolute level of reduction in the level of KRAS in a system, cell, tissue or organism. For example, in certain embodiments, a DsiRNA of the invention is deemed to possess KRAS inhibitory activity if at least a 5% reduction or at least a 10% reduction in KRAS RNA is observed in the presence of a DsiRNA of the invention relative to KRAS levels seen for a suitable control. (For example, in vivo KRAS levels in a tissue and/or subject can, in certain embodiments, be deemed to be inhibited by a DsiRNA agent of the invention if, e.g., a 5% or 10% reduction in KRAS levels is observed relative to a control.) In certain other embodiments, a DsiRNA of the invention is deemed to possess KRAS inhibitory activity if KRAS RNA levels are observed to be reduced by at least 15% relative to an appropriate control, by at least 20% relative to an appropriate control, by at least 25% relative to an appropriate control, by at least 30% relative to an appropriate control, by at least 35% relative to an appropriate control, by at least 40% relative to an appropriate control, by at least 45% relative to an appropriate control, by at least 50% relative to an appropriate control, by at least 55% relative to an appropriate control, by at least 60% relative to an appropriate control, by at least 65% relative to an appropriate control, by at least 70% relative to an appropriate control, by at least 75% relative to an appropriate control, by at least 80% relative to an appropriate control, by at least 85% relative to an appropriate control, by at least 90% relative to an appropriate control, by at least 95% relative to an appropriate control, by at least 96% relative to an appropriate control, by at least 97% relative to an appropriate control, by at least 98% relative to an appropriate control or by at least 99% relative to an appropriate control. In some embodiments, complete inhibition of KRAS is required for a DsiRNA to be deemed to possess KRAS inhibitory activity. In certain models (e.g., cell culture), a DsiRNA is deemed to possess KRAS inhibitory activity if at least a 50% reduction in KRAS levels is observed relative to a suitable control. In certain other embodiments, a DsiRNA is deemed to possess KRAS inhibitory activity if at least an 80% reduction in KRAS levels is observed relative to a suitable control.

KRAS inhibitory activity can also be evaluated over time (duration) and over concentration ranges (potency), with assessment of what constitutes a DsiRNA possessing KRAS inhibitory activity adjusted in accordance with concentrations administered and duration of time following administration. Thus, in certain embodiments, a DsiRNA of the invention is deemed to possess KRAS inhibitory activity if at least a 50% reduction in KRAS activity is observed at a duration of time of 2 hours, 5 hours, 10 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days or more after administration is observed/persists. In additional embodiments, a DsiRNA of the invention is deemed to be a potent KRAS inhibitory agent if KRAS inihibitory activity (e.g., in certain embodiments, at least 50% inhibition of KRAS) is observed at a concentration of 1 nM or less, 500 pM or less, 200 pM or less, 100 pM or less, 50 pM or less, 20 pM or less, 10 pM or less, 5 pM or less, 2 pM or less or even 1 pM or less in the environment of a cell.

In certain embodiments, the phrase “consists essentially of” is used in reference to the anti-KRAS DsiRNAs of the invention. In some such embodiments, “consists essentially of” refers to a composition that comprises a DsiRNA of the invention which possesse at least a certain level of KRAS inhibitory activity (e.g., at least 50% KRAS inhibitory activity) and that also comprises one or more additional components and/or modifications that do not significantly impact the KRAS inhibitory activity of the DsiRNA. For example, in certain embodiments, a composition “consists essentially of” a DsiRNA of the invention where modifications of the DsiRNA of the invention and/or DsiRNA-associated components of the composition do not alter the KRAS inhibitory activity (optionally including potency or duration of KRAS inhibitory activity) by greater than 3%, greater than 5%, greater than 10%, greater than 15%, greater than 20%, greater than 25%, greater than 30%, greater than 35%, greater than 40%, greater than 45%, or greater than 50% relative to the DsiRNA of the invention in isolation. In certain embodiments, a composition is deemed to consist essentially of a DsiRNA of the invention even if more dramatic reduction of KRAS inhibitory activity (e.g., 80% reduction, 90% reduction, etc. in efficacy, duration and/or potency) occurs in the presence of additional components or modifications, yet where KRAS inhibitory activity is not significantly elevated (e.g., observed levels of KRAS inhibitory activity are within 10% those observed for the isolated DsiRNA of the invention) in the presence of additional components and/or modifications.

As used herein, the term “nucleic acid” refers to deoxyribonucleotides, ribonucleotides, or modified nucleotides, and polymers thereof in single- or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).

As used herein, “nucleotide” is used as recognized in the art to include those with natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1′ position of a nucleotide sugar moiety. Nucleotides generally comprise a base, sugar and a phosphate group. The nucleotides can be unmodified or modified at the sugar, phosphate and/or base moiety, (also referred to interchangeably as nucleotide analogs, modified nucleotides, non-natural nucleotides, non-standard nucleotides and other; see, e.g., Usman and McSwiggen, supra; Eckstein, et al., International PCT Publication No. WO 92/07065; Usman et al, International PCT Publication No. WO 93/15187; Uhlman & Peyman, supra, all are hereby incorporated by reference herein). There are several examples of modified nucleic acid bases known in the art as summarized by Limbach, et al, Nucleic Acids Res. 22:2183, 1994. Some of the non-limiting examples of base modifications that can be introduced into nucleic acid molecules include, hypoxanthine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2,4,6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine), propyne, and others (Burgin, et al., Biochemistry 35:14090, 1996; Uhlman & Peyman, supra). By “modified bases” in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1′ position or their equivalents.

As used herein, “modified nucleotide” refers to a nucleotide that has one or more modifications to the nucleoside, the nucleobase, pentose ring, or phosphate group. For example, modified nucleotides exclude ribonucleotides containing adenosine monophosphate, guanosine monophosphate, uridine monophosphate, and cytidine monophosphate and deoxyribonucleotides containing deoxyadenosine monophosphate, deoxyguanosine monophosphate, deoxythymidine monophosphate, and deoxycytidine monophosphate. Modifications include those naturally occurring that result from modification by enzymes that modify nucleotides, such as methyltransferases. Modified nucleotides also include synthetic or non-naturally occurring nucleotides. Synthetic or non-naturally occurring modifications in nucleotides include those with 2′ modifications, e.g., 2′-methoxyethoxy, 2′-fluoro, 2′-allyl, 2′-O-[2-(methylamino)-2-oxoethyl], 4′-thio, 4′-CH₂-O-2′-bridge, 4′-(CH₂)₂-O-2′-bridge, 2′-LNA, and 2′-O—(N-methylcarbamate) or those comprising base analogs. In connection with 2′-modified nucleotides as described for the present disclosure, by “amino” is meant 2′—NH₂ or 2′-O—NH₂, which can be modified or unmodified. Such modified groups are described, e.g., in Eckstein et al., U.S. Pat. No. 5,672,695 and Matulic-Adamic et al., U.S. Pat. No. 6,248,878.

In reference to the nucleic acid molecules of the present disclosure, modifications may exist upon these agents in patterns on one or both strands of the double stranded ribonucleic acid (dsRNA). As used herein, “alternating positions” refers to a pattern where every other nucleotide is a modified nucleotide or there is an unmodified nucleotide (e.g., an unmodified ribonucleotide) between every modified nucleotide over a defined length of a strand of the dsRNA (e.g., 5′-MNMNMN-3′; 3′-MNMNMN-5′; where M is a modified nucleotide and N is an unmodified nucleotide). The modification pattern starts from the first nucleotide position at either the 5′ or 3′ terminus according to a position numbering convention, e.g., as described herein (in certain embodiments, position 1 is designated in reference to the terminal residue of a strand following a projected Dicer cleavage event of a DsiRNA agent of the invention; thus, position 1 does not always constitute a 3′ terminal or 5′ terminal residue of a pre-processed agent of the invention). The pattern of modified nucleotides at alternating positions may run the full length of the strand, but in certain embodiments includes at least 4, 6, 8, 10, 12, 14 nucleotides containing at least 2, 3, 4, 5, 6 or 7 modified nucleotides, respectively. As used herein, “alternating pairs of positions” refers to a pattern where two consecutive modified nucleotides are separated by two consecutive unmodified nucleotides over a defined length of a strand of the dsRNA (e.g., 5′-MMNNMMNNMMNN-3′; 3′-MMNNMMNNMMNN-5′; where M is a modified nucleotide and N is an unmodified nucleotide). The modification pattern starts from the first nucleotide position at either the 5′ or 3′ terminus according to a position numbering convention such as those described herein. The pattern of modified nucleotides at alternating positions may run the full length of the strand, but preferably includes at least 8, 12, 16, 20, 24, 28 nucleotides containing at least 4, 6, 8, 10, 12 or 14 modified nucleotides, respectively. It is emphasized that the above modification patterns are exemplary and are not intended as limitations on the scope of the invention.

As used herein, “base analog” refers to a heterocyclic moiety which is located at the 1′ position of a nucleotide sugar moiety in a modified nucleotide that can be incorporated into a nucleic acid duplex (or the equivalent position in a nucleotide sugar moiety substitution that can be incorporated into a nucleic acid duplex). In the dsRNAs of the invention, a base analog is generally either a purine or pyrimidine base excluding the common bases guanine (G), cytosine (C), adenine (A), thymine (T), and uracil (U). Base analogs can duplex with other bases or base analogs in dsRNAs. Base analogs include those useful in the compounds and methods of the invention, e.g., those disclosed in U.S. Pat. Nos. 5,432,272 and 6,001,983 to Benner and US Patent Publication No. 20080213891 to Manoharan, which are herein incorporated by reference. Non-limiting examples of bases include hypoxanthine (I), xanthine (X), 3β-D-ribofuranosyl-(2,6-diaminopyrimidine) (K), 3-β-D-ribofuranosyl-(1-methyl-pyrazolo[4,3-d]pyrimidine-5,7(4H,6H)-dione) (P), iso-cytosine (iso-C), iso-guanine (iso-G), 1-β-D-ribofuranosyl-(5-nitroindole), ribofuranosyl-(3-nitropyrrole), 5-bromouracil, 2-aminopurine, 4-thio-dT, 7-(2-thienyl)-imidazo[4,5-b]pyridine (Ds) and pyrrole-2-carbaldehyde (Pa), 2-amino-6-(2-thienyl)purine (S), 2-oxopyridine (Y), difluorotolyl, 4-fluoro-6-methylbenzimidazole, 4-methylbenzimidazole, 3-methyl isocarbostyrilyl, 5-methyl isocarbostyrilyl, and 3-methyl-7-propynyl isocarbostyrilyl, 7-azaindolyl, 6-methyl-7-azaindolyl, imidizopyridinyl, 9-methyl-imidizopyridinyl, pyrrolopyrizinyl, isocarbostyrilyl, 7-propynyl isocarbostyrilyl, propynyl-7-azaindolyl, 2,4,5-trimethylphenyl, 4-methylindolyl, 4,6-dimethylindolyl, phenyl, napthalenyl, anthracenyl, phenanthracenyl, pyrenyl, stilbenzyl, tetracenyl, pentacenyl, and structural derivates thereof (Schweitzer et al., J. Org. Chem., 59:7238-7242 (1994); Berger et al., Nucleic Acids Research, 28(15):2911-2914 (2000); Moran et al., J. Am. Chem. Soc., 119:2056-2057 (1997); Morales et al., J. Am. Chem. Soc., 121:2323-2324 (1999); Guckian et al., J. Am. Chem. Soc., 118:8182-8183 (1996); Morales et al., J. Am. Chem. Soc., 122(6):1001-1007 (2000); McMinn et al., J. Am. Chem. Soc., 121:11585-11586 (1999); Guckian et al., J. Org. Chem., 63:9652-9656 (1998); Moran et al., Proc. Natl. Acad. Sci., 94:10506-10511 (1997); Das et al., J. Chem. Soc., Perkin Trans., 1:197-206 (2002); Shibata et al., J. Chem. Soc., Perkin Trans., 1: 1605-1611 (2001); Wu et al., J. Am. Chem. Soc., 122(32):7621-7632 (2000); O'Neill et al., J. Org. Chem., 67:5869-5875 (2002); Chaudhuri et al., J. Am. Chem. Soc., 117:10434-10442 (1995); and U.S. Pat. No. 6,218,108.). Base analogs may also be a universal base.

As used herein, “universal base” refers to a heterocyclic moiety located at the 1′ position of a nucleotide sugar moiety in a modified nucleotide, or the equivalent position in a nucleotide sugar moiety substitution, that, when present in a nucleic acid duplex, can be positioned opposite more than one type of base without altering the double helical structure (e.g., the structure of the phosphate backbone). Additionally, the universal base does not destroy the ability of the single stranded nucleic acid in which it resides to duplex to a target nucleic acid. The ability of a single stranded nucleic acid containing a universal base to duplex a target nucleic can be assayed by methods apparent to one in the art (e.g., UV absorbance, circular dichroism, gel shift, single stranded nuclease sensitivity, etc.). Additionally, conditions under which duplex formation is observed may be varied to determine duplex stability or formation, e.g., temperature, as melting temperature (Tm) correlates with the stability of nucleic acid duplexes. Compared to a reference single stranded nucleic acid that is exactly complementary to a target nucleic acid, the single stranded nucleic acid containing a universal base forms a duplex with the target nucleic acid that has a lower Tm than a duplex formed with the complementary nucleic acid. However, compared to a reference single stranded nucleic acid in which the universal base has been replaced with a base to generate a single mismatch, the single stranded nucleic acid containing the universal base forms a duplex with the target nucleic acid that has a higher Tm than a duplex formed with the nucleic acid having the mismatched base.

Some universal bases are capable of base pairing by forming hydrogen bonds between the universal base and all of the bases guanine (G), cytosine (C), adenine (A), thymine (T), and uracil (U) under base pair forming conditions. A universal base is not a base that forms a base pair with only one single complementary base. In a duplex, a universal base may form no hydrogen bonds, one hydrogen bond, or more than one hydrogen bond with each of G, C, A, T, and U opposite to it on the opposite strand of a duplex. Preferably, the universal bases does not interact with the base opposite to it on the opposite strand of a duplex. In a duplex, base pairing between a universal base occurs without altering the double helical structure of the phosphate backbone. A universal base may also interact with bases in adjacent nucleotides on the same nucleic acid strand by stacking interactions. Such stacking interactions stabilize the duplex, especially in situations where the universal base does not form any hydrogen bonds with the base positioned opposite to it on the opposite strand of the duplex. Non-limiting examples of universal-binding nucleotides include inosine, 1-β-D-ribo furanosyl-5-nitroindole, and/or 1-β-D-ribofuranosyl-3-nitropyrrole (US Pat. Appl. Publ. No. 20070254362 to Quay et al.; Van Aerschot et al., An acyclic 5-nitroindazole nucleoside analogue as ambiguous nucleoside. Nucleic Acids Res. 1995 Nov. 11; 23(21):4363-70; Loakes et al., 3-Nitropyrrole and 5-nitroindole as universal bases in primers for DNA sequencing and PCR. Nucleic Acids Res. 1995 Jul. 11; 23(13):2361-6; Loakes and Brown, 5-Nitroindole as an universal base analogue. Nucleic Acids Res. 1994 Oct. 11; 22(20):4039-43).

As used herein, “loop” refers to a structure formed by a single strand of a nucleic acid, in which complementary regions that flank a particular single stranded nucleotide region hybridize in a way that the single stranded nucleotide region between the complementary regions is excluded from duplex formation or Watson-Crick base pairing. A loop is a single stranded nucleotide region of any length. Examples of loops include the unpaired nucleotides present in such structures as hairpins, stem loops, or extended loops.

As used herein, “extended loop” in the context of a dsRNA refers to a single stranded loop and in addition 1, 2, 3, 4, 5, 6 or up to 20 base pairs or duplexes flanking the loop. In an extended loop, nucleotides that flank the loop on the 5′ side form a duplex with nucleotides that flank the loop on the 3′ side. An extended loop may form a hairpin or stem loop.

As used herein, “tetraloop” in the context of a dsRNA refers to a loop (a single stranded region) consisting of four nucleotides that forms a stable secondary structure that contributes to the stability of an adjacent Watson-Crick hybridized nucleotides. Without being limited to theory, a tetraloop may stabilize an adjacent Watson-Crick base pair by stacking interactions. In addition, interactions among the four nucleotides in a tetraloop include but are not limited to non-Watson-Crick base pairing, stacking interactions, hydrogen bonding, and contact interactions (Cheong et al., Nature 1990 Aug. 16; 346(6285):680-2; Heus and Pardi, Science 1991 July 12; 253(5016):191-4). A tetraloop confers an increase in the melting temperature (Tm) of an adjacent duplex that is higher than expected from a simple model loop sequence consisting of four random bases. For example, a tetraloop can confer a melting temperature of at least 55° C. in 10 mM NaHPO₄ to a hairpin comprising a duplex of at least 2 base pairs in length. A tetraloop may contain ribonucleotides, deoxyribonucleotides, modified nucleotides, and combinations thereof. Examples of RNA tetraloops include the UNCG family of tetraloops (e.g., UUCG), the GNRA family of tetraloops (e.g., GAAA), and the CUUG tetraloop. (Woese et al., Proc Natl Acad Sci USA. 1990 November; 87(21):8467-71; Antao et al., Nucleic Acids Res. 1991 November 11; 19(21):5901-5). Examples of DNA tetraloops include the d(GNNA) family of tetraloops (e.g., d(GTTA), the d(GNRA)) family of tetraloops, the d(GNAB) family of tetraloops, the d(CNNG) family of tetraloops, the d(TNCG) family of tetraloops (e.g., d(TTCG)). (Nakano et al. Biochemistry, 41 (48), 14281-14292, 2002.; SHINJI et al. Nippon Kagakkai Koen Yokoshu VOL.78th; NO.2; PAGE.731 (2000).)

As used herein, the term “siRNA” refers to a double stranded nucleic acid in which each strand comprises RNA, RNA analog(s) or RNA and DNA. The siRNA comprises between 19 and 23 nucleotides or comprises 21 nucleotides. The siRNA typically has 2 by overhangs on the 3′ ends of each strand such that the duplex region in the siRNA comprises 17-21 nucleotides, or 19 nucleotides. Typically, the antisense strand of the siRNA is sufficiently complementary with the target sequence of the KRAS gene/RNA.

An anti-KRAS DsiRNA of the instant invention possesses strand lengths of at least 25 nucleotides. Accordingly, an anti-KRAS DsiRNA contains one oligonucleotide sequence, a first sequence, that is at least 25 nucleotides in length and no longer thin 35 or up to 50 nucleotides. This sequence of RNA can be between 26 and 35, 26 and 34, 26 and 33, 26 and 32, 26 and 31, 26 and 30, and 26 and 29 nucleotides in length. This sequence can be 27 or 28 nucleotides in length or 27 nucleotides in length. The second sequence of the DsiRNA agent can be a sequence that anneals to the first sequence under biological conditions, such as within the cytoplasm of a eukaryotic cell. Generally, the second oligonucleotide sequence will have at least 19 complementary base pairs with the first oligonucleotide sequence, more typically the second oligonucleotide sequence will have 21 or more complementary base pairs, or 25 or more complementary base pairs with the first oligonucleotide sequence. In one embodiment, the second sequence is the same length as the first sequence, and the DsiRNA agent is blunt ended. In another embodiment, the ends of the DsiRNA agent have one or more overhangs.

In certain embodiments, the first and second oligonucleotide sequences of the DsiRNA agent exist on separate oligonucleotide strands that can be and typically are chemically synthesized. In some embodiments, both strands are between 26 and 35 nucleotides in length. In other embodiments, both strands are between 25 and 30 or 26 and 30 nucleotides in length. In one embodiment, both strands are 27 nucleotides in length, are completely complementary and have blunt ends. In certain embodiments of the instant invention, the first and second sequences of an anti-KRAS DsiRNA exist on separate RNA oligonucleotides (strands). In one embodiment, one or both oligonucleotide strands are capable of serving as a substrate for Dicer. In other embodiments, at least one modification is present that promotes Dicer to bind to the double-stranded RNA structure in an orientation that maximizes the double-stranded RNA structure's effectiveness in inhibiting gene expression. In certain embodiments of the instant invention, the anti-KRAS DsiRNA agent is comprised of two oligonucleotide strands of differing lengths, with the anti-KRAS DsiRNA possessing a blunt end at the 3′ terminus of a first strand (sense strand) and a 3′ overhang at the 3′ terminus of a second strand (antisense strand). The DsiRNA can also contain one or more deoxyribonucleic acid (DNA) base substitutions.

Suitable DsiRNA compositions that contain two separate oligonucleotides can be chemically linked outside their annealing region by chemical linking groups. Many suitable chemical linking groups are known in the art and can be used. Suitable groups will not block Dicer activity on the DsiRNA and will not interfere with the directed destruction of the RNA transcribed from the target gene. Alternatively, the two separate oligonucleotides can be linked by a third oligonucleotide such that a hairpin structure is produced upon annealing of the two oligonucleotides making up the DsiRNA composition. The hairpin structure will not block Dicer activity on the DsiRNA and will not interfere with the directed destruction of the target RNA.

As used herein, a dsRNA, e.g., DsiRNA or siRNA, having a sequence “sufficiently complementary” to a target RNA or cDNA sequence (e.g., KRAS mRNA) means that the dsRNA has a sequence sufficient to trigger the destruction of the target RNA (where a cDNA sequence is recited, the RNA sequence corresponding to the recited cDNA sequence) by the RNAi machinery (e.g., the RISC complex) or process. The dsRNA molecule can be designed such that every residue of the antisense strand is complementary to a residue in the target molecule. Alternatively, substitutions can be made within the molecule to increase stability and/or enhance processing activity of said molecule. Substitutions can be made within the strand or can be made to residues at the ends of the strand. In certain embodiments, substitutions and/or modifications are made at specific residues within a DsiRNA agent. Such substitutions and/or modifications can include, e.g., deoxy-modifications at one or more residues of positions 1, 2 and 3 when numbering from the 3′ terminal position of the sense strand of a DsiRNA agent; and introduction of 2′-O-alkyl (e.g., 2′-O-methyl) modifications at the 3′ terminal residue of the antisense strand of DsiRNA agents, with such modifications also being performed at overhang positions of the 3′ portion of the antisense strand and at alternating residues of the antisense strand of the DsiRNA that are included within the region of a DsiRNA agent that is processed to form an active siRNA agent. The preceding modifications are offered as exemplary, and are not intended to be limiting in any manner. Further consideration of the structure of preferred DsiRNA agents, including further description of the modifications and substitutions that can be performed upon the anti-KRAS DsiRNA agents of the instant invention, can be found below.

The phrase “duplex region” refers to the region in two complementary or substantially complementary oligonucleotides that form base pairs with one another, either by Watson-Crick base pairing or other manner that allows for a duplex between oligonucleotide strands that are complementary or substantially complementary. For example, an oligonucleotide strand having 21 nucleotide units can base pair with another oligonucleotide of 21 nucleotide units, yet only 19 bases on each strand are complementary or substantially complementary, such that the “duplex region” consists of 19 base pairs. The remaining base pairs may, for example, exist as 5′ and 3′ overhangs. Further, within the duplex region, 100% complementarity is not required; substantial complementarity is allowable within a duplex region. Substantial complementarity refers to complementarity between the strands such that they are capable of annealing under biological conditions. Techniques to empirically determine if two strands are capable of annealing under biological conditions are well know in the art. Alternatively, two strands can be synthesized and added together under biological conditions to determine if they anneal to one another.

Single-stranded nucleic acids that base pair over a number of bases are said to “hybridize.” Hybridization is typically determined under physiological or biologically relevant conditions (e.g., intracellular: pH 7.2, 140 mM potassium ion; extracellular pH 7.4, 145 mM sodium ion). Hybridization conditions generally contain a monovalent cation and biologically acceptable buffer and may or may not contain a divalent cation, complex anions, e.g. gluconate from potassium gluconate, uncharged species such as sucrose, and inert polymers to reduce the activity of water in the sample, e.g. PEG. Such conditions include conditions under which base pairs can form.

Hybridization is measured by the temperature required to dissociate single stranded nucleic acids forming a duplex, i.e., (the melting temperature; Tm). Hybridization conditions are also conditions under which base pairs can form. Various conditions of stringency can be used to determine hybridization (see, e.g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol. 152:399; Kimmel, A. R. (1987) Methods Enzymol. 152:507). Stringent temperature conditions will ordinarily include temperatures of at least about 30° C., more preferably of at least about 37° C., and most preferably of at least about 42° C. The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10° C. less than the melting temperature (Tm) of the hybrid, where Tm is determined according to the following equations. For hybrids less than 18 base pairs in length, Tm(° C.)=2(# of A+T bases)+4(# of G+C bases). For hybrids between 18 and 49 base pairs in length, Tm(° C.)=81.5+16.6(log 10[Na+])+0.41 (% G+C)−(600/N), where N is the number of bases in the hybrid, and [Na+] is the concentration of sodium ions in the hybridization buffer ([Na+] for 1×SSC=0.165 M). For example, a hybridization determination buffer is shown in Table 1.

TABLE 1 To make 50 final conc. Vender Cat# Lot# m.w./Stock mL solution NaCl 100 mM Sigma S-5150 41K8934 5M 1 mL KCl 80 mM Sigma P-9541 70K0002  74.55 0.298 g MgCl₂ 8 mM Sigma M-1028 120K8933 1M 0.4 mL sucrose 2% w/v Fisher BP220-212 907105 342.3 1 g Tris-HCl 16 mM Fisher BP1757-500 12419 1M 0.8 mL NaH₂PO₄ 1 mM Sigma S-3193 52H-029515 120.0 0.006 g EDTA 0.02 mM Sigma E-7889 110K89271 0.5M   2 μL H₂O Sigma W-4502 51K2359 to 50 mL pH = 7.0 adjust with HCl at 20° C.

Useful variations on hybridization conditions will be readily apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (Science 196:180, 1977); Grunstein and Hogness (Proc. Natl. Acad. Sci., USA 72:3961, 1975); Ausubel et al. (Current Protocols in Molecular Biology, Wiley

Interscience, New York, 2001); Berger and Kimmel (Antisense to Molecular Cloning Techniques, 1987, Academic Press, New York); and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.

As used herein, “oligonucleotide strand” is a single stranded nucleic acid molecule. An oligonucleotide may comprise ribonucleotides, deoxyribonucleotides, modified nucleotides (e.g., nucleotides with 2′ modifications, synthetic base analogs, etc.) or combinations thereof. Such modified oligonucleotides can be preferred over native forms because of properties such as, for example, enhanced cellular uptake and increased stability in the presence of nucleases.

As used herein, the term “ribonucleotide” encompasses natural and synthetic, unmodified and modified ribonucleotides. Modifications include changes to the sugar moiety, to the base moiety and/or to the linkages between ribonucleotides in the oligonucleotide. As used herein, the term “ribonucleotide” specifically excludes a deoxyribonucleotide, which is a nucleotide possessing a single proton group at the 2′ ribose ring position.

As used herein, the term “deoxyribonucleotide” encompasses natural and synthetic, unmodified and modified deoxyribonucleotides. Modifications include changes to the sugar moiety, to the base moiety and/or to the linkages between deoxyribonucleotide in the oligonucleotide. As used herein, the term “deoxyribonucleotide” also includes a modified ribonucleotide that does not permit Dicer cleavage of a dsRNA agent, e.g., a 2′-O-methyl ribonucleotide, a phosphorothioate-modified ribonucleotide residue, etc., that does not permit Dicer cleavage to occur at a bond of such a residue.

As used herein, the term “PS-NA” refers to a phosphorothioate-modified nucleotide residue. The term “PS-NA” therefore encompasses both phosphorothioate-modified ribonucleotides (“PS-RNAs”) and phosphorothioate-modified deoxyriibonucleotides (“PS-DNAs”).

As used herein, “Dicer” refers to an endoribonuclease in the RNase III family that cleaves a dsRNA or dsRNA-containing molecule, e.g., double-stranded RNA (dsRNA) or pre-microRNA (miRNA), into double-stranded nucleic acid fragments 19-25 nucleotides long, usually with a two-base overhang on the 3′ end. With respect to the dsRNAs of the invention, the duplex formed by a dsRNA region of an agent of the invention is recognized by Dicer and is a Dicer substrate on at least one strand of the duplex. Dicer catalyzes the first step in the RNA interference pathway, which consequently results in the degradation of a target RNA. The protein sequence of human Dicer is provided at the NCBI database under accession number NP_(—)085124, hereby incorporated by reference.

Dicer “cleavage” is determined as follows (e.g., see Collingwood et al., Oligonucleotides 18:187-200 (2008)). In a Dicer cleavage assay, RNA duplexes (100 pmol) are incubated in 20 μL of 20 mM Tris pH 8.0, 200 mM NaCl, 2.5 mM MgCl2 with or without 1 unit of recombinant human Dicer (Stratagene, La Jolla, Calif.) at 37° C. for 18-24 hours. Samples are desalted using a Performa SR 96-well plate (Edge Biosystems, Gaithersburg, Md.). Electrospray-ionization liquid chromatography mass spectroscopy (ESI-LCMS) of duplex RNAs pre- and post-treatment with Dicer is done using an Oligo HTCS system (Novatia, Princeton, N.J.; Hail et al., 2004), which consists of a ThermoFinnigan TSQ7000, Xcalibur data system, ProMass data processing software and Paradigm MS4 HPLC (Michrom BioResources, Auburn, Calif.). In this assay, Dicer cleavage occurs where at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or even 100% of the Dicer substrate dsRNA, (i.e., 25-30 bp, dsRNA, preferably 26-30 by dsRNA) is cleaved to a shorter dsRNA (e.g., 19-23 by dsRNA, preferably, 21-23 by dsRNA).

As used herein, “Dicer cleavage site” refers to the sites at which Dicer cleaves a dsRNA (e.g., the dsRNA region of a DsiRNA agent of the invention). Dicer contains two RNase III domains which typically cleave both the sense and antisense strands of a dsRNA. The average distance between the RNase III domains and the PAZ domain determines the length of the short double-stranded nucleic acid fragments it produces and this distance can vary (Macrae I, et al. (2006). “Structural basis for double-stranded RNA processing by Dicer”. Science 311 (5758): 195-8.). As shown in FIGS. 1 and 4, Dicer is projected to cleave certain double-stranded ribonucleic acids of the instant invention that possess an antisense strand having a 2 nucleotide 3′ overhang at a site between the 21^(st) and 22^(nd) nucleotides removed from the 3′ terminus of the antisense strand, and at a corresponding site between the 21^(st) and 22^(nd) nucleotides removed from the 5′ terminus of the sense strand. The projected and/or prevalent Dicer cleavage site(s) for dsRNA molecules distinct from those depicted in FIGS. 1 and 4 may be similarly identified via art-recognized methods, including those described in Macrae et al. While the Dicer cleavage events depicted in FIGS. 1 and 4 generate 21 nucleotide siRNAs, it is noted that Dicer cleavage of a dsRNA (e.g., DsiRNA) can result in generation of Dicer-processed siRNA lengths of 19 to 23 nucleotides in length. Indeed, in certain embodiments, a double-stranded DNA region may be included within a dsRNA for purpose of directing prevalent Dicer excision of a typically non-preferred 19mer or 20mer siRNA, rather than a 21mer.

As used herein, “overhang” refers to unpaired nucleotides, in the context of a duplex having one or more free ends at the 5′ terminus or 3′ terminus of a dsRNA. In certain embodiments, the overhang is a 3′ or 5′ overhang on the antisense strand or sense strand. In some embodiments, the overhang is a 3′ overhang having a length of between one and six nucleotides, optionally one to five, one to four, one to three, one to two, two to six, two to five, two to four, two to three, three to six, three to five, three to four, four to six, four to five, five to six nucleotides, or one, two, three, four, five or six nucleotides.

As used herein, the term “RNA processing” refers to processing activities performed by components of the siRNA, miRNA or RNase H pathways (e.g., Drosha, Dicer, Argonaute2 or other RISC endoribonucleases, and RNaseH), which are described in greater detail below (see “RNA Processing” section below). The term is explicitly distinguished from the post-transcriptional processes of 5′ capping of RNA and degradation of RNA via non-RISC- or non-RNase H-mediated processes. Such “degradation” of an RNA can take several forms, e.g. deadenylation (removal of a 3′ poly(A) tail), and/or nuclease digestion of part or all of the body of the RNA by one or more of several endo- or exo-nucleases (e.g., RNase III, RNase P, RNase T1, RNase A (1, 2, 3, 4/5), oligonucleotidase, etc.).

By “homologous sequence” is meant, a nucleotide sequence that is shared by one or more polynucleotide sequences, such as genes, gene transcripts and/or non-coding polynucleotides. For example, a homologous sequence can be a nucleotide sequence that is shared by two or more genes encoding related but different proteins, such as different members of a gene family, different protein epitopes, different protein isoforms or completely divergent genes, such as a cytokine and its corresponding receptors. A homologous sequence can be a nucleotide sequence that is shared by two or more non-coding polynucleotides, such as noncoding DNA or RNA, regulatory sequences, introns, and sites of transcriptional control or regulation. Homologous sequences can also include conserved sequence regions shared by more than one polynucleotide sequence. Homology does not need to be perfect homology (e.g., 100%), as partially homologous sequences are also contemplated by the instant invention (e.g., 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80% etc.). Indeed, design and use of the DsiRNA agents of the instant invention contemplates the possibility of using such DsiRNA agents not only against target RNAs of KRAS possessing perfect complementarity with the presently described DsiRNA agents, but also against target KRAS RNAs possessing sequences that are, e.g., only 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80% etc. complementary to said DsiRNA agents. Similarly, it is contemplated that the presently described DsiRNA agents of the instant invention might be readily altered by the skilled artisan to enhance the extent of complementarity between said DsiRNA agents and a target KRAS RNA, e.g., of a specific allelic variant of KRAS (e.g., an allele of enhanced therapeutic interest). Indeed, DsiRNA agent sequences with insertions, deletions, and single point mutations relative to the target KRAS sequence can also be effective for inhibition. Alternatively, DsiRNA agent sequences with nucleotide analog substitutions or insertions can be effective for inhibition.

Sequence identity may be determined by sequence comparison and alignment algorithms known in the art. To determine the percent identity of two nucleic acid sequences (or of two amino acid sequences), the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the first sequence or second sequence for optimal alignment). The nucleotides (or amino acid residues) at corresponding nucleotide (or amino acid) positions are then compared. When a position in the first sequence is occupied by the same residue as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology=# of identical positions/total # of positions.times.100), optionally penalizing the score for the number of gaps introduced and/or length of gaps introduced.

The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In one embodiment, the alignment generated over a certain portion of the sequence aligned having sufficient identity but not over portions having low degree of identity (i.e., a local alignment). A preferred, non-limiting example of a local alignment algorithm utilized for the comparison of sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-68, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77. Such an algorithm is incorporated into the BLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10.

In another embodiment, the alignment is optimized by introducing appropriate gaps and percent identity is determined over the length of the aligned sequences (i.e., a gapped alignment). To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17):3389-3402. In another embodiment, the alignment is optimized by introducing appropriate gaps and percent identity is determined over the entire length of the sequences aligned (i.e., a global alignment). A preferred, non-limiting example of a mathematical algorithm utilized for the global comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

Greater than 80% sequence identity, e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or even 100% sequence identity, between the DsiRNA antisense strand and the portion of the KRAS RNA sequence is preferred. Alternatively, the DsiRNA may be defined functionally as a nucleotide sequence (or oligonucleotide sequence) that is capable of hybridizing with a portion of the KRAS RNA (e.g., 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50° C. or 70° C. hybridization for 12-16 hours; followed by washing). Additional preferred hybridization conditions include hybridization at 70° C. in 1×SSC or 50° C. in 1×SSC, 50% formamide followed by washing at 70° C. in 0.3×SSC or hybridization at 70° C. in 4×SSC or 50° C. in 4×SSC, 50% formamide followed by washing at 67° C. in 1×SSC. The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10° C. less than the melting temperature (Tm) of the hybrid, where Tm is determined according to the following equations. For hybrids less than 18 base pairs in length, Tm(° C.)=2(# of A+T bases)+4(# of G+C bases). For hybrids between 18 and 49 base pairs in length, Tm(° C.)=81.5+16.6(log 10[Na+])+0.41 (% G+C)−(600/N), where N is the number of bases in the hybrid, and [Na+] is the concentration of sodium ions in the hybridization buffer ([Na+] for 1×SSC=0.165 M). Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E. F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., chapters 9 and 11, and Current Protocols in Molecular Biology, 1995, F. M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4. The length of the identical nucleotide sequences may be at least 10, 12, 15, 17, 20, 22, 25, 27 or 30 bases.

By “conserved sequence region” is meant, a nucleotide sequence of one or more regions in a polynucleotide does not vary significantly between generations or from one biological system, subject, or organism to another biological system, subject, or organism. The polynucleotide can include both coding and non-coding DNA and RNA.

By “sense region” is meant a nucleotide sequence of a DsiRNA molecule having complementarity to an antisense region of the DsiRNA molecule. In addition, the sense region of a DsiRNA molecule can comprise a nucleic acid sequence having homology with a target nucleic acid sequence.

By “antisense region” is meant a nucleotide sequence of a DsiRNA molecule having complementarity to a target nucleic acid sequence. In addition, the antisense region of a DsiRNA molecule comprises a nucleic acid sequence having complementarity to a sense region of the DsiRNA molecule.

As used herein, “antisense strand” refers to a single stranded nucleic acid molecule which has a sequence complementary to that of a target RNA. When the antisense strand contains modified nucleotides with base analogs, it is not necessarily complementary over its entire length, but must at least hybridize with a target RNA.

As used herein, “sense strand” refers to a single stranded nucleic acid molecule which has a sequence complementary to that of an antisense strand. When the antisense strand contains modified nucleotides with base analogs, the sense strand need not be complementary over the entire length of the antisense strand, but must at least duplex with the antisense strand.

As used herein, “guide strand” refers to a single stranded nucleic acid molecule of a dsRNA or dsRNA-containing molecule, which has a sequence sufficiently complementary to that of a target RNA to result in RNA interference. After cleavage of the dsRNA or dsRNA-containing molecule by Dicer, a fragment of the guide strand remains associated with RISC, binds a target RNA as a component of the RISC complex, and promotes cleavage of a target RNA by RISC. As used herein, the guide strand does not necessarily refer to a continuous single stranded nucleic acid and may comprise a discontinuity, preferably at a site that is cleaved by Dicer. A guide strand is an antisense strand.

As used herein, “passenger strand” refers to an oligonucleotide strand of a dsRNA or dsRNA-containing molecule, which has a sequence that is complementary to that of the guide strand. As used herein, the passenger strand does not necessarily refer to a continuous single stranded nucleic acid and may comprise a discontinuity, preferably at a site that is cleaved by Dicer. A passenger strand is a sense strand.

By “target nucleic acid” is meant a nucleic acid sequence whose expression, level or activity is to be modulated. The target nucleic acid can be DNA or RNA. For agents that target KRAS, in certain embodiments target nucleic acid is KRAS RNA. KRAS RNA target sites can also interchangeably be referenced by corresponding cDNA sequences. Levels of KRAS may also be targeted via targeting of upstream effectors of KRAS, or the effects of modulated or misregulated KRAS may also be modulated by targeting of molecules downstream of KRAS in the Ras signalling pathway.

By “complementarity” is meant that a nucleic acid can form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick or other non-traditional types. In reference to the nucleic molecules of the present invention, the binding free energy for a nucleic acid molecule with its complementary sequence is sufficient to allow the relevant function of the nucleic acid to proceed, e.g., RNAi activity. Determination of binding free energies for nucleic acid molecules is well known in the art (see, e.g., Turner et al., 1987, CSH Symp. Quant. Biol. LII pp. 123-133; Frier et al., 1986, Proc. Nat. Acad. Sci. USA 83:9373-9377; Turner et al., 1987, J. Am. Chem. Soc. 109:3783-3785). A percent complementarity indicates the percentage of contiguous residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, or 10 nucleotides out of a total of 10 nucleotides in the first oligonucleotide being based paired to a second nucleic acid sequence having 10 nucleotides represents 50%, 60%, 70%, 80%, 90%, and 100% complementary respectively). “Perfectly complementary” means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence. In one embodiment, a DsiRNA molecule of the invention comprises 19 to 30 (e.g., 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 or more) nucleotides that are complementary to one or more target nucleic acid molecules or a portion thereof.

In one embodiment, DsiRNA molecules of the invention that down regulate or reduce KRAS gene expression are used for treating, preventing or reducing KRAS-related diseases or disorders (e.g., cancer) in a subject or organism.

In one embodiment of the present invention, each sequence of a DsiRNA molecule of the invention is independently 25 to 35 nucleotides in length, in specific embodiments 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 nucleotides in length. In another embodiment, the DsiRNA duplexes of the invention independently comprise 25 to 30 base pairs (e.g., 25, 26, 27, 28, 29, or 30). In another embodiment, one or more strands of the DsiRNA molecule of the invention independently comprises 19 to 35 nucleotides (e.g., 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35) that are complementary to a target (KRAS) nucleic acid molecule. In certain embodiments, a DsiRNA molecule of the invention possesses a length of duplexed nucleotides between 25 and 34 nucleotides in length (e.g., 25, 26, 27, 28, 29, 30, 31, 32, 33 or 34 nucleotides in length; optionally, all such nucleotides base pair with cognate nucleotides of the opposite strand). (Exemplary DsiRNA molecules of the invention are shown in FIGS. 1 and 4, and below.

As used herein “cell” is used in its usual biological sense, and does not refer to an entire multicellular organism, e.g., specifically does not refer to a human. The cell can be present in an organism, e.g., birds, plants and mammals such as humans, cows, sheep, apes, monkeys, swine, dogs, and cats. The cell can be prokaryotic (e.g., bacterial cell) or eukaryotic (e.g., mammalian or plant cell). The cell can be of somatic or germ line origin, totipotent or pluripotent, dividing or non-dividing. The cell can also be derived from or can comprise a gamete or embryo, a stem cell, or a fully differentiated cell. Within certain aspects, the term “cell” refers specifically to mammalian cells, such as human cells, that contain one or more isolated dsRNA molecules of the present disclosure. In particular aspects, a cell processes dsRNAs or dsRNA-containing molecules resulting in RNA intereference of target nucleic acids, and contains proteins and protein complexes required for RNAi, e.g., Dicer and RISC.

The DsiRNA molecules of the invention are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to target cells or tissues. The nucleic acid or nucleic acid complexes can be locally administered to relevant tissues ex vivo, or in vivo through direct dermal application, transdermal application, or injection, with or without their incorporation in biopolymers. In particular embodiments, the nucleic acid molecules of the invention comprise sequences shown in FIGS. 1 and 4, and the below exemplary structures. Examples of such nucleic acid molecules consist essentially of sequences defined in these figures and exemplary structures. Furthermore, where such agents are modified in accordance with the below description of modification patterning of DsiRNA agents, chemically modified forms of constructs described in FIGS. 1 and 4, and the below exemplary structures can be used in all uses described for the DsiRNA agents of FIGS. 1 and 4, and the below exemplary structures.

In another aspect, the invention provides mammalian cells containing one or more DsiRNA molecules of this invention. The one or more DsiRNA molecules can independently be targeted to the same or different sites.

By “RNA” is meant a molecule comprising at least one ribonucleotide residue. By “ribonucleotide” is meant a nucleotide with a hydroxyl group at the 2′ position of a β-D-ribofuranose moiety. The terms include double-stranded RNA, single-stranded RNA, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, as well as altered RNA that differs from naturally occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides. Such alterations can include addition of non-nucleotide material, such as to the end(s) of the DsiRNA or internally, for example at one or more nucleotides of the RNA. Nucleotides in the RNA molecules of the instant invention can also comprise non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs can be referred to as analogs or analogs of naturally-occurring RNA.

By “subject” is meant an organism, which is a donor or recipient of explanted cells or the cells themselves. “Subject” also refers to an organism to which the DsiRNA agents of the invention can be administered. A subject can be a mammal or mammalian cells, including a human or human cells.

The phrase “pharmaceutically acceptable carrier” refers to a carrier for the administration of a therapeutic agent. Exemplary carriers include saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. For drugs administered orally, pharmaceutically acceptable carriers include, but are not limited to pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract. The pharmaceutically acceptable carrier of the disclosed dsRNA compositions may be micellar structures, such as a liposomes, capsids, capsoids, polymeric nanocapsules, or polymeric microcapsules.

Polymeric nanocapsules or microcapsules facilitate transport and release of the encapsulated or bound dsRNA into the cell. They include polymeric and monomeric materials, especially including polybutylcyanoacrylate. A summary of materials and fabrication methods has been published (see Kreuter, 1991). The polymeric materials which are formed from monomeric and/or oligomeric precursors in the polymerization/nanoparticle generation step, are per se known from the prior art, as are the molecular weights and molecular weight distribution of the polymeric material which a person skilled in the field of manufacturing nanoparticles may suitably select in accordance with the usual skill.

Various methodologies of the instant invention include step that involves comparing a value, level, feature, characteristic, property, etc. to a “suitable control”, referred to interchangeably herein as an “appropriate control”. A “suitable control” or “appropriate control” is a control or standard familiar to one of ordinary skill in the art useful for comparison purposes. In one embodiment, a “suitable control” or “appropriate control” is a value, level, feature, characteristic, property, etc. determined prior to performing an RNAi methodology, as described herein. For example, a transcription rate, mRNA level, translation rate, protein level, biological activity, cellular characteristic or property, genotype, phenotype, etc. can be determined prior to introducing an RNA silencing agent (e.g., DsiRNA) of the invention into a cell or organism. In another embodiment, a “suitable control” or “appropriate control” is a value, level, feature, characteristic, property, etc. determined in a cell or organism, e.g., a control or normal cell or organism, exhibiting, for example, normal traits. In yet another embodiment, a “suitable control” or “appropriate control” is a predefined value, level, feature, characteristic, property, etc.

The term “in vitro” has its art recognized meaning, e.g., involving purified reagents or extracts, e.g., cell extracts. The term “in vivo” also has its art recognized meaning, e.g., involving living cells, e.g., immortalized cells, primary cells, cell lines, and/or cells in an organism.

“Treatment”, or “treating” as used herein, is defined as the application or administration of a therapeutic agent (e.g., a DsiRNA agent or a vector or transgene encoding same) to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient, who has a disorder with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease or disorder, or symptoms of the disease or disorder. The term “treatment” or “treating” is also used herein in the context of administering agents prophylactically. The term “effective dose” or “effective dosage” is defined as an amount sufficient to achieve or at least partially achieve the desired effect. The term “therapeutically effective dose” is defined as an amount sufficient to cure or at least partially arrest the disease and its complications in a patient already suffering from the disease. The term “patient” includes human and other mammalian subjects that receive either prophylactic or therapeutic treatment.

Structures of Anti-KRAS DsiRNA Agents

In certain embodiments, the anti-KRAS DsiRNA agents of the invention can have the following structures:

In one such embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers. In a related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, and “D”=DNA. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand.

In an additional embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. In a related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In another such embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. In a related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In another such embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. In a related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. In a related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In one related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. In a related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In other embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In a related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In one related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In a related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In one related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In a related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In other embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In one related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In a related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In a related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In one related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In other embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In a related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In one related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In one related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In one related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In other embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In one related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′430-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In one related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In a related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In one related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXX XXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In one related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In one related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers and underlined residues are 2′-O-methyl RNA monomers. The top strand is the sense strand, and the bottom strand is the antisense strand. In one related embodiment, the DsiRNA comprises:

5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In another related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group and “X”=2′-O-methyl RNA. The top strand is the sense strand, and the bottom strand is the antisense strand. In a further related embodiment, the DsiRNA comprises:

 5′-pXXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “p”=a phosphate group, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

The above modification patterns can also be incorporated into, e.g., the extended DsiRNA structures and mismatch and/or frayed DsiRNA structures described below.

In another embodiment, the DsiRNA comprises strands having equal lengths possessing 1-3 mismatched residues that serve to orient Dicer cleavage (specifically, one or more of positions 1, 2 or 3 on the first strand of the DsiRNA, when numbering from the 3′-terminal residue, are mismatched with corresponding residues of the 5′-terminal region on the second strand when first and second strands are annealed to one another). An exemplary 27mer DsiRNA agent with two terminal mismatched residues is shown:

5′-pXXXXXXXXXXXXXXXXXXXXXXXXX^(M) ^(M) -3′  3′-XXXXXXXXXXXXXXXXXXXXXXXXX_(M) _(Mp) -5′ wherein “X”=RNA, “p”=a phosphate group, “M”=Nucleic acid residues (RNA, DNA or non-natural or modified nucleic acids) that do not base pair (hydrogen bond) with corresponding “M” residues of otherwise complementary strand when strands are annealed. Any of the residues of such agents can optionally be 2′-O-methyl RNA monomers—alternating positioning of 2′-O-methyl RNA monomers that commences from the 3′-terminal residue of the bottom (second) strand, as shown for above asymmetric agents, can also be used in the above “blunt/fray” DsiRNA agent. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand.

In certain additional embodiments, the present invention provides compositions for RNA interference (RNAi) that possess one or more base paired deoxyribonucleotides within a region of a double stranded ribonucleic acid (dsRNA) that is positioned 3′ of a projected sense strand Dicer cleavage site and correspondingly 5′ of a projected antisense strand Dicer cleavage site. The compositions of the invention comprise a dsRNA which is a precursor molecule, i.e., the dsRNA of the present invention is processed in vivo to produce an active small interfering nucleic acid (siRNA). The dsRNA is processed by Dicer to an active siRNA which is incorporated into RISC.

In certain embodiments, the DsiRNA agents of the invention can have the following exemplary structures (noting that any of the following exemplary structures can be combined, e.g., with the bottom strand modification patterns of the above-described structures—in one specific example, the bottom strand modification pattern shown in any of the above structures is applied to the 27 most 3′ residues of the bottom strand of any of the following structures; in another specific example, the bottom strand modification pattern shown in any of the above structures upon the 23 most 3′ residues of the bottom strand is applied to the 23 most 3′ residues of the bottom strand of any of the following structures):

In one such embodiment, the DsiRNA comprises the following (an exemplary “right-extended”, “DNA extended” DsiRNA):

 5′-XXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N)DD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N)XX-5′ wherein “X”=RNA, “Y” is an optional overhang domain comprised of 0-10 RNA monomers that are optionally 2′-O-methyl RNA monomers—in certain embodiments, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, “D”=DNA, and “N”=1 to 50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand.

In a related embodiment, the DsiRNA comprises:

 5′-XXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N)DD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N)DD-5′ wherein “X”=RNA, “Y” is an optional overhang domain comprised of 0-10 RNA monomers that are optionally 2′-O-methyl RNA monomers—in certain embodiments, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, “D”=DNA, and “N”=1 to 50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand.

In an additional embodiment, the DsiRNA comprises:

 5′-XXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N)DD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N)ZZ-5′ wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an optional overhang domain comprised of 0-10 RNA monomers that are optionally 2′-O-methyl RNA monomers—in certain embodiments, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, “D”=DNA, “Z”=DNA or RNA, and “N”=1 to 50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand, with 2′-O-methyl RNA monomers located at alternating residues along the top strand, rather than the bottom strand presently depicted in the above schematic.

In another such embodiment, the DsiRNA comprises:

 5′-XXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N)DD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N)ZZ-5′ wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an optional overhang domain comprised of 0-10 RNA monomers that are optionally 2′-O-methyl RNA monomers—in certain embodiments, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, “D”=DNA, “Z”=DNA or RNA, and “N”=1 to 50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand, with 2′-O-methyl RNA monomers located at alternating residues along the top strand, rather than the bottom strand presently depicted in the above schematic.

In another such embodiment, the DsiRNA comprises:

 5′-XXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N)DD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N)ZZ-5′ wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an optional overhang domain comprised of 0-10 RNA monomers that are optionally 2′-O-methyl RNA monomers—in certain embodiments, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, “D”=DNA, “Z”=DNA or RNA, and “N”=1 to 50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand, with 2′-O-methyl RNA monomers located at alternating residues along the top strand, rather than the bottom strand presently depicted in the above schematic.

In another embodiment, the DsiRNA comprises:

 5′-XXXXXXXXXXXXXXXXXXXXXXXX_(N*)[X1/D1]_(N)DD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXX_(N*)[X2/D2]_(N)ZZ-5′ wherein “X”=RNA, “Y” is an optional overhang domain comprised of 0-10 RNA monomers that are optionally 2′-O-methyl RNA monomers—in certain embodiments, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, “D”=DNA, “Z”=DNA or RNA, and “N”=1 to 50 or more, but is optionally 1-8 or 1-10, where at least one D1_(N) is present in the top strand and is base paired with a corresponding D2_(N) in the bottom strand. Optionally, D1_(N) and D1_(N+1) are base paired with corresponding D2_(N) and D2_(N+1); D1_(N), D1_(N+1) and D1_(N+2) are base paired with corresponding D2_(N), D1_(N+1) and D1_(N+2), etc. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand, with 2′-O-methyl RNA monomers located at alternating residues along the top strand, rather than the bottom strand presently depicted in the above schematic.

In the structures depicted herein, the 5′ end of either the sense strand or antisense strand can optionally comprise a phosphate group.

In another embodiment, the DNA:DNA-extended DsiRNA comprises strands having equal lengths possessing 1-3 mismatched residues that serve to orient Dicer cleavage (specifically, one or more of positions 1, 2 or 3 on the first strand of the DsiRNA, when numbering from the 3′-terminal residue, are mismatched with corresponding residues of the 5′-terminal region on the second strand when first and second strands are annealed to one another). An exemplary DNA:DNA-extended DsiRNA agent with two terminal mismatched residues is shown:

5′-XXXXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N) ^(M) ^(M-3′) 3′-XXXXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N) _(MM-5′)                                               wherein “X”=RNA, “M”=Nucleic acid residues (RNA, DNA or non-natural or modified nucleic acids) that do not base pair (hydrogen bond) with corresponding “M” residues of otherwise complementary strand when strands are annealed, “D”=DNA and “N”=1 to 50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. Any of the residues of such agents can optionally be 2′-O-methyl RNA monomers—alternating positioning of 2′-O-methyl RNA monomers that commences from the 3′-terminal residue of the bottom (second) strand, as shown for above asymmetric agents, can also be used in the above “blunt/fray” DsiRNA agent. In one embodiment, the top strand (first strand) is the sense strand, and the bottom strand (second strand) is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand. Modification and DNA:DNA extension patterns paralleling those shown above for asymmetric/overhang agents can also be incorporated into such “blunt/frayed” agents.

In one embodiment, a length-extended DsiRNA agent is provided that comprises deoxyribonucleotides positioned at sites modeled to function via specific direction of Dicer cleavage, yet which does not require the presence of a base-paired deoxyribonucleotide in the dsRNA structure. An exemplary structure for such a molecule is shown:

 5′-XXXXXXXXXXXXXXXXXXXDDXX-3′ 3′-YXXXXXXXXXXXXXXXXXDDXXXX-5′ wherein “X”=RNA, “Y” is an optional overhang domain comprised of 0-10 RNA monomers that are optionally 2′-O-methyl RNA monomers—in certain embodiments, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, and “D”=DNA. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand. The above structure is modeled to force Dicer to cleave a minimum of a 21mer duplex as its primary post-processing form. In embodiments where the bottom strand of the above structure is the antisense strand, the positioning of two deoxyribonucleotide residues at the ultimate and penultimate residues of the 5′ end of the antisense strand is likely to reduce off-target effects (as prior studies have shown a 2′-O-methyl modification of at least the penultimate position from the 5′ terminus of the antisense strand to reduce off-target effects; see, e.g., US 2007/0223427).

In one embodiment, the DsiRNA comprises the following (an exemplary “left-extended”, “DNA extended” DsiRNA):

5′-DNXXXXXXXXXXXXXXXXXXXXXXXX_(N*)Y-3′ 3′-DNXXXXXXXXXXXXXXXXXXXXXXXX_(N*)-5′ wherein “X”=RNA, “Y” is an optional overhang domain comprised of 0-10 RNA monomers that are optionally 2′-O-methyl RNA monomers—in certain embodiments, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, “D”=DNA, and “N”=1 to 50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand.

In a related embodiment, the DsiRNA comprises:

5′-D_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N*)DD-3′ 3′-D_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N*)XX-5′ wherein “X”=RNA, optionally a 2′-O-methyl RNA monomers “D”=DNA, “N”=1 to 50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand.

In an additional embodiment, the DsiRNA comprises:

5′-D_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N*)DD-3′ 3′-D_(N) XXXXXXXXXXXXXXXXXXXXXXXX_(N*)ZZ-5′ wherein “X”=RNA, optionally a 2′-O-methyl RNA monomers “D”=DNA, “N”=1 to 50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. “Z”=DNA or RNA. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand, with 2′-O-methyl RNA monomers located at alternating residues along the top strand, rather than the bottom strand presently depicted in the above schematic.

In another such embodiment, the DsiRNA comprises:

5′-D_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N*)DD-3′ 3′-D_(N) XXXXXXXXXXXXXXXXXXXXXXXX_(N*)ZZ-5′ wherein “X”=RNA, optionally a 2′-O-methyl RNA monomers “D”=DNA, “N”=1 to 50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. “Z”=DNA or RNA. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand, with 2′-O-methyl RNA monomers located at alternating residues along the top strand, rather than the bottom strand presently depicted in the above schematic.

In another such embodiment, the DsiRNA comprises:

5′-D_(N)ZZXXXXXXXXXXXXXXXXXXXXXXXX_(N*)DD-3′ 3′-D_(N) XXXXXXXXXXXXXXXXXXXXXXXXXX_(N*)ZZ-5′ wherein “X”=RNA, “X”=2′-O-methyl RNA, “D”=DNA, “Z”=DNA or RNA, and “N”=1 to 50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand, with 2′-O-methyl RNA monomers located at alternating residues along the top strand, rather than the bottom strand presently depicted in the above schematic.

In another such embodiment, the DsiRNA comprises:

5′-D_(N)ZZXXXXXXXXXXXXXXXXXXXXXXXX_(N*)Y-3′ 3′-D_(N) XXXXXXXXXXXXXXXXXXXXXXXXXX_(N*)-5′ wherein “X”=RNA, “X”=2′-O-methyl RNA, “D”=DNA, “Z”=DNA or RNA, and “N”=1 to 50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. “Y” is an optional overhang domain comprised of 0-10 RNA monomers that are optionally 2′-O-methyl RNA monomers—in certain embodiments, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand, with 2′-O-methyl RNA monomers located at alternating residues along the top strand, rather than the bottom strand presently depicted in the above schematic.

In another embodiment, the DsiRNA comprises:

5′-[X1/D1]_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N*)DD-3′ 3′-[X2/D2]_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N*)ZZ-5′ wherein “X”=RNA, “D”=DNA, “Z”=DNA or RNA, and “N”=1 to 50 or more, but is optionally 1-8 or 1-10, where at least one D1_(N) is present in the top strand and is base paired with a corresponding D2_(N) in the bottom strand. Optionally, D1_(N) and D1_(N+1) are base paired with corresponding D2_(N) and D2_(N+1); D1_(N), D1_(N+1) and D1_(N+2) are base paired with corresponding D2_(N), D1_(N+1) and D1_(N+2), etc. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand, with 2′-O-methyl RNA monomers located at alternating residues along the top strand, rather than the bottom strand presently depicted in the above schematic.

In a related embodiment, the DsiRNA comprises:

5′-[X1/D1]_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N*)Y-3′ 3′-[X2/D2]_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N*)-5′ wherein “X”=RNA, “D”=DNA, “Y” is an optional overhang domain comprised of 0-10 RNA monomers that are optionally 2′-O-methyl RNA monomers—in certain embodiments, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, and “N”=1 to 50 or more, but is optionally 1-8 or 1-10, where at least one D1_(N) is present in the top strand and is base paired with a corresponding D2_(N) in the bottom strand. Optionally, D1_(N) and D1_(N+1) are base paired with corresponding D2_(N) and D2_(N+1); D1_(N), D1_(N+1) and D1_(N+2) are base paired with corresponding D2_(N), D1_(N+1) and D1_(N+2), etc. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand, with 2′-O-methyl RNA monomers located at alternating residues along the top strand, rather than the bottom strand presently depicted in the above schematic.

In another embodiment, the DNA:DNA-extended DsiRNA comprises strands having equal lengths possessing 1-3 mismatched residues that serve to orient Dicer cleavage (specifically, one or more of positions 1, 2 or 3 on the first strand of the DsiRNA, when numbering from the 3′-terminal residue, are mismatched with corresponding residues of the 5′-terminal region on the second strand when first and second strands are annealed to one another). An exemplary DNA:DNA-extended DsiRNA agent with two terminal mismatched residues is shown:

5′-D_(N)XXXXXXXXXXXXXXXXXXXXXXXXXX_(N*) ^(M) ^(M) -3′ 3′-D_(N)XXXXXXXXXXXXXXXXXXXXXXXXXX_(N*) _(M) _(M) -5′ wherein “X”=RNA, “M”=Nucleic acid residues (RNA, DNA or non-natural or modified nucleic acids) that do not base pair (hydrogen bond) with corresponding “M” residues of otherwise complementary strand when strands are annealed, “D”=DNA and “N”=1 to 50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. Any of the residues of such agents can optionally be 2′-O-methyl RNA monomers—alternating positioning of 2′-O-methyl RNA monomers that commences from the 3′-terminal residue of the bottom (second) strand, as shown for above asymmetric agents, can also be used in the above “blunt/fray” DsiRNA agent. In one embodiment, the top strand (first strand) is the sense strand, and the bottom strand (second strand) is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand. Modification and DNA:DNA extension patterns paralleling those shown above for asymmetric/overhang agents can also be incorporated into such “blunt/frayed” agents.

In another embodiment, a length-extended DsiRNA agent is provided that comprises deoxyribonucleotides positioned at sites modeled to function via specific direction of Dicer cleavage, yet which does not require the presence of a base-paired deoxyribonucleotide in the dsRNA structure. An exemplary structure for such a molecule is shown:

5′-XXDDXXXXXXXXXXXXXXXXXXXX_(N*)Y-3′ 3′-DDXXXXXXXXXXXXXXXXXXXXXX_(N*)-5′ wherein “X”=RNA, “Y” is an optional overhang domain comprised of 0-10 RNA monomers that are optionally 2′-O-methyl RNA monomers—in certain embodiments, “Y” is an overhang domain comprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, and “D”=DNA. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strand is the sense strand, and the bottom strand is the antisense strand. Alternatively, the bottom strand is the sense strand and the top strand is the antisense strand. The above structure is modeled to force Dicer to cleave a minimum of a 21mer duplex as its primary post-processing form. In embodiments where the bottom strand of the above structure is the antisense strand, the positioning of two deoxyribonucleotide residues at the ultimate and penultimate residues of the 5′ end of the antisense strand is likely to reduce off-target effects (as prior studies have shown a 2′-O-methyl modification of at least the penultimate position from the 5′ terminus of the antisense strand to reduce off-target effects; see, e.g., US 2007/0223427).

In certain embodiments, the “D” residues of the above structures include at least one PS-DNA or PS-RNA. Optionally, the “D” residues of the above structures include at least one modified nucleotide that inhibits Dicer cleavage.

While the above-described “DNA-extended” DsiRNA agents can be categorized as either “left extended” or “right extended”, DsiRNA agents comprising both left- and right-extended DNA-containing sequences within a single agent (e.g., both flanks surrounding a core dsRNA structure are dsDNA extensions) can also be generated and used in similar manner to those described herein for “right-extended” and “left-extended” agents.

In some embodiments, the DsiRNA of the instant invention further comprises a linking moiety or domain that joins the sense and antisense strands of a DNA:DNA-extended DsiRNA agent. Optionally, such a linking moiety domain joins the 3′ end of the sense strand and the 5′ end of the antisense strand. The linking moiety may be a chemical (non-nucleotide) linker, such as an oligomethylenediol linker, oligoethylene glycol linker, or other art-recognized linker moiety. Alternatively, the linker can be a nucleotide linker, optionally including an extended loop and/or tetraloop.

In one embodiment, the DsiRNA agent has an asymmetric structure, with the sense strand having a 25-base pair length, and the antisense strand having a 27-base pair length with a 1-4 base 3′-overhang (e.g., a one base 3′-overhang, a two base 3′-overhang, a three base 3′-overhang or a four base 3′-overhang). In another embodiment, this DsiRNA agent has an asymmetric structure further containing 2 deoxynucleotides at the 3′ end of the sense strand.

In another embodiment, the DsiRNA agent has an asymmetric structure, with the antisense strand having a 25-base pair length, and the sense strand having a 27-base pair length with a 1-4 base 3′-overhang (e.g., a one base 3′-overhang, a two base 3′-overhang, a three base 3′-overhang or a four base 3′-overhang). In another embodiment, this DsiRNA agent has an asymmetric structure further containing 2 deoxynucleotides at the 3′ end of the antisense strand.

Exemplary KRAS targeting DsiRNA agents of the invention include the following: KRAS-355 Target Site

  5′-CAGGUCAAGAGGAGUACAGUGCAau-3′ (SEQ ID NO: 5; DP1148P) 3′-UCGUCCAGUUCUCCUCAUGUCACGUUA-5′ (SEQ ID NO: 14; DP1151G) 5′-AGCAGGUCAAGAGGAGUACAGUGCAAU-3′ (SEQ ID NO: 6; DP1149P) 3′-UCGUCCAGUUCUCCUCAUGUCACGUUA-5′ (SEQ ID NO: 14; DP1151G) 5′-AGCAGGUCAAGAGGAGUACAGUGCA^(U) ^(A) -3′ (SEQ ID NO: 7; DP1150P) 3′-UCGUCCAGUUCUCCUCAUGUCACGU_(U) _(A) -5' (SEQ ID NO: 14; DP1151G)

KRAS-940 Target Site

  5′-UUAGCAUUUGUUUUAGCAUUACCta-3′ (SEQ ID NO: 8; DP1136P) 3′-AUAAUCGUAAACAAAAUCGUAAUGGAU-5′ (SEQ ID NO: 43; DP1139G) 5′-UAUUAGCAUUUGUUUUAGCAUUACCUA-3′ (SEQ ID NO: 9; DP1137P) 3′-AUAAUCGUAAACAAAAUCGUAAUGGAU-5′ (SEQ ID NO: 43; DP1139G) 5′-UAUUAGCAUUUGUUUUAGCAUUACC^(C) ^(C) -3' (SEQ ID NO: 10; DP1145P) 3′-AUAAUCGUAAACAAAAUCGUAAUGG_(A) _(U) -5' (SEQ ID NO: 43; DP1139G)

KRAS-355*Alternative (Polymorphic) Target Site

  5′-CAGGUCAUGAGGAGUACAGUGCAau-3′ (SEQ ID NO: 132) 3′-UCGUCCAGUACUCCUCAUGUCACGUUA-5′ (SEQ ID NO: 138) 5′-AGCAGGUCAUGAGGAGUACAGUGCAAU-3′ (SEQ ID NO: 187) 3′-UCGUCCAGUACUCCUCAUGUCACGUUA-5′ (SEQ ID NO: 138) 5′-AGCAGGUCAUGAGGAGUACAGUGCA^(U) ^(A) -3′ (SEQ ID NO: 188) 3′-UCGUCCAGUACUCCUCAUGUCACGU_(U) _(A) -5′ (SEQ ID NO: 138)

Other exemplary KRAS targeting DsiRNA agents of the invention include the following:

Lengthy table referenced here US20110021604A1-20110127-T00001 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20110021604A1-20110127-T00002 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20110021604A1-20110127-T00003 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20110021604A1-20110127-T00004 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20110021604A1-20110127-T00005 Please refer to the end of the specification for access instructions. Projected 21mer target sequences for each DsiRNA are shown in Table 7.

TABLE 7  DsiRNA Target Sequences (21 mers) KRAS-204 Target: 5′-TAGTTGGAGCTGGTGGCGTAG-3′ (SEQ ID NO: 6843) KRAS-204* Target: 5′-TAGTTGGAGCTGTTGGCGTAG-3′ (SEQ ID NO: 6844) KRAS-341 Target: 5′-GATATTCTCGACACAGCAGGT-3′ (SEQ ID NO: 6845) KRAS-341* Target: 5′-GATATTCTCGACACAGCAGGT-3′ (SEQ ID NO: 6846) KRAS-343 Target: 5′-TATTCTCGACACAGCAGGTCA-3′ (SEQ ID NO: 6847) KRAS-343* Target: 5′-TATTCTCGACACAGCAGGTCA-3′ (SEQ ID NO: 6848) KRAS-355 Target: 5′-AGCAGGTCAAGAGGAGTACAG-3′ (SEQ ID NO: 6849) KRAS-355* Target: 5′-AGCAGGTCATGAGGAGTACAG-3′ (SEQ ID NO: 6850) KRAS-361 Target: 5′-TCAAGAGGAGTACAGTGCAAT-3′ (SEQ ID NO: 6851) KRAS-361* Target: 5′-TCATGAGGAGTACAGTGCAAT-3′ (SEQ ID NO: 6852) KRAS-371 Target: 5′-TACAGTGCAATGAGGGACCAG-3′ (SEQ ID NO: 6853) KRAS-401 Target: 5′-ACTGGGGAGGGCTTTCTTTGT-3′ (SEQ ID NO: 6854) KRAS-404 Target: 5′-GGGGAGGGCTTTCTTTGTGTA-3′ (SEQ ID NO: 6855) KRAS-406 Target: 5′-GGAGGGCTTTCTTTGTGTATT-3′ (SEQ ID NO: 6856) KRAS-410 Target: 5′-GGCTTTCTTTGTGTATTTGCC-3′ (SEQ ID NO: 6857) KRAS-415 Target: 5′-TCTTTGTGTATTTGCCATAAA-3′ (SEQ ID NO: 6858) KRAS-416 Target: 5′-CTTTGTGTATTTGCCATAAAT-3′ (SEQ ID NO: 6859) KRAS-417 Target: 5′-TTTGTGTATTTGCCATAAATA-3′ (SEQ ID NO: 6860) KRAS-418 Target: 5′-TTGTGTATTTGCCATAAATAA-3′ (SEQ ID NO: 6861) KRAS-419 Target: 5′-TGTGTATTTGCCATAAATAAT-3′ (SEQ ID NO: 6862) KRAS-420 Target: 5′-GTGTATTTGCCATAAATAATA-3′ (SEQ ID NO: 6863) KRAS-429 Target: 5′-CCATAAATAATACTAAATCAT-3′ (SEQ ID NO: 6864) KRAS-434 Target: 5′-AATAATACTAAATCATTTGAA-3′ (SEQ ID NO: 6865) KRAS-438 Target: 5′-ATACTAAATCATTTGAAGATA-3′ (SEQ ID NO: 6866) KRAS-440 Target: 5′-ACTAAATCATTTGAAGATATT-3′ (SEQ ID NO: 6867) KRAS-445 Target: 5′-ATCATTTGAAGATATTCACCA-3′ (SEQ ID NO: 6868) KRAS-450 Target: 5′-TTGAAGATATTCACCATTATA-3′ (SEQ ID NO: 6869) KRAS-452 Target: 5′-GAAGATATTCACCATTATAGA-3′ (SEQ ID NO: 6870) KRAS-508 Target: 5′-ACCTATGGTCCTAGTAGGAAA-3′ (SEQ ID NO: 6871) KRAS-534 Target: 5′-GTGATTTGCCTTCTAGAACAG-3′ (SEQ ID NO: 6872) KRAS-760 Target: 5′-TTGATGATGCCTTCTATACAT-3′ (SEQ ID NO: 6873) KRAS-776 Target: 5′-TACATTAGTTCGAGAAATTCG-3′ (SEQ ID NO: 6874) KRAS-786 Target: 5′-CGAGAAATTCGAAAACATAAA-3′ (SEQ ID NO: 6875) KRAS-795 Target: 5′-CGAAAACATAAAGAAAAGATG-3′ (SEQ ID NO: 6876) KRAS-800 Target: 5′-ACATAAAGAAAAGATGAGCAA-3′ (SEQ ID NO: 6877) KRAS-800* Target: 5′-ACATAAAGAAAAGATGAGCAA-3′ (SEQ ID NO: 6878) KRAS-920 Target: 5′-TTTTGTACATTACACTAAATT-3′ (SEQ ID NO: 6879) KRAS-935 Target: 5′-TAAATTATTAGCATTTGTTTT-3′ (SEQ ID NO: 6880) KRAS-940 Target: 5′-TATTAGCATTTGTTTTAGCAT-3′ (SEQ ID NO: 6881) KRAS-1032 Target: 5′-GAAGTTTTTTTTTCCTCTAAG-3′ (SEQ ID NO: 6882) KRAS-1048 Target: 5′-CTAAGTGCCAGTATTCCCAGA3′ (SEQ ID NO: 6883) KRAS-1188 Target: 5′-TTGGTGTGAAACAAATTAATG-3′ (SEQ ID NO: 6884) KRAS-1256 Target: 5′-GGATTAATTACTAATTTCAGT-3′ (SEQ ID NO: 6885) KRAS-1634 Target: 5′-GCTATATTTACATGCTACTAA-3′ (SEQ ID NO: 6886) KRAS-5134 Target: 5′-ATTTTAACTATTTTTGTATAG-3′ (SEQ ID NO: 6887) KRAS-5208 Target: 5′-TGCAGTGTGATCCAGTTGTTT-3′ (SEQ ID NO: 6888) KRAS-174 Target: 5′-TGCTGAAAATGACTGAATATA-3′ (SEQ ID NO: 6889) KRAS-180 Target: 5′-AAATGACTGAATATAAACTTG-3′ (SEQ ID NO: 6890) KRAS-184 Target: 5′-GACTGAATATAAACTTGTGGT-3′ (SEQ ID NO: 6891) KRAS-246 Target: 5′-AGCTAATTCAGAATCATTTTG-3′ (SEQ ID NO: 6892) KRAS-270 Target: 5′-ACGAATATGATCCAACAATAG-3′ (SEQ ID NO: 6893) KRAS-306 Target: 5′-AGCAAGTAGTAATTGATGGAG-3′ (SEQ ID NO: 6894) KRAS-406 Target: 5′-GGAGGGCTTTCTTTGTGTATT-3′ (SEQ ID NO: 6895) KRAS-415 Target: 5′-TCTTTGTGTATTTGCCATAAA-3′ (SEQ ID NO: 6896) KRAS-416 Target: 5′-CTTTGTGTATTTGCCATAAAT-3′ (SEQ ID NO: 6897) KRAS-417 Target: 5′-TTTGTGTATTTGCCATAAATA-3′ (SEQ ID NO: 6898) KRAS-418 Target: 5′-TTGTGTATTTGCCATAAATAA-3′ (SEQ ID NO: 6899) KRAS-422 Target: 5′-GTATTTGCCATAAATAATACT-3′ (SEQ ID NO: 6900) KRAS-423 Target: 5′-TATTTGCCATAAATAATACTA73′ (SEQ ID NO: 6901) KRAS-429 Target: 5′-CCATAAATAATACTAAATCAT-3′ (SEQ ID NO: 6902) KRAS-430 Target: 5′-CATAAATAATACTAAATCATT-3′ (SEQ ID NO: 6903) KRAS-432 Target: 5′-TAAATAATACTAAATCATTTG-3′ (SEQ ID NO: 6904) KRAS-433 Target: 5′-AAATAATACTAAATCATTTGA-3′ (SEQ ID NO: 6905) KRAS-434 Target: 5′-AATAATACTAAATCATTTGAA-3′ (SEQ ID NO: 6906) KRAS-435 Target: 5′-ATAATACTAAATCATTTGAAG-3′ (SEQ ID NO: 6907) KRAS-448 Target: 5′-ATTTGAAGATATTCACCATTA-3′ (SEQ ID NO: 6908) KRAS-450 Target: 5′-TTGAAGATATTCACCATTATA-3′ (SEQ ID NO: 6909) KRAS-451 Target: 5′-TGAAGATATTCACCATTATAG-3′ (SEQ ID NO: 6910) KRAS-452 Target: 5′-GAAGATATTCACCATTATAGA-3′ (SEQ ID NO: 6911) KRAS-453 Target: 5′-AAGATATTCACCATTATAGAG-3′ (SEQ ID NO: 6912) KRAS-463 Target: 5′-CCATTATAGAGAACAAATTAA-3′ (SEQ ID NO: 6913) KRAS-465 Target: 5′-ATTATAGAGAACAAATTAAAA-3′ (SEQ ID NO: 6914) KRAS-466 Target: 5′-TTATAGAGAACAAATTAAAAG-3′ (SEQ ID NO: 6915) KRAS-467 Target: 5′-TATAGAGAACAAATTAAAAGA-3′ (SEQ ID NO: 6916) KRAS-468 Target: 5′-ATAGAGAACAAATTAAAAGAG-3′ (SEQ ID NO: 6917) KRAS-518 Target: 5′-CTAGTAGGAAATAAATGTGAT-3′ (SEQ ID NO: 6918) KRAS-519 Target: 5′-TAGTAGGAAATAAATGTGATT-3′ (SEQ ID NO: 6919) KRAS-583 Target: 5′-AAGAAGTTATGGAATTCCTTT-3′ (SEQ ID NO: 6920) KRAS-586 Target: 5′-AAGTTATGGAATTCCTTTTAT-3′ (SEQ ID NO: 6921) KRAS-587 Target: 5′-AGTTATGGAATTCCTTTTATT-3′ (SEQ ID NO: 6922) KRAS-588 Target: 5′-GTTATGGAATTCCTTTTATTG-3′ (SEQ ID NO: 6923) KRAS-589 Target: 5′-TTATGGAATTCCTTTTATTGA-3′ (SEQ ID NO: 6924) KRAS-636 Target: 5′-TGGAGGATGCTTTTTATACAT-3′ (SEQ ID NO: 6925) KRAS-638 Target: 5′-GAGGATGCTTTTTATACATTG-3′ (SEQ ID NO: 6926) KRAS-678 Target: 5′-ACAGATTGAAAAAAATCAGCA-3′ (SEQ ID NO: 6927) KRAS-679 Target: 5′-CAGATTGAAAAAAATCAGCAA-3′ (SEQ ID NO: 6928) KRAS-681 Target: 5′-GATTGAAAAAAATCAGCAAAG-3′ (SEQ ID NO: 6929) KRAS-682 Target: 5′-ATTGAAAAAAATCAGCAAAGA-3′ (SEQ ID NO: 6930) KRAS-683 Target: 5′-TTGAAAAAAATCAGCAAAGAA-3′ (SEQ ID NO: 6931) KRAS-684 Target: 5′-TGAAAAAAATCAGCAAAGAAG-3′ (SEQ ID NO: 6932) KRAS-712 Target: 5′-TCCTGGCTGTGTGAAAATTAA-3′ (SEQ ID NO: 6933) KRAS-716 Target: 5′-GGCTGTGTGAAAATTAAAAAA-3′ (SEQ ID NO: 6934) KRAS-720 Target: 5′-GTGTGAAAATTAAAAAATGCA-3′ (SEQ ID NO: 6935) KRAS-721 Target: 5′-TGTGAAAATTAAAAAATGCAT-3′ (SEQ ID NO: 6936) KRAS-722 Target: 5′-GTGAAAATTAAAAAATGCATT-3′ (SEQ ID NO: 6937) KRAS-723 Target: 5′-TGAAAATTAAAAAATGCATTA-3′ (SEQ ID NO: 6938) KRAS-725 Target: 5′-AAAATTAAAAAATGCATTATA-3′ (SEQ ID NO: 6939) KRAS-726 Target: 5′-AAATTAAAAAATGCATTATAA-3′ (SEQ ID NO: 6940) KRAS-727 Target: 5′-AATTAAAAAATGCATTATAAT-3′ (SEQ ID NO: 6941) KRAS-728 Target: 5′-ATTAAAAAATGCATTATAATG-3′ (SEQ ID NO: 6942) KRAS-730 Target: 5′-TAAAAAATGCATTATAATGTA-3′ (SEQ ID NO: 6943) KRAS-737 Target: 5′-TGCATTATAATGTAATCTGGG-3′ (SEQ ID NO: 6944) KRAS-784 Target: 5′-TTCGAGAAATTCGAAAACATA-3′ (SEQ ID NO: 6945) KRAS-785 Target: 5′-TCGAGAAATTCGAAAACATAA-3′ (SEQ ID NO: 6946) KRAS-786 Target: 5′-CGAGAAATTCGAAAACATAAA-3′ (SEQ ID NO: 6947) KRAS-789 Target: 5′-GAAATTCGAAAACATAAAGAA-3′ (SEQ ID NO: 6948) KRAS-794 Target: 5′-TCGAAAACATAAAGAAAAGAT-3′ (SEQ ID NO: 6949) KRAS-795 Target: 5′-CGAAAACATAAAGAAAAGATG-3′ (SEQ ID NO: 6950) KRAS-819 Target: 5′-AAAGATGGTAAAAAGAAGAAA-3′ (SEQ ID NO: 6951) KRAS-820 Target: 5′-AAGATGGTAAAAAGAAGAAAA-3′ (SEQ ID NO: 6952) KRAS-822 Target: 5′-GATGGTAAAAAGAAGAAAAAG-3′ (SEQ ID NO: 6953) KRAS-823 Target: 5′-ATGGTAAAAAGAAGAAAAAGA-3′ (SEQ ID NO: 6954) KRAS-828 Target: 5′-AAAAAGAAGAAAAAGAAGTCA-3′ (SEQ ID NO: 6955) KRAS-829 Target: 5′-AAAAGAAGAAAAAGAAGTCAA-3′ (SEQ ID NO: 6956) KRAS-830 Target: 5′-AAAGAAGAAAAAGAAGTCAAA-3′ (SEQ ID NO: 6957) KRAS-846 Target: 5′-TCAAAGACAAAGTGTGTAATT-3′ (SEQ ID NO: 6958) KRAS-847 Target: 5′-CAAAGACAAAGTGTGTAATTA-3′ (SEQ ID NO: 6959) KRAS-851 Target: 5′-GACAAAGTGTGTAATTATGTA-3′ (SEQ ID NO: 6960) KRAS-853 Target: 5′-CAAAGTGTGTAATTATGTAAA-3′ (SEQ ID NO: 6961) KRAS-857 Target: 5′-GTGTGTAATTATGTAAATACA-3′ (SEQ ID NO: 6962) KRAS-859 Target: 5′-GTGTAATTATGTAAATACAAT-3′ (SEQ ID NO: 6963) KRAS-861 Target: 5′-GTAATTATGTAAATACAATTT-3′ (SEQ ID NO: 6964) KRAS-862 Target: 5′-TAATTATGTAAATACAATTTG-3′ (SEQ ID NO: 6965) KRAS-866 Target: 5′-TATGTAAATACAATTTGTACT-3′ (SEQ ID NO: 6966) KRAS-867 Target: 5′-ATGTAAATACAATTTGTACTT-3′ (SEQ ID NO: 6967) KRAS-868 Target: 5′-TGTAAATACAATTTGTACTTT-3′ (SEQ ID NO: 6968) KRAS-869 Target: 5′-GTAAATACAATTTGTACTTTT-3′ (SEQ ID NO: 6969) KRAS-875 Target: 5′-ACAATTTGTACTTTTTTCTTA-3′ (SEQ ID NO: 6970) KRAS-876 Target: 5′-CAATTTGTACTTTTTTCTTAA-3′ (SEQ ID NO: 6971) KRAS-901 Target: 5′-TACTAGTACAAGTGGTAATTT-3′ (SEQ ID NO: 6972) KRAS-902 Target: 5′-ACTAGTACAAGTGGTAATTTT-3′ (SEQ ID NO: 6973) KRAS-908 Target: 5′-ACAAGTGGTAATTTTTGTACA-3′ (SEQ ID NO: 6974) KRAS-909 Target: 5′-CAAGTGGTAATTTTTGTACAT-3′ (SEQ ID NO: 6975) KRAS-916 Target: 5′-TAATTTTTGTACATTACACTA-3′ (SEQ ID NO: 6976) KRAS-917 Target: 5′-AATTTTTGTACATTACACTAA-3′ (SEQ ID NO: 6977) KRAS-918 Target: 5′-ATTTTTGTACATTACACTAAA-3′ (SEQ ID NO: 6978) KRAS-919 Target: 5′-TTTTTGTACATTACACTAAAT-3′ (SEQ ID NO: 6979) KRAS-920 Target: 5′-TTTTGTACATTACACTAAATT-3′ (SEQ ID NO: 6980) KRAS-932 Target: 5′-CACTAAATTATTAGCATTTGT-3′ (SEQ ID NO: 6981) KRAS-934 Target: 5′-CTAAATTATTAGCATTTGTTT-3′ (SEQ ID NO: 6982) KRAS-935 Target: 5′-TAAATTATTAGCATTTGTTTT-3′ (SEQ ID NO: 6983) KRAS-940 Target: 5′-TATTAGCATTTGTTTTAGCAT-3′ (SEQ ID NO: 6984) KRAS-946 Target: 5′-CATTTGTTTTAGCATTACCTA-3′ (SEQ ID NO: 6985) KRAS-947 Target: 5′-ATTTGTTTTAGCATTACCTAA-3′ (SEQ ID NO: 6986) KRAS-949 Target: 5′-TTGTTTTAGCATTACCTAATT-3′ (SEQ ID NO: 6987) KRAS-950 Target: 5′-TGTTTTAGCATTACCTAATTT-3′ (SEQ ID NO: 6988) KRAS-951 Target: 5′-GTTTTAGCATTACCTAATTTT-3′ (SEQ ID NO: 6989) KRAS-952 Target: 5′-TTTTAGCATTACCTAATTTTT-3′ (SEQ ID NO: 6990) KRAS-988 Target: 5′-GACTGTTAGCTTTTACCTTAA-3′ (SEQ ID NO: 6991) KRAS-989 Target: 5′-ACTGTTAGCTTTTACCTTAAA-3′ (SEQ ID NO: 6992) KRAS-995 Target: 5′-AGCTTTTACCTTAAATGCTTA-3′ (SEQ ID NO: 6993) KRAS-996 Target: 5′-GCTTTTACCTTAAATGCTTAT-3′ (SEQ ID NO: 6994) KRAS-997 Target: 5′-CTTTTACCTTAAATGCTTATT-3′ (SEQ ID NO: 6995) KRAS-1003 Target: 5′-CCTTAAATGCTTATTTTAAAA-3′ (SEQ ID NO: 6996) KRAS-1004 Target: 5′-CTTAAATGCTTATTTTAAAAT-3′ (SEQ ID NO: 6997) KRAS-1010 Target: 5′-TGCTTATTTTAAAATGACAGT-3′ (SEQ ID NO: 6998) KRAS-1012 Target: 5′-CTTATTTTAAAATGACAGTGG-3′ (SEQ ID NO: 6999) KRAS-1029 Target: 5′-GTGGAAGTTTTTTTTTCCTCT-3′ (SEQ ID NO: 7000) KRAS-1031 Target: 5′-GGAAGTTTTTTTTTCCTCTAA-3′ (SEQ ID NO: 7001) KRAS-1032 Target: 5′-GAAGTTTTTTTTTCCTCTAAG-3′ (SEQ ID NO: 7002) KRAS-1070 Target: 5′-TTTTGGTTTTTGAACTAGCAA-3′ (SEQ ID NO: 7003) KRAS-1092 Target: 5′-GCCTGTGAAAAAGAAACTGAA-3′ (SEQ ID NO: 7004) KRAS-1099 Target: 5′-AAAAAGAAACTGAATACCTAA-3′ (SEQ ID NO: 7005) KRAS-1100 Target: 5′-AAAAGAAACTGAATACCTAAG-3′ (SEQ ID NO: 7006) KRAS-1106 Target: 5′-AACTGAATACCTAAGATTTCT-3′ (SEQ ID NO: 7007) KRAS-1147 Target: 5′-TGCAGTTGATTACTTCTTATT-3′ (SEQ ID NO: 7008) KRAS-1148 Target: 5′-GCAGTTGATTACTTCTTATTT-3′ (SEQ ID NO: 7009) KRAS-1152 Target: 5′-TTGATTACTTCTTATTTTTCT-3′ (SEQ ID NO: 7010) KRAS-1160 Target: 5′-TTCTTATTTTTCTTACCAATT-3′ (SEQ ID NO: 7011) KRAS-1161 Target: 5′-TCTTATTTTTCTTACCAATTG-3′ (SEQ ID NO: 7012) KRAS-1162 Target: 5′-CTTATTTTTCTTACCAATTGT-3′ (SEQ ID NO: 7013) KRAS-1185 Target: 5′-ATGTTGGTGTGAAACAAATTA-3′ (SEQ ID NO: 7014) KRAS-1188 Target: 5′-TTGGTGTGAAACAAATTAATG-3′ (SEQ ID NO: 7015) KRAS-1189 Target: 5′-TGGTGTGAAACAAATTAATGA-3′ (SEQ ID NO: 7016) KRAS-1197 Target: 5′-AACAAATTAATGAAGCTTTTG-3′ (SEQ ID NO: 7017) KRAS-1198 Target: 5′-ACAAATTAATGAAGCTTTTGA-3′ (SEQ ID NO: 7018) KRAS-1230 Target: 5′-TCTGTGTTTTATCTAGTCACA-3′ (SEQ ID NO: 7019) KRAS-1231 Target: 5′-CTGTGTTTTATCTAGTCACAT-3′ (SEQ ID NO: 7020) KRAS-1234 Target: 5′-TGTTTTATCTAGTCACATAAA-3′ (SEQ ID NO: 7021) KRAS-1235 Target: 5′-GTTTTATCTAGTCACATAAAT-3′ (SEQ ID NO: 7022) KRAS-1240 Target: 5′-ATCTAGTCACATAAATGGATT-3′ (SEQ ID NO: 7023) KRAS-1241 Target: 5′-TCTAGTCACATAAATGGATTA-3′ (SEQ ID NO: 7024) KRAS-1249 Target: 5′-CATAAATGGATTAATTACTAA-3′ (SEQ ID NO: 7025) KRAS-1250 Target: 5′-ATAAATGGATTAATTACTAAT-3′ (SEQ ID NO: 7026) KRAS-1255 Target: 5′-TGGATTAATTACTAATTTCAG-3′ (SEQ ID NO: 7027) KRAS-1257 Target: 5′-GATTAATTACTAATTTCAGTT-3′ (SEQ ID NO: 7028) KRAS-1258 Target: 5′-ATTAATTACTAATTTCAGTTG-3′ (SEQ ID NO: 7029) KRAS-1259 Target: 5′-TTAATTACTAATTTCAGTTGA-3′ (SEQ ID NO: 7030) KRAS-1287 Target: 5′-TAATTGGTTTTTACTGAAACA-3′ (SEQ ID NO: 7031) KRAS-1291 Target: 5′-TGGTTTTTACTGAAACATTGA-3′ (SEQ ID NO: 7032) KRAS-1292 Target: 5′-GGTTTTTACTGAAACATTGAG-3′ (SEQ ID NO: 7033) KRAS-1307 Target: 5′-ATTGAGGGAACACAAATTTAT-3′ (SEQ ID NO: 7034) KRAS-1308 Target: 5′-TTGAGGGAACACAAATTTATG-3′ (SEQ ID NO: 7035) KRAS-1381 Target: 5′-TGATGAATGTAAAGTTACACT-3′ (SEQ ID NO: 7036) KRAS-1382 Target: 5′-GATGAATGTAAAGTTACACTG-3′ (SEQ ID NO: 7037) KRAS-1454 Target: 5′-CCAAAATATTATATTTTTTCT-3′ (SEQ ID NO: 7038) KRAS-1455 Target: 5′-CAAAATATTATATTTTTTCTA-3′ (SEQ ID NO: 7039) KRAS-1456 Target: 5′-AAAAtATTATATTTTTTCTAT-3′ (SEQ ID NO: 7040) KRAS-1457 Target: 5′-AAATATTATATTTTTTCTATA-3′ (SEQ ID NO: 7041) KRAS-1459 Target: 5′-ATATTATATTTTTTCTATAAA-3′ (SEQ ID NO: 7042) KRAS-1460 Target: 5′-TATTATATTTTTTCTATAAAA-3′ (SEQ ID NO: 7043) KRAS-1461 Target: 5′-ATTATATTTTTTCTATAAAAA-3′ (SEQ ID NO: 7044) KRAS-1462 Target: 5′-TTATATTTTTTCTATAAAAAG-3′ (SEQ ID NO: 7045) KRAS-1463 Target: 5′-TATATTTTTTCTATAAAAAGA-3′ (SEQ ID NO: 7046) KRAS-1464 Target: 5′-ATATTTTTTCTATAAAAAGAA-3′ (SEQ ID NO: 7047) KRAS-1465 Target: 5′-TATTTTTTCTATAAAAAGAAA-3′ (SEQ ID NO: 7048) KRAS-1466 Target: 5′-ATTTTTTCTATAAAAAGAAAA-3′ (SEQ ID NO: 7049) KRAS-1471 Target: 5′-TTCTATAAAAAGAAAAAAATG-3′ (SEQ ID NO: 7050) KRAS-1472 Target: 5′-TCTATAAAAAGAAAAAAATGG-3′ (SEQ ID NO: 7051) KRAS-1474 Target: 5′-TATAAAAAGAAAAAAATGGAA-3′ (SEQ ID NO: 7052) KRAS-1475 Target: 5′-ATAAAAAGAAAAAAATGGAAA-3′ (SEQ ID NO: 7053) KRAS-1476 Target: 5′-TAAAAAGAAAAAAATGGAAAA-3′ (SEQ ID NO: 7054) KRAS-1477 Target: 5′-AAAAAGAAAAAAATGGAAAAA-3′ (SEQ ID NO: 7055) KRAS-1478 Target: 5′-AAAAGAAAAAAATGGAAAAAA-3′ (SEQ ID NO: 7056) KRAS-1479 Target: 5′-AAAGAAAAAAATGGAAAAAAA-3′ (SEQ ID NO: 7057) KRAS-1480 Target: 5′-AAGAAAAAAATGGAAAAAAAT-3′ (SEQ ID NO: 7058) KRAS-1484 Target: 5′-AAAAAATGGAAAAAAATTACA-3′ (SEQ ID NO: 7059) KRAS-1485 Target: 5′-AAAAATGGAAAAAAATTACAA-3′ (SEQ ID NO: 7060) KRAS-1490 Target: 5′-TGGAAAAAAATTACAAGGCAA-3′ (SEQ ID NO: 7061) KRAS-1491 Target: 5′-GGAAAAAAATTACAAGGCAAT-3′ (SEQ ID NO: 7062) KRAS-1492 Target: 5′-GAAAAAAATTACAAGGCAATG-3′ (SEQ ID NO: 7063) KRAS-1527 Target: 5′-GCCATTTCCTTTTCACATTAG-3′ (SEQ ID NO: 7064) KRAS-1533 Target: 5′-TCCTTTTCACATTAGATAAAT-3′ (SEQ ID NO: 7065) KRAS-1540 Target: 5′-CACATTAGATAAATTACTATA-3′ (SEQ ID NO: 7066) KRAS-1541 Target: 5′-ACATTAGATAAATTACTATAA-3′ (SEQ ID NO: 7067) KRAS-1542 Target: 5′-CATTAGATAAATTACTATAAA-3′ (SEQ ID NO: 7068) KRAS-1597 Target: 5′-AGTATGAAATGGGGATTATTA-3′ (SEQ ID NO: 7069) KRAS-1606 Target: 5′-TGGGGATTATTATAGCAACCA-3′ (SEQ ID NO: 7070) KRAS-1633 Target: 5′-GGCTATATTTACATGCTACTA-3′ (SEQ ID NO: 7071) KRAS-1634 Target: 5′-GCTATATTTACATGCTACTAA-3′ (SEQ ID NO: 7072) KRAS-1635 Target: 5′-CTATATTTACATGCTACTAAA-3′ (SEQ ID NO: 7073) KRAS-1636 Target: 5′-TATATTTACATGCTACTAAAT-3′ (SEQ ID NO: 7074) KRAS-1637 Target: 5′-ATATTTACATGCTACTAAATT-3′ (SEQ ID NO: 7075) KRAS-1642 Target: 5′-TACATGCTACTAAATTTTTAT-3′ (SEQ ID NO: 7076) KRAS-1649 Target: 5′-TACTAAATTTTTATAATAATT-3′ (SEQ ID NO: 7077) KRAS-1650 Target: 5′-ACTAAATTTTTATAATAATTG-3′ (SEQ ID NO: 7078) KRAS-1652 Target: 5′-TAAATTTTTATAATAATTGAA-3′ (SEQ ID NO: 7079) KRAS-1653 Target: 5′-AAATTTTTATAATAATTGAAA-3′ (SEQ ID NO: 7080) KRAS-1654 Target: 5′-AATTTTTATAATAATTGAAAA-3′ (SEQ ID NO: 7081) KRAS-1655 Target: 5′-ATTTTTATAATAATTGAAAAG-3′ (SEQ ID NO: 7082) KRAS-1656 Target: 5′-TTTTTATAATAATTGAAAAGA-3′ (SEQ ID NO: 7083) KRAS-1657 Target: 5′-TTTTATAATAATTGAAAAGAT-3′ (SEQ ID NO: 7084) KRAS-1658 Target: 5′-TTTATAATAATTGAAAAGATT-3′ (SEQ ID NO: 7085) KRAS-1659 Target: 5′-TTATAATAATTGAAAAGATTT-3′ (SEQ ID NO: 7086) KRAS-1660 Target: 5′-TATAATAATTGAAAAGATTTT-3′ (SEQ ID NO: 7087) KRAS-1664 Target: 5′-ATAATTGAAAAGATTTTAACA-3′ (SEQ ID NO: 7088) KRAS-1665 Target: 5′-TAATTGAAAAGATTTTAACAA-3′ (SEQ ID NO: 7089) KRAS-1667 Target: 5′-ATTGAAAAGATTTTAACAAGT-3′ (SEQ ID NO: 7090) KRAS-1668 Target: 5′-TTGAAAAGATTTTAACAAGTA-3′ (SEQ ID NO: 7091) KRAS-1669 Target: 5′-TGAAAAGATTTTAACAAGTAT-3′ (SEQ ID NO: 7092) KRAS-1670 Target: 5′-GAAAAGATTTTAACAAGTATA-3′ (SEQ ID NO: 7093) KRAS-1671 Target: 5′-AAAAGATTTTAACAAGTATAA-3′ (SEQ ID NO: 7094) KRAS-1672 Target: 5′-AAAGATTTTAACAAGTATAAA-3′ (SEQ ID NO: 7095) KRAS-1673 Target: 5′-AAGATTTTAACAAGTATAAAA-3′ (SEQ ID NO: 7096) KRAS-1674 Target: 5′-AGATTTTAACAAGTATAAAAA-3′ (SEQ ID NO: 7097) KRAS-1675 Target: 5′-GATTTTAACAAGTATAAAAAA-3′ (SEQ ID NO: 7098) KRAS-1682 Target: 5′-ACAAGTATAAAAAATTCTCAT-3′ (SEQ ID NO: 7099) KRAS-1683 Target: 5′-CAAGTATAAAAAATTCTCATA-3′ (SEQ ID NO: 7100) KRAS-1684 Target: 5′-AAGTATAAAAAATTCTCATAG-3′ (SEQ ID NO: 7101) KRAS-1685 Target: 5′-AGTATAAAAAATTCTCATAGG-3′ (SEQ ID NO: 7102) KRAS-1686 Target: 5′-GTATAAAAAATTCTCATAGGA-3′ (SEQ ID NO: 7103) KRAS-1687 Target: 5′-TATAAAAAATTCTCATAGGAA-3′ (SEQ ID NO: 7104) KRAS-1688 Target: 5′-ATAAAAAATTCTCATAGGAAT-3′ (SEQ ID NO: 7105) KRAS-1689 Target: 5′-TAAAAAATTCTCATAGGAATT-3′ (SEQ ID NO: 7106) KRAS-1691 Target: 5′-AAAAATTCTCATAGGAATTAA-3′ (SEQ ID NO: 7107) KRAS-1692 Target: 5′-AAAATTCTCATAGGAATTAAA-3′ (SEQ ID NO: 7108) KRAS-1736 Target: 5′-CTCTTTCATAGTATAACTTTA-3′ (SEQ ID NO: 7109) KRAS-1741 Target: 5′-TCATAGTATAACTTTAAATCT-3′ (SEQ ID NO: 7110) KRAS-1742 Target: 5′-CATAGTATAACTTTAAATCTT-3′ (SEQ ID NO: 7111) KRAS-1753 Target: 5′-TTTAAATCTTTTCTTCAACTT-3′ (SEQ ID NO: 7112) KRAS-1754 Target: 5′-TTAAATCTTTTCTTCAACTTG-3′ (SEQ ID NO: 7113) KRAS-1769 Target: 5′-AACTTGAGTCTTTGAAGATAG-3′ (SEQ ID NO: 7114) KRAS-1771 Target: 5′-CTTGAGTCTTTGAAGATAGTT-3′ (SEQ ID NO: 7115) KRAS-1772 Target: 5′-TTGAGTCTTTGAAGATAGTTT-3′ (SEQ ID NO: 7116) KRAS-1783 Target: 5′-AAGATAGTTTTAATTCTGCTT-3′ (SEQ ID NO: 7117) KRAS-1784 Target: 5′-AGATAGTTTTAATTCTGCTTG-3′ (SEQ ID NO: 7118) KRAS-1785 Target: 5′-GATAGTTTTAATTCTGCTTGT-3′ (SEQ ID NO: 7119) KRAS-1799 Target: 5′-TGCTTGTGACATTAAAAGATT-3′ (SEQ ID NO: 7120) KRAS-2047 Target: 5′-AGCATTGCTTTTGTTTCTTAA-3′ (SEQ ID NO: 7121) KRAS-2048 Target: 5′-GCATTGCTTTTGTTTCTTAAG-3′ (SEQ ID NO: 7122) KRAS-2054 Target: 5′-CTTTTGTTTCTTAAGAAAACA-3′ (SEQ ID NO: 7123) KRAS-2061 Target: 5′-TTCTTAAGAAAACAAACTCTT-3′ (SEQ ID NO: 7124) KRAS-2062 Target: 5′-TCTTAAGAAAACAAACTCTTT-3′ (SEQ ID NO: 7125) KRAS-2063 Target: 5′-CTTAAGAAAACAAACTCTTTT-3′ (SEQ ID NO: 7126) KRAS-2064 Target: 5′-TTAAGAAAACAAACTCTTTTT-3′ (SEQ ID NO: 7127) KRAS-2065 Target: 5′-TAAGAAAACAAACTCTTTTTT-3′ (SEQ ID NO: 7128) KRAS-2066 Target: 5′-AAGAAAACAAACTCTTTTTTA-3′ (SEQ ID NO: 7129) KRAS-2067 Target: 5′-AGAAAACAAACTCTTTTTTAA-3′ (SEQ ID NO: 7130) KRAS-2071 Target: 5′-AACAAACTCTTTTTTAAAAAT-3′ (SEQ ID NO: 7131) KRAS-2077 Target: 5′-CTCTTTTTTAAAAATTACTTT-3′ (SEQ ID NO: 7132) KRAS-2078 Target: 5′-TCTTTTTTAAAAATTACTTTT-3′ (SEQ ID NO: 7133) KRAS-2079 Target: 5′-CTTTTTTAAAAATTACTTTTA-3′ (SEQ ID NO: 7134) KRAS-2080 Target: 5′-TTTTTTAAAAATTACTTTTAA-3′ (SEQ ID NO: 7135) KRAS-2081 Target: 5′-TTTTTAAAAATTACTTTTAAA-3′ (SEQ ID NO: 7136) KRAS-2082 Target: 5′-TTTTAAAAATTACTTTTAAAT-3′ (SEQ ID NO: 7137) KRAS-2083 Target: 5′-TTTAAAAATTACTTTTAAATA-3′ (SEQ ID NO: 7138) KRAS-2084 Target: 5′-TTAAAAATTACTTTTAAATAT-3′ (SEQ ID NO: 7139) KRAS-2085 Target: 5′-TAAAAATTACTTTTAAATATT-3′ (SEQ ID NO: 7140) KRAS-2092 Target: 5′-TACTTTTAAATATTAACTCAA-3′ (SEQ ID NO: 7141) KRAS-2093 Target: 5′-ACTTTTAAATATTAACTCAAA-3′ (SEQ ID NO: 7142) KRAS-2095 Target: 5′-TTTTAAATATTAACTCAAAAG-3′ (SEQ ID NO: 7143) KRAS-2097 Target: 5′-TTAAATATTAACTCAAAAGTT-3′ (SEQ ID NO: 7144) KRAS-2098 Target: 5′-TAAATATTAACTCAAAAGTTG-3′ (SEQ ID NO: 7145) KRAS-2099 Target: 5′-AAATATTAACTCAAAAGTTGA-3′ (SEQ ID NO: 7146) KRAS-2100 Target: 5′-AATATTAACTCAAAAGTTGAG-3′ (SEQ ID NO: 7147) KRAS-2134 Target: 5′-GGTGTGCCAAGACATTAATTT-3′ (SEQ ID NO: 7148) KRAS-2139 Target: 5′-GCCAAGACATTAATTTTTTTT-3′ (SEQ ID NO: 7149) KRAS-2140 Target: 5′-CCAAGACATTAATTTTTTTTT-3′ (SEQ ID NO: 7150) KRAS-2146 Target: 5′-CATTAATTTTTTTTTTAAACA-3′ (SEQ ID NO: 7151) KRAS-2147 Target: 5′-ATTAATTTTTTTTTTAAACAA-3′ (SEQ ID NO: 7152) KRAS-2149 Target: 5′-TAATTTTTTTTTTAAACAATG-3′ (SEQ ID NO: 7153) KRAS-2151 Target: 5′-ATTTTTTTTTTAAACAATGAA-3′ (SEQ ID NO: 7154) KRAS-2152 Target: 5′-TTTTTTTTTTAAACAATGAAG-3′ (SEQ ID NO: 7155) KRAS-2153 Target: 5′-TTTTTTTTTAAACAATGAAGT-3′ (SEQ ID NO: 7156) KRAS-2154 Target: 5′-TTTTTTTTAAACAATGAAGTG-3′ (SEQ ID NO: 7157) KRAS-2155 Target: 5′-TTTTTTTAAACAATGAAGTGA-3′ (SEQ ID NO: 7158) KRAS-2157 Target: 5′-TTTTTAAACAATGAAGTGAAA-3′ (SEQ ID NO: 7159) KRAS-2158 Target: 5′-TTTTAAACAATGAAGTGAAAA-3′ (SEQ ID NO: 7160) KRAS-2159 Target: 5′-TTTAAACAATGAAGTGAAAAA-3′ (SEQ ID NO: 7161) KRAS-2167 Target: 5′-ATGAAGTGAAAAAGTTTTACA-3′ (SEQ ID NO: 7162) KRAS-2173 Target: 5′-TGAAAAAGTTTTACAATCTCT-3′ (SEQ ID NO: 7163) KRAS-2174 Target: 5′-GAAAAAGTTTTACAATCTCTA-3′ (SEQ ID NO: 7164) KRAS-2175 Target: 5′-AAAAAGTTTTACAATCTCTAG-3′ (SEQ ID NO: 7165) KRAS-2216 Target: 5′-ACTGGTTAAATTAACATTGCA-3′ (SEQ ID NO: 7166) KRAS-2217 Target: 5′-CTGGTTAAATTAACATTGCAT-3′ (SEQ ID NO: 7167) KRAS-2218 Target: 5′-TGGTTAAATTAACATTGCATA-3′ (SEQ ID NO: 7168) KRAS-2229 Target: 5′-ACATTGCATAAACACTTTTCA-3′ (SEQ ID NO: 7169) KRAS-2247 Target: 5′-TCAAGTCTGATCCATATTTAA-3′ (SEQ ID NO: 7170) KRAS-2257 Target: 5′-TCCATATTTAATAATGCTTTA-3′ (SEQ ID NO: 7171) KRAS-2258 Target: 5′-CCATATTTAATAATGCTTTAA-3′ (SEQ ID NO: 7172) KRAS-2259 Target: 5′-CATATTTAATAATGCTTTAAA-3′ (SEQ ID NO: 7173) KRAS-2260 Target: 5′-ATATTTAATAATGCTTTAAAA-3′ (SEQ ID NO: 7174) KRAS-2261 Target: 5′-TATTTAATAATGCTTTAAAAT-3′ (SEQ ID NO: 7175) KRAS-2262 Target: 5′-ATTTAATAATGCTTTAAAATA-3′ (SEQ ID NO: 7176) KRAS-2264 Target: 5′-TTAATAATGCTTTAAAATAAA-3′ (SEQ ID NO: 7177) KRAS-2265 Target: 5′-TAATAATGCTTTAAAATAAAA-3′ (SEQ ID NO: 7178) KRAS-2266 Target: 5′-AATAATGCTTTAAAATAAAAA-3′ (SEQ ID NO: 7179) KRAS-2267 Target: 5′-ATAATGCTTTAAAATAAAAAT-3′ (SEQ ID NO: 7180) KRAS-2274 Target: 5′-TTTAAAATAAAAATAAAAACA-3′ (SEQ ID NO: 7181) KRAS-2280 Target: 5′-ATAAAAATAAAAACAATCCTT-3′ (SEQ ID NO: 7182) KRAS-2281 Target: 5′-TAAAAATAAAAACAATCCTTT-3′ (SEQ ID NO: 7183) KRAS-2282 Target: 5′-AAAAATAAAAACAATCCTTTT-3′ (SEQ ID NO: 7184) KRAS-2283 Target: 5′-AAAATAAAAACAATCCTTTTG-3′ (SEQ ID NO: 7185) KRAS-2284 Target: 5′-AAATAAAAACAATCCTTTTGA-3′ (SEQ ID NO: 7186) KRAS-2285 Target: 5′-AATAAAAACAATCCTTTTGAT-3′ (SEQ ID NO: 7187) KRAS-2286 Target: 5′-ATAAAAACAATCCTTTTGATA-3′ (SEQ ID NO: 7188) KRAS-2287 Target: 5′-TAAAAACAATCCTTTTGATAA-3′ (SEQ ID NO: 7189) KRAS-2291 Target: 5′-AACAATCCTTTTGATAAATTT-3′ (SEQ ID NO: 7190) KRAS-2296 Target: 5′-TCCTTTTGATAAATTTAAAAT-3′ (SEQ ID NO: 7191) KRAS-2297 Target: 5′-CCTTTTGATAAATTTAAAATG-3′ (SEQ ID NO: 7192) KRAS-2298 Target: 5′-CTTTTGATAAATTTAAAATGT-3′ (SEQ ID NO: 7193) KRAS-2302 Target: 5′-TGATAAATTTAAAATGTTACT-3′ (SEQ ID NO: 7194) KRAS-2303 Target: 5′-GATAAATTTAAAATGTTACTT-3′ (SEQ ID NO: 7195) KRAS-2304 Target: 5′-ATAAATTTAAAATGTTACTTA-3′ (SEQ ID NO: 7196) KRAS-2305 Target: 5′-TAAATTTAAAATGTTACTTAT-3′ (SEQ ID NO: 7197) KRAS-2306 Target: 5′-AAATTTAAAATGTTACTTATT-3′ (SEQ ID NO: 7198) KRAS-2307 Target: 5′-AATTTAAAATGTTACTTATTT-3′ (SEQ ID NO: 7199) KRAS-2309 Target: 5′-TTTAAAATGTTACTTATTTTA-3′ (SEQ ID NO: 7200) KRAS-2310 Target: 5′-TTAAAATGTTACTTATTTTAA-3′ (SEQ ID NO: 7201) KRAS-2311 Target: 5′-TAAAATGTTACTTATTTTAAA-3′ (SEQ ID NO: 7202) KRAS-2312 Target: 5′-AAAATGTTACTTATTTTAAAA-3′ (SEQ ID NO: 7203) KRAS-2313 Target: 5′-AAATGTTACTTATTTTAAAAT-3′ (SEQ ID NO: 7204) KRAS-2315 Target: 5′-ATGTTACTTATTTTAAAATAA-3′ (SEQ ID NO: 7205) KRAS-2320 Target: 5′-ACTTATTTTAAAATAAATGAA-3′ (SEQ ID NO: 7206) KRAS-2322 Target: 5′-TTATTTTAAAATAAATGAAGT-3′ (SEQ ID NO: 7207) KRAS-2323 Target: 5′-TATTTTAAAATAAATGAAGTG-3′ (SEQ ID NO: 7208) KRAS-2326 Target: 5′-TTTAAAATAAATGAAGTGAGA-3′ (SEQ ID NO: 7209) KRAS-2327 Target: 5′-TTAAAATAAATGAAGTGAGAT-3′ (SEQ ID NO: 7210) KRAS-2447 Target: 5′-TCCATTTCTTCATGTTAAAAG-3′ (SEQ ID NO: 7211) KRAS-2448 Target: 5′-CCATTTCTTCATGTTAAAAGA-3′ (SEQ ID NO: 7212) KRAS-2475 Target: 5′-CTCAAACTCTTAGTTTTTTTT-3′ (SEQ ID NO: 7213) KRAS-2485 Target: 5′-TAGTTTTTTTTTTTTACAACT-3′ (SEQ ID NO: 7214) KRAS-2486 Target: 5′-AGTTTTTTTTTTTTACAACTA-3′ (SEQ ID NO: 7215) KRAS-2487 Target: 5′-GTTTTTTTTTTTTACAACTAT-3′ (SEQ ID NO: 7216) KRAS-2488 Target: 5′-TTTTTTTTTTTTACAACTATG-3′ (SEQ ID NO: 7217) KRAS-2489 Target: 5′-TTTTTTTTTTTACAACTATGT-3′ (SEQ ID NO: 7218) KRAS-2490 Target: 5′-TTTTTTTTTTACAACTATGTA-3′ (SEQ ID NO: 7219) KRAS-2491 Target: 5′-TTTTTTTTTACAACTATGTAA-3′ (SEQ ID NO: 7220) KRAS-2492 Target: 5′-TTTTTTTTACAACTATGTAAT-3′ (SEQ ID NO: 7221) KRAS-2493 Target: 5′-TTTTTTTACAACTATGTAATT-3′ (SEQ ID NO: 7222) KRAS-2494 Target: 5′-TTTTTTACAACTATGTAATTT-3′ (SEQ ID NO: 7223) KRAS-2495 Target: 5′-TTTTTACAACTATGTAATTTA-3′ (SEQ ID NO: 7224) KRAS-2502 Target: 5′-AACTATGTAATTTATATTCCA-3′ (SEQ ID NO: 7225) KRAS-2503 Target: 5′-ACTATGTAATTTATATTCCAT-3′ (SEQ ID NO: 7226) KRAS-2504 Target: 5′-CTATGTAATTTATATTCCATT-3′ (SEQ ID NO: 7227) KRAS-2510 Target: 5′-AATTTATATTCCATTTACATA-3′ (SEQ ID NO: 7228) KRAS-2511 Target: 5′-ATTTATATTCCATTTACATAA-3′ (SEQ ID NO: 7229) KRAS-2512 Target: 5′-TTTATATTCCATTTACATAAG-3′ (SEQ ID NO: 7230) KRAS-2513 Target: 5′-TTATATTCCATTTACATAAGG-3′ (SEQ ID′NO: 7231) KRAS-2525 Target: 5′-TACATAAGGATACACTTATTT-3′ (SEQ ID NO: 7232) KRAS-2529 Target: 5′-TAAGGATACACTTATTTGTCA-3′ (SEQ ID NO: 7233) KRAS-2561 Target: 5′-ATCTGTAAATTTTTAACCTAT-3′ (SEQ ID NO: 7234) KRAS-2562 Target: 5′-TCTGTAAATTTTTAACCTATG-3′ (SEQ ID NO: 7235) KRAS-2563 Target: 5′-CTGTAAATTTTTAACCTATGT-3′ (SEQ ID NO: 7236) KRAS-2619 Target: 5′-TGCAAGAGGTGAAGTTTATAT-3′ (SEQ ID NO: 7237) KRAS-2621 Target: 5′-CAAGAGGTGAAGTTTATATTT-3′ (SEQ ID NO: 7238) KRAS-2622 Target: 5′-AAGAGGTGAAGTTTATATTTG-3′ (SEQ ID NO: 7239) KRAS-2624 Target: 5′-GAGGTGAAGTTTATATTTGAA-3′ (SEQ ID NO: 7240) KRAS-2625 Target: 5′-AGGTGAAGTTTATATTTGAAT-3′ (SEQ ID NO: 7241) KRAS-2630 Target: 5′-AAGTTTATATTTGAATATCCA-3′ (SEQ ID NO: 7242) KRAS-2718 Target: 5′-ACTTGATGCAGTTTTAATACT-3′ (SEQ ID NO: 7243) KRAS-2720 Target: 5′-TTGATGCAGTTTTAATACTTG-3′ (SEQ ID NO: 7244) KRAS-2871 Target: 5′-GATTTGACCTAATCACTAATT-3′ (SEQ ID NO: 7245) KRAS-2877 Target: 5′-ACCTAATCACTAATTTTCAGG-3′ (SEQ ID NO: 7246) KRAS-2946 Target: 5′-CAGTAGGATTTTTCAAACCTG-3′ (SEQ ID NO: 7247) KRAS-2991 Target: 5′-AGTGGAAGGAGAATTTAATAA-3′ (SEQ ID NO: 7248) KRAS-2994 Target: 5′-GGAAGGAGAATTTAATAAAGA-3′ (SEQ ID NO: 7249) KRAS-2996 Target: 5′-AAGGAGAATTTAATAAAGATA-3′ (SEQ ID NO: 7250) KRAS-2997 Target: 5′-AGGAGAATTTAATAAAGATAG-3′ (SEQ ID NO: 7251) KRAS-3001 Target: 5′-GAATTTAATAAAGATAGTGCT-3′ (SEQ ID NO: 7252) KRAS-3030 Target: 5′-TCCTTAGGTAATCTATAACTA-3′ (SEQ ID NO: 7253) KRAS-3031 Target: 5′-CCTTAGGTAATCTATAACTAG-3′ (SEQ ID NO: 7254) KRAS-3065 Target: 5′-AACAGTAATACATTCCATTGT-3′ (SEQ ID NO: 7255) KRAS-3067 Target: 5′-CAGTAATACATTCCATTGTTT-3′ (SEQ ID NO: 7256) KRAS-3068 Target: 5′-AGTAATACATTCCATTGTTTT-3′ (SEQ ID NO: 7257) KRAS-3069 Target: 5′-GTAATACATTCCATTGTTTTA-3′ (SEQ ID NO: 7258) KRAS-3079 Target: 5′-CCATTGTTTTAGTAACCAGAA-3′ (SEQ ID NO: 7259) KRAS-3093 Target: 5′-ACCAGAAATCTTCATGCAATG-3′ (SEQ ID NO: 7260) KRAS-3103 Target: 5′-TTCATGCAATGAAAAATACTT-3′ (SEQ ID NO: 7261) KRAS-3110 Target: 5′-AATGAAAAATACTTTAATTCA-3′ (SEQ ID NO: 7262) KRAS-3112 Target: 5′-TGAAAAATACTTTAATTCATG-3′ (SEQ ID NO: 7263) KRAS-3113 Target: 5′-GAAAAATACTTTAATTCATGA-3′ (SEQ ID NO: 7264) KRAS-3127 Target: 5′-TTCATGAAGCTTACTTTTTTT-3′ (SEQ ID NO: 7265) KRAS-3130 Target: 5′-ATGAAGCTTACTTTTTTTTTT-3′ (SEQ ID NO: 7266) KRAS-3134 Target: 5′-AGCTTACTTTTTTTTTTTGGT-3′ (SEQ ID NO: 7267) KRAS-3138 Target: 5′-TACTTTTTTTTTTTGGTGTCA-3′ (SEQ ID NO: 7268) KRAS-3139 Target: 5′-ACTTTTTTTTTTTGGTGTCAG-3′ (SEQ ID NO: 7269) KRAS-3297 Target: 5′-AACTAATTTTTGTATTTTTAG-3′ (SEQ ID NO: 7270) KRAS-3300 Target: 5′-TAATTTTTGTATTTTTAGGAG-3′ (SEQ ID NO: 7271) KRAS-3413 Target: 5′-CTCATTTATTCAGCAAATATT-3′ (SEQ ID NO: 7272) KRAS-3415 Target: 5′-CATTTATTCAGCAAATATTTA-3′ (SEQ ID NO: 7273) KRAS-3417 Target: 5′-TTTATTCAGCAAATATTTATT-3′ (SEQ ID NO: 7274) KRAS-3589 Target: 5′-TATTTTAGTTTTGCAAAGAAG-3′ (SEQ ID NO: 7275) KRAS-3630 Target: 5′-CTCTATAATTGTTTTGCTACG-3′ (SEQ ID NO: 7276) KRAS-3677 Target: 5′-TACTTTATGTAAATCACTTCA-3′ (SEQ ID NO: 7277) KRAS-3678 Target: 5′-ACTTTATGTAAATCACTTCAT-3′ (SEQ ID NO: 7278) KRAS-3679 Target: 5′-CTTTATGTAAATCACTTCATT-3′ (SEQ ID NO: 7279) KRAS-3680 Target: 5′-TTTATGTAAATCACTTCATTG-3′ (SEQ ID NO: 7280) KRAS-3681 Target: 5′-TTATGTAAATCACTTCATTGT-3′ (SEQ ID NO: 7281) KRAS-3682 Target: 5′-TATGTAAATCACTTCATTGTT-3′ (SEQ ID NO: 7282) KRAS-3683 Target: 5′-ATGTAAATCACTTCATTGTTT-3′ (SEQ ID NO: 7283) KRAS-3697 Target: 5′-ATTGTTTTAAAGGAATAAACT-3′ (SEQ ID NO: 7284) KRAS-3698 Target: 5′-TTGTTTTAAAGGAATAAACTT-3′ (SEQ ID NO: 7285) KRAS-3701 Target: 5′-TTTTAAAGGAATAAACTTGAT-3′ (SEQ ID NO: 7286) KRAS-3702 Target: 5′-TTTAAAGGAATAAACTTGATT-3′ (SEQ ID NO: 7287) KRAS-3703 Target: 5′-TTAAAGGAATAAACTTGATTA-3′ (SEQ ID NO: 7288) KRAS-3705 Target: 5′-AAAGGAATAAACTTGATTATA-3′ (SEQ ID NO: 7289) KRAS-3706 Target: 5′-AAGGAATAAACTTGATTATAT-3′ (SEQ ID NO: 7290) KRAS-3707 Target: 5′-AGGAATAAACTTGATTATATT-3′ (SEQ ID NO: 7291) KRAS-3708 Target: 5′-GGAATAAACTTGATTATATTG-3′ (SEQ ID NO: 7292) KRAS-3709 Target: 5′-GAATAAACTTGATTATATTGT-3′ (SEQ ID NO: 7293) KRAS-3714 Target: 5′-AACTTGATTATATTGTTTTTT-3′ (SEQ ID NO: 7294) KRAS-3715 Target: 5′-ACTTGATTATATTGTTTTTTT-3′ (SEQ ID NO: 7295) KRAS-3718 Target: 5′-TGATTATATTGTTTTTTTATT-3′ (SEQ ID NO: 7296) KRAS-3723 Target: 5′-ATATTGTTTTTTTATTTGGCA-3′ (SEQ ID NO: 7297) KRAS-3724 Target: 5′-TATTGTTTTTTTATTTGGCAT-3′ (SEQ ID NO: 7298) KRAS-3728 Target: 5′-GTTTTTTTATTTGGCATAACT-3′ (SEQ ID NO: 7299) KRAS-3729 Target: 5′-TTTTTTTATTTGGCATAACTG-3′ (SEQ ID NO: 7300) KRAS-3741 Target: 5′-GCATAACTGTGATTCTTTTAG-3′ (SEQ ID NO: 7301) KRAS-3746 Target: 5′-ACTGTGATTCTTTTAGGACAA-3′ (SEQ ID NO: 7302) KRAS-3747 Target: 5′-CTGTGATTCTTTTAGGACAAT-3′ (SEQ ID NO: 7303) KRAS-3783 Target: 5′-GGTGTATGTCAGATATTCATA-3′ (SEQ ID NO: 7304) KRAS-3784 Target: 5′-GTGTATGTCAGATATTCATAT-3′ (SEQ ID NO: 7305) KRAS-3810 Target: 5′-CAAATGTGTAATATTCCAGTT-3′ (SEQ ID NO: 7306) KRAS-3838 Target: 5′-CATAAGTAATTAAAATATACT-3′ (SEQ ID NO: 7307) KRAS-3839 Target: 5′-ATAAGTAATTAAAATATACTT-3′ (SEQ ID NO: 7308) KRAS-3840 Target: 5′-TAAGTAATTAAAATATACTTA-3′ (SEQ ID NO: 7309) KRAS-3841 Target: 5′-AAGTAATTAAAATATACTTAA-3′ (SEQ ID NO: 7310) KRAS-3842 Target: 5′-AGTAATTAAAATATACTTAAA-3′ (SEQ ID NO: 7311) KRAS-3843 Target: 5′-GTAATTAAAATATACTTAAAA-3′ (SEQ ID NO: 7312) KRAS-3844 Target: 5′-TAATTAAAATATACTTAAAAA-3′ (SEQ ID NO: 7313) KRAS-3845 Target: 5′-AATTAAAATATACTTAAAAAT-3′ (SEQ ID NO: 7314) KRAS-3846 Target: 5′-ATTAAAATATACTTAAAAATT-3′ (SEQ ID NO: 7315) KRAS-3848 Target: 5′-TAAAATATACTTAAAAATTAA-3′ (SEQ ID NO: 7316) KRAS-3849 Target: 5′-AAAATATACTTAAAAATTAAT-3′ (SEQ ID NO: 7317) KRAS-3850 Target: 5′-AAATATACTTAAAAATTAATA-3′ (SEQ ID NO: 7318) KRAS-3851 Target: 5′-AATATACTTAAAAATTAATAG-3′ (SEQ ID NO: 7319) KRAS-3855 Target: 5′-TACTTAAAAATTAATAGTTTT-3′ (SEQ ID NO: 7320) KRAS-3859 Target: 5′-TAAAAATTAATAGTTTTATCT-3′ (SEQ ID NO: 7321) KRAS-3860 Target: 5′-AAAAATTAATAGTTTTATCTG-3′ (SEQ ID NO: 7322) KRAS-3861 Target: 5′-AAAATTAATAGTTTTATCTGG-3′ (SEQ ID NO: 7323) KRAS-3876 Target: 5′-ATCTGGGTACAAATAAACAGG-3′ (SEQ ID NO: 7324) KRAS-3915 Target: 5′-GACAAGGAAACTTCTATGTAA-3′ (SEQ ID NO: 7325) KRAS-3916 Target: 5′-ACAAGGAAACTTCTATGTAAA-3′ (SEQ ID NO: 7326) KRAS-3917 Target: 5′-CAAGGAAACTTCTATGTAAAA-3′ (SEQ ID NO: 7327) KRAS-3926 Target: 5′-TTCTATGTAAAAATCACTATG-3′ (SEQ ID NO: 7328) KRAS-3927 Target: 5′-TCTATGTAAAAATCACTATGA-3′ (SEQ ID NO: 7329) KRAS-3928 Target: 5′-CTATGTAAAAATCACTATGAT-3′ (SEQ ID NO: 7330) KRAS-3932 Target: 5′-GTAAAAATCACTATGATTTCT-3′ (SEQ ID NO: 7331) KRAS-3933 Target: 5′-TAAAAATCACTATGATTTCTG-3′ (SEQ ID NO: 7332) KRAS-3942 Target: 51-CTATGATTTCTGAATTGCTAT-3′ (SEQ ID NO: 7333) KRAS-3943 Target: 5′-TATGATTTCTGAATTGCTATG-3′ (SEQ ID NO: 7334) KRAS-3960 Target: 5′-TATGTGAAACTACAGATCTTT-3′ (SEQ ID NO: 7335) KRAS-3961 Target: 5′-ATGTGAAACTACAGATCTTTG-3′ (SEQ ID NO: 7336) KRAS-3997 Target: 5′-AGGGTGTTAAGACTTACACAG-3′ (SEQ ID NO: 7337) KRAS-4084 Target: 5′-TTTAGGCCTCTTGAATTTTTG-3′ (SEQ ID NO: 7338) KRAS-4092 Target: 5′-TCTTGAATTTTTGATGTAGAT-3′ (SEQ ID NO: 7339) KRAS-4093 Target: 5′-CTTGAATTTTTGATGTAGATG-3′ (SEQ ID NO: 7340) KRAS-4108 Target: 5′-TAGATGGGCATTTTTTTAAGG-3′ (SEQ ID NO: 7341) KRAS-4114 Target: 5′-GGCATTTTTTTAAGGTAGTGG-3′ (SEQ ID NO: 7342) KRAS-4126 Target: 5′-AGGTAGTGGTTAATTACCTTT-3′ (SEQ ID NO: 7343) KRAS-4128 Target: 5′-GTAGTGGTTAATTACCTTTAT-3′ (SEQ ID NO: 7344) KRAS-4129 Target: 5′-TAGTGGTTAATTACCTTTATG-3′ (SEQ ID NO: 7345) KRAS-4130 Target: 5′-AGTGGTTAATTACCTTTATGT-3′ (SEQ ID NO: 7346) KRAS-4131 Target: 5′-GTGGTTAATTACCTTTATGTG-3′ (SEQ ID NO: 7347) KRAS-4141 Target: 5′-ACCTTTATGTGAACTTTGAAT-3′ (SEQ ID NO: 7348) KRAS-4146 Target: 5′-TATGTGAACTTTGAATGGTTT-3′ (SEQ ID NO: 7349) KRAS-4152 Target: 5′-AACTTTGAATGGTTTAACAAA-3′ (SEQ ID NO: 7350) KRAS-4156 Target: 5′-TTGAATGGTTTAACAAAAGAT-3′ (SEQ ID NO: 7351) KRAS-4157 Target: 5′-TGAATGGTTTAACAAAAGATT-3′ (SEQ ID NO: 7352) KRAS-4158 Target: 5′-GAATGGTTTAACAAAAGATTT-3′ (SEQ ID NO: 7353) KRAS-4159 Target: 5′-AATGGTTTAACAAAAGATTTG-3′ (SEQ ID NO: 7354) KRAS-4160 Target: 5′-ATGGTTTAACAAAAGATTTGT-3′ (SEQ ID NO: 7355) KRAS-4162 Target: 5′-GGTTTAACAAAAGATTTGTTT-3′ (SEQ ID NO: 7356) KRAS-4163 Target: 5′-GTTTAACAAAAGATTTGTTTT-3′ (SEQ ID NO: 7357) KRAS-4167 Target: 5′-AACAAAAGATTTGTTTTTGTA-3′ (SEQ ID NO: 7358) KRAS-4168 Target: 5′-ACAAAAGATTTGTTTTTGTAG-3′ (SEQ ID NO: 7359) KRAS-4169 Target: 5′-CAAAAGATTTGTTTTTGTAGA-3′ (SEQ ID NO: 7360) KRAS-4171 Target: 5′-AAAGATTTGTTTTTGTAGAGA-3′ (SEQ ID NO: 7361) KRAS-4172 Target: 5′-AAGATTTGTTTTTGTAGAGAT-3′ (SEQ ID NO: 7362) KRAS-4173 Target: 5′-AGATTTGTTTTTGTAGAGATT-3′ (SEQ ID NO: 7363) KRAS-4174 Target: 5′-GATTTGTTTTTGTAGAGATTT-3′ (SEQ ID NO: 7364) KRAS-4180 Target: 5′-TTTTTGTAGAGATTTTAAAGG-3′ (SEQ ID NO: 7365) KRAS-4197 Target: 5′-AAGGGGGAGAATTCTAGAAAT-3′ (SEQ ID NO: 7366) KRAS-4199 Target: 5′-GGGGGAGAATTCTAGAAATAA-3′ (SEQ ID NO: 7367) KRAS-4200 Target: 5′-GGGGAGAATTCTAGAAATAAA-3′ (SEQ ID NO: 7368) KRAS-4201 Target: 5′-GGGAGAATTCTAGAAATAAAT-3′ (SEQ ID NO: 7369) KRAS-4202 Target: 5′-GGAGAATTCTAGAAATAAATG-3′ (SEQ ID NO: 7370) KRAS-4203 Target: 5′-GAGAATTCTAGAAATAAATGT-3′ (SEQ ID NO: 7371) KRAS-4208 Target: 5′-TTCTAGAAATAAATGTTACCT-3′ (SEQ ID NO: 7372) KRAS-4209 Target: 5′-TCTAGAAATAAATGTTACCTA-3′ (SEQ ID NO: 7373) KRAS-4210 Target: 5′-CTAGAAATAAATGTTACCTAA-3′ (SEQ ID NO: 7374) KRAS-4211 Target: 5′-TAGAAATAAATGTTACCTAAT-3′ (SEQ ID NO: 7375) KRAS-4212 Target: 5′-AGAAATAAATGTTACCTAATT-3′ (SEQ ID NO: 7376) KRAS-4214 Target: 5′-AAATAAATGTTACCTAATTAT-3′ (SEQ ID NO: 7377) KRAS-4225 Target: 5′-ACCTAATTATTACAGCCTTAA-3′ (SEQ ID NO: 7378) KRAS-4226 Target: 5′-CCTAATTATTACAGCCTTAAA-3′ (SEQ ID NO: 7379) KRAS-4240 Target: 5′-CCTTAAAGACAAAAATCCTTG-3′ (SEQ ID NO: 7380) KRAS-4243 Target: 5′-TAAAGACAAAAATCCTTGTTG-3′ (SEQ ID NO: 7381) KRAS-4255 Target: 5′-TCCTTGTTGAAGTTTTTTTAA-3′ (SEQ ID NO: 7382) KRAS-4256 Target: 5′-CCTTGTTGAAGTTTTTTTAAA-3′ (SEQ ID NO: 7383) KRAS-4258 Target: 5′-TTGTTGAAGTTTTTTTAAAAA-3′ (SEQ ID NO: 7384) KRAS-4259 Target: 5′-TGTTGAAGTTTTTTTAAAAAA-3′ (SEQ ID NO: 7385) KRAS-4263 Target: 5′-GAAGTTTTTTTAAAAAAAGCT-3′ (SEQ ID NO: 7386) KRAS-4264 Target: 5′-AAGTTTTTTTAAAAAAAGCTA-3′ (SEQ ID NO: 7387) KRAS-4265 Target: 5′-AGTTTTTTTAAAAAAAGCTAA-3′ (SEQ ID NO: 7388) KRAS-4266 Target: 5′-GTTTTTTTAAAAAAAGCTAAA-3′ (SEQ ID NO: 7389) KRAS-4267 Target: 5′-TTTTTTTAAAAAAAGCTAAAT-3′ (SEQ ID NO: 7390) KRAS-4271 Target: 5′-TTTAAAAAAAGCTAAATTACA-3′ (SEQ ID NO: 7391) KRAS-4273 Target: 5′-TAAAAAAAGCTAAATTACATA-3′ (SEQ ID NO: 7392) KRAS-4295 Target: 5′-ACTTAGGCATTAACATGTTTG-3′ (SEQ ID NO: 7393) KRAS-4296 Target: 5′-CTTAGGCATTAACATGTTTGT-3′ (SEQ ID NO: 7394) KRAS-4327 Target: 5′-AGCAGACGTATATTGTATCAT-3′ (SEQ ID NO: 7395) KRAS-4331 Target: 5′-GACGTATATTGTATCATTTGA-3′ (SEQ ID NO: 7396) KRAS-4333 Target: 5′-CGTATATTGTATCATTTGAGT-3′ (SEQ ID NO: 7397) KRAS-4336 Target: 5′-ATATTGTATCATTTGAGTGAA-3′ (SEQ ID NO: 7398) KRAS-4337 Target: 5′-TATTGTATCATTTGAGTGAAT-3′ (SEQ ID NO: 7399) KRAS-4338 Target: 5′-ATTGTATCATTTGAGTGAATG-3′ (SEQ ID NO: 7400) KRAS-4404 Target: 5′-ATAGGAATTTAGAACCTAACT-3′ (SEQ ID NO: 7401) KRAS-4405 Target: 5′-TAGGAATTTAGAACCTAACTT-3′ (SEQ ID NO: 7402) KRAS-4409 Target: 5′-AATTTAGAACCTAACTTTTAT-3′ (SEQ ID NO: 7403) KRAS-4410 Target: 5′-ATTTAGAACCTAACTTTTATA-3′ (SEQ ID NO: 7404) KRAS-4411 Target: 5′-TTTAGAACCTAACTTTTATAG-3′ (SEQ ID NO: 7405) KRAS-4412 Target: 5′-TTAGAACCTAACTTTTATAGG-3′ (SEQ ID NO: 7406) KRAS-4424 Target: 5′-TTTTATAGGTTATCAAAACTG-3′ (SEQ ID NO: 7407) KRAS-4426 Target: 5′-TTATAGGTTATCAAAACTGTT-3′ (SEQ ID NO: 7408) KRAS-4460 Target: 5′-AATTTTGTCCTAATATATACA-3′ (SEQ ID NO: 7409) KRAS-4461 Target: 5′-ATTTTGTCCTAATATATACAT-3′ (SEQ ID NO: 7410) KRAS-4462 Target: 5′-TTTTGTCCTAATATATACATA-3′ (SEQ ID NO: 7411) KRAS-4468 Target: 5′-CCTAATATATACATAGAAACT-3′ (SEQ ID NO: 7412) KRAS-4473 Target: 5′-TATATACATAGAAACTTTGTG-3′ (SEQ ID NO: 7413) KRAS-4516 Target: 5′-CACAAGTTCATCTCATTTGTA-3′ (SEQ ID NO: 7414) KRAS-4527 Target: 5′-CTCATTTGTATTCCATTGATT-3′ (SEQ ID NO: 7415) KRAS-4528 Target: 5′-TCATTTGTATTCCATTGATTT-3′ (SEQ ID NO: 7416) KRAS-4529 Target: 5′-CATTTGTATTCCATTGATTTT-3′ (SEQ ID NO: 7417) KRAS-4530 Target: 5′-ATTTGTATTCCATTGATTTTT-3′ (SEQ ID NO: 7418) KRAS-4531 Target: 5′-TTTGTATTCCATTGATTTTTT-3′ (SEQ ID NO: 7419) KRAS-4532 Target: 5′-TTGTATTCCATTGATTTTTTT-3′ (SEQ ID NO: 7420) KRAS-4533 Target: 5′-TGTATTCCATTGATTTTTTTT-3′ (SEQ ID NO: 7421) KRAS-4540 Target: 5′-CATTGATTTTTTTTTTCTTCT-3′ (SEQ ID NO: 7422) KRAS-4541 Target: 5′-ATTGATTTTTTTTTTCTTCTA-3′ (SEQ ID NO: 7423) KRAS-4545 Target: 5′-ATTTTTTTTTTCTTCTAAACA-3′ (SEQ ID NO: 7424) KRAS-4546 Target: 5′-TTTTTTTTTTCTTCTAAACAT-3′ (SEQ ID NO: 7425) KRAS-4547 Target: 5′-TTTTTTTTTCTTCTAAACATT-3′ (SEQ ID NO: 7426) KRAS-4548 Target: 5′-TTTTTTTTCTTCTAAACATTT-3′ (SEQ ID NO: 7427) KRAS-4549 Target: 5′-TTTTTTTCTTCTAAACATTTT-3′ (SEQ ID NO: 7428) KRAS-4562 Target: 5′-AACATTTTTTCTTCAAACAGT-3′ (SEQ ID NO: 7429) KRAS-4563 Target: 5′-ACATTTTTTCTTCAAACAGTA-3′ (SEQ ID NO: 7430) KRAS-4564 Target: 5′-CATTTTTTCTTCAAACAGTAT-3′ (SEQ ID NO: 7431) KRAS-4565 Target: 5′-ATTTTTTCTTCAAACAGTATA-3′ (SEQ ID NO: 7432) KRAS-4566 Target: 5′-TTTTTTCTTCAAACAGTATAT-3′ (SEQ ID NO: 7433) KRAS-4573 Target: 5′-TTCAAACAGTATATAACTTTT-3′ (SEQ ID NO: 7434) KRAS-4578 Target: 5′-ACAGTATATAACTTTTTTTAG-3′ (SEQ ID NO: 7435) KRAS-4579 Target: 5′-CAGTATATAACTTTTTTTAGG-3′ (SEQ ID NO: 7436) KRAS-4580 Target: 5′-AGTATATAACTTTTTTTAGGG-3′ (SEQ ID NO: 7437) KRAS-4581 Target: 5′-GTATATAACTTTTTTTAGGGG-3′ (SEQ ID NO: 7438) KRAS-4587 Target: 5′-AACTTTTTTTAGGGGATTTTT-3′ (SEQ ID NO: 7439) KRAS-4588 Target: 5′-ACTTTTTTTAGGGGATTTTTT-3′ (SEQ ID NO: 7440) KRAS-4599 Target: 5′-GGGATTTTTTTTTAGACAGCA-3′ (SEQ ID NO: 7441) KRAS-4600 Target: 5′-GGATTTTTTTTTAGACAGCAA-3′ (SEQ ID NO: 7442) KRAS-4601 Target: 5′-GATTTTTTTTTAGACAGCAAA-3′ (SEQ ID NO: 7443) KRAS-4629 Target: 5′-TGAAGATTTCCATTTGTCAAA-3′ (SEQ ID NO: 7444) KRAS-4630 Target: 5′-GAAGATTTCCATTTGTCAAAA-3′ (SEQ ID NO: 7445) KRAS-4631 Target: 5′-AAGATTTCCATTTGTCAAAAA-3′ (SEQ ID NO: 7446) KRAS-4632 Target: 5′-AGATTTCCATTTGTCAAAAAG-3′ (SEQ ID NO: 7447) KRAS-4637 Target: 5′-TCCATTTGTCAAAAAGTAATG-3′ (SEQ ID NO: 7448) KRAS-4638 Target: 5′-CCATTTGTCAAAAAGTAATGA-3′ (SEQ ID NO: 7449) KRAS-4639 Target: 5′-CATTTGTCAAAAAGTAATGAT-3′ (SEQ ID NO: 7450) KRAS-4644 Target: 5′-GTCAAAAAGTAATGATTTCTT-3′ (SEQ ID NO: 7451) KRAS-4645 Target: 5′-TCAAAAAGTAATGATTTCTTG-3′ (SEQ ID NO: 7452) KRAS-4646 Target: 5′-CAAAAAGTAATGATTTCTTGA-3′ (SEQ ID NO: 7453) KRAS-4647 Target: 5′-AAAAAGTAATGATTTCTTGAT-3′ (SEQ ID NO: 7454) KRAS-4649 Target: 5′-AAAGTAATGATTTCTTGATAA-3′ (SEQ ID NO: 7455) KRAS-4651 Target: 5′-AGTAATGATTTCTTGATAATT-3′ (SEQ ID NO: 7456) KRAS-4652 Target: 5′-GTAATGATTTCTTGATAATTG-3′ (SEQ ID NO: 7457) KRAS-4654 Target: 5′-AATGATTTCTTGATAATTGTG-3′ (SEQ ID NO: 7458) KRAS-4655 Target: 5′-ATGATTTCTTGATAATTGTGT-3′ (SEQ ID NO: 7459) KRAS-4660 Target: 5′-TTCTTGATAATTGTGTAGTAA-3′ (SEQ ID NO: 7460) KRAS-4661 Target: 5′-TCTTGATAATTGTGTAGTAAT-3′ (SEQ ID NO: 7461) KRAS-4662 Target: 5′-CTTGATAATTGTGTAGTAATG-3′ (SEQ ID NO: 7462) KRAS-4664 Target: 5′-TGATAATTGTGTAGTAATGTT-3′ (SEQ ID NO: 7463) KRAS-4667 Target: 5′-TAATTGTGTAGTAATGTTTTT-3′ (SEQ ID NO: 7464) KRAS-4669 Target: 5′-ATTGTGTAGTAATGTTTTTTA-3′ (SEQ ID NO: 7465) KRAS-4670 Target: 5′-TTGTGTAGTAATGTTTTTTAG-3′ (SEQ ID NO: 7466) KRAS-4704 Target: 5′-CCTTAAAGCTGAATTTATATT-3′ (SEQ ID NO: 7467) KRAS-4706 Target: 5′-TTAAAGCTGAATTTATATTTA-3′ (SEQ ID NO: 7468) KRAS-4715 Target: 5′-AATTTATATTTAGTAACTTCT-3′ (SEQ ID NO: 7469) KRAS-4716 Target: 5′-ATTTATATTTAGTAACTTCTG-3′ (SEQ ID NO: 7470) KRAS-4717 Target: 5′-TTTATATTTAGTAACTTCTGT-3′ (SEQ ID NO: 7471) KRAS-4722 Target: 5′-ATTTAGTAACTTCTGTGTTAA-3′ (SEQ ID NO: 7472) KRAS-4773 Target: 5′-ACTGAATAGCTGTCATAAAAT-3′ (SEQ ID NO: 7473) KRAS-4774 Target: 5′-CTGAATAGCTGTCATAAAATG-3′ (SEQ ID NO: 7474) KRAS-4788 Target: 5′-TAAAATGAAACTTTCTTTCTA-3′ (SEQ ID NO: 7475) KRAS-4789 Target: 5′-AAAATGAAACTTTCTTTCTAA-3′ (SEQ ID NO: 7476) KRAS-4790 Target: 5′-AAATGAAACTTTCTTTCTAAA-3′ (SEQ ID NO: 7477) KRAS-4792 Target: 5′-ATGAAACTTTCTTTCTAAAGA-3′ (SEQ ID NO: 7478) KRAS-4796 Target: 5′-AACTTTCTTTCTAAAGAAAGA-3′ (SEQ ID NO: 7479) KRAS-4821 Target: 5′-CACATGAGTTCTTGAAGAATA-3′ (SEQ ID NO: 7480) KRAS-4830 Target: 5′-TCTTGAAGAATAGTCATAACT-3′ (SEQ ID NO:.7481) KRAS-4831 Target: 5′-CTTGAAGAATAGTCATAACTA-3′ (SEQ ID NO: 7482) KRAS-4832 Target: 5′-TTGAAGAATAGTCATAACTAG-3′ (SEQ ID NO: 7483) KRAS-4835 Target: 5′-AAGAATAGTCATAACTAGATT-3′ (SEQ ID NO: 7484) KRAS-4836 Target: 5′-AGAATAGTCATAACTAGATTA-3′ (SEQ ID NO: 7485) KRAS-4837 Target: 5′-GAATAGTCATAACTAGATTAA-3′ (SEQ ID NO: 7486) KRAS-4838 Target: 5′-AATAGTCATAACTAGATTAAG-3′ (SEQ ID NO: 7487) KRAS-4842 Target: 5′-GTCATAACTAGATTAAGATCT-3′ (SEQ ID NO: 7488) KRAS-4848 Target: 5′-ACTAGATTAAGATCTGTGTTT-3′ (SEQ ID NO: 7489) KRAS-4850 Target: 5′-TAGATTAAGATCTGTGTTTTA-3′ (SEQ ID NO: 7490) KRAS-4851 Target: 5′-AGATTAAGATCTGTGTTTTAG-3′ (SEQ ID NO: 7491) KRAS-4853 Target: 5′-ATTAAGATCTGTGTTTTAGTT-3′ (SEQ ID NO: 7492) KRAS-4860 Target: 5′-TCTGTGTTTTAGTTTAATAGT-3′ (SEQ ID NO: 7493) KRAS-4861 Target: 5′-CTGTGTTTTAGTTTAATAGTT-3′ (SEQ ID NO: 7494) KRAS-4863 Target: 5′-GTGTTTTAGTTTAATAGTTTG-3′ (SEQ ID NO: 7495) KRAS-4865 Target: 5′-GTTTTAGTTTAATAGTTTGAA-3′ (SEQ ID NO: 7496) KRAS-4866 Target: 5′-TTTTAGTTTAATAGTTTGAAG-3′ (SEQ ID NO: 7497) KRAS-4892 Target: 5′-GTTTGGGATAATGATAGGTAA-3′ (SEQ ID NO: 7498) KRAS-4894 Target: 5′-TTGGGATAATGATAGGTAATT-3′ (SEQ ID NO: 7499) KRAS-4897 Target: 5′-GGATAATGATAGGTAATTTAG-3′ (SEQ ID NO: 7500) KRAS-4898 Target: 5′-GATAATGATAGGTAATTTAGA-3′ (SEQ ID NO: 7501) KRAS-4901 Target: 5′-AATGATAGGTAATTTAGATGA-3′ (SEQ ID NO: 7502) KRAS-4902 Target: 5′-ATGATAGGTAATTTAGATGAA-3′ (SEQ ID NO: 7503) KRAS-4907 Target: 5′-AGGTAATTTAGATGAATTTAG-3′ (SEQ ID NO: 7504) KRAS-4909 Target: 5′-GTAATTTAGATGAATTTAGGG-3′ (SEQ ID NO: 7505) KRAS-4916 Target: 5′-AGATGAATTTAGGGGAAAAAA-3′ (SEQ ID NO: 7506) KRAS-4917 Target: 5′-GATGAATTTAGGGGAAAAAAA-3′ (SEQ ID NO: 7507) KRAS-4928 Target: 5′-GGGAAAAAAAAGTTATCTGCA-3′ (SEQ ID NO: 7508) KRAS-4929 Target: 5′-GGAAAAAAAAGTTATCTGCAG-3′ (SEQ ID NO: 7509) KRAS-4934 Target: 5′-AAAAAGTTATCTGCAGATATG-3′ (SEQ ID NO: 7510) KRAS-5035 Target: 5′-GTCTTGTGTTTTCATGTTGAA-3′ (SEQ ID NO: 7511) KRAS-5036 Target: 5′-TCTTGTGTTTTCATGTTGAAA-3′ (SEQ ID NO: 7512) KRAS-5037 Target: 5′-CTTGTGTTTTCATGTTGAAAA-3′ (SEQ ID NO: 7513) KRAS-5047 Target: 5′-CATGTTGAAAATACTTTTGCA-3′ (SEQ ID NO: 7514) KRAS-5048 Target: 5′-ATGTTGAAAATACTTTTGCAT-3′ (SEQ ID NO: 7515) KRAS-5049 Target: 5′-TGTTGAAAATACTTTTGCATT-3′ (SEQ ID NO: 7516) KRAS-5050 Target: 5′-GTTGAAAATACTTTTGCATTT-3′ (SEQ ID NO: 7517) KRAS-5060 Target: 5′-CTTTTGCATTTTTCCTTTGAG-3′ (SEQ ID NO: 7518) KRAS-5077 Target: 5′-TGAGTGCCAATTTCTTACTAG-3′ (SEQ ID NO: 7519) KRAS-5082 Target: 5′-GCCAATTTCTTACTAGTACTA-3′ (SEQ ID NO: 7520) KRAS-5083 Target: 5′-CCAATTTCTTACTAGTACTAT-3′ (SEQ ID NO: 7521) KRAS-5092 Target: 5′-TACTAGTACTATTTCTTAATG-3′ (SEQ ID NO: 7522) KRAS-5093 Target: 5′-ACTAGTACTATTTCTTAATGT-3′ (SEQ ID NO: 7523) KRAS-5098 Target: 5′-TACTATTTCTTAATGTAACAT-3′ (SEQ ID NO: 7524) KRAS-5099 Target: 5′-ACTATTTCTTAATGTAACATG-3′ (SEQ ID NO: 7525) KRAS-5100 Target: 5′-CTATTTCTTAATGTAACATGT-3′ (SEQ ID NO: 7526) KRAS-5107 Target: 5′-TTAATGTAACATGTTTACCTG-3′ (SEQ ID NO: 7527) KRAS-5124 Target: 5′-CCTGGAATGTATTTTAACTAT-3′ (SEQ ID NO: 7528) KRAS-5126 Target: 5′-TGGAATGTATTTTAACTATTT-3′ (SEQ ID NO: 7529) KRAS-5127 Target: 5′-GGAATGTATTTTAACTATTTT-3′ (SEQ ID NO: 7530) KRAS-5128 Target: 5′-GAATGTATTTTAACTATTTTT-3′ (SEQ ID NO: 7531) KRAS-5129 Target: 5′-AATGTATTTTAACTATTTTTG-3′ (SEQ ID NO: 7532) KRAS-5131 Target: 5′-TGTATTTTAACTATTTTTGTA-3′ (SEQ ID NO: 7533) KRAS-5133 Target: 5′-TATTTTAACTATTTTTGTATA-3′ (SEQ ID NO: 7534) KRAS-5134 Target: 5′-ATTTTAACTATTTTTGTATAG-3′ (SEQ ID NO: 7535) KRAS-5135 Target: 5′-TTTTAACTATTTTTGTATAGT-3′ (SEQ ID NO: 7536) KRAS-5142 Target: 5′-TATTTTTGTATAGTGTAAACT-3′ (SEQ ID NO: 7537) KRAS-5143 Target: 5′-ATTTTTGTATAGTGTAAACTG-3′ (SEQ ID NO: 7538) KRAS-5144 Target: 5′-TTTTTGTATAGTGTAAACTGA-3′ (SEQ ID NO: 7539) KRAS-5159 Target: 5′-AACTGAAACATGCACATTTTG-3′ (SEQ ID NO: 7540) KRAS-5165 Target: 5′-AACATGCACATTTTGTACATT-3′ (SEQ ID NO: 7541) KRAS-5218 Target: 5′-TCCAGTTGTTTTCCATCATTT-3′ (SEQ ID NO: 7542) KRAS-5220 Target: 5′-CAGTTGTTTTCCATCATTTGG-3′ (SEQ ID NO: 7543) KRAS-5257 Target: 5′-ATGTTGGTCATATCAAACATT-3′ (SEQ ID NO: 7544) KRAS-5258 Target: 5′-TGTTGGTCATATCAAACATTA-3′ (SEQ ID NO: 7545) KRAS-5259 Target: 5′-GTTGGTCATATCAAACATTAA-3′ (SEQ ID NO: 7546) KRAS-5263 Target: 5′-GTCATATCAAACATTAAAAAT-3′ (SEQ ID NO: 7547) KRAS-5279 Target: 5′-AAAATGACCACTCTTTTAATT-3′ (SEQ ID NO: 7548) KRAS-5280 Target: 5′-AAATGACCACTCTTTTAATTG-3′ (SEQ ID NO: 7549) KRAS-5289 Target: 5′-CTCTTTTAATTGAAATTAACT-3′ (SEQ ID NO: 7550) KRAS-5290 Target: 5′-TCTTTTAATTGAAATTAACTT-3′ (SEQ ID NO: 7551) KRAS-5292 Target: 5′-TTTTAATTGAAATTAACTTTT-3′ (SEQ ID NO: 7552) KRAS-5294 Target: 5′-TTAATTGAAATTAACTTTTAA-3′ (SEQ ID NO: 7553) KRAS-5295 Target: 5′-TAATTGAAATTAACTTTTAAA-3′ (SEQ ID NO: 7554) KRAS-5296 Target: 5′-AATTGAAATTAACTTTTAAAT-3′ (SEQ ID NO: 7555) KRAS-5297 Target: 5′-ATTGAAATTAACTTTTAAATG-3′ (SEQ ID NO: 7556) KRAS-5298 Target: 5′-TTGAAATTAACTTTTAAATGT-3′ (SEQ ID NO: 7557) KRAS-5299 Target: 5′-TGAAATTAACTTTTAAATGTT-3′ (SEQ ID NO: 7558) KRAS-5302 Target: 5′-AATTAACTTTTAAATGTTTAT-3′ (SEQ ID NO: 7559) KRAS-5306 Target: 5′-AACTTTTAAATGTTTATAGGA-3′ (SEQ ID NO: 7560) KRAS-5310 Target: 5′-TTTAAATGTTTATAGGAGTAT-3′ (SEQ ID NO: 7561) KRAS-5311 Target: 5′-TTAAATGTTTATAGGAGTATG-3′ (SEQ ID NO: 7562) KRAS-5333 Target: 5′-GCTGTGAAGTGATCTAAAATT-3′ (SEQ ID NO: 7563) KRAS-5335 Target: 5′-TGTGAAGTGATCTAAAATTTG-3′ (SEQ ID NO: 7564) KRAS-5336 Target: 5′-GTGAAGTGATCTAAAATTTGT-3′ (SEQ ID NO: 7565) KRAS-5337 Target: 5′-TGAAGTGATCTAAAATTTGTA-3′ (SEQ ID NO: 7566) KRAS-5338 Target: 5′-GAAGTGATCTAAAATTTGTAA-3′ (SEQ ID NO: 7567) KRAS-5339 Target: 5′-AAGTGATCTAAAATTTGTAAT-3′ (SEQ ID NO: 7568) KRAS-5340 Target: 5′-AGTGATCTAAAATTTGTAATA-3′ (SEQ ID NO: 7569) KRAS-5344 Target: 5′-ATCTAAAATTTGTAATATTTT-3′ (SEQ ID NO: 7570) KRAS-5345 Target: 5′-TCTAAAATTTGTAATATTTTT-3′ (SEQ ID NO: 7571) KRAS-5349 Target: 5′-AAATTTGTAATATTTTTGTCA-3′ (SEQ ID NO: 7572) KRAS-5350 Target: 5′-AATTTGTAATATTTTTGTCAT-3′ (SEQ ID NO: 7573) KRAS-5351 Target: 5′-ATTTGTAATATTTTTGTCATG-3′ (SEQ ID NO: 7574) KRAS-5355 Target: 5′-GTAATATTTTTGTCATGAACT-3′ (SEQ ID NO: 7575) KRAS-5356 Target: 5′-TAATATTTTTGTCATGAACTG-3′ (SEQ ID NO: 7576) KRAS-5372 Target: 5′-AACTGTACTACTCCTAATTAT-3′ (SEQ ID NO: 7577) KRAS-5373 Target: 5′-ACTGTACTACTCCTAATTATT-3′ (SEQ ID NO: 7578) KRAS-5383 Target: 5′-TCCTAATTATTGTAATGTAAT-3′ (SEQ ID NO: 7579) KRAS-5384 Target: 5′-CCTAATTATTGTAATGTAATA-3′ (SEQ ID NO: 7580) KRAS-5386 Target: 5′-TAATTATTGTAATGTAATAAA-3′ (SEQ ID NO: 7581) KRAS-5388 Target: 5′-ATTATTGTAATGTAATAAAAA-3′ (SEQ ID NO: 7582) KRAS-5389 Target: 5′-TTATTGTAATGTAATAAAAAT-3′ (SEQ ID NO: 7583) KRAS-5391 Target: 5′-ATTGTAATGTAATAAAAATAG-3′ (SEQ ID NO: 7584) KRAS-5392 Target: 5′-TTGTAATGTAATAAAAATAGT-3′ (SEQ ID NO: 7585) KRAS-5396 Target: 5′-AATGTAATAAAAATAGTTACA-3′ (SEQ ID NO: 7586) KRAS-5397 Target: 5′-ATGTAATAAAAATAGTTACAG-3′ (SEQ ID NO: 7587) KRAS-5398 Target: 5′-TGTAATAAAAATAGTTACAGT-3′ (SEQ ID NO: 7588) KRAS-5406 Target: 5′-AAATAGTTACAGTGACAAAAA-3′ (SEQ ID NO: 7589) KRAS-5407 Target: 5′-AATAGTTACAGTGACAAAAAA-3′ (SEQ ID NO: 7590) KRAS-5409 Target: 5′-TAGTTACAGTGACAAAAAAAA-3′ (SEQ ID NO: 7591) KRAS-172 Target: 5′-CCTGCTGAAAATGACTGAATA-3′ (SEQ ID NO: 7592) KRAS-178 Target: 5′-GAAAATGACTGAATATAAACT-3′ (SEQ ID NO: 7593) KRAS-182 Target: 5′-ATGACTGAATATAAACTTGTG-3′ (SEQ ID NO: 7594) KRAS-244 Target: 5′-ACAGCTAATTCAGAATCATTT-3′ (SEQ ID NO: 7595) KRAS-268 Target: 5′-GGACGAATATGATCCAACAAT-3′ (SEQ ID NO: 7596) KRAS-304 Target: 5′-GAAGCAAGTAGTAATTGATGG-3′ (SEQ ID NO: 7597) KRAS-404 Target: 5′-GGGGAGGGCTTTCTTTGTGTA-3′ (SEQ ID NO: 7598) KRAS-413 Target: 5′-TTTCTTTGTGTATTTGCCATA-3′ (SEQ ID NO: 7599) KRAS-414 Target: 5′-TTCTTTGTGTATTTGCCATAA-3′ (SEQ ID NO: 7600) KRAS-415 Target: 5′-TCTTTGTGTATTTGCCATAAA-3′ (SEQ ID NO: 7601) KRAS-416 Target: 5′-CTTTGTGTATTTGCCATAAAT-3′ (SEQ ID NO: 7602) KRAS-420 Target: 5′-GTGTATTTGCCATAAATAATA-3′ (SEQ ID NO: 7603) KRAS-421 Target: 5′-TGTATTTGCCATAAATAATAC-3′ (SEQ ID NO: 7604) KRAS-427 Target: 5′-TGCCATAAATAATACTAAATC-3′ (SEQ ID NO: 7605) KRAS-428 Target: 5′-GCCATAAATAATACTAAATCA-3′ (SEQ ID NO: 7606) KRAS-430 Target: 5′-CATAAATAATACTAAATCATT-3′ (SEQ ID NO: 7607) KRAS-431 Target: 5′-ATAAATAATACTAAATCATTT-3′ (SEQ ID NO: 7608) KRAS-432 Target: 5′-TAAATAATACTAAATCATTTG-3′ (SEQ ID NO: 7609) KRAS-433 Target: 5′-AAATAATACTAAATCATTTGA-3′ (SEQ ID NO: 7610) KRAS-446 Target: 5′-TCATTTGAAGATATTCACCAT-3′ (SEQ ID NO: 7611) KRAS-448 Target: 5′-ATTTGAAGATATTCACCATTA-3′ (SEQ ID NO: 7612) KRAS-449 Target: 5′-TTTGAAGATATTCACCATTAT-3′ (SEQ ID NO: 7613) KRAS-450 Target: 5′-TTGAAGATATTCACCATTATA-3′ (SEQ ID NO: 7614) KRAS-451 Target: 5′-TGAAGATATTCACCATTATAG-3′ (SEQ ID NO: 7615) KRAS-461 Target: 5′-CACCATTATAGAGAACAAATT-3′ (SEQ ID NO: 7616) KRAS-463 Target: 5′-CCATTATAGAGAACAAATTAA-3′ (SEQ ID NO: 7617) KRAS-464 Target: 5′-CATTATAGAGAACAAATTAAA-3′ (SEQ ID NO: 7618) KRAS-465 Target: 5′-ATTATAGAGAACAAATTAAAA-3′ (SEQ ID NO: 7619) KRAS-466 Target: 5′-TTATAGAGAACAAATTAAAAG-3′ (SEQ ID NO: 7620) KRAS-516 Target: 5′-TCCTAGTAGGAAATAAATGTG-3′ (SEQ ID NO: 7621) KRAS-517 Target: 5′-CCTAGTAGGAAATAAATGTGA-3′ (SEQ ID NO: 7622) KRAS-581 Target: 5′-GCAAGAAGTTATGGAATTCCT-3′ (SEQ ID NO: 7623) KRAS-584 Target: 5′-AGAAGTTATGGAATTCCTTTT-3′ (SEQ ID NO: 7624) KRAS-585 Target: 5′-GAAGTTATGGAATTCCTTTTA-3′ (SEQ ID NO: 7625) KRAS-586 Target: 5′-AAGTTATGGAATTCCTTTTAT-3′ (SEQ ID NO: 7626) KRAS-587 Target: 5′-AGTTATGGAATTCCTTTTATT-3′ (SEQ ID NO: 7627) KRAS-634 Target: 5′-AGTGGAGGATGCTTTTTATAC-3′ (SEQ ID NO: 7628) KRAS-636 Target: 5′-TGGAGGATGCTTTTTATACAT-3′ (SEQ ID NO: 7629) KRAS-676 Target: 5′-ATACAGATTGAAAAAAATCAG-3′ (SEQ ID NO: 7630) KRAS-677 Target: 5′-TACAGATTGAAAAAAATCAGC-3′ (SEQ ID NO: 7631) KRAS-679 Target: 5′-CAGATTGAAAAAAATCAGCAA-3′ (SEQ ID NO: 7632) KRAS-680 Target: 5′-AGATTGAAAAAAATCAGCAAA-3′ (SEQ ID NO: 7633) KRAS-681 Target: 5′-GATTGAAAAAAATCAGCAAAG-3′ (SEQ ID NO: 7634) KRAS-682 Target: 5′-ATTGAAAAAAATCAGCAAAGA-3′ (SEQ ID NO: 7635) KRAS-710 Target: 5′-ACTCCTGGCTGTGTGAAAATT-3′ (SEQ ID NO: 7636) KRAS-714 Target: 5′-CTGGCTGTGTGAAAATTAAAA-3′ (SEQ ID NO: 7637) KRAS-718 Target: 5′-CTGTGTGAAAATTAAAAAATG-3′ (SEQ ID NO: 7638) KRAS-719 Target: 5′-TGTGTGAAAATTAAAAAATGC-3′ (SEQ ID NO: 7639) KRAS-720 Target: 5′-GTGTGAAAATTAAAAAATGCA-3′ (SEQ ID NO: 7640) KRAS-721 Target: 5′-TGTGAAAATTAAAAAATGCAT-3′ (SEQ ID NO: 7641) KRAS-723 Target: 5′-TGAAAATTAAAAAATGCATTA-3′ (SEQ ID NO: 7642) KRAS-724 Target: 5′-GAAAATTAAAAAATGCATTAT-3′ (SEQ ID NO: 7643) KRAS-725 Target: 5′-AAAATTAAAAAATGCATTATA-3′ (SEQ ID NO: 7644) KRAS-726 Target: 5′-AAATTAAAAAATGCATTATAA-3′ (SEQ ID NO: 7645) KRAS-728 Target: 5′-ATTAAAAAATGCATTATAATG-3′ (SEQ ID NO: 7646) KRAS-735 Target: 5′-AATGCATTATAATGTAATCTG-3′ (SEQ ID NO: 7647) KRAS-782 Target: 5′-AGTTCGAGAAATTCGAAAACA-3′ (SEQ ID NO: 7648) KRAS-783 Target: 5′-GTTCGAGAAATTCGAAAACAT-3′ (SEQ ID NO: 7649) KRAS-784 Target: 5′-TTCGAGAAATTCGAAAACATA-3′ (SEQ ID NO: 7650) KRAS-787 Target: 5′-GAGAAATTCGAAAACATAAAG-3′ (SEQ ID NO: 7651) KRAS-792 Target: 5′-ATTCGAAAACATAAAGAAAAG-3′ (SEQ ID NO: 7652) KRAS-793 Target: 5′-TTCGAAAACATAAAGAAAAGA-3′ (SEQ ID NO: 7653) KRAS-817 Target: 5′-GCAAAGATGGTAAAAAGAAGA-3′ (SEQ ID NO: 7654) KRAS-818 Target: 5′-CAAAGATGGTAAAAAGAAGAA-3′ (SEQ ID NO: 7655) KRAS-820 Target: 5′-AAGATGGTAAAAAGAAGAAAA-3′ (SEQ ID NO: 7656) KRAS-821 Target: 5′-AGATGGTAAAAAGAAGAAAAA-3′ (SEQ ID NO: 7657) KRAS-826 Target: 5′-GTAAAAAGAAGAAAAAGAAGT-3′ (SEQ ID NO: 7658) KRAS-827 Target: 5′-TAAAAAGAAGAAAAAGAAGTC-3′ (SEQ ID NO: 7659) KRAS-828 Target: 5′-AAAAAGAAGAAAAAGAAGTCA-3′ (SEQ ID NO: 7660) KRAS-844 Target: 5′-AGTCAAAGACAAAGTGTGTAA-3′ (SEQ ID NO: 7661) KRAS-845 Target: 5′-GTCAAAGACAAAGTGTGTAAT-3′ (SEQ ID NO: 7662) KRAS-849 Target: 5′-AAGACAAAGTGTGTAATTATG-3′ (SEQ ID NO: 7663) KRAS-851 Target: 5′-GACAAAGTGTGTAATTATGTA-3′ (SEQ ID NO: 7664) KRAS-855 Target: 5′-AAGTGTGTAATTATGTAAATA-3′ (SEQ ID NO: 7665) KRAS-857 Target: 5′-GTGTGTAATTATGTAAATACA-3′ (SEQ ID NO: 7666) KRAS-859 Target: 5′-GTGTAATTATGTAAATACAAT-3′ (SEQ ID NO: 7667) KRAS-860 Target: 5′-TGTAATTATGTAAATACAATT-3′ (SEQ ID NO: 7668) KRAS-864 Target: 5′-ATTATGTAAATACAATTTGTA-3′ (SEQ ID NO: 7669) KRAS-865 Target: 5′-TTATGTAAATACAATTTGTAC-3′ (SEQ ID NO: 7670) KRAS-866 Target: 5′-TATGTAAATACAATTTGTACT-3′ (SEQ ID NO: 7671) KRAS-867 Target: 5′-ATGTAAATACAATTTGTACTT-3′ (SEQ ID NO: 7672) KRAS-873 Target: 5′-ATACAATTTGTACTTTTTTCT-3′ (SEQ ID NO: 7673) KRAS-874 Target: 5′-TACAATTTGTACTTTTTTCTT-3′ (SEQ ID NO: 7674) KRAS-899 Target: 5′-CATACTAGTACAAGTGGTAAT-3′ (SEQ ID NO: 7675) KRAS-900 Target: 5′-ATACTAGTACAAGTGGTAATT-3′ (SEQ ID NO: 7676) KRAS-906 Target: 5′-GTACAAGTGGTAATTTTTGTA-3′ (SEQ ID NO: 7677) KRAS-907 Target: 5′-TACAAGTGGTAATTTTTGTAC-3′ (SEQ ID NO: 7678) KRAS-914 Target: 5′-GGTAATTTTTGTACATTACAC-3′ (SEQ ID NO: 7679) KRAS-915 Target: 5′-GTAATTTTTGTACATTACACT-3′ (SEQ ID NO: 7680) KRAS-916 Target: 5′-TAATTTTTGTACATTACACTA-3′ (SEQ ID NO: 7681) KRAS-917 Target: 5′-AATTTTTGTACATTACACTAA-3′ (SEQ ID NO: 7682) KRAS-918 Target: 5′-ATTTTTGTACATTACACTAAA-3′ (SEQ ID NO: 7683) KRAS-930 Target: 5′-TACACTAAATTATTAGCATTT-3′ (SEQ ID NO: 7684) KRAS-932 Target: 5′-CACTAAATTATTAGCATTTGT-3′ (SEQ ID NO: 7685) KRAS-933 Target: 5′-ACTAAATTATTAGCATTTGTT-3′ (SEQ ID NO: 7686) KRAS-938 Target: 5′-ATTATTAGCATTTGTTTTAGC-3′ (SEQ ID NO: 7687) KRAS-944 Target: 5′-AGCATTTGTTTTAGCATTACC-3′ (SEQ ID NO: 7688) KRAS-945 Target: 5′-GCATTTGTTTTAGCATTACCT-3′ (SEQ ID NO: 7689) KRAS-947 Target: 5′-ATTTGTTTTAGCATTACCTAA-3′ (SEQ ID NO: 7690) KRAS-948 Target: 5′-TTTGTTTTAGCATTACCTAAT-3′ (SEQ ID NO: 7691) KRAS-949 Target: 5′-TTGTTTTAGCATTACCTAATT-3′ (SEQ ID NO: 7692) KRAS-950 Target: 5′-TGTTTTAGCATTACCTAATTT-3′ (SEQ ID NO: 7693) KRAS-986 Target: 5′-CAGACTGTTAGCTTTTACCTT-3′ (SEQ ID NO: 7694) KRAS-987 Target: 5′-AGACTGTTAGCTTTTACCTTA-3′ (SEQ ID NO: 7695) KRAS-993 Target: 5′-TTAGCTTTTACCTTAAATGCT-3′ (SEQ ID NO: 7696) KRAS-994 Target: 5′-TAGCTTTTACCTTAAATGCTT-3′ (SEQ ID NO: 7697) KRAS-995 Target: 5′-AGCTTTTACCTTAAATGCTTA-3′ (SEQ ID NO: 7698) KRAS-1001 Target: 5′-TACCTTAAATGCTTATTTTAA-3′ (SEQ ID NO: 7699) KRAS-1002 Target: 5′-ACCTTAAATGCTTATTTTAAA-3′ (SEQ ID NO: 7700) KRAS-1008 Target: 5′-AATGCTTATTTTAAAATGACA-3′ (SEQ ID NO: 7701) KRAS-1010 Target: 5′-TGCTTATTTTAAAATGACAGT-3′ (SEQ ID NO: 7702) KRAS-1027 Target: 5′-CAGTGGAAGTTTTTTTTTCCT-3′ (SEQ ID NO: 7703) KRAS-1029 Target: 5′-GTGGAAGTTTTTTTTTCCTCT-3′ (SEQ ID NO: 7704) KRAS-1030 Target: 5′-TGGAAGTTTTTTTTTCCTCTA-3′ (SEQ ID NO: 7705) KRAS-1068 Target: 5′-AGTTTTGGTTTTTGAACTAGC-3′ (SEQ ID NO: 7706) KRAS-1090 Target: 5′-ATGCCTGTGAAAAAGAAACTG-3′ (SEQ ID NO: 7707) KRAS-1097 Target: 5′-TGAAAAAGAAACTGAATACCT-3′ (SEQ ID NO: 7708) KRAS-1098 Target: 5′-GAAAAAGAAACTGAATACCTA-3′ (SEQ ID NO: 7709) KRAS-1104 Target: 5′-GAAACTGAATACCTAAGATTT-3′ (SEQ ID NO: 7710) KRAS-1145 Target: 5′-CATGCAGTTGATTACTTCTTA-3′ (SEQ ID NO: 7711) KRAS-1146 Target: 5′-ATGCAGTTGATTACTTCTTAT-3′ (SEQ ID NO: 7712) KRAS-1150 Target: 5′-AGTTGATTACTTCTTATTTTT-3′ (SEQ ID NO: 7713) KRAS-1158 Target: 5′-ACTTCTTATTTTTCTTACCAA-3′ (SEQ ID NO: 7714) KRAS-1159 Target: 5′-CTTCTTATTTTTCTTACCAAT-3′ (SEQ ID NO: 7715) KRAS-1160 Target: 5′-TTCTTATTTTTCTTACCAATT-3′ (SEQ ID NO: 7716) KRAS-1183 Target: 5′-GAATGTTGGTGTGAAACAAAT-3′ (SEQ ID NO: 7717) KRAS-1186 Target: 5′-TGTTGGTGTGAAACAAATTAA-3′ (SEQ ID NO: 7718) KRAS-1187 Target: 5′-GTTGGTGTGAAACAAATTAAT-3′ (SEQ ID NO: 7719) KRAS-1195 Target: 5′-GAAACAAATTAATGAAGCTTT-3′ (SEQ ID NO: 7720) KRAS-1196 Target: 5′-AAACAAATTAATGAAGCTTTT-3′ (SEQ ID NO: 7721) KRAS-1228 Target: 5′-ATTCTGTGTTTTATCTAGTCA-3′ (SEQ ID NO: 7722) KRAS-1229 Target: 5′-TTCTGTGTTTTATCTAGTCAC-3′ (SEQ ID NO: 7723) KRAS-1232 Target: 5′-TGTGTTTTATCTAGTCACATA-3′ (SEQ ID NO: 7724) KRAS-1233 Target: 5′-GTGTTTTATCTAGTCACATAA-3′ (SEQ ID NO: 7725) KRAS-1238 Target: 5′-TTATCTAGTCACATAAATGGA-3′ (SEQ ID NO: 7726) KRAS-1239 Target: 5′-TATCTAGTCACATAAATGGAT-3′ (SEQ ID NO: 7727) KRAS-1247 Target: 5′-CACATAAATGGATTAATTACT-3′ (SEQ ID NO: 7728) KRAS-1248 Target: 5′-ACATAAATGGATTAATTACTA-3′ (SEQ ID NO: 7729) KRAS-1253 Target: 5′-AATGGATTAATTACTAATTTC-3′ (SEQ ID NO: 7730) KRAS-1255 Target: 5′-TGGATTAATTACTAATTTCAG-3′ (SEQ ID NO: 7731) KRAS-1256 Target: 5′-GGATTAATTACTAATTTCAGT-3′ (SEQ ID NO: 7732) KRAS-1257 Target: 5′-GATTAATTACTAATTTCAGTT-3′ (SEQ ID NO: 7733) KRAS-1285 Target: 5′-TCTAATTGGTTTTTACTGAAA-3′ (SEQ ID NO: 7734) KRAS-1289 Target: 5′-ATTGGTTTTTACTGAAACATT-3′ (SEQ ID NO: 7735) KRAS-1290 Target: 5′-TTGGTTTTTACTGAAACATTG-3′ (SEQ ID NO: 7736) KRAS-1305 Target: 5′-ACATTGAGGGAACACAAATTT-3′ (SEQ ID NO: 7737) KRAS-1306 Target: 5′-CATTGAGGGAACACAAATTTA-3′ (SEQ ID NO: 7738) KRAS-1379 Target: 5′-CCTGATGAATGTAAAGTTACA-3′ (SEQ ID NO: 7739) KRAS-1380 Target: 5′-CTGATGAATGTAAAGTTACAC-3′ (SEQ ID NO: 7740) KRAS-1452 Target: 5′-CCCCAAAATATTATATTTTTT-3′ (SEQ ID NO: 7741) KRAS-1453 Target: 5′-CCCAAAATATTATATTTTTTC-3′ (SEQ ID NO: 7742) KRAS-1454 Target: 5′-CCAAAATATTATATTTTTTCT-3′ (SEQ ID NO: 7743) KRAS-1455 Target: 5′-CAAAATATTATATTTTTTCTA-3′ (SEQ ID NO: 7744) KRAS-1457 Target: 5′-AAATATTATATTTTTTCTATA-3′ (SEQ ID NO: 7745) KRAS-1458 Target: 5′-AATATTATATTTTTTCTATAA-3′ (SEQ ID NO: 7746) KRAS-1459 Target: 5′-ATATTATATTTTTTCTATAAA-3′ (SEQ ID NO: 7747) KRAS-1460 Target: 5′-TATTATATTTTTTCTATAAAA-3′ (SEQ ID NO: 7748) KRAS-1461 Target: 5′-ATTATATTTTTTCTATAAAAA-3′ (SEQ ID NO: 7749) KRAS-1462 Target: 5′-TTATATTTTTTCTATAAAAAG-3′ (SEQ ID NO: 7750) KRAS-1463 Target: 5′-TATATTTTTTCTATAAAAAGA-3′ (SEQ ID NO: 7751) KRAS-1464 Target: 5′-ATATTTTTTCTATAAAAAGAA-3′ (SEQ ID NO: 7752) KRAS-1469 Target: 5′-TTTTCTATAAAAAGAAAAAAA-3′ (SEQ ID NO: 7753) KRAS-1470 Target: 5′-TTTCTATAAAAAGAAAAAAAT-3′ (SEQ ID NO: 7754) KRAS-1472 Target: 5′-TCTATAAAAAGAAAAAAATGG-3′ (SEQ ID NO: 7755) KRAS-1473 Target: 5′-CTATAAAAAGAAAAAAATGGA-3′ (SEQ ID NO: 7756) KRAS-1474 Target: 5′-TATAAAAAGAAAAAAATGGAA-3′ (SEQ ID NO: 7757) KRAS-1475 Target: 5′-ATAAAAAGAAAAAAATGGAAA-3′ (SEQ ID NO: 7758) KRAS-1476 Target: 5′-TAAAAAGAAAAAAATGGAAAA-3′ (SEQ ID NO: 7759) KRAS-1477 Target: 5′-AAAAAGAAAAAAATGGAAAAA-3′ (SEQ ID NO: 7760) KRAS-1478 Target: 5′-AAAAGAAAAAAATGGAAAAAA-3′ (SEQ ID NO: 7761) KRAS-1482 Target: 5′-GAAAAAAATGGAAAAAAATTA-3′ (SEQ ID NO: 7762) KRAS-1483 Target: 5′-AAAAAAATGGAAAAAAATTAC-3′ (SEQ ID NO: 7763) KRAS-1488 Target: 5′-AATGGAAAAAAATTACAAGGC-3′ (SEQ ID NO: 7764) KRAS-1489 Target: 5′-ATGGAAAAAAATTACAAGGCA-3′ (SEQ ID NO: 7765) KRAS-1490 Target: 5′-TGGAAAAAAATTACAAGGCAA-3′ (SEQ ID NO: 7766) KRAS-1525 Target: 5′-AGGCCATTTCCTTTTCACATT-3′ (SEQ ID NO: 7767) KRAS-1531 Target: 5′-TTTCCTTTTCACATTAGATAA-3′ (SEQ ID NO: 7768) KRAS-1538 Target: 5′-TTCACATTAGATAAATTACTA-3′ (SEQ ID NO: 7769) KRAS-1539 Target: 5′-TCACATTAGATAAATTACTAT-3′ (SEQ ID NO: 7770) KRAS-1540 Target: 5′-CACATTAGATAAATTACTATA-3′ (SEQ ID NO: 7771) KRAS-1595 Target: 5′-CCAGTATGAAATGGGGATTAT-3′ (SEQ ID NO: 7772) KRAS-1604 Target: 5′-AATGGGGATTATTATAGCAAC-3′ (SEQ ID NO: 7773) KRAS-1631 Target: 5′-GGGGCTATATTTACATGCTAC-3′ (SEQ ID NO: 7774) KRAS-1632 Target: 5′-GGGCTATATTTACATGCTACT-3′ (SEQ ID NO: 7775) KRAS-1633 Target: 5′-GGCTATATTTACATGCTACTA-3′ (SEQ ID NO: 7776) KRAS-1634 Target: 5′-GCTATATTTACATGCTACTAA-3′ (SEQ ID NO: 7777) KRAS-1635 Target: 5′-CTATATTTACATGCTACTAAA-3′ (SEQ ID NO: 7778) KRAS-1640 Target: 5′-TTTACATGCTACTAAATTTTT-3′ (SEQ ID NO: 7779) KRAS-1647 Target: 5′-GCTACTAAATTTTTATAATAA-3′ (SEQ ID NO: 7780) KRAS-1648 Target: 5′-CTACTAAATTTTTATAATAAT-3′ (SEQ ID NO: 7781) KRAS-1650 Target: 5′-ACTAAATTTTTATAATAATTG-3′ (SEQ ID NO: 7782) KRAS-1651 Target: 5′-CTAAATTTTTATAATAATTGA-3′ (SEQ ID NO: 7783) KRAS-1652 Target: 5′-TAAATTTTTATAATAATTGAA-3′ (SEQ ID NO: 7784) KRAS-1653 Target: 5′-AAATTTTTATAATAATTGAAA-3′ (SEQ ID NO:.7785) KRAS-1654 Target: 5′-AATTTTTATAATAATTGAAAA-3′ (SEQ ID NO: 7786) KRAS-1655 Target: 5′-ATTTTTATAATAATTGAAAAG-3′ (SEQ ID NO: 7787) KRAS-1656 Target: 5′-TTTTTATAATAATTGAAAAGA-3′ (SEQ ID NO: 7788) KRAS-1657 Target: 5′-TTTTATAATAATTGAAAAGAT-3′ (SEQ ID NO: 7789) KRAS-1658 Target: 5′-TTTATAATAATTGAAAAGATT-3′ (SEQ ID NO: 7790) KRAS-1662 Target: 5′-TAATAATTGAAAAGATTTTAA-3′ (SEQ ID NO: 7791) KRAS-1663 Target: 5′-AATAATTGAAAAGATTTTAAC-3′ (SEQ ID NO: 7792) KRAS-1665 Target: 5′-TAATTGAAAAGATTTTAACAA-3′ (SEQ ID NO: 7793) KRAS-1666 Target: 5′-AATTGAAAAGATTTTAACAAG-3′ (SEQ ID NO: 7794) KRAS-1667 Target: 5′-ATTGAAAAGATTTTAACAAGT-3′ (SEQ ID NO: 7795) KRAS-1668 Target: 5′-TTGAAAAGATTTTAACAAGTA-3′ (SEQ ID NO: 7796) KRAS-1669 Target: 5′-TGAAAAGATTTTAACAAGTAT-3′ (SEQ ID NO: 7797) KRAS-1670 Target: 5′-GAAAAGATTTTAACAAGTATA-3′ (SEQ ID NO: 7798) KRAS-1671 Target: 5′-AAAAGATTTTAACAAGTATAA-3′ (SEQ ID NO: 7799) KRAS-1672 Target: 5′-AAAGATTTTAACAAGTATAAA-3′ (SEQ ID NO: 7800) KRAS-1673 Target: 5′-AAGATTTTAACAAGTATAAAA-3′ (SEQ ID NO: 7801) KRAS-1680 Target: 5′-TAACAAGTATAAAAAATTCTC-3′ (SEQ ID NO: 7802) KRAS-1681 Target: 5′-AACAAGTATAAAAAATTCTCA-3′ (SEQ ID NO: 7803) KRAS-1682 Target: 5′-ACAAGTATAAAAAATTCTCAT-3′ (SEQ ID NO: 7804) KRAS-1683 Target: 5′-CAAGTATAAAAAATTCTCATA-3′ (SEQ ID NO: 7805) KRAS-1684 Target: 5′-AAGTATAAAAAATTCTCATAG-3′ (SEQ ID NO: 7806) KRAS-1685 Target: 5′-AGTATAAAAAATTCTCATAGG-3′ (SEQ ID NO: 7807) KRAS-1686 Target: 5GTATAAAAAATTCTCATAGGA-3′ (SEQ ID NO: 7808) KRAS-1687 Target: 5′-TATAAAAAATTCTCATAGGAA-3′ (SEQ ID NO: 7809) KRAS-1689 Target: 5′-TAAAAAATTCTCATAGGAATT-3′ (SEQ ID NO: 7810) KRAS-1690 Target: 5′-AAAAAATTCTCATAGGAATTA-3′ (SEQ ID NO: 7811) KRAS-1734 Target: 5′-TGCTCTTTCATAGTATAACTT-3′ (SEQ ID NO: 7812) KRAS-1739 Target: 5′-TTTCATAGTATAACTTTAAAT-3′ (SEQ ID NO: 7813) KRAS-1740 Target: 5′-TTCATAGTATAACTTTAAATC-3′ (SEQ ID NO: 7814) KRAS-1751 Target: 5′-ACTTTAAATCTTTTCTTCAAC-3′ (SEQ ID NO: 7815) KRAS-1752 Target: 5′-CTTTAAATCTTTTCTTCAACT-3′ (SEQ ID NO: 7816) KRAS-1767 Target: 5′-TCAACTTGAGTCTTTGAAGAT-3′ (SEQ ID NO: 7817) KRAS-1769 Target: 5′-AACTTGAGTCTTTGAAGATAG-3′ (SEQ ID NO: 7818) KRAS-1770 Target: 5′-ACTTGAGTCTTTGAAGATAGT-3′ (SEQ ID NO: 7819) KRAS-1781 Target: 5′-TGAAGATAGTTTTAATTCTGC-3′ (SEQ ID NO: 7820) KRAS-1782 Target: 5′-GAAGATAGTTTTAATTCTGCT-3′ (SEQ ID NO: 7821) KRAS-1783 Target: 5′-AAGATAGTTTTAATTCTGCTT-3′ (SEQ ID NO: 7822) KRAS-1797 Target: 5′-TCTGCTTGTGACATTAAAAGA-3′ (SEQ ID NO: 7823) KRAS-2045 Target: 5′-AGAGCATTGCTTTTGTTTCTT-3′ (SEQ ID NO: 7824) KRAS-2046 Target: 5′-GAGCATTGCTTTTGTTTCTTA-3′ (SEQ ID NO: 7825) KRAS-2052 Target: 5′-TGCTTTTGTTTCTTAAGAAAA-3′ (SEQ ID NO: 7826) KRAS-2059 Target: 5′-GTTTCTTAAGAAAACAAACTC-3′ (SEQ ID NO: 7827) KRAS-2060 Target: 5′-TTTCTTAAGAAAACAAACTCT-3′ (SEQ ID NO: 7828) KRAS-2061 Target: 5′-TTCTTAAGAAAACAAACTCTT-3′ (SEQ ID NO: 7829) KRAS-2062 Target: 5′-TCTTAAGAAAACAAACTCTTT-3′ (SEQ ID NO: 7830) KRAS-2063 Target: 5′-CTTAAGAAAACAAACTCTTTT-3′ (SEQ ID NO: 7831) KRAS-2064 Target: 5′-TTAAGAAAACAAACTCTTTTT-3′ (SEQ ID NO: 7832) KRAS-2065 Target: 5′-TAAGAAAACAAACTCTTTTTT-3′ (SEQ ID NO: 7833) KRAS-2069 Target: 5′-AAAACAAACTCTTTTTTAAAA-3′ (SEQ ID NO: 7834) KRAS-2075 Target: 5′-AACTCTTTTTTAAAAATTACT-3′ (SEQ ID NO: 7835) KRAS-2076 Target: 5′-ACTCTTTTTTAAAAATTACTT-3′ (SEQ ID NO: 7836) KRAS-2077 Target: 5′-CTCTTTTTTAAAAATTACTTT-3′ (SEQ ID NO: 7837) KRAS-2078 Target: 5′-TCTTTTTTAAAAATTACTTTT-3′ (SEQ ID NO: 7838) KRAS-2079 Target: 5′-CTTTTTTAAAAATTACTTTTA-3′ (SEQ ID NO: 7839) KRAS-2080 Target: 5′-TTTTTTAAAAATTACTTTTAA-3′ (SEQ ID NO: 7840) KRAS-2081 Target: 5′-TTTTTAAAAATTACTTTTAAA-3′ (SEQ ID NO: 7841) KRAS-2082 Target: 5′-TTTTAAAAATTACTTTTAAAT-3′ (SEQ ID NO: 7842) KRAS-2083 Target: 5′-TTTAAAAATTACTTTTAAATA-3′ (SEQ ID NO: 7843) KRAS-2090 Target: 5′-ATTACTTTTAAATATTAACTC-3′ (SEQ ID NO: 7844) KRAS-2091 Target: 5′-TTACTTTTAAATATTAACTCA-3′ (SEQ ID NO: 7845) KRAS-2093 Target: 5′-ACTTTTAAATATTAACTCAAA-3′ (SEQ ID NO: 7846) KRAS-2095 Target: 5′-TTTTAAATATTAACTCAAAAG-3′ (SEQ ID NO: 7847) KRAS-2096 Target: 5′-TTTAAATATTAACTCAAAAGT-3′ (SEQ ID NO: 7848) KRAS-2097 Target: 5′-TTAAATATTAACTCAAAAGTT-3′ (SEQ ID NO: 7849) KRAS-2098 Target: 5′-TAAATATTAACTCAAAAGTTG-3′ (SEQ ID NO: 7850) KRAS-2132 Target: 5′-GTGGTGTGCCAAGACATTAAT-3′ (SEQ ID NO: 7851) KRAS-2137 Target: 5′-GTGCCAAGACATTAATTTTTT-3′ (SEQ ID NO: 7852) KRAS-2138 Target: 5′-TGCCAAGACATTAATTTTTTT-3′ (SEQ ID NO: 7853) KRAS-2144 Target: 5′-GACATTAATTTTTTTTTTAAA-3′ (SEQ ID NO: 7854) KRAS-2145 Target: 5′-ACATTAATTTTTTTTTTAAAC-3′ (SEQ ID NO: 7855) KRAS-2147 Target: 5′-ATTAATTTTTTTTTTAAACAA-3′ (SEQ ID NO: 7856) KRAS-2149 Target: 5′-TAATTTTTTTTTTAAACAATG-3′ (SEQ ID NO: 7857) KRAS-2150 Target: 5′-AATTTTTTTTTTAAACAATGA-3′ (SEQ ID NO: 7858) KRAS-2151 Target: 5′-ATTTTTTTTTTAAACAATGAA-3′ (SEQ ID NO: 7859) KRAS-2152 Target: 5′-TTTTTTTTTTAAACAATGAAG-3′ (SEQ ID NO: 7860) KRAS-2153 Target: 5′-TTTTTTTTTAAACAATGAAGT-3′ (SEQ ID NO: 7861) KRAS-2155 Target: 5′-TTTTTTTAAACAATGAAGTGA-3′ (SEQ ID NO: 7862) KRAS-2156 Target: 5′-TTTTTTAAACAATGAAGTGAA-3′ (SEQ ID NO: 7863) KRAS-2157 Target: 5′-TTTTTAAACAATGAAGTGAAA-3′ (SEQ ID NO: 7864) KRAS-2165 Target: 5′-CAATGAAGTGAAAAAGTTTTA-3′ (SEQ ID NO: 7865) KRAS-2171 Target: 5′-AGTGAAAAAGTTTTACAATCT-3′ (SEQ ID NO: 7866) KRAS-2172 Target: 5′-GTGAAAAAGTTTTACAATCTC-3′ (SEQ ID NO: 7867) KRAS-2173 Target: 5′-TGAAAAAGTTTTACAATCTCT-3′ (SEQ ID NO: 7868) KRAS-2214 Target: 5′-ACACTGGTTAAATTAACATTG-3′ (SEQ ID NO: 7869) KRAS-2215 Target: 5′-CACTGGTTAAATTAACATTGC-3′ (SEQ ID NO: 7870) KRAS-2216 Target: 5′-ACTGGTTAAATTAACATTGCA-3′ (SEQ ID NO: 7871) KRAS-2227 Target: 5′-TAACATTGCATAAACACTTTT-3′ (SEQ ID NO: 7872) KRAS-2245 Target: 5′-TTTCAAGTCTGATCCATATTT-3′ (SEQ ID NO: 7873) KRAS-2255 Target: 5′-GATCCATATTTAATAATGCTT-3′ (SEQ ID NO: 7874) KRAS-2256 Target: 5′-ATCCATATTTAATAATGCTTT-3′ (SEQ ID NO: 7875) KRAS-2257 Target: 5′-TCCATATTTAATAATGCTTTA-3′ (SEQ ID NO: 7876) KRAS-2258 Target: 5′-CCATATTTAATAATGCTTTAA-3′ (SEQ ID NO: 7877) KRAS-2259 Target: 5′-CATATTTAATAATGCTTTAAA-3′ (SEQ ID NO: 7878) KRAS-2260 Target: 5′-ATATTTAATAATGCTTTAAAA-3′ (SEQ ID NO: 7879) KRAS-2262 Target: 5′-ATTTAATAATGCTTTAAAATA-3′ (SEQ ID NO: 7880) KRAS-2263 Target: 5′-TTTAATAATGCTTTAAAATAA-3′ (SEQ ID NO: 7881) KRAS-2264 Target: 5′-TTAATAATGCTTTAAAATAAA-3′ (SEQ ID NO: 7882) KRAS-2265 Target: 5′-TAATAATGCTTTAAAATAAAA-3′ (SEQ ID NO: 7883) KRAS-2272 Target: 5′-GCTTTAAAATAAAAATAAAAA-3′ (SEQ ID NO: 7884) KRAS-2278 Target: 5′-AAATAAAAATAAAAACAATCC-3′ (SEQ ID NO: 7885) KRAS-2279 Target: 5′-AATAAAAATAAAAACAATCCT-3′ (SEQ ID NO: 7886) KRAS-2280 Target: 5′-ATAAAAATAAAAACAATCCTT-3′ (SEQ ID NO: 7887) KRAS-2281 Target: 5′-TAAAAATAAAAACAATCCTTT-3′ (SEQ ID NO: 7888) KRAS-2282 Target: 5′-AAAAATAAAAACAATCCTTTT-3′ (SEQ ID NO: 7889) KRAS-2283 Target: 5′-AAAATAAAAACAATCCTTTTG-3′ (SEQ ID NO: 7890) KRAS-2284 Target: 5′-AAATAAAAACAATCCTTTTGA-3′ (SEQ ID NO: 7891) KRAS-2285 Target: 5′-AATAAAAACAATCCTTTTGAT-3′ (SEQ ID NO: 7892) KRAS-2289 Target: 5′-AAAACAATCCTTTTGATAAAT-3′ (SEQ ID NO: 7893) KRAS-2294 Target: 5′-AATCCTTTTGATAAATTTAAA-3′ (SEQ ID NO: 7894) KRAS-2295 Target: 5′-ATCCTTTTGATAAATTTAAAA-3′ (SEQ ID NO: 7895) KRAS-2296 Target: 5′-TCCTTTTGATAAATTTAAAAT-3′ (SEQ ID NO: 7896) KRAS-2300 Target: 5′-TTTGATAAATTTAAAATGTTA-3′ (SEQ ID NO: 7897) KRAS-2301 Target: 5′-TTGATAAATTTAAAATGTTAC-3′ (SEQ ID NO: 7898) KRAS-2302 Target: 5′-TGATAAATTTAAAATGTTACT-3′ (SEQ ID NO: 7899) KRAS-2303 Target: 5′-GATAAATTTAAAATGTTACTT-3′ (SEQ ID NO: 7900) KRAS-2304 Target: 5′-ATAAATTTAAAATGTTACTTA-3′ (SEQ ID NO: 7901) KRAS-2305 Target: 5′-TAAATTTAAAATGTTACTTAT-3′ (SEQ ID NO: 7902) KRAS-2307 Target: 5′-AATTTAAAATGTTACTTATTT-3′ (SEQ ID NO: 7903) KRAS-2308 Target: 5′-ATTTAAAATGTTACTTATTTT-3′ (SEQ ID NO: 7904) KRAS-2309 Target: 5′-TTTAAAATGTTACTTATTTTA-3′ (SEQ ID NO: 7905) KRAS-2310 Target: 5′-TTAAAATGTTACTTATTTTAA-3′ (SEQ ID NO: 7906) KRAS-2311 Target: 5′-TAAAATGTTACTTATTTTAAA-3′ (SEQ ID NO: 7907) KRAS-2313 Target: 5′-AAATGTTACTTATTTTAAAAT-3′ (SEQ ID NO: 7908) KRAS-2318 Target: 5′-TTACTTATTTTAAAATAAATG-3′ (SEQ ID NO: 7909) KRAS-2320 Target: 5′-ACTTATTTTAAAATAAATGAA-3′ (SEQ ID NO: 7910) KRAS-2321 Target: 5′-CTTATTTTAAAATAAATGAAG-3′ (SEQ ID NO: 7911) KRAS-2324 Target: 5′-ATTTTAAAATAAATGAAGTGA-3′ (SEQ ID NO: 7912) KRAS-2325 Target: 5′-TTTTAAAATAAATGAAGTGAG-3′ (SEQ ID NO: 7913) KRAS-2445 Target: 5′-TATCCATTTCTTCATGTTAAA-3′ (SEQ ID NO: 7914) KRAS-2446 Target: 5′-ATCCATTTCTTCATGTTAAAA-3′ (SEQ ID NO: 7915) KRAS-2473 Target: 5′-ATCTCAAACTCTTAGTTTTTT-3′ (SEQ ID NO: 7916) KRAS-2483 Target: 5′-CTTAGTTTTTTTTTTTTACAA-3′ (SEQ ID NO: 7917) KRAS-2484 Target: 5′-TTAGTTTTTTTTTTTTACAAC-3′ (SEQ ID NO: 7918) KRAS-2485 Target: 5′-TAGTTTTTTTTTTTTACAACT-3′ (SEQ ID NO: 7919) KRAS-2486 Target: 5′-AGTTTTTTTTTTTTACAACTA-3′ (SEQ ID NO: 7920) KRAS-2487 Target: 5′-GTTTTTTTTTTTTACAACTAT-3′ (SEQ ID NO: 7921) KRAS-2488 Target: 5′-TTTTTTTTTTTTACAACTATG-3′ (SEQ ID NO: 7922) KRAS-2489 Target: 5′-TTTTTTTTTTTACAACTATGT-3′ (SEQ ID NO: 7923) KRAS-2490 Target: 5′-TTTTTTTTTTACAACTATGTA-3′ (SEQ ID NO: 7924) KRAS-2491 Target: 5′-TTTTTTTTTACAACTATGTAA-3′ (SEQ ID NO: 7925) KRAS-2492 Target: 5′-TTTTTTTTACAACTATGTAAT-3′ (SEQ ID NO: 7926) KRAS-2493 Target: 5′-TTTTTTTACAACTATGTAATT-3′ (SEQ ID NO: 7927) KRAS-2500 Target: 5′-ACAACTATGTAATTTATATTC-3′ (SEQ ID NO: 7928) KRAS-2501 Target: 5′-CAACTATGTAATTTATATTCC-3′ (SEQ ID NO: 7929) KRAS-2502 Target: 5′-AACTATGTAATTTATATTCCA-3′ (SEQ ID NO: 7930) KRAS-2508 Target: 5′-GTAATTTATATTCCATTTACA-3′ (SEQ ID NO: 7931) KRAS-2509 Target: 5′-TAATTTATATTCCATTTACAT-3′ (SEQ ID NO: 7932) KRAS-2510 Target: 5′-AATTTATATTCCATTTACATA-3′ (SEQ ID NO: 7933) KRAS-2511 Target: 5′-ATTTATATTCCATTTACATAA-3′ (SEQ ID NO: 7934) KRAS-2523 Target: 5′-TTTACATAAGGATACACTTAT-3′ (SEQ ID NO: 7935) KRAS-2527 Target: 5′-CATAAGGATACACTTATTTGT-3′ (SEQ ID NO: 7936) KRAS-2559 Target: 5′-CAATCTGTAAATTTTTAACCT-3′ (SEQ ID NO: 7937) KRAS-2560 Target: 5′-AATCTGTAAATTTTTAACCTA-3′ (SEQ ID NO: 7938) KRAS-2561 Target: 5′-ATCTGTAAATTTTTAACCTAT-3′ (SEQ ID NO: 7939) KRAS-2617 Target: 5′-TGTGCAAGAGGTGAAGTTTAT-3′ (SEQ ID NO: 7940) KRAS-2619 Target: 5′-TGCAAGAGGTGAAGTTTATAT-3′ (SEQ ID NO: 7941) KRAS-2620 Target: 5′-GCAAGAGGTGAAGTTTATATT-3′ (SEQ ID NO: 7942) KRAS-2622 Target: 5′-AAGAGGTGAAGTTTATATTTG-3′ (SEQ ID NO: 7943) KRAS-2623 Target: 5′-AGAGGTGAAGTTTATATTTGA-3′ (SEQ ID NO: 7944) KRAS-2628 Target: 5′-TGAAGTTTATATTTGAATATC-3′ (SEQ ID NO: 7945) KRAS-2716 Target: 5′-TGACTTGATGCAGTTTTAATA-3′ (SEQ ID NO: 7946) KRAS-2718 Target: 5′-ACTTGATGCAGTTTTAATACT-3′ (SEQ ID NO: 7947) KRAS-2869 Target: 5′-GGGATTTGACCTAATCACTAA-3′ (SEQ ID NO: 7948) KRAS-2875 Target: 5′-TGACCTAATCACTAATTTTCA-3′ (SEQ ID NO: 7949) KRAS-2944 Target: 5′-GACAGTAGGATTTTTCAAACC-3′ (SEQ ID NO: 7950) KRAS-2989 Target: 5′-CCAGTGGAAGGAGAATTTAAT-3′ (SEQ ID NO: 7951) KRAS-2992 Target: 5′-GTGGAAGGAGAATTTAATAAA-3′ (SEQ ID NO: 7952) KRAS-2994 Target: 5′-GGAAGGAGAATTTAATAAAGA-3′ (SEQ ID NO: 7953) KRAS-2995 Target: 5′-GAAGGAGAATTTAATAAAGAT-3′ (SEQ ID NO: 7954) KRAS-2999 Target: 5′-GAGAATTTAATAAAGATAGTG-3′ (SEQ ID NO: 7955) KRAS-3028 Target: 5′-ATTCCTTAGGTAATCTATAAC-3′ (SEQ ID NO: 7956) KRAS-3029 Target: 5′-TTCCTTAGGTAATCTATAACT-3′ (SEQ ID NO: 7957) KRAS-3063 Target: 5′-GTAACAGTAATACATTCCATT-3′ (SEQ ID NO: 7958) KRAS-3065 Target: 5′-AACAGTAATACATTCCATTGT-3′ (SEQ ID NO: 7959) KRAS-3066 Target: 5′-ACAGTAATACATTCCATTGTT-3′ (SEQ ID NO: 7960) KRAS-3067 Target: 5′-CAGTAATACATTCCATTGTTT-3′ (SEQ ID NO: 7961) KRAS-3077 Target: 5′-TTCCATTGTTTTAGTAACCAG-3′ (SEQ ID NO: 7962) KRAS-3091 Target: 5′-TAACCAGAAATCTTCATGCAA-3′ (SEQ ID NO: 7963) KRAS-3101 Target: 5′-TCTTCATGCAATGAAAAATAC-3′ (SEQ ID NO: 7964) KRAS-3108 Target: 5′-GCAATGAAAAATACTTTAATT-3′ (SEQ ID NO: 7965) KRAS-3110 Target: 5′-AATGAAAAATACTTTAATTCA-3′ (SEQ ID NO: 7966) KRAS-3111 Target: 5′-ATGAAAAATACTTTAATTCAT-3′ (SEQ ID NO: 7967) KRAS-3125 Target: 5′-AATTCATGAAGCTTACTTTTT-3′ (SEQ ID NO: 7968) KRAS-3128 Target: 5′-TCATGAAGCTTACTTTTTTTT-3′ (SEQ ID NO: 7969) KRAS-3132 Target: 5′-GAAGCTTACTTTTTTTTTTTG-3′ (SEQ ID NO: 7970) KRAS-3136 Target: 5′-CTTACTTTTTTTTTTTGGTGT-3′ (SEQ ID NO: 7971) KRAS-3137 Target: 5′-TTACTTTTTTTTTTTGGTGTC-3′ (SEQ ID NO: 7972) KRAS-3295 Target: 5′-TCAACTAATTTTTGTATTTTT-3′ (SEQ ID NO: 7973) KRAS-3298 Target: 5′-ACTAATTTTTGTATTTTTAGG-3′ (SEQ ID NO: 7974) KRAS-3411 Target: 5′-AACTCATTTATTCAGCAAATA-3′ (SEQ ID NO: 7975) KRAS-3413 Target: 5′-CTCATTTATTCAGCAAATATT-3′ (SEQ ID NO: 7976) KRAS-3415 Target: 5′-CATTTATTCAGCAAATATTTA-3′ (SEQ ID NO: 7977) KRAS-3587 Target: 5′-CGTATTTTAGTTTTGCAAAGA-3′ (SEQ ID NO: 7978) KRAS-3628 Target: 5′-AGCTCTATAATTGTTTTGCTA-3′ (SEQ ID NO: 7979) KRAS-3675 Target: 5′-GCTACTTTATGTAAATCACTT-3′ (SEQ ID NO: 7980) KRAS-3676 Target: 5′-CTACTTTATGTAAATCACTTC-3′ (SEQ ID NO: 7981) KRAS-3677 Target: 5′-TACTTTATGTAAATCACTTCA-3′ (SEQ ID NO: 7982) KRAS-3678 Target: 5′-ACTTTATGTAAATCACTTCAT-3′ (SEQ ID NO: 7983) KRAS-3679 Target: 5′-CTTTATGTAAATCACTTCATT-3′ (SEQ ID NO: 7984) KRAS-3680 Target: 5′-TTTATGTAAATCACTTCATTG-3′ (SEQ ID NO: 7985) KRAS-3681 Target: 5′-TTATGTAAATCACTTCATTGT-3′ (SEQ ID NO: 7986) KRAS-3695 Target: 5′-TCATTGTTTTAAAGGAATAAA-3′ (SEQ ID NO: 7987) KRAS-3696 Target: 5′-CATTGTTTTAAAGGAATAAAC-3′ (SEQ ID NO: 7988) KRAS-3699 Target: 5′-TGTTTTAAAGGAATAAACTTG-3′ (SEQ ID NO: 7989) KRAS-3700 Target: 5′-GTTTTAAAGGAATAAACTTGA-3′ (SEQ ID NO: 7990) KRAS-3701 Target: 5′-TTTTAAAGGAATAAACTTGAT-3′ (SEQ ID NO: 7991) KRAS-3703 Target: 5′-TTAAAGGAATAAACTTGATTA-3′ (SEQ ID NO: 7992) KRAS-3704 Target: 5′-TAAAGGAATAAACTTGATTAT-3′ (SEQ ID NO: 7993) KRAS-3705 Target: 5′-AAAGGAATAAACTTGATTATA-3′ (SEQ ID NO: 7994) KRAS-3706 Target: 5′-AAGGAATAAACTTGATTATAT-3′ (SEQ ID NO: 7995) KRAS-3707 Target: 5′-AGGAATAAACTTGATTATATT-3′ (SEQ ID NO: 7996) KRAS-3712 Target: 5′-TAAACTTGATTATATTGTTTT-3′ (SEQ ID NO: 7997) KRAS-3713 Target: 5′-AAACTTGATTATATTGTTTTT-3′ (SEQ ID NO: 7998) KRAS-3716 Target: 5′-CTTGATTATATTGTTTTTTTA-3′ (SEQ ID NO: 7999) KRAS-3721 Target: 5′-TTATATTGTTTTTTTATTTGG-3′ (SEQ ID NO: 8000) KRAS-3722 Target: 5′-TATATTGTTTTTTTATTTGGC-3′ (SEQ ID NO: 8001) KRAS-3726 Target: 5′-TTGTTTTTTTATTTGGCATAA-3′ (SEQ ID NO: 8002) KRAS-3727 Target: 5′-TGTTTTTTTATTTGGCATAAC-3′ (SEQ ID NO: 8003) KRAS-3739 Target: 5′-TGGCATAACTGTGATTCTTTT-3′ (SEQ ID NO: 8004) KRAS-3744 Target: 5′-TAACTGTGATTCTTTTAGGAC-3′ (SEQ ID NO: 8005) KRAS-3745 Target: 5′-AACTGTGATTCTTTTAGGACA-3′ (SEQ ID NO: 8006) KRAS-3781 Target: 5′-AAGGTGTATGTCAGATATTCA-3′ (SEQ ID NO: 8007) KRAS-3782 Target: 5′-AGGTGTATGTCAGATATTCAT-3′ (SEQ ID NO: 8008) KRAS-3808 Target: 5′-CCCAAATGTGTAATATTCCAG-3′ (SEQ ID NO: 8009) KRAS-3836 Target: 5′-TGCATAAGTAATTAAAATATA-3′ (SEQ ID NO: 8010) KRAS-3837 Target: 5′-GCATAAGTAATTAAAATATAC-3′ (SEQ ID NO: 8011) KRAS-3838 Target: 5′-CATAAGTAATTAAAATATACT-3′ (SEQ ID NO: 8012) KRAS-3839 Target: 5′-ATAAGTAATTAAAATATACTT-3′ (SEQ ID NO: 8013) KRAS-3840 Target: 5′-TAAGTAATTAAAATATACTTA-3′ (SEQ ID NO: 8014) KRAS-3841 Target: 5′-AAGTAATTAAAATATACTTAA-3′ (SEQ ID NO: 8015) KRAS-3842 Target: 5′-AGTAATTAAAATATACTTAAA-3′ (SEQ ID NO: 8016) KRAS-3843 Target: 5′-GTAATTAAAATATACTTAAAA-3′ (SEQ ID NO: 8017) KRAS-3844 Target: 5′-TAATTAAAATATACTTAAAAA-3′ (SEQ ID NO: 8018) KRAS-3846 Target: 5′-ATTAAAATATACTTAAAAATT-3′ (SEQ ID NO: 8019) KRAS-3847 Target: 5′-TTAAAATATACTTAAAAATTA-3′ (SEQ ID NO: 8020) KRAS-3848 Target: 5′-TAAAATATACTTAAAAATTAA-3′ (SEQ ID NO: 8021) KRAS-3849 Target: 5′-AAAATATACTTAAAAATTAAT-3′ (SEQ ID NO: 8022) KRAS-3853 Target: 5′-TATACTTAAAAATTAATAGTT-3′ (SEQ ID NO: 8023) KRAS-3857 Target: 5′-CTTAAAAATTAATAGTTTTAT-3′ (SEQ ID NO: 8024) KRAS-3858 Target: 5′-TTAAAAATTAATAGTTTTATC-3′ (SEQ ID NO: 8025) KRAS-3859 Target: 5′-TAAAAATTAATAGTTTTATCT-3′ (SEQ ID NO: 8026) KRAS-3874 Target: 5′-TTATCTGGGTACAAATAAACA-3′ (SEQ ID NO: 8027) KRAS-3913 Target: 5′-CAGACAAGGAAACTTCTATGT-3′ (SEQ ID NO: 8028) KRAS-3914 Target: 5′-AGACAAGGAAACTTCTATGTA-3′ (SEQ ID NO: 8029) KRAS-3915 Target: 5′-GACAAGGAAACTTCTATGTAA-3′ (SEQ ID NO: 8030) KRAS-3924 Target: 5′-ACTTCTATGTAAAAATCACTA-3′ (SEQ ID NO: 8031) KRAS-3925 Target: 5′-CTTCTATGTAAAAATCACTAT-3′ (SEQ ID NO: 8032) KRAS-3926 Target: 5′-TTCTATGTAAAAATCACTATG-3′ (SEQ ID NO: 8033) KRAS-3930 Target: 5′-ATGTAAAAATCACTATGATTT-3′ (SEQ ID NO: 8034) KRAS-3931 Target: 5′-TGTAAAAATCACTATGATTTC-3′ (SEQ ID NO: 8035) KRAS-3940 Target: 5′-CACTATGATTTCTGAATTGCT-3′ (SEQ ID NO: 8036) KRAS-3941 Target: 5′-ACTATGATTTCTGAATTGCTA-3′ (SEQ ID NO: 8037) KRAS-3958 Target: 5′-GCTATGTGAAACTACAGATCT-3′ (SEQ ID NO: 8038) KRAS-3959 Target: 5′-CTATGTGAAACTACAGATCTT-3′ (SEQ ID NO: 8039) KRAS-3995 Target: 5′-GTAGGGTGTTAAGACTTACAC-3′ (SEQ ID NO: 8040) KRAS-4082 Target: 5′-TATTTAGGCCTCTTGAATTTT-3′ (SEQ ID NO: 8041) KRAS-4090 Target: 5′-CCTCTTGAATTTTTGATGTAG-3′ (SEQ ID NO: 8042) KRAS-4091 Target: 5′-CTCTTGAATTTTTGATGTAGA-3′ (SEQ ID NO: 8043) KRAS-4106 Target: 5′-TGTAGATGGGCATTTTTTTAA-3′ (SEQ ID NO: 8044) KRAS-4112 Target: 5′-TGGGCATTTTTTTAAGGTAGT-3′ (SEQ ID NO: 8045) KRAS-4124 Target: 5′-TAAGGTAGTGGTTAATTACCT-3′ (SEQ ID NO: 8046) KRAS-4126 Target: 5′-AGGTAGTGGTTAATTACCTTT-3′ (SEQ ID NO: 8047) KRAS-4127 Target: 5′-GGTAGTGGTTAATTACCTTTA-3′ (SEQ ID NO: 8048) KRAS-4128 Target: 5′-GTAGTGGTTAATTACCTTTAT-3′ (SEQ ID NO: 8049) KRAS-4129 Target: 5′-TAGTGGTTAATTACCTTTATG-3′ (SEQ ID NO: 8050) KRAS-4139 Target: 5′-TTACCTTTATGTGAACTTTGA-3′ (SEQ ID NO: 8051) KRAS-4144 Target: 5′-TTTATGTGAACTTTGAATGGT-3′ (SEQ ID NO: 8052) KRAS-4150 Target: 5′-TGAACTTTGAATGGTTTAACA-3′ (SEQ ID NO: 8053) KRAS-4154 Target: 5′-CTTTGAATGGTTTAACAAAAG-3′ (SEQ ID NO: 8054) KRAS-4155 Target: 5′-TTTGAATGGTTTAACAAAAGA-3′ (SEQ ID NO: 8055) KRAS-4156 Target: 5′-TTGAATGGTTTAACAAAAGAT-3′ (SEQ ID NO: 8056) KRAS-4157 Target: 5′-TGAATGGTTTAACAAAAGATT-3′ (SEQ ID NO: 8057) KRAS-4158 Target: 5′-GAATGGTTTAACAAAAGATTT-3′ (SEQ ID NO: 8058) KRAS-4160 Target: 5′-ATGGTTTAACAAAAGATTTGT-3′ (SEQ ID NO: 8059) KRAS-4161 Target: 5′-TGGTTTAACAAAAGATTTGTT-3′ (SEQ ID NO: 8060) KRAS-4165 Target: 5′-TTAACAAAAGATTTGTTTTTG-3′ (SEQ ID NO: 8061) KRAS-4166 Target: 5′-TAACAAAAGATTTGTTTTTGT-3′ (SEQ ID NO: 8062) KRAS-4167 Target: 5′-AACAAAAGATTTGTTTTTGTA-3′ (SEQ ID NO: 8063) KRAS-4169 Target: 5′-CAAAAGATTTGTTTTTGTAGA-3′ (SEQ ID NO: 8064) KRAS-4170 Target: 5′-AAAAGATTTGTTTTTGTAGAG-3′ (SEQ ID NO: 8065) KRAS-4171 Target: 5′-AAAGATTTGTTTTTGTAGAGA-3′ (SEQ ID NO: 8066) KRAS-4172 Target: 5′-AAGATTTGTTTTTGTAGAGAT-3′ (SEQ ID NO: 8067) KRAS-4178 Target: 5′-TGTTTTTGTAGAGATTTTAAA-3′ (SEQ ID NO: 8068) KRAS-4195 Target: 5′-TAAAGGGGGAGAATTCTAGAA-3′ (SEQ ID NO: 8069) KRAS-4197 Target: 5′-AAGGGGGAGAATTCTAGAAAT-3′ (SEQ ID NO: 8070) KRAS-4198 Target: 5′-AGGGGGAGAATTCTAGAAATA-3′ (SEQ ID NO: 8071) KRAS-4199 Target: 5′-GGGGGAGAATTCTAGAAATAA-3′ (SEQ ID NO: 8072) KRAS-4200 Target: 5′-GGGGAGAATTCTAGAAATAAA-3′ (SEQ ID NO: 8073) KRAS-4201 Target: 5′-GGGAGAATTCTAGAAATAAAT-3′ (SEQ ID NO: 8074) KRAS-4206 Target: 5′-AATTCTAGAAATAAATGTTAC-3′ (SEQ ID NO: 8075) KRAS-4207 Target: 5′-ATTCTAGAAATAAATGTTACC-3′ (SEQ ID NO: 8076) KRAS-4208 Target: 5′-TTCTAGAAATAAATGTTACCT-3′ (SEQ ID NO: 8077) KRAS-4209 Target: 5′-TCTAGAAATAAATGTTACCTA-3′ (SEQ ID NO: 8078) KRAS-4210 Target: 5′-CTAGAAATAAATGTTACCTAA-3′ (SEQ ID NO: 8079) KRAS-4212 Target: 5′-AGAAATAAATGTTACCTAATT-3′ (SEQ ID NO: 8080) KRAS-4223 Target: 5′-TTACCTAATTATTACAGCCTT-3′ (SEQ ID NO: 8081) KRAS-4224 Target: 5′-TACCTAATTATTACAGCCTTA-3′ (SEQ ID NO: 8082) KRAS-4238 Target: 5′-AGCCTTAAAGACAAAAATCCT-3′ (SEQ ID NO: 8083) KRAS-4241 Target: 5′-CTTAAAGACAAAAATCCTTGT-3′ (SEQ ID NO: 8084) KRAS-4253 Target: 5′-AATCCTTGTTGAAGTTTTTTT-3′ (SEQ ID NO: 8085) KRAS-4254 Target: 5′-ATCCTTGTTGAAGTTTTTTTA-3′ (SEQ ID NO: 8086) KRAS-4256 Target: 5′-CCTTGTTGAAGTTTTTTTAAA-3′ (SEQ ID NO: 8087) KRAS-4257 Target: 5′-CTTGTTGAAGTTTTTTTAAAA-3′ (SEQ ID NO: 8088) KRAS-4261 Target: 5′-TTGAAGTTTTTTTAAAAAAAG-3′ (SEQ ID NO: 8089) KRAS-4262 Target: 5′-TGAAGTTTTTTTAAAAAAAGC-3′ (SEQ ID NO: 8090) KRAS-4263 Target: 5′-GAAGTTTTTTTAAAAAAAGCT-3′ (SEQ ID NO: 8091) KRAS-4264 Target: 5′-AAGTTTTTTTAAAAAAAGCTA-3′ (SEQ ID NO: 8092) KRAS-4265 Target: 5′-AGTTTTTTTAAAAAAAGCTAA-3′ (SEQ ID NO: 8093) KRAS-4269 Target: 5′-TTTTTAAAAAAAGCTAAATTA-3′ (SEQ ID NO: 8094) KRAS-4271 Target: 5′-TTTAAAAAAAGCTAAATTACA-3′ (SEQ ID NO: 8095) KRAS-4293 Target: 5′-AGACTTAGGCATTAACATGTT-3′ (SEQ ID NO: 8096) KRAS-4294 Target: 5′-GACTTAGGCATTAACATGTTT-3′ (SEQ ID NO: 8097) KRAS-4325 Target: 5′-ATAGCAGACGTATATTGTATC-3′ (SEQ ID NO: 8098) KRAS-4329 Target: 5′-CAGACGTATATTGTATCATTT-3′ (SEQ ID NO: 8099) KRAS-4331 Target: 5′-GACGTATATTGTATCATTTGA-3′ (SEQ ID NO: 8100) KRAS-4334 Target: 5′-GTATATTGTATCATTTGAGTG-3′ (SEQ ID NO: 8101) KRAS-4335 Target: 5′-TATATTGTATCATTTGAGTGA-3′ (SEQ ID NO: 8102) KRAS-4336 Target: 5′-ATATTGTATCATTTGAGTGAA-3′ (SEQ ID NO: 8103) KRAS-4402 Target: 5′-GCATAGGAATTTAGAACCTAA-3′ (SEQ ID NO: 8104) KRAS-4403 Target: 5′-CATAGGAATTTAGAACCTAAC-3′ (SEQ ID NO: 8105) KRAS-4407 Target: 5′-GGAATTTAGAACCTAACTTTT-3′ (SEQ ID NO: 8106) KRAS-4408 Target: 5′-GAATTTAGAACCTAACTTTTA-3′ (SEQ ID NO: 8107) KRAS-4409 Target: 5′-AATTTAGAACCTAACTTTTAT-3′ (SEQ ID NO: 8108) KRAS-4410 Target: 5′-ATTTAGAACCTAACTTTTATA-3′ (SEQ ID NO: 8109) KRAS-4422 Target: 5′-ACTTTTATAGGTTATCAAAAC-3′ (SEQ ID NO: 8110) KRAS-4424 Target: 5′-TTTTATAGGTTATCAAAACTG-3′ (SEQ ID NO: 8111) KRAS-4458 Target: 5′-ACAATTTTGTCCTAATATATA-3′ (SEQ ID NO: 8112) KRAS-4459 Target: 5′-CAATTTTGTCCTAATATATAC-3′ (SEQ ID NO: 8113) KRAS-4460 Target: 5′-AATTTTGTCCTAATATATACA-3′ (SEQ ID NO: 8114) KRAS-4466 Target: 5′-GTCCTAATATATACATAGAAA-3′ (SEQ ID NO: 8115) KRAS-4471 Target: 5′-AATATATACATAGAAACTTTG-3′ (SEQ ID NO: 8116) KRAS-4514 Target: 5′-TGCACAAGTTCATCTCATTTG-3′ (SEQ ID NO: 8117) KRAS-4525 Target: 5′-ATCTCATTTGTATTCCATTGA-3′ (SEQ ID NO: 8118) KRAS-4526 Target: 5′-TCTCATTTGTATTCCATTGAT-3′ (SEQ ID NO: 8119) KRAS-4527 Target: 5′-CTCATTTGTATTCCATTGATT-3′ (SEQ ID NO: 8120) KRAS-4528 Target: 5′-TCATTTGTATTCCATTGATTT-3′ (SEQ ID NO: 8121) KRAS-4529 Target: 5′-CATTTGTATTCCATTGATTTT-3′ (SEQ ID NO: 8122) KRAS-4530 Target: 5′-ATTTGTATTCCATTGATTTTT-3′ (SEQ ID NO: 8123) KRAS-4531 Target: 5′-TTTGTATTCCATTGATTTTTT-3′ (SEQ ID NO: 8124) KRAS-4538 Target: 5′-TCCATTGATTTTTTTTTTCTT-3′ (SEQ ID NO: 8125) KRAS-4539 Target: 5′-CCATTGATTTTTTTTTTCTTC-3′ (SEQ ID NO: 8126) KRAS-4543 Target: 5′-TGATTTTTTTTTTCTTCTAAA-3′ (SEQ ID NO: 8127) KRAS-4544 Target: 5′-GATTTTTTTTTTCTTCTAAAC-3′ (SEQ ID NO: 8128) KRAS-4545 Target: 5′-ATTTTTTTTTTCTTCTAAACA-3′ (SEQ ID NO: 8129) KRAS-4546 Target: 5′-TTTTTTTTTTCTTCTAAACAT-3′ (SEQ ID NO: 8130) KRAS-4547 Target: 5′-TTTTTTTTTCTTCTAAACATT-3′ (SEQ ID NO: 8131) KRAS-4560 Target: 5′-TAAACATTTTTTCTTCAAACA-3′ (SEQ ID NO: 8132) KRAS-4561 Target: 5′-AAACATTTTTTCTTCAAACAG-3′ (SEQ ID NO: 8133) KRAS-4562 Target: 5′-AACATTTTTTCTTCAAACAGT-3′ (SEQ ID NO: 8134) KRAS-4563 Target: 5′-ACATTTTTTCTTCAAACAGTA-3′ (SEQ ID NO: 8135) KRAS-4564 Target: 5′-CATTTTTTCTTCAAACAGTAT-3′ (SEQ ID NO: 8136) KRAS-4571 Target: 5′-TCTTCAAACAGTATATAACTT-3′ (SEQ ID NO: 8137) KRAS-4576 Target: 5′-AAACAGTATATAACTTTTTTT-3′ (SEQ ID NO: 8138) KRAS-4577 Target: 5′-AACAGTATATAACTTTTTTTA-3′ (SEQ ID NO: 8139) KRAS-4578 Target: 5′-ACAGTATATAACTTTTTTTAG-3′ (SEQ ID NO: 8140) KRAS-4579 Target: 5′-CAGTATATAACTTTTTTTAGG-3′ (SEQ ID NO: 8141) KRAS-4585 Target: 5′-ATAACTTTTTTTAGGGGATTT-3′ (SEQ ID NO: 8142) KRAS-4586 Target: 5′-TAACTTTTTTTAGGGGATTTT-3′ (SEQ ID NO: 8143) KRAS-4597 Target: 5′-AGGGGATTTTTTTTTAGACAG-3′ (SEQ ID NO: 8144) KRAS-4598 Target: 5′-GGGGATTTTTTTTTAGACAGC-3′ (SEQ ID NO: 8145) KRAS-4599 Target: 5′-GGGATTTTTTTTTAGACAGCA-3′ (SEQ ID NO: 8146) KRAS-4627 Target: 5′-TCTGAAGATTTCCATTTGTCA-3′ (SEQ ID NO: 8147) KRAS-4628 Target: 5′-CTGAAGATTTCCATTTGTCAA-3′ (SEQ ID NO: 8148) KRAS-4629 Target: 5′-TGAAGATTTCCATTTGTCAAA-3′ (SEQ ID NO: 8149) KRAS-4630 Target: 5′-GAAGATTTCCATTTGTCAAAA-3′ (SEQ ID NO: 8150) KRAS-4635 Target: 5′-TTTCCATTTGTCAAAAAGTAA-3′ (SEQ ID NO: 8151) KRAS-4636 Target: 5′-TTCCATTTGTCAAAAAGTAAT-3′ (SEQ ID NO: 8152) KRAS-4637 Target: 5′-TCCATTTGTCAAAAAGTAATG-3′ (SEQ ID NO: 8153) KRAS-4642 Target: 5′-TTGTCAAAAAGTAATGATTTC-3′ (SEQ ID NO: 8154) KRAS-4643 Target: 5′-TGTCAAAAAGTAATGATTTCT-3′ (SEQ ID NO: 8155) KRAS-4644 Target: 5′-GTCAAAAAGTAATGATTTCTT-3′ (SEQ ID NO: 8156) KRAS-4645 Target: 5′-TCAAAAAGTAATGATTTCTTG-3′ (SEQ ID NO: 8157) KRAS-4647 Target: 5′-AAAAAGTAATGATTTCTTGAT-3′ (SEQ ID NO: 8158) KRAS-4649 Target: 5′-AAAGTAATGATTTCTTGATAA-3′ (SEQ ID NO: 8159) KRAS-4650 Target: 5′-AAGTAATGATTTCTTGATAAT-3′ (SEQ ID NO: 8160) KRAS-4652 Target: 5′-GTAATGATTTCTTGATAATTG-3′ (SEQ ID NO: 8161) KRAS-4653 Target: 5′-TAATGATTTCTTGATAATTGT-3′ (SEQ ID NO: 8162) KRAS-4658 Target: 5′-ATTTCTTGATAATTGTGTAGT-3′ (SEQ ID NO: 8163) KRAS-4659 Target: 5′-TTTCTTGATAATTGTGTAGTA-3′ (SEQ ID NO: 8164) KRAS-4660 Target: 5′-TTCTTGATAATTGTGTAGTAA-3′ (SEQ ID NO: 8165) KRAS-4662 Target: 5′-CTTGATAATTGTGTAGTAATG-3′ (SEQ ID NO: 8166) KRAS-4665 Target: 5′-GATAATTGTGTAGTAATGTTT-3′ (SEQ ID NO: 8167) KRAS-4667 Target: 5′-TAATTGTGTAGTAATGTTTTT-3′ (SEQ ID NO: 8168) KRAS-4668 Target: 5′-AATTGTGTAGTAATGTTTTTT-3′ (SEQ ID NO: 8169) KRAS-4702 Target: 5′-TACCTTAAAGCTGAATTTATA-3′ (SEQ ID NO: 8170) KRAS-4704 Target: 5′-CCTTAAAGCTGAATTTATATT-3′ (SEQ ID NO: 8171) KRAS-4713 Target: 5′-TGAATTTATATTTAGTAACTT-3′ (SEQ ID NO: 8172) KRAS-4714 Target: 5′-GAATTTATATTTAGTAACTTC-3′ (SEQ ID NO: 8173) KRAS-4715 Target: 5′-AATTTATATTTAGTAACTTCT-3′ (SEQ ID NO: 8174) KRAS-4720 Target: 5′-ATATTTAGTAACTTCTGTGTT-3′ (SEQ ID NO: 8175) KRAS-4771 Target: 5′-AAACTGAATAGCTGTCATAAA-3′ (SEQ ID NO: 8176) KRAS-4772 Target: 5′-AACTGAATAGCTGTCATAAAA-3′ (SEQ ID NO: 8177) KRAS-4786 Target: 5′-CATAAAATGAAACTTTCTTTC-3′ (SEQ ID NO: 8178) KRAS-4787 Target: 5′-ATAAAATGAAACTTTCTTTCT-3′ (SEQ ID NO: 8179) KRAS-4788 Target: 5′-TAAAATGAAACTTTCTTTCTA-3′ (SEQ ID NO: 8180) KRAS-4790 Target: 5′-AAATGAAACTTTCTTTCTAAA-3′ (SEQ ID NO: 8181) KRAS-4794 Target: 5′-GAAACTTTCTTTCTAAAGAAA-3′ (SEQ ID NO: 8182) KRAS-4819 Target: 5′-CTCACATGAGTTCTTGAAGAA-3′ (SEQ ID NO: 8183) KRAS-4828 Target: 5′-GTTCTTGAAGAATAGTCATAA-3′ (SEQ ID NO: 8184) KRAS-4829 Target: 5′-TTCTTGAAGAATAGTCATAAC-3′ (SEQ ID NO: 8185) KRAS-4830 Target: 5′-TCTTGAAGAATAGTCATAACT-3′ (SEQ ID NO: 8186) KRAS-4833 Target: 5′-TGAAGAATAGTCATAACTAGA-3′ (SEQ ID NO: 8187) KRAS-4834 Target: 5′-GAAGAATAGTCATAACTAGAT-3′ (SEQ ID NO: 8188) KRAS-4835 Target: 5′-AAGAATAGTCATAACTAGATT-3′ (SEQ ID NO: 8189) KRAS-4836 Target: 5′-AGAATAGTCATAACTAGATTA-3′ (SEQ ID NO: 8190) KRAS-4840 Target: 5′-TAGTCATAACTAGATTAAGAT-3′ (SEQ ID NO: 8191) KRAS-4846 Target: 5′-TAACTAGATTAAGATCTGTGT-3′ (SEQ ID NO: 8192 KRAS-4848 Target: 5′-ACTAGATTAAGATCTGTGTTT-3′ (SEQ ID NO: 8193) KRAS-4849 Target: 5′-CTAGATTAAGATCTGTGTTTT-3′ (SEQ ID NO: 8194) KRAS-4851 Target: 5′-AGATTAAGATCTGTGTTTTAG-3′ (SEQ ID NO: 8195) KRAS-4858 Target: 5′-GATCTGTGTTTTAGTTTAATA-3′ (SEQ ID NO: 8196) KRAS-4859 Target: 5′-ATCTGTGTTTTAGTTTAATAG-3′ (SEQ ID NO: 8197) KRAS-4861 Target: 5′-CTGTGTTTTAGTTTAATAGTT-3′ (SEQ ID NO: 8198) KRAS-4863 Target: 5′-GTGTTTTAGTTTAATAGTTTG-3′ (SEQ ID NO: 8199) KRAS-4864 Target: 5′-TGTTTTAGTTTAATAGTTTGA-3′ (SEQ ID NO: 8200) KRAS-4890 Target: 5′-CTGTTTGGGATAATGATAGGT-3′ (SEQ ID NO: 8201) KRAS-4892 Target: 5′-GTTTGGGATAATGATAGGTAA-3′ (SEQ ID NO: 8202) KRAS-4895 Target: 5′-TGGGATAATGATAGGTAATTT-3′ (SEQ ID NO: 8203) KRAS-4896 Target: 5′-GGGATAATGATAGGTAATTTA-3′ (SEQ ID NO: 8204) KRAS-4899 Target: 5′-ATAATGATAGGTAATTTAGAT-3′ (SEQ ID NO: 8205) KRAS-4900 Target: 5′-TAATGATAGGTAATTTAGATG-3′ (SEQ ID NO: 8206) KRAS-4905 Target: 5′-ATAGGTAATTTAGATGAATTT-3′ (SEQ ID NO: 8207) KRAS-4907 Target: 5′-AGGTAATTTAGATGAATTTAG-3′ (SEQ ID NO: 8208) KRAS-4914 Target: 5′-TTAGATGAATTTAGGGGAAAA-3′ (SEQ ID NO: 8209) KRAS-4915 Target: 5′-TAGATGAATTTAGGGGAAAAA-3′ (SEQ ID NO: 8210) KRAS-4926 Target: 5′-AGGGGAAAAAAAAGTTATCTG-3′ (SEQ ID NO: 8211) KRAS-4927 Target: 5′-GGGGAAAAAAAAGTTATCTGC-3′ (SEQ ID NO: 8212) KRAS-4932 Target: 5′-AAAAAAAGTTATCTGCAGATA-3′ (SEQ ID NO: 8213) KRAS-5033 Target: 5′-CTGTCTTGTGTTTTCATGTTG-3′ (SEQ ID NO: 8214) KRAS-5034 Target: 5′-TGTCTTGTGTTTTCATGTTGA-3′ (SEQ ID NO: 8215) KRAS-5035 Target: 5′-GTCTTGTGTTTTCATGTTGAA-3′ (SEQ ID NO: 8216) KRAS-5045 Target: 5′-TTCATGTTGAAAATACTTTTG-3′ (SEQ ID NO: 8217) KRAS-5046 Target: 5′-TCATGTTGAAAATACTTTTGC-3′ (SEQ ID NO: 8218) KRAS-5047 Target: 5′-CATGTTGAAAATACTTTTGCA-3′ (SEQ ID NO: 8219) KRAS-5048 Target: 5′-ATGTTGAAAATACTTTTGCAT-3′ (SEQ ID NO: 8220) KRAS-5058 Target: 5′-TACTTTTGCATTTTTCCTTTG-3′ (SEQ ID NO: 8221) KRAS-5075 Target: 5′-TTTGAGTGCCAATTTCTTACT-3′ (SEQ ID NO: 8222) KRAS-5080 Target: 5′-GTGCCAATTTCTTACTAGTAC-3′ (SEQ ID NO: 8223) KRAS-5081 Target: 5′-TGCCAATTTCTTACTAGTACT-3′ (SEQ ID NO: 8224) KRAS-5090 Target: 5′-CTTACTAGTACTATTTCTTAA-3′ (SEQ ID NO: 8225) KRAS-5091 Target: 5′-TTACTAGTACTATTTCTTAAT-3′ (SEQ ID NO: 8226) KRAS-5096 Target: 5′-AGTACTATTTCTTAATGTAAC-3′ (SEQ ID NO: 8227) KRAS-5097 Target: 5′-GTACTATTTCTTAATGTAACA-3′ (SEQ ID NO: 8228) KRAS-5098 Target: 5′-TACTATTTCTTAATGTAACAT-3′ (SEQ ID NO: 8229) KRAS-5105 Target: 5′-TCTTAATGTAACATGTTTACC-3′ (SEQ ID NO: 8230)′ KRAS-5122 Target: 5′-TACCTGGAATGTATTTTAACT-3′ (SEQ ID NO: 8231) KRAS-5124 Target: 5′-CCTGGAATGTATTTTAACTAT-3′ (SEQ ID NO: 8232) KRAS-5125 Target: 5′-CTGGAATGTATTTTAACTATT-3′ (SEQ ID NO: 8233) KRAS-5126 Target: 5′-TGGAATGTATTTTAACTATTT-3′ (SEQ ID NO: 8234) KRAS-5127 Target: 5′-GGAATGTATTTTAACTATTTT-3′ (SEQ ID NO: 8235) KRAS-5129 Target: 5′-AATGTATTTTAACTATTTTTG-3′ (SEQ ID NO: 8236) KRAS-5131 Target: 5′-TGTATTTTAACTATTTTTGTA-3′ (SEQ ID NO: 8237) KRAS-5132 Target: 5′-GTATTTTAACTATTTTTGTAT-3′ (SEQ ID NO: 8238) KRAS-5133 Target: 5′-TATTTTAACTATTTTTGTATA-3′ (SEQ ID NO: 8239) KRAS-5140 Target: 5′-ACTATTTTTGTATAGTGTAAA-3′ (SEQ ID NO: 8240) KRAS-5141 Target: 5′-CTATTTTTGTATAGTGTAAAC-3′ (SEQ ID NO: 8241) KRAS-5142 Target: 5′-TATTTTTGTATAGTGTAAACT-3′ (SEQ ID NO: 8242) KRAS-5157 Target: 5′-TAAACTGAAACATGCACATTT-3′ (SEQ ID NO: 8243) KRAS-5163 Target: 5′-GAAACATGCACATTTTGTACA-3′ (SEQ ID NO: 8244) KRAS-5216 Target: 5′-GATCCAGTTGTTTTCCATCAT-3′ (SEQ ID NO: 8245) KRAS-5218 Target: 5′-TCCAGTTGTTTTCCATCATTT-3′ (SEQ ID NO: 8246) KRAS-5255 Target: 5′-GAATGTTGGTCATATCAAACA-3′ (SEQ ID NO: 8247) KRAS-5256 Target: 5′-AATGTTGGTCATATCAAACAT-3′ (SEQ ID NO: 8248) KRAS-5257 Target: 5′-ATGTTGGTCATATCAAACATT-3′ (SEQ ID NO: 8249) KRAS-5261 Target: 5′-TGGTCATATCAAACATTAAAA-3′ (SEQ ID NO: 8250) KRAS-5277 Target: 5′-TAAAAATGACCACTCTTTTAA-3′ (SEQ ID NO: 8251) KRAS-5278 Target: 5′-AAAAATGACCACTCTTTTAAT-3′ (SEQ ID NO: 8252) KRAS-5287 Target: 5′-CACTCTTTTAATTGAAATTAA-3′ (SEQ ID NO: 8253) KRAS-5288 Target: 5′-ACTCTTTTAATTGAAATTAAC-3′ (SEQ ID NO: 8254) KRAS-5290 Target: 5′-TCTTTTAATTGAAATTAACTT-3′ (SEQ ID NO: 8255) KRAS-5292 Target: 5′-TTTTAATTGAAATTAACTTTT-3′ (SEQ ID NO: 8256) KRAS-5293 Target: 5′-TTTAATTGAAATTAACTTTTA-3′ (SEQ ID NO: 8257) KRAS-5294 Target: 5′-TTAATTGAAATTAACTTTTAA-3′ (SEQ ID NO: 8258) KRAS-5295 Target: 5′-TAATTGAAATTAACTTTTAAA-3′ (SEQ ID NO: 8259) KRAS-5296 Target: 5′-AATTGAAATTAACTTTTAAAT-3′ (SEQ ID.NO: 8260) KRAS-5297 Target: 5′-ATTGAAATTAACTTTTAAATG-3′ (SEQ ID NO: 8261) KRAS-5300 Target: 5′-GAAATTAACTTTTAAATGTTT-3′ (SEQ ID NO: 8262) KRAS-5304 Target: 5′-TTAACTTTTAAATGTTTATAG-3′ (SEQ ID NO: 8263) KRAS-5308 Target: 5′-CTTTTAAATGTTTATAGGAGT-3′ (SEQ ID NO: 8264) KRAS-5309 Target: 5′-TTTTAAATGTTTATAGGAGTA-3′ (SEQ ID NO: 8265) KRAS-5331 Target: 5′-GTGCTGTGAAGTGATCTAAAA-3′ (SEQ ID NO: 8266) KRAS-5333 Target: 5′-GCTGTGAAGTGATCTAAAATT-3′ (SEQ ID NO: 8267) KRAS-5334 Target: 5′-CTGTGAAGTGATCTAAAATTT-3′ (SEQ ID NO: 8268) KRAS-5335 Target: 5′-TGTGAAGTGATCTAAAATTTG-3′ (SEQ ID NO: 8269) KRAS-5336 Target: 5′-GTGAAGTGATCTAAAATTTGT-3′ (SEQ ID NO: 8270) KRAS-5337 Target: 5′-TGAAGTGATCTAAAATTTGTA-3′ (SEQ ID NO: 8271) KRAS-5338 Target: 5′-GAAGTGATCTAAAATTTGTAA-3′ (SEQ ID NO: 8272) KRAS-5342 Target: 5′-TGATCTAAAATTTGTAATATT-3′ (SEQ ID NO: 8273) KRAS-5343 Target: 5′-GATCTAAAATTTGTAATATTT-3′ (SEQ ID NO: 8274) KRAS-5347 Target: 5′-TAAAATTTGTAATATTTTTGT-3′ (SEQ ID NO: 8275) KRAS-5348 Target: 5′-AAAATTTGTAATATTTTTGTC-3′ (SEQ ID NO: 8276) KRAS-5349 Target: 5′-AAATTTGTAATATTTTTGTCA-3′ (SEQ ID NO: 8277) KRAS-5353 Target: 5′-TTGTAATATTTTTGTCATGAA-3′ (SEQ ID NO: 8278) KRAS-5354 Target: 5′-TGTAATATTTTTGTCATGAAC-3′ (SEQ ID NO: 8279) KRAS-5370 Target: 5′-TGAACTGTACTACTCCTAATT-3′ (SEQ ID NO: 8280) KRAS-5371 Target: 5′-GAACTGTACTACTCCTAATTA-3′ (SEQ ID NO: 8281) KRAS-5381 Target: 5′-ACTCCTAATTATTGTAATGTA-3′ (SEQ ID NO: 8282) KRAS-5382 Target: 5′-CTCCTAATTATTGTAATGTAA-3′ (SEQ ID NO: 8283) KRAS-5384 Target: 5′-CCTAATTATTGTAATGTAATA-3′ (SEQ ID NO: 8284) KRAS-5386 Target: 5′-TAATTATTGTAATGTAATAAA-3′ (SEQ ID NO: 8285) KRAS-5387 Target: 5′-AATTATTGTAATGTAATAAAA-3′ (SEQ ID NO: 8286) KRAS-5389 Target: 5′-TTATTGTAATGTAATAAAAAT-3′ (SEQ ID NO: 8287) KRAS-5390 Target: 5′-TATTGTAATGTAATAAAAATA-3′ (SEQ ID NO: 8288) KRAS-5394 Target: 5′-GTAATGTAATAAAAATAGTTA-3′ (SEQ ID NO: 8289) KRAS-5395 Target: 5′-TAATGTAATAAAAATAGTTAC-3′ (SEQ ID NO: 8290) KRAS-5396 Target: 5′-AATGTAATAAAAATAGTTACA-3′ (SEQ ID NO: 8291) KRAS-5404 Target: 5′-AAAAATAGTTACAGTGACAAA-3′ (SEQ ID NO: 8292) KRAS-5405 Target: 5′-AAAATAGTTACAGTGACAAAA-3′ (SEQ ID NO: 8293) KRAS-5407 Target: 5′-AATAGTTACAGTGACAAAAAA-3′ (SEQ ID NO: 8294) KRAS-166 Target: 5′-GAGAGGCCTGCTGAAAATGAC-3′ (SEQ ID NO: 8295) KRAS-167 Target: 5′-AGAGGCCTGCTGAAAATGACT-3′ (SEQ ID NO: 8296) KRAS-168 Target: 5′-GAGGCCTGCTGAAAATGACTG-3′ (SEQ ID NO: 8297) KRAS-169 Target: 5′-AGGCCTGCTGAAAATGACTGA-3′ (SEQ ID NO: 8298) KRAS-204 Target: 5′-TAGTTGGAGCTGGTGGCGTAG-3′ (SEQ ID NO: 8299) KRAS-205 Target: 5′-AGTTGGAGCTGGTGGCGTAGG-3′ (SEQ ID NO: 8300) KRAS-206 Target: 5′-GTTGGAGCTGGTGGCGTAGGC-3′ (SEQ ID NO: 8301) KRAS-207 Target: 5′-TTGGAGCTGGTGGCGTAGGCA-3′ (SEQ ID NO: 8302) KRAS-208 Target: 5′-TGGAGCTGGTGGCGTAGGCAA-3′ (SEQ ID NO: 8303) KRAS-209 Target: 5′-GGAGCTGGTGGCGTAGGCAAG-3′ (SEQ ID NO: 8304) KRAS-210 Target: 5′-GAGCTGGTGGCGTAGGCAAGA-3′ (SEQ ID NO: 8305) KRAS-241 Target: 5′-GATACAGCTAATTCAGAATCA-3′ (SEQ ID NO: 8306) KRAS-313 Target: 5′-AGTAATTGATGGAGAAACCTG-3′ (SEQ ID NO: 8307) KRAS-314 Target: 5′-GTAATTGATGGAGAAACCTGT-3′ (SEQ ID NO: 8308) KRAS-318 Target: 5′-TTGATGGAGAAACCTGTCTCT-3′ (SEQ ID NO: 8309) KRAS-328 Target: 5′-AACCTGTCTCTTGGATATTCT-3′ (SEQ ID NO: 8310) KRAS-330 Target: 5′-CCTGTCTCTTGGATATTCTCG-3′ (SEQ ID NO: 8311) KRAS-331 Target: 5′-CTGTCTCTTGGATATTCTCGA-3′ (SEQ ID NO: 8312) KRAS-332 Target: 5′-TGTCTCTTGGATATTCTCGAC-3′ (SEQ ID NO: 8313) KRAS-333 Target: 5′-GTCTCTTGGATATTCTCGACA-3′ (SEQ ID NO: 8314) KRAS-334 Target: 5′-TCTCTTGGATATTCTCGACAC-3′ (SEQ ID NO: 8315) KRAS-335 Target: 5′-CTCTTGGATATTCTCGACACA-3′ (SEQ ID NO: 8316) KRAS-336 Target: 5′-TCTTGGATATTCTCGACACAG-3′ (SEQ ID NO: 8317) KRAS-352 Target: 5′-CACAGCAGGTCAAGAGGAGTA-3′ (SEQ ID NO: 8318) KRAS-353 Target: 5′-ACAGCAGGTCAAGAGGAGTAC-3′ (SEQ ID NO: 8319) KRAS-354 Target: 5′-CAGCAGGTCAAGAGGAGTACA-3′ (SEQ ID NO: 8320) KRAS-364 Target: 5′-AGAGGAGTACAGTGCAATGAG-3′ (SEQ ID NO: 8321) KRAS-365 Target: 5′-GAGGAGTACAGTGCAATGAGG-3′ (SEQ ID NO: 8322) KRAS-366 Target: 5′-AGGAGTACAGTGCAATGAGGG-3′ (SEQ ID NO: 8323) KRAS-367 Target: 5′-GGAGTACAGTGCAATGAGGGA-3′ (SEQ ID NO: 8324) KRAS-368 Target: 5′-GAGTACAGTGCAATGAGGGAC-3′ (SEQ ID NO: 8325) KRAS-369 Target: 5′-AGTACAGTGCAATGAGGGACC-3′ (SEQ ID NO: 8326) KRAS-370 Target: 5′-GTACAGTGCAATGAGGGACCA-3′ (SEQ ID NO: 8327) KRAS-371 Target: 5′-TACAGTGCAATGAGGGACCAG-3′ (SEQ ID NO: 8328) KRAS-372 Target: 5′-ACAGTGCAATGAGGGACCAGT-3′ (SEQ ID NO: 8329) KRAS-420 Target: 5′-GTGTATTTGCCATAAATAATA-3′ (SEQ ID NO: 8330) KRAS-421 Target: 5′-TGTATTTGCCATAAATAATAC-3′ (SEQ ID NO: 8331) KRAS-422 Target: 5′-GTATTTGCCATAAATAATACT-3′ (SEQ ID NO: 8332) KRAS-423 Target: 5′-TATTTGCCATAAATAATACTA-3′ (SEQ ID NO: 8333) KRAS-424 Target: 5′-ATTTGCCATAAATAATACTAA-3′ (SEQ ID NO: 8334) KRAS-425 Target: 5′-TTTGCCATAAATAATACTAAA-3′ (SEQ ID NO: 8335) KRAS-426 Target: 5′-TTGCCATAAATAATACTAAAT-3′ (SEQ ID NO: 8336) KRAS-436 Target: 5′-TAATACTAAATCATTTGAAGA-3′ (SEQ ID NO: 8337) KRAS-437 Target: 5′-AATACTAAATCATTTGAAGAT-3′ (SEQ ID NO: 8338) KRAS-438 Target: 5′-ATACTAAATCATTTGAAGATA-3′ (SEQ ID NO: 8339) KRAS-439 Target: 5′-TACTAAATCATTTGAAGATAT-3′ (SEQ ID NO: 8340) KRAS-440 Target: 5′-ACTAAATCATTTGAAGATATT-3′ (SEQ ID NO: 8341) KRAS-441 Target: 5′-CTAAATCATTTGAAGATATTC-3′ (SEQ ID NO: 8342) KRAS-442 Target: 5′-TAAATCATTTGAAGATATTCA-3′ (SEQ ID NO: 8343) KRAS-443 Target: 5′-AAATCATTTGAAGATATTCAC-3′ (SEQ ID NO: 8344) KRAS-444 Target: 5′-AATCATTTGAAGATATTCACC-3′ (SEQ ID NO: 8345) KRAS-454 Target: 5′-AGATATTCACCATTATAGAGA-3′ (SEQ ID NO: 8346) KRAS-455 Target: 5′-GATATTCACCATTATAGAGAA-3′ (SEQ ID NO: 8347) KRAS-456 Target: 5′-ATATTCACCATTATAGAGAAC-3′ (SEQ ID NO: 8348) KRAS-457 Target: 5′-TATTCACCATTATAGAGAACA-3′ (SEQ ID NO: 8349) KRAS-458 Target: 5′-ATTCACCATTATAGAGAACAA-3′ (SEQ ID NO: 8350) KRAS-459 Target: 5′-TTCACCATTATAGAGAACAAA-3′ (SEQ ID NO: 8351) KRAS-460 Target: 5′-TCACCATTATAGAGAACAAAT-3′ (SEQ ID NO: 8352) KRAS-461 Target: 5′-CACCATTATAGAGAACAAATT-3′ (SEQ ID NO: 8353) KRAS-462 Target: 5′-ACCATTATAGAGAACAAATTA-3′ (SEQ ID NO: 8354) KRAS-508 Target: 5′-ACCTATGGTCCTAGTAGGAAA-3′ (SEQ ID NO: 8355) KRAS-531 Target: 5′-AATGTGATTTGCCTTCTAGAA-3′ (SEQ ID NO: 8356) KRAS-532 Target: 5′-ATGTGATTTGCCTTCTAGAAC-3′ (SEQ ID NO: 8357) KRAS-534 Target: 5′-GTGATTTGCCTTCTAGAACAG-3′ (SEQ ID NO: 8358) KRAS-586 Target: 5′-AAGTTATGGAATTCCTTTTAT-3′ (SEQ ID NO: 8359) KRAS-587 Target: 5′-AGTTATGGAATTCCTTTTATT-3′ (SEQ ID NO: 8360) KRAS-588 Target: 5′-GTTATGGAATTCCTTTTATTG-3′ (SEQ ID NO: 8361) KRAS-763 Target: 5′-ATGATGCCTTCTATACATTAG-3′ (SEQ ID NO: 8362) KRAS-764 Target: 5′-TGATGCCTTCTATACATTAGT-3′ (SEQ ID NO: 8363) KRAS-784 Target: 5′-TTCGAGAAATTCGAAAACATA-3′ (SEQ ID NO: 8364) KRAS-794 Target: 5′-TCGAAAACATAAAGAAAAGAT-3′ (SEQ ID NO: 8365) KRAS-795 Target: 5′-CGAAAACATAAAGAAAAGATG-3′ (SEQ ID NO: 8366) KRAS-796 Target: 5′-GAAAACATAAAGAAAAGATGA-3′ (SEQ ID NO: 8367) KRAS-797 Target: 5′-AAAACATAAAGAAAAGATGAG-3′ (SEQ ID NO: 8368) KRAS-798 Target: 5′-AAACATAAAGAAAAGATGAGC-3′ (SEQ ID NO: 8369) KRAS-799 Target: 5′-AACATAAAGAAAAGATGAGCA-3′ (SEQ ID NO: 8370) KRAS-800 Target: 5′-ACATAAAGAAAAGATGAGCAA-3′ (SEQ ID NO: 8371) KRAS-801 Target: 5′-CATAAAGAAAAGATGAGCAAA-3′ (SEQ ID NO: 8372) KRAS-802 Target: 5′-ATAAAGAAAAGATGAGCAAAG-3′ (SEQ ID NO: 8373) KRAS-908 Target: 5′-ACAAGTGGTAATTTTTGTACA-3′ (SEQ ID NO: 8374) KRAS-909 Target: 5′-CAAGTGGTAATTTTTGTACAT-3′ (SEQ ID NO: 8375) KRAS-920 Target: 5′-TTTTGTACATTACACTAAATT-3′ (SEQ ID NO: 8376) KRAS-921 Target: 5′-TTTGTACATTACACTAAATTA-3′ (SEQ ID NO: 8377) KRAS-922 Target: 5′-TTGTACATTACACTAAATTAT-3′ (SEQ ID NO: 8378) KRAS-923 Target: 5′-TGTACATTACACTAAATTATT-3′ (SEQ ID NO: 8379) KRAS-924 Target: 5′-GTACATTACACTAAATTATTA-3′ (SEQ ID NO: 8380) KRAS-925 Target: 5′-TACATTACACTAAATTATTAG-3′ (SEQ ID NO: 8381) KRAS-926 Target: 5′-ACATTACACTAAATTATTAGC-3′ (SEQ ID NO: 8382) KRAS-927 Target: 5′-CATTACACTAAATTATTAGCA-3′ (SEQ ID NO: 8383) KRAS-928 Target: 5′-ATTACACTAAATTATTAGCAT-3′ (SEQ ID NO: 8384) KRAS-938 Target: 5′-ATTATTAGCATTTGTTTTAGC-3′ (SEQ ID NO: 8385) KRAS-939 Target: 5′-TTATTAGCATTTGTTTTAGCA-3′ (SEQ ID NO: 8386) KRAS-940 Target: 5′-TATTAGCATTTGTTTTAGCAT-3′ (SEQ ID NO: 8387) KRAS-941 Target: 5′-ATTAGCATTTGTTTTAGCATT-3′ (SEQ ID NO: 8388) KRAS-942 Target: 5′-TTAGCATTTGTTTTAGCATTA-3′ (SEQ ID NO: 8389) KRAS-943 Target: 5′-TAGCATTTGTTTTAGCATTAC-3′ (SEQ ID NO: 8390) KRAS-944 Target: 5′-AGCATTTGTTTTAGCATTACC-3′ (SEQ ID NO: 8391) KRAS-945 Target: 5′-GCATTTGTTTTAGCATTACCT-3′ (SEQ ID NO: 8392) KRAS-946 Target: 5′-CATTTGTTTTAGCATTACCTA-3′ (SEQ ID NO: 8393) KRAS-1010 Target: 5′-TGCTTATTTTAAAATGACAGT-3′ (SEQ ID NO: 8394) KRAS-1012 Target: 5′-CTTATTTTAAAATGACAGTGG-3′ (SEQ ID NO: 8395) KRAS-1045 Target: 5′-CCTCTAAGTGCCAGTATTCCC-3′ (SEQ ID NO: 8396) KRAS-1197 Target: 5′-AACAAATTAATGAAGCTTTTG-3′ (SEQ ID NO: 8397) KRAS-1198 Target: 5′-ACAAATTAATGAAGCTTTTGA-3′ (SEQ ID NO: 8398) KRAS-1230 Target: 5′-TCTGTGTTTTATCTAGTCACA-3′ (SEQ ID NO: 8399) KRAS-1231 Target: 5′-CTGTGTTTTATCTAGTCACAT-3′ (SEQ ID NO: 8400) KRAS-1234 Target: 5′-TGTTTTATCTAGTCACATAAA-3′ (SEQ ID NO: 8401) KRAS-1249 Target: 5′-CATAAATGGATTAATTACTAA-3′ (SEQ ID NO: 8402) KRAS-1250 Target: 5′-ATAAATGGATTAATTACTAAT-3′ (SEQ ID NO: 8403) KRAS-1287 Target: 5′-TAATTGGTTTTTACTGAAACA-3′ (SEQ ID NO: 8404) KRAS-1527 Target: 5′-GCCATTTCCTTTTCACATTAG-3′ (SEQ ID NO: 8405) KRAS-1533 Target: 5′-TCCTTTTCACATTAGATAAAT-3′ (SEQ ID NO: 8406) KRAS-1540 Target: 5′-CACATTAGATAAATTACTATA-3′ (SEQ ID NO: 8407) KRAS-1541 Target: 5′-ACATTAGATAAATTACTATAA-3′ (SEQ ID NO: 8408) KRAS-1542 Target: 5′-CATTAGATAAATTACTATAAA-3′ (SEQ ID NO: 8409) KRAS-1583 Target: 5′-GTTAAGGCAGACCCAGTATGA-3′ (SEQ ID NO: 8410) KRAS-1584 Target: 5′-TTAAGGCAGACCCAGTATGAA-3′ (SEQ ID NO: 8411) KRAS-1585 Target: 5′-TAAGGCAGACCCAGTATGAAA-3′ (SEQ ID NO: 8412) KRAS-1586 Target: 5′-AAGGCAGACCCAGTATGAAAT-3′ (SEQ ID NO: 8413) KRAS-1597 Target: 5′-AGTATGAAATGGGGATTATTA-3′ (SEQ ID NO: 8414) KRAS-1606 Target: 5′-TGGGGATTATTATAGCAACCA-3′ (SEQ ID NO: 8415) KRAS-1630 Target: 5′-TGGGGCTATATTTACATGCTA-3′ (SEQ ID NO: 8416) KRAS-1631 Target: 5′-GGGGCTATATTTACATGCTAC-3′ (SEQ ID NO: 8417) KRAS-1632 Target: 5′-GGGCTATATTTACATGCTACT-3′ (SEQ ID NO: 8418) KRAS-1633 Target: 5′-GGCTATATTTACATGCTACTA-3′ (SEQ ID NO: 8419) KRAS-1634 Target: 5′-GCTATATTTACATGCTACTAA-3′ (SEQ ID NO: 8420) KRAS-1635 Target: 5′-CTATATTTACATGCTACTAAA-3′ (SEQ ID NO: 8421) KRAS-1636 Target: 5′-TATATTTACATGCTACTAAAT-3′ (SEQ ID NO: 8422) KRAS-1637 Target: 5′-ATATTTACATGCTACTAAATT-3′ (SEQ ID NO: 8423) KRAS-1638 Target: 5′-TATTTACATGCTACTAAATTT-3′ (SEQ ID NO: 8424) KRAS-1639 Target: 5′-ATTTACATGCTACTAAATTTT-3′ (SEQ ID NO: 8425) KRAS-1640 Target: 5′-TTTACATGCTACTAAATTTTT-3′ (SEQ ID NO: 8426) KRAS-1736 Target: 5′-CTCTTTCATAGTATAACTTTA-3′ (SEQ ID NO: 8427) KRAS-1741 Target: 5′-TCATAGTATAACTTTAAATCT-3′ (SEQ ID NO: 8428) KRAS-1742 Target: 5′-CATAGTATAACTTTAAATCTT-3′ (SEQ ID NO: 8429) KRAS-1753 Target: 5′-TTTAAATCTTTTCTTCAACTT-3′ (SEQ ID NO: 8430) KRAS-1754 Target: 5′-TTAAATCTTTTCTTCAACTTG-3′ (SEQ ID NO: 8431) KRAS-1769 Target: 5′-AACTTGAGTCTTTGAAGATAG-3′ (SEQ ID NO: 8432) KRAS-1771 Target: 5′-CTTGAGTCTTTGAAGATAGTT-3′ (SEQ ID NO: 8433) KRAS-1772 Target: 5′-TTGAGTCTTTGAAGATAGTTT-3′ (SEQ ID NO: 8434) KRAS-1783 Target: 5′-AAGATAGTTTTAATTCTGCTT-3′ (SEQ ID NO: 8435) KRAS-1784 Target: 5′-AGATAGTTTTAATTCTGCTTG-3′ (SEQ ID NO: 8436) KRAS-1785 Target: 5′-GATAGTTTTAATTCTGCTTGT-3′ (SEQ ID NO: 8437) KRAS-1799 Target: 5′-TGCTTGTGACATTAAAAGATT-3′ (SEQ ID NO: 8438) KRAS-2100 Target: 5′-AATATTAACTCAAAAGTTGAG-3′ (SEQ ID NO: 8439) KRAS-2134 Target: 5′-GGTGTGCCAAGACATTAATTT-3′ (SEQ ID NO: 8440) KRAS-2216 Target: 5′-ACTGGTTAAATTAACATTGCA-3′ (SEQ ID NO: 8441) KRAS-2217 Target: 5′-CTGGTTAAATTAACATTGCAT-3′ (SEQ ID NO: 8442) KRAS-2218 Target: 5′-TGGTTAAATTAACATTGCATA-3′ (SEQ ID NO: 8443) KRAS-2229 Target: 5′-ACATTGCATAAACACTTTTCA-3′ (SEQ ID NO: 8444) KRAS-2247 Target: 5′-TCAAGTCTGATCCATATTTAA-3′ (SEQ ID NO: 8445) KRAS-2326 Target: 5′-TTTAAAATAAATGAAGTGAGA-3′ (SEQ ID NO: 8446) KRAS-2327 Target: 5′-TTAAAATAAATGAAGTGAGAT-3′ (SEQ ID NO: 8447) KRAS-2547 Target: 5′-TCAAGCTCAGCACAATCTGTA-3′ (SEQ ID NO: 8448) KRAS-2548 Target: 5′-CAAGCTCAGCACAATCTGTAA-3′ (SEQ ID NO: 8449) KRAS-3741 Target: 5′-GCATAACTGTGATTCTTTTAG-3′ (SEQ ID NO: 8450) KRAS-3746 Target: 5′-ACTGTGATTCTTTTAGGACAA-3′ (SEQ ID NO: 8451) KRAS-3747 Target: 5′-CTGTGATTCTTTTAGGACAAT-3′ (SEQ ID NO: 8452) KRAS-3783 Target: 5′-GGTGTATGTCAGATATTCATA-3′ (SEQ ID NO: 8453) KRAS-3784 Target: 5′-GTGTATGTCAGATATTCATAT-3′ (SEQ ID NO: 8454) KRAS-3810 Target: 5′-CAAATGTGTAATATTCCAGTT-3′ (SEQ ID NO: 8455) KRAS-4396 Target: 5′-CACACTGCATAGGAATTTAGA-3′ (SEQ ID NO: 8456) KRAS-4447 Target: 5′-GTCACCATTGCACAATTTTGT-3′ (SEQ ID NO: 8457) KRAS-4448 Target: 5′-TCACCATTGCACAATTTTGTC-3′ (SEQ ID NO: 8458) KRAS-4449 Target: 5′-CACCATTGCACAATTTTGTCC-3′ (SEQ ID NO: 8459) KRAS-4450 Target: 5′-ACCATTGCACAATTTTGTCCT-3′ (SEQ ID NO: 8460) KRAS-4451 Target: 5′-CCATTGCACAATTTTGTCCTA-3′ (SEQ ID NO: 8461) KRAS-4452 Target: 5′-CATTGCACAATTTTGTCCTAA-3′ (SEQ ID NO: 8462) KRAS-4748 Target: 5′-GATAGCATGAATTCTGCATTG-3′ (SEQ ID NO: 8463) KRAS-4749 Target: 5′-ATAGCATGAATTCTGCATTGA-3′ (SEQ ID NO: 8464) KRAS-4878 Target: 5′-AGTTTGAAGTGCCTGTTTGGG-3′ (SEQ ID NO: 8465) KRAS-4879 Target: 5′-GTTTGAAGTGCCTGTTTGGGA-3′ (SEQ ID NO: 8466) KRAS-4880 Target: 5′-TTTGAAGTGCCTGTTTGGGAT-3′ (SEQ ID NO: 8467) KRAS-5073 Target: 5′-CCTTTGAGTGCCAATTTCTTA-3′ (SEQ ID NO: 8468) KRAS-5074 Target: 5′-CTTTGAGTGCCAATTTCTTAC-3′ (SEQ ID NO: 8469) KRAS-5075 Target: 5′-TTTGAGTGCCAATTTCTTACT-3′ (SEQ ID NO: 8470) KRAS-5076 Target: 5′-TTGAGTGCCAATTTCTTACTA-3′ (SEQ ID NO: 8471) KRAS-5077 Target: 5′-TGAGTGCCAATTTCTTACTAG-3′ (SEQ ID NO: 8472) KRAS-5078 Target: 5′-GAGTGCCAATTTCTTACTAGT-3′ (SEQ ID NO: 8473) KRAS-5128 Target: 5′-GAATGTATTTTAACTATTTTT-3′ (SEQ ID NO: 8474) KRAS-5129 Target: 5′-AATGTATTTTAACTATTTTTG-3′ (SEQ ID NO: 8475) KRAS-5138 Target: 5′-TAACTATTTTTGTATAGTGTA-3′ (SEQ ID NO: 8476) KRAS-5139 Target: 5′-AACTATTTTTGTATAGTGTAA-3′ (SEQ ID NO: 8477) KRAS-5140 Target: 5′-ACTATTTTTGTATAGTGTAAA-3′ (SEQ ID NO: 8478) KRAS-5141 Target: 5′-CTATTTTTGTATAGTGTAAAC-3′ (SEQ ID NO: 8479) KRAS-5142 Target: 5′-TATTTTTGTATAGTGTAAACT-3′ (SEQ ID NO: 8480) KRAS-5143 Target: 5′-ATTTTTGTATAGTGTAAACTG-3′ (SEQ ID NO: 8481) KRAS-5163 Target: 5′-GAAACATGCACATTTTGTACA-3′ (SEQ ID NO: 8482) KRAS-5164 Target: 5′-AAACATGCACATTTTGTACAT-3′ (SEQ ID NO: 8483) KRAS-5167 Target: 5′-CATGCACATTTTGTACATTGT-3′ (SEQ ID NO: 8484) KRAS-5168 Target: 5′-ATGCACATTTTGTACATTGTG-3′ (SEQ ID NO: 8485) KRAS-5169 Target: 5′-TGCACATTTTGTACATTGTGC-3′ (SEQ ID NO: 8486) KRAS-5170 Target: 5′-GCACATTTTGTACATTGTGCT-3′ (SEQ ID NO: 8487) KRAS-5171 Target: 5′-CACATTTTGTACATTGTGCTT-3′ (SEQ ID NO: 8488) KRAS-5172 Target: 5′-ACATTTTGTACATTGTGCTTT-3′ (SEQ ID NO: 8489) KRAS-5173 Target: 5′-CATTTTGTACATTGTGCTTTC-3′ (SEQ ID NO: 8490) KRAS-5197 Target: 5′-TGTGGGACATATGCAGTGTGA-3′ (SEQ ID NO: 8491) KRAS-5198 Target: 5′-GTGGGACATATGCAGTGTGAT-3′ (SEQ ID NO: 8492) KRAS-5199 Target: 5′-TGGGACATATGCAGTGTGATC-3′ (SEQ ID NO: 8493) KRAS-5200 Target: 5′-GGGACATATGCAGTGTGATCC-3′ (SEQ ID NO: 8494) KRAS-5201 Target: 5′-GGACATATGCAGTGTGATCCA-3′ (SEQ ID NO: 8495) KRAS-5202 Target: 5′-GACATATGCAGTGTGATCCAG-3′ (SEQ ID NO: 8496) KRAS-5203 Target: 5′-ACATATGCAGTGTGATCCAGT-3′ (SEQ ID NO: 8497) KRAS-5204 Target: 5′-CATATGCAGTGTGATCCAGTT-3′ (SEQ ID NO: 8498) KRAS-5205 Target: 5′-ATATGCAGTGTGATCCAGTTG-3′ (SEQ ID NO: 8499) KRAS-5209 Target: 5′-GCAGTGTGATCCAGTTGTTTT-3′ (SEQ ID NO: 8500) KRAS-5210 Target: 5′-CAGTGTGATCCAGTTGTTTTC-3′ (SEQ ID NO: 8501) KRAS-5211 Target: 5′-AGTGTGATCCAGTTGTTTTCC-3′ (SEQ ID NO: 8502) KRAS-5212 Target: 5′-GTGTGATCCAGTTGTTTTCCA-3′ (SEQ ID NO: 8503) KRAS-5213 Target: 5′-TGTGATCCAGTTGTTTTCCAT-3′ (SEQ ID NO: 8504) KRAS-5214 Target: 5′-GTGATCCAGTTGTTTTCCATC-3′ (SEQ ID NO: 8505) KRAS-5234 Target: 5′-CATTTGGTTGCGCTGACCTAG-3′ (SEQ ID NO: 8506) KRAS-5235 Target: 5′-ATTTGGTTGCGCTGACCTAGG-3′ (SEQ ID NO: 8507) KRAS-5252 Target: 5′-TAGGAATGTTGGTCATATCAA-3′ (SEQ ID NO: 8508) KRAS-5253 Target: 5′-AGGAATGTTGGTCATATCAAA-3′ (SEQ ID NO: 8509) KRAS-5254 Target: 5′-GGAATGTTGGTCATATCAAAC-3′ (SEQ ID NO: 8510) KRAS-5255 Target: 5′-GAATGTTGGTCATATCAAACA-3′ (SEQ ID NO: 8511) KRAS-5256 Target: 5′-AATGTTGGTCATATCAAACAT-3′ (SEQ ID NO: 8512) KRAS-5257 Target: 5′-ATGTTGGTCATATCAAACATT-3′ (SEQ ID NO: 8513) KRAS-5258 Target: 5′-TGTTGGTCATATCAAACATTA-3′ (SEQ ID NO: 8514) KRAS-5259 Target: 5′-GTTGGTCATATCAAACATTAA-3′ (SEQ ID NO: 8515) KRAS-5260 Target: 5′-TTGGTCATATCAAACATTAAA-3′ (SEQ ID NO: 8516) KRAS-5299 Target: 5′-TGAAATTAACTTTTAAATGTT-3′ (SEQ ID NO: 8517) KRAS-5300 Target: 5′-GAAATTAACTTTTAAATGTTT-3′ (SEQ ID NO: 8518) KRAS-5304 Target: 5′-TTAACTTTTAAATGTTTATAG-3′ (SEQ ID NO: 8519) KRAS-5305 Target: 5′-TAACTTTTAAATGTTTATAGG-3′ (SEQ ID NO: 8520) KRAS-5306 Target: 5′-AACTTTTAAATGTTTATAGGA-3′ (SEQ ID NO: 8521) KRAS-5307 Target: 5′-ACTTTTAAATGTTTATAGGAG-3′ (SEQ ID NO: 8522) KRAS-5308 Target: 5′-CTTTTAAATGTTTATAGGAGT-3′ (SEQ ID NO: 8523) KRAS-5309 Target: 5′-TTTTAAATGTTTATAGGAGTA-3′ (SEQ ID NO: 8524) KRAS-5347 Target: 5′-TAAAATTTGTAATATTTTTGT-3′ (SEQ ID NO: 8525) KRAS-5348 Target: 5′-AAAATTTGTAATATTTTTGTC-3′ (SEQ ID NO: 8526) KRAS-5349 Target: 5′-AAATTTGTAATATTTTTGTCA-3′ (SEQ ID NO: 8527) KRAS-5350 Target: 5′-AATTTGTAATATTTTTGTCAT-3′ (SEQ ID NO: 8528) KRAS-5351 Target: 5′-ATTTGTAATATTTTTGTCATG-3′ (SEQ ID NO: 8529) KRAS-5352 Target: 5′-TTTGTAATATTTTTGTCATGA-3′ (SEQ ID NO: 8530) KRAS-5353 Target: 5′-TTGTAATATTTTTGTCATGAA-3′ (SEQ ID NO: 8531) KRAS-5354 Target: 5′-TGTAATATTTTTGTCATGAAC-3′ (SEQ ID NO: 8532) KRAS-5389 Target: 5′-TTATTGTAATGTAATAAAAAT-3′ (SEQ ID NO: 8533) KRAS-5390 Target: 5′-TATTGTAATGTAATAAAAATA-3′ (SEQ ID NO: 8534) KRAS-5391 Target: 5′-ATTGTAATGTAATAAAAATAG-3′ (SEQ ID NO: 8535) KRAS-5392 Target: 5′-TTGTAATGTAATAAAAATAGT-3′ (SEQ ID NO: 8536) KRAS-5393 Target: 5′-TGTAATGTAATAAAAATAGTT-3′ (SEQ ID NO: 8537)

Within Tables 2-7 above, underlined residues indicate 2′-O-methyl residues, UPPER CASE indicates ribonucleotides, lower case denotes deoxyribonucleotides, and in Table 2, “P-” indicates a 5′-terminal phosphate group. The above DsiRNA agents of Tables 3-6 are 25/27mer agents possessing a blunt end. The structures and/or modification patterning of the agents of Tables 3-6 can be readily adapted to the above generic sequence structures, e.g., the 3′ overhang of the second strand can be extended or contracted, 2′-O-methylation of the second strand can be expanded towards the 5′ end of the second strand, optionally at alternating sites, etc. Such further modifications are optional, as 25/27mer DsiRNAs with such modifications can also be readily designed from the above DsiRNA agents and are also expected to be functional inhibitors of KRAS expression.

In certain embodiments, the DsiRNA agents of the invention require, e.g., at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25 or at least 26 residues of the first strand to be complementary to corresponding residues of the second strand. In certain related embodiments, these first strand residues complementary to corresponding residues of the second strand are optionally consecutive residues.

As used herein “DsiRNAmm” refers to a DisRNA having a “mismatch tolerant region” containing one, two, three or four mismatched base pairs of the duplex formed by the sense and antisense strands of the DsiRNA, where such mismatches are positioned within the DsiRNA at a location(s) lying between (and thus not including) the two terminal base pairs of either end of the DsiRNA. The mismatched base pairs are located within a “mismatch-tolerant region” which is defined herein with respect to the location of the projected Ago2 cut site of the corresponding target nucleic acid. The mismatch tolerant region is located “upstream of” the projected Ago2 cut site of the target strand. “Upstream” in this context will be understood as the 5′-most portion of the DsiRNAmm duplex, where 5′ refers to the orientation of the sense strand of the DsiRNA duplex. Therefore, the mismatch tolerant region is upstream of the base on the sense (passenger) strand that corresponds to the projected Ago2 cut site of the target nucleic acid (see FIG. 1); alternatively, when referring to the antisense (guide) strand of the DsiRNAmm, the mismatch tolerant region can also be described as positioned downstream of the base that is complementary to the projected Ago2 cut site of the target nucleic acid, that is, the 3′-most portion of the antisense strand of the DsiRNAmm (where position 1 of the antisense strand is the 5′ terminal nucleotide of the antisense strand, see FIG. 1).

In one embodiment, for example with numbering as depicted in FIG. 1, the mismatch tolerant region is positioned between and including base pairs 3-9 when numbered from the nucleotide starting at the 5′ end of the sense strand of the duplex. Therefore, a DsiRNAmm of the invention possesses a single mismatched base pair at any one of positions 3, 4, 5, 6, 7, 8 or 9 of the sense strand of a right-hand extended DsiRNA (where position 1 is the 5′ terminal nucleotide of the sense strand and position 9 is the nucleotide residue of the sense strand that is immediately 5′ of the projected Ago2 cut site of the target KRAS RNA sequence corresponding to the sense strand sequence). In certain embodiments, for a DsiRNAmm that possesses a mismatched base pair nucleotide at any of positions 3, 4, 5, 6, 7, 8 or 9 of the sense strand, the corresponding mismatched base pair nucleotide of the antisense strand not only forms a mismatched base pair with the DsiRNAmm sense strand sequence, but also forms a mismatched base pair with a DsiRNAmm target KRAS RNA sequence (thus, complementarity between the antisense strand sequence and the sense strand sequence is disrupted at the mismatched base pair within the DsiRNAmm, and complementarity is similarly disrupted between the antisense strand sequence of the DsiRNAmm and the target KRAS RNA sequence). In alternative embodiments, the mismatch base pair nucleotide of the antisense strand of a DsiRNAmm only form a mismatched base pair with a corresponding nucleotide of the sense strand sequence of the DsiRNAmm, yet base pairs with its corresponding target KRAS RNA sequence nucleotide (thus, complementarity between the antisense strand sequence and the sense strand sequence is disrupted at the mismatched base pair within the DsiRNAmm, yet complementarity is maintained between the antisense strand sequence of the DsiRNAmm and the target KRAS RNA sequence).

A DsiRNAmm of the invention that possesses a single mismatched base pair within the mismatch-tolerant region (mismatch region) as described above (e.g., a DsiRNAmm harboring a mismatched nucleotide residue at any one of positions 3, 4, 5, 6, 7, 8 or 9 of the sense strand) can further include one, two or even three additional mismatched base pairs. In preferred embodiments, these one, two or three additional mismatched base pairs of the DsiRNAmm occur at position(s) 3, 4, 5, 6, 7, 8 and/or 9 of the sense strand (and at corresponding residues of the antisense strand). In one embodiment where one additional mismatched base pair is present within a DsiRNAmm, the two mismatched base pairs of the sense strand can occur, e.g., at nucleotides of both position 4 and position 6 of the sense strand (with mismatch also occurring at corresponding nucleotide residues of the antisense strand).

In DsiRNAmm agents possessing two mismatched base pairs, mismatches can occur consecutively (e.g., at consecutive positions along the sense strand nucleotide sequence). Alternatively, nucleotides of the sense strand that form mismatched base pairs with the antisense strand sequence can be interspersed by nucleotides that base pair with the antisense strand sequence (e.g., for a DsiRNAmm possessing mismatched nucleotides at positions 3 and 6, but not at positions 4 and 5, the mismatched residues of sense strand positions 3 and 6 are interspersed by two nucleotides that form matched base pairs with corresponding residues of the antisense strand). For example, two residues of the sense strand (located within the mismatch-tolerant region of the sense strand) that form mismatched base pairs with the corresponding antisense strand sequence can occur with zero, one, two, three, four or five matched base pairs located between these mismatched base pairs.

For certain DsiRNAmm agents possessing three mismatched base pairs, mismatches can occur consecutively (e.g., in a triplet along the sense strand nucleotide sequence). Alternatively, nucleotides of the sense strand that form mismatched base pairs with the antisense strand sequence can be interspersed by nucleotides that form matched base pairs with the antisense strand sequence (e.g., for a DsiRNAmm possessing mismatched nucleotides at positions 3, 4 and 8, but not at positions 5, 6 and 7, the mismatched residues of sense strand positions 3 and 4 are adjacent to one another, while the mismatched residues of sense strand positions 4 and 8 are interspersed by three nucleotides that form matched base pairs with corresponding residues of the antisense strand). For example, three residues of the sense strand (located within the mismatch-tolerant region of the sense strand) that form mismatched base pairs with the corresponding antisense strand sequence can occur with zero, one, two, three or four matched base pairs located between any two of these mismatched base pairs.

For certain DsiRNAmm agents possessing four mismatched base pairs, mismatches can occur consecutively (e.g., in a quadruplet along the sense strand nucleotide sequence). Alternatively, nucleotides of the sense strand that form mismatched base pairs with the antisense strand sequence can be interspersed by nucleotides that form matched base pairs with the antisense strand sequence (e.g., for a DsiRNAmm possessing mismatched nucleotides at positions 3, 5, 7 and 8, but not at positions 4 and 6, the mismatched residues of sense strand positions 7 and 8 are adjacent to one another, while the mismatched residues of sense strand positions 3 and 5 are interspersed by one nucleotide that forms a matched base pair with the corresponding residue of the antisense strand—similarly, the mismatched residues of sense strand positions 5 and 7 are also interspersed by one nucleotide that forms a matched base pair with the corresponding residue of the antisense strand). For example, four residues of the sense strand (located within the mismatch-tolerant region of the sense strand) that form mismatched base pairs with the corresponding antisense strand sequence can occur with zero, one, two or three matched base pairs located between any two of these mismatched base pairs.

In another embodiment, for example with numbering also as depicted in FIG. 1, a DsiRNAmm of the invention comprises a mismatch tolerant region which possesses a single mismatched base pair nucleotide at any one of positions 17, 18, 19, 20, 21, 22 or 23 of the antisense strand of the DsiRNA (where position 1 is the 5′ terminal nucleotide of the antisense strand and position 17 is the nucleotide residue of the antisense strand that is immediately 3′ (downstream) in the antisense strand of the projected Agog cut site of the target KRAS RNA sequence sufficiently complementary to the antisense strand sequence). In certain embodiments, for a DsiRNAmm that possesses a mismatched base pair nucleotide at any of positions 17, 18, 19, 20, 21, 22 or 23 of the antisense strand with respect to the sense strand of the DsiRNAmm, the mismatched base pair nucleotide of the antisense strand not only forms a mismatched base pair with the DsiRNAmm sense strand sequence, but also forms a mismatched base pair with a DsiRNAmm target KRAS RNA sequence (thus, complementarity between the antisense strand sequence and the sense strand sequence is disrupted at the mismatched base pair within the DsiRNAmm, and complementarity is similarly disrupted between the antisense strand sequence of the DsiRNAmm and the target KRAS RNA sequence). In alternative embodiments, the mismatch base pair nucleotide of the antisense strand of a DsiRNAmm only forms a mismatched base pair with a corresponding nucleotide of the sense strand sequence of the DsiRNAmm, yet base pairs with its corresponding target KRAS RNA sequence nucleotide (thus, complementarity between the antisense strand sequence and the sense strand sequence is disrupted at the mismatched base pair within the DsiRNAmm, yet complementarity is maintained between the antisense strand sequence of the DsiRNAmm and the target KRAS RNA sequence).

A DsiRNAmm of the invention that possesses a single mismatched base pair within the mismatch-tolerant region as described above (e.g., a DsiRNAmm harboring a mismatched nucleotide residue at positions 17, 18, 19, 20, 21, 22 or 23 of the antisense strand) can further include one, two or even three additional mismatched base pairs. In preferred embodiments, these one, two or three additional mismatched base pairs of the DsiRNAmm occur at position(s) 17, 18, 19, 20, 21, 22 and/or 23 of the antisense strand (and at corresponding residues of the sense strand). In one embodiment where one additional mismatched base pair is present within a DsiRNAmm, the two mismatched base pairs of the antisense strand can occur, e.g., at nucleotides of both position 18 and position 20 of the antisense strand (with mismatch also occurring at corresponding nucleotide residues of the sense strand).

In DsiRNAmm agents possessing two mismatched base pairs, mismatches can occur consecutively (e.g., at consecutive positions along the antisense strand nucleotide sequence). Alternatively, nucleotides of the antisense strand that form mismatched base pairs with the sense strand sequence can be interspersed by nucleotides that base pair with the sense strand sequence (e.g., for a DsiRNAmm possessing mismatched nucleotides at positions 17 and 20, but not at positions 18 and 19, the mismatched residues of antisense strand positions 17 and 20 are interspersed by two nucleotides that form matched base pairs with corresponding residues of the sense strand). For example, two residues of the antisense strand (located within the mismatch-tolerant region of the sense strand) that form mismatched base pairs with the corresponding sense strand sequence can occur with zero, one, two, three, four, five, six or seven matched base pairs located between these mismatched base pairs.

For certain DsiRNAmm agents possessing three mismatched base pairs, mismatches can occur consecutively (e.g., in a triplet along the antisense strand nucleotide sequence). Alternatively, nucleotides of the antisense strand that form mismatched base pairs with the sense strand sequence can be interspersed by nucleotides that form matched base pairs with the sense strand sequence (e.g., for a DsiRNAmm possessing mismatched nucleotides at positions 17, 18 and 22, but not at positions 19, 20 and 21, the mismatched residues of antisense strand positions 17 and 18 are adjacent to one another, while the mismatched residues of antisense strand positions 18 and 122 are interspersed by three nucleotides that form matched base pairs with corresponding residues of the sense strand). For example, three residues of the antisense strand (located within the mismatch-tolerant region of the antisense strand) that form mismatched base pairs with the corresponding sense strand sequence can occur with zero, one, two, three, four, five or six matched base pairs located between any two of these mismatched base pairs.

For certain DsiRNAmm agents possessing four mismatched base pairs, mismatches can occur consecutively (e.g., in a quadruplet along the antisense strand nucleotide sequence). Alternatively, nucleotides of the antisense strand that form mismatched base pairs with the sense strand sequence can be interspersed by nucleotides that form matched base pairs with the sense strand sequence (e.g., for a DsiRNAmm possessing mismatched nucleotides at positions 18, 20, 22 and 23, but not at positions 19 and 21, the mismatched residues of antisense strand positions 22 and 23 are adjacent to one another, while the mismatched residues of antisense strand positions 18 and 20 are interspersed by one nucleotide that forms a matched base pair with the corresponding residue of the sense strand—similarly, the mismatched residues of antisense strand positions 20 and 22 are also interspersed by one nucleotide that forms a matched base pair with the corresponding residue of the sense strand). For example, four residues of the antisense strand (located within the mismatch-tolerant region of the antisense strand) that form mismatched base pairs with the corresponding sense strand sequence can occur with zero, one, two, three, four or five matched base pairs located between any two of these mismatched base pairs.

For reasons of clarity, the location(s) of mismatched nucleotide residues within the above DsiRNAmm agents are numbered in reference to the 5′ terminal residue of either sense or antisense strands of the DsiRNAmm. The numbering of positions located within the mismatch-tolerant region (mismatch region) of the antisense strand can shift with variations in the proximity of the 5′ terminus of the sense or antisense strand to the projected Ago2 cleavage site. Thus, the location(s) of preferred mismatch sites within either antisense strand or sense strand can also be identified as the permissible proximity of such mismatches to the projected Ago2 cut site. Accordingly, in one preferred embodiment, the position of a mismatch nucleotide of the sense strand of a DsiRNAmm is the nucleotide residue of the sense strand that is located immediately 5′ (upstream) of the projected Ago2 cleavage site of the corresponding target KRAS RNA sequence. In other preferred embodiments, a mismatch nucleotide of the sense strand of a DsiRNAmm is positioned at the nucleotide residue of the sense strand that is located two nucleotides 5′ (upstream) of the projected Ago2 cleavage site, three nucleotides 5′ (upstream) of the projected Ago2 cleavage site, four nucleotides 5′ (upstream) of the projected Ago2 cleavage site, five nucleotides 5′ (upstream) of the projected Ago2 cleavage site, six nucleotides 5′ (upstream) of the projected Ago2 cleavage site, seven nucleotides 5′ (upstream) of the projected Ago2 cleavage site, eight nucleotides 5′ (upstream) of the projected Ago2 cleavage site, or nine nucleotides 5′ (upstream) of the projected Ago2 cleavage site.

Exemplary single mismatch-containing 25/27mer DsiRNAs (DsiRNAmm) include the following structures (such mismatch-containing structures may also be incorporated into other exemplary DsiRNA structures shown herein).

5′-pXX^(M)XXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXX_(M)XXXXXXXXXXXXXXXXXXXXXXp-5′ 5′-pXXX^(M)XXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXX_(M)XXXXXXXXXXXXXXXXXXXXXp-5′ 5′-pXXXX^(M)XXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXX_(M)XXXXXXXXXXXXXXXXXXXXp-5′ 5′-pXXXXX^(M)XXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXX_(M)XXXXXXXXXXXXXXXXXXXp-5′ 5′-pXXXXXX^(M)XXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXX_(M)XXXXXXXXXXXXXXXXXXp-5′ 5′-pXXXXXXX^(M)XXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXX_(M)XXXXXXXXXXXXXXXXXp-5′ 5′-pXXXXXXXX^(M)XXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXX_(M)XXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “D”=DNA, “p”=a phosphate group, “M”=Nucleic acid residues (RNA, DNA or non-natural or modified nucleic acids) that do not base pair (hydrogen bond) with corresponding “M” residues of otherwise complementary strand when strands are annealed. Any of the residues of such agents can optionally be 2′-O-methyl RNA monomers—alternating positioning of 2′-O-methyl RNA monomers that commences from the 3′-terminal residue of the bottom (second) strand, as shown above, can also be used in the above DsiRNAmm agents. For the above mismatch structures, the top strand is the sense strand, and the bottom strand is the antisense strand.

In certain embodiments, a DsiRNA of the invention can contain mismatches that exist in reference to the target KRAS RNA sequence yet do not necessarily exist as mismatched base pairs within the two strands of the DsiRNA—thus, a DsiRNA can possess perfect complementarity between first and second strands of a DsiRNA, yet still possess mismatched residues in reference to a target KRAS RNA (which, in certain embodiments, may be advantageous in promoting efficacy and/or potency and/or duration of effect). In certain embodiments, where mismatches occur between antisense strand and target KRAS RNA sequence, the position of a mismatch is located within the antisense strand at a position(s) that corresponds to a sequence of the sense strand located 5′ of the projected Ago2 cut site of the target region—e.g., antisense strand residue(s) positioned within the antisense strand to the 3′ of the antisense residue which is complementary to the projected Ago2 cut site of the target sequence.

Exemplary 25/27mer DsiRNAs that harbor a single mismatched residue in reference to target sequences include the following preferred structures.

Target RNA Sequence: 5′-. . . XXAXXXXXXXXXXXXXXXX . . .-3′ DsiRNAmm Sense Strand: 5′-pXXBXXXXXXXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand: 3′-XXXXEXXXXXXXXXXXXXXXXXXXXXXp-5′ Target RNA Sequence: 5′-. . . XXXAXXXXXXXXXXXXXXX . . .-3′ DsiRNAmm Sense Strand: 5′-pXXXBXXXXXXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand: 3′-XXXXXEXXXXXXXXXXXXXXXXXXXXXp-5′ Target RNA Sequence: 5′-. . . XXXXAXXXXXXXXXXXXXX . . .-3′ DsiRNAmm Sense Strand: 5′-pXXXXBXXXXXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand: 3′-XXXXXXEXXXXXXXXXXXXXXXXXXXXp-5′ Target RNA Sequence: 5′-. . . XXXXXAXXXXXXXXXXXXX . . .-3′ DsiRNAmm Sense Strand: 5′-pXXXXXBXXXXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand: 3′-XXXXXXXEXXXXXXXXXXXXXXXXXXXp-5′ Target RNA Sequence: 5′-. . . XXXXXXAXXXXXXXXXXXX . . .-3′ DsiRNAmm Sense Strand: 5′-pXXXXXXBXXXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand: 3′-XXXXXXXXEXXXXXXXXXXXXXXXXXXp-5′ Target RNA Sequence: 5′-. . . XXXXXXXAXXXXXXXXXXX . . .-3′ DsiRNAmm Sense Strand: 5′-pXXXXXXXBXXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand: 3′-XXXXXXXXXEXXXXXXXXXXXXXXXXXp-5′ Target RNA Sequence: 5′-. . . XXXXXXXXAXXXXXXXXXX . . .-3′ DsiRNAmm Sense Strand: 5′-pXXXXXXXXBXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand: 3′-XXXXXXXXXXEXXXXXXXXXXXXXXXXp-5′ wherein “X”=RNA, “D”=DNA, “p”=a phosphate group, “E”=Nucleic acid residues (RNA, DNA or non-natural or modified nucleic acids) that do not base pair (hydrogen bond) with corresponding “A” RNA residues of otherwise complementary (target) strand when strands are annealed, yet optionally do base pair with corresponding “B” residues (“B” residues are also RNA, DNA or non-natural or modified nucleic acids). Any of the residues of such agents can optionally be 2′-O-methyl RNA monomers—alternating positioning of 2′-O-methyl RNA monomers that commences from the 3′-terminal residue of the bottom (second) strand, as shown above, can also be used in the above DsiRNA agents.

In addition to the above-exemplified structures, DsiRNAs of the invention can also possess one, two or three additional residues that form further mismatches with the target KRAS RNA sequence. Such mismatches can be consecutive, or can be interspersed by nucleotides that form matched base pairs with the target KRAS RNA sequence. Where interspersed by nucleotides that form matched base pairs, mismatched residues can be spaced apart from each other within a single strand at an interval of one, two, three, four, five, six, seven or even eight base paired nucleotides between such mismatch-forming residues.

As for the above-described DsiRNAmm agents, a preferred location within DsiRNAs for antisense strand nucleotides that form mismatched base pairs with target KRAS RNA sequence (yet may or may not form mismatches with corresponding sense strand nucleotides) is within the antisense strand region that is located 3′ (downstream) of the antisense strand sequence which is complementary to the projected Ago2 cut site of the DsiRNA (e.g., in FIG. 1, the region of the antisense strand which is 3′ of the projected Ago2 cut site is preferred for mismatch-forming residues and happens to be located at positions 17-23 of the antisense strand for the 25/27mer agent shown in FIG. 1). Thus, in one preferred embodiment, the position of a mismatch nucleotide (in relation to the target KRAS RNA sequence) of the antisense strand of a DsiRNAmm is the nucleotide residue of the antisense strand that is located immediately 3′ (downstream) within the antisense strand sequence of the projected Ago2 cleavage site of the corresponding target KRAS RNA sequence. In other preferred embodiments, a mismatch nucleotide of the antisense strand of a DsiRNAmm (in relation to the target KRAS RNA sequence) is positioned at the nucleotide residue of the antisense strand that is located two nucleotides 3′ (downstream) of the corresponding projected Ago2 cleavage site, three nucleotides 3′ (downstream) of the corresponding projected Ago2 cleavage site, four nucleotides 3′ (downstream) of the corresponding projected Ago2 cleavage site, five nucleotides 3′ (downstream) of the corresponding projected Ago2 cleavage site, six nucleotides 3′ (downstream) of the projected Ago2 cleavage site, seven nucleotides 3′ (downstream) of the projected Ago2 cleavage site, eight nucleotides 3′ (downstream) of the projected Ago2 cleavage site, or nine nucleotides 3′ (downstream) of the projected Ago2 cleavage site.

In DsiRNA agents possessing two mismatch-forming nucleotides of the antisense strand (where mismatch-forming nucleotides are mismatch forming in relation to target KRAS RNA sequence), mismatches can occur consecutively (e.g., at consecutive positions along the antisense strand nucleotide sequence). Alternatively, nucleotides of the antisense strand that form mismatched base pairs with the target KRAS RNA sequence can be interspersed by nucleotides that base pair with the target KRAS RNA sequence (e.g., for a DsiRNA possessing mismatch-forming nucleotides at positions 17 and 20 (starting from the 5′ terminus (position 1) of the antisense strand of the 25/27mer agent shown in FIG. 1), but not at positions 18 and 19, the mismatched residues of sense strand positions 17 and 20 are interspersed by two nucleotides that form matched base pairs with corresponding residues of the target KRAS RNA sequence). For example, two residues of the antisense strand (located within the mismatch-tolerant region of the antisense strand) that form mismatched base pairs with the corresponding target KRAS RNA sequence can occur with zero, one, two, three, four or five matched base pairs (with respect to target KRAS RNA sequence) located between these mismatch-forming base pairs.

For certain DsiRNAs possessing three mismatch-forming base pairs (mismatch-forming with respect to target KRAS RNA sequence), mismatch-forming nucleotides can occur consecutively (e.g., in a triplet along the antisense strand nucleotide sequence). Alternatively, nucleotides of the antisense strand that form mismatched base pairs with the target KRAS RNA sequence can be interspersed by nucleotides that form matched base pairs with the target KRAS RNA sequence (e.g., for a DsiRNA possessing mismatched nucleotides at positions 17, 18 and 22, but not at positions 19, 20 and 21, the mismatch-forming residues of antisense strand positions 17 and 18 are adjacent to one another, while the mismatch-forming residues of antisense strand positions 18 and 22 are interspersed by three nucleotides that form matched base pairs with corresponding residues of the target KRAS RNA). For example, three residues of the antisense strand (located within the mismatch-tolerant region of the antisense strand) that form mismatched base pairs with the corresponding target KRAS RNA sequence can occur with zero, one, two, three or four matched base pairs located between any two of these mismatch-forming base pairs.

For certain DsiRNAs possessing four mismatch-forming base pairs (mismatch-forming with respect to target KRAS RNA sequence), mismatch-forming nucleotides can occur consecutively (e.g., in a quadruplet along the sense strand nucleotide sequence). Alternatively, nucleotides of the antisense strand that form mismatched base pairs with the target KRAS RNA sequence can be interspersed by nucleotides that form matched base pairs with the target KRAS RNA sequence (e.g., for a DsiRNA possessing mismatch-forming nucleotides at positions 17, 19, 21 and 22, but not at positions 18 and 20, the mismatch-forming residues of antisense strand positions 21 and 22 are adjacent to one another, while the mismatch-forming residues of antisense strand positions 17 and 19 are interspersed by one nucleotide that forms a matched base pair with the corresponding residue of the target KRAS RNA sequence—similarly, the mismatch-forming residues of antisense strand positions 19 and 21 are also interspersed by one nucleotide that forms a matched base pair with the corresponding residue of the target KRAS RNA sequence). For example, four residues of the antisense strand (located within the mismatch-tolerant region of the antisense strand) that form mismatched base pairs with the corresponding target KRAS RNA sequence can occur with zero, one, two or three matched base pairs located between any two of these mismatch-forming base pairs.

The above DsiRNAmm and other DsiRNA structures are described in order to exemplify certain structures of DsiRNAmm and DsiRNA agents. Design of the above DsiRNAmm and DsiRNA structures can be adapted to generate, e.g., DsiRNAmm forms of other DsiRNA structures shown infra. As exemplified above, DsiRNAs can also be designed that possess single mismatches (or two, three or four mismatches) between the antisense strand of the DsiRNA and a target sequence, yet optionally can retain perfect complementarity between sense and antisense strand sequences of a DsiRNA.

It is further noted that the DsiRNA agents exemplified infra can also possess insertion/deletion (in/del) structures within their double-stranded and/or target KRAS RNA-aligned structures. Accordingly, the DsiRNAs of the invention can be designed to possess in/del variations in, e.g., antisense strand sequence as compared to target KRAS RNA sequence and/or antisense strand sequence as compared to sense strand sequence, with preferred location(s) for placement of such in/del nucleotides corresponding to those locations described above for positioning of mismatched and/or mismatch-forming base pairs.

It is also noted that the DsiRNAs of the instant invention can tolerate mismatches within the 3′-terminal region of the sense strand/5′-terminal region of the antisense strand, as this region is modeled to be processed by Dicer and liberated from the guide strand sequence that loads into RISC. Exemplary DsiRNA structures of the invention that harbor such mismatches include the following:

Target RNA Sequence: 5′-. . . XXXXXXXXXXXXXXXXXXXXXHXXX . . .-3′ DsiRNA Sense Strand: 5′-pXXXXXXXXXXXXXXXXXXXXXIXDD-3′ DsiRNA Antisense Strand: 3′ -XXXXXXXXXXXXXXXXXXXXXXXJXXXp-5′ Target RNA Sequence: 5′-. . . XXXXXXXXXXXXXXXXXXXXXXHXX. . .-3′ DsiRNA Sense Strand: 5′-pXXXXXXXXXXXXXXXXXXXXXXIDD-3′ DsiRNA Antisense Strand: 3′-XXXXXXXXXXXXXXXXXXXXXXXXJXXp-5′ Target RNA Sequence: 5′-. . . XXXXXXXXXXXXXXXXXXXXXXXHX . . .-3′ DsiRNA Sense Strand: 5′-pXXXXXXXXXXXXXXXXXXXXXXXID-3′ DsiRNA Antisense Strand: 3′-XXXXXXXXXXXXXXXXXXXXXXXXXJXp-5′ Target RNA Sequence: 5′-. . . XXXXXXXXXXXXXXXXXXXXXXXXH . . .-3′ DsiRNA Sense Strand: 5′-pXXXXXXXXXXXXXXXXXXXXXXXDI-3′ DsiRNA Antisense Strand: 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXJp-5′ wherein “X”=RNA, “D”=DNA, “p”=a phosphate group, “I” and “J”=Nucleic acid residues (RNA, DNA or non-natural or modified nucleic acids) that do not base pair (hydrogen bond) with one another, yet optionally “J” is complementary to target RNA sequence nucleotide “H”. Any of the residues of such agents can optionally be 2′-O-methyl RNA monomers—alternating positioning of 2′-O-methyl RNA monomers that commences from the 3′-terminal residue of the bottom (second) strand, as shown above—or any of the above-described methylation patterns—can also be used in the above DsiRNA agents. The above mismatches can also be combined within the DsiRNAs of the instant invention.

In the below structures, such mismatches are introduced within the asymmetric KRAS-420 DsiRNA (newly-introduced mismatch residues are italicized):

KRAS-420 25/27mer DsiRNA, mismatch position=22 of sense strand (from 5′-terminus)

  5′-GUAUUUGCCAUAAAUAAUACU^(C)Aat-3′ (SEQ ID NO: 5136) 3′-CACAUAAACGGUAUUUAUUAUGA_(U)UUA-5′ (SEQ ID NO: 26) Optionally, the mismatched “C” residue of position 22 of the sense strand is alternatively “G” or “U”, KRAS-420 25/27mer DsiRNA, mismatch position=23 of sense strand

  5′-GUAUUUGCCAUAAAUAAUACUA^(C)at-3′ (SEQ ID NO: 5137) 3′-CACAUAAACGGUAUUUAUUAUGAU_(U)UA-5′ (SEQ ID NO: 26)

Optionally, the mismatched “C” residue of position 23 of the sense strand is alternatively “G” or “U”.

KRAS-420 25/27mer DsiRNA, mismatch position=24 of sense strand

  5′-GUAUUUGCCAUAAAUAAUACUAA^(c)t-3′ (SEQ ID NO: 5138) 3′-CACAUAAACGGUAUUUAUUAUGAUU_(U)A-5′ (SEQ ID NO: 26) Optionally, the mismatched “c” residue of position 24 of the sense strand is alternatively “g” or “t”. KRAS-420 25/27mer DsiRNA, mismatch position=25 of sense strand

  5′-GUAUUUGCCAUAAAUAAUACUAAa^(g)-3′ (SEQ ID NO: 5139) 3′-CACAUAAACGGUAUUUAUUAUGAUUU_(A)-5′ (SEQ ID NO: 26) Optionally, the mismatched “g” residue of position 25 of the sense strand is alternatively “c” or “a”. KRAS-420 25/27mer DsiRNA, mismatch position=1 of antisense strand

  5′-GUAUUUGCCAUAAAUAAUACUAAa^(t)-3′ (SEQ ID NO: 105) 3′-CACAUAAACGGUAUUUAUUAUGAUUU_(C)-5′ (SEQ ID NO: 5140) Optionally, the mismatched “C” residue of position 1 of the antisense strand is alternatively “G” or “U”. KRAS-420 25/27mer DsiRNA, mismatch position=2 of antisense strand

  5′-GUAUUUGCCAUAAAUAAUACUAA^(a)t-3′ (SEQ ID NO: 105) 3′-CACAUAAACGGUAUUUAUUAUGAUU_(C)A-5′ (SEQ ID NO: 5141) Optionally, the mismatched “C” residue of position 2 of the antisense strand is alternatively “G” or “A”. KRAS-420 25/27mer DsiRNA, mismatch position=3 of antisense strand

  5′-GUAUUUGCCAUAAAUAAUACUA^(A)at-3′ (SEQ ID NO: 105) 3′-CACAUAAACGGUAUUUAUUAUGAU_(G)UA-5′. (SEQ ID NO: 5142) Optionally, the mismatched “G” residue of position 3 of the antisense strand is alternatively “A” or “C” KRAS-420 25/27mer DsiRNA, mismatch position=4 of antisense strand

  5′-GUAUUUGCCAUAAAUAAUACU^(A)Aat-3′ (SEQ ID NO: 105) 3′-CACAUAAACGGUAUUUAUUAUGA_(G)UUA-5′ (SEQ ID NO: 5143) Optionally, the mismatched “G” residue of position 4 of the antisense strand is alternatively “A” or “C”.

As noted above, introduction of such mismatches can be performed upon any of the DsiRNAs described herein.

The mismatches of such DsiRNA structures can be combined to produce a DsiRNA possessing, e.g., two, three or even four mismatches within the 3′-terminal four nucleotides of the sense strand/5′-terminal four nucleotides of the antisense strand.

Indeed, in view of the flexibility of sequences which can be incorporated into DsiRNAs at the 3′-terminal residues of the sense strand/5′-terminal residues of the antisense strand, in certain embodiments, the sequence requirements of an asymmetric DsiRNA of the instant invention can be represented as the following (minimalist) structure (shown for an exemplary KRAS-420 DsiRNA sequence):

  5′-GUAUUUGCCAUAAAUAAUACUXXX[X]_(n)-3′ (SEQ ID NO: 6839) 3′-CACAUAAACGGUAUUUAUUAUXXXXX[X]_(n)-5′ (SEQ ID NO: 6840) where n=1 to 5, 1 to 10, 1 to 20, 1 to 30, 1 to 50, or 1 to 80 or more.

KRAS-420 Target:

(SEQ ID NO: 6841) 5′-GTGTATTTGCCATAAATAATAXXXXXX-3′

The KRAS target sight may also be a site which is targeted by one or more of several oligonucleotides whose complementary target sites overlap with a stated target site. For example, for the exemplary KRAS-420 DsiRNA, it is noted that certain DsiRNAs targeting overlapping and only slightly offset KRAS sequences can exhibit activity levels similar to that of KRAS-420 (specifically, see KRAS-415, KRAS-417 and KRAS-418 DsiRNAs of FIG. 10, and KRAS-422, KRAS-423, KRAS-424, KRAS-425 and KRAS-426 DsiRNAs of Table 9 and FIGS. 12 and 13. Thus, in certain embodiments, a designated target sequence region can be effectively targeted by a series of DsiRNAs possessing largely overlapping sequences. (E.g., if considering DsiRNAs surrounding the KRAS-420 site, a more encompassing KRAS target sequence might be recited as, e.g., 5′-TCTTTGTGTATTTGCCATAAATAATACTAAATCA-3′ (SEQ ID NO: 6842), wherein any given DsiRNA (e.g., a DsiRNA selected from KRAS-415, KRAS-417, KRAS-418, KRAS-420, KRAS-422, KRAS-423, KRAS-424, KRAS-425 and KRAS-426) only targets a sub-sequence within such a sequence region, yet the entire sequence can be considered a viable target for such a series of DsiRNAs).

Additionally and/or alternatively, mismatches within the 3′-terminal four nucleotides of the sense strand/5′-terminal four nucleotides of the antisense strand can be combined with mismatches positioned at other mismatch-tolerant positions, as described above.

In view of the present identification of the above-described Dicer substrate agents (DsiRNAs) as inhibitors of KRAS levels via targeting of specific KRAS sequences, it is also recognized that DsiRNAs having structures similar to those described herein can also be synthesized which target other sequences within the KRAS sequence of SEQ ID NO: 1 or SEQ ID NO: 3, or within variants thereof (e.g., target sequences possessing 80% identity, 90% identity, 95% identity, 96% identity, 97% identity, 98% identity, 99% or more identity to a sequence of SEQ ID NO: 1 and/or SEQ ID NO: 3).

Anti-KRAS DsiRNA Design/Synthesis

It has been found empirically that longer dsRNA species of from 25 to 35 nucleotides (DsiRNAs) and especially from 25 to 30 nucleotides give unexpectedly effective results in terms of potency and duration of action, as compared to 19-23mer siRNA agents. Without wishing to be bound by the underlying theory of the dsRNA processing mechanism, it is thought that the longer dsRNA species serve as a substrate for the Dicer enzyme in the cytoplasm of a cell. In addition to cleaving the dsRNA of the invention into shorter segments, Dicer is thought to facilitate the incorporation of a single-stranded cleavage product derived from the cleaved dsRNA into the RISC complex that is responsible for the destruction of the cytoplasmic RNA (e.g., KRAS RNA) of or derived from the target gene, KRAS (or other gene associated with a KRAS-associated disease or disorder). Prior studies (Rossi et al., U.S. Patent Application No. 2007/0265220) have shown that the cleavability of a dsRNA species (specifically, a DsiRNA agent) by Dicer corresponds with increased potency and duration of action of the dsRNA species.

Certain preferred anti-KRAS DsiRNA agents were selected from a pre-screened population. Design of DsiRNAs can optionally involve use of predictive scoring algorithms that perform in silico assessments of the projected activity/efficacy of a number of possible DsiRNA agents spanning a region of sequence. Information regarding the design of such scoring algorithms can be found, e.g., in Gong et al. (BMC Bioinformatics 2006, 7:516), though a more recent “v3” algorithm represents a theoretically improved algorithm relative to siRNA scoring algorithms previously available in the art. (The “v3” scoring algorithm is a machine learning algorithm that is not reliant upon any biases in human sequence. In addition, the “v3” algorithm derives from a data set that is approximately three-fold larger than that from which an older “v2” algorithm such as that described in Gong et al. derives.)

The first and second oligonucleotides of the DsiRNA agents of the instant invention are not required to be completely complementary. In fact, in one embodiment, the 3′-terminus of the sense strand contains one or more mismatches. In one aspect, two mismatches are incorporated at the 3′ terminus of the sense strand. In another embodiment, the DsiRNA of the invention is a double stranded RNA molecule containing two RNA oligonucleotides each of which is 27 nucleotides in length and, when annealed to each other, have blunt ends and a two nucleotide mismatch on the 3′-terminus of the sense strand (the 5′-terminus of the antisense strand). The use of mismatches or decreased thermodynamic stability (specifically at the 3′-sense/5′-antisense position) has been proposed to facilitate or favor entry of the antisense strand into RISC (Schwarz et al., 2003, Cell 115: 199-208; Khvorova et al., 2003, Cell 115: 209-216), presumably by affecting some rate-limiting unwinding steps that occur with entry of the siRNA into RISC. Thus, terminal base composition has been included in design algorithms for selecting active 21mer siRNA duplexes (Ui-Tei et al., 2004, Nucleic Acids Res 32: 936-948; Reynolds et al., 2004, Nat Biotechnol 22: 326-330). With Dicer cleavage of the dsRNA of this embodiment, the small end-terminal sequence which contains the mismatches will either be left unpaired with the antisense strand (become part of a 3′-overhang) or be cleaved entirely off the final 21-mer siRNA. These “mismatches”, therefore, do not persist as mismatches in the final RNA component of RISC. The finding that base mismatches or destabilization of segments at the 3′-end of the sense strand of Dicer substrate improved the potency of synthetic duplexes in RNAi, presumably by facilitating processing by Dicer, was a surprising finding of past works describing the design and use of 25-30mer dsRNAs (also termed “DsiRNAs” herein; Rossi et al., U.S. Patent Application Nos. 2005/0277610, 2005/0244858 and 2007/0265220).

Modification of Anti-KRAS DsiRNAs

One major factor that inhibits the effect of double stranded RNAs (“dsRNAs”) is the degradation of dsRNAs (e.g., siRNAs and DsiRNAs) by nucleases. A 3′-exonuclease is the primary nuclease activity present in serum and modification of the 3′-ends of antisense DNA oligonucleotides is crucial to prevent degradation (Eder et al., 1991, Antisense Res Dev, 1: 141-151). An RNase-T family nuclease has been identified called ERI-1 which has 3′ to 5′ exonuclease activity that is involved in regulation and degradation of siRNAs (Kennedy et al., 2004, Nature 427: 645-649; Hong et al., 2005, Biochem J, 390: 675-679). This gene is also known as Thex1 (NM_(—)02067) in mice or THEX1 (NM_(—)153332) in humans and is involved in degradation of histone mRNA; it also mediates degradation of 3′-overhangs in siRNAs, but does not degrade duplex RNA (Yang et al., 2006, J Biol Chem, 281: 30447-30454). It is therefore reasonable to expect that 3′-end-stabilization of dsRNAs, including the DsiRNAs of the instant invention, will improve stability.

XRN1 (NM_(—)019001) is a 5′ to 3′ exonuclease that resides in P-bodies and has been implicated in degradation of mRNA targeted by miRNA (Rehwinkel et al., 2005, RNA 11: 1640-1647) and may also be responsible for completing degradation initiated by internal cleavage as directed by a siRNA. XRN2 (NM_(—)012255) is a distinct 5′ to 3′ exonuclease that is involved in nuclear RNA processing.

RNase A is a major endonuclease activity in mammals that degrades RNAs. It is specific for ssRNA and cleaves at the 3′-end of pyrimidine bases. SiRNA degradation products consistent with RNase A cleavage can be detected by mass spectrometry after incubation in serum (Turner et al., 2007, Mol Biosyst 3: 43-50). The 3′-overhangs enhance the susceptibility of siRNAs to RNase degradation. Depletion of RNase A from serum reduces degradation of siRNAs; this degradation does show some sequence preference and is worse for sequences having poly A/U sequence on the ends (Haupenthal et al., 2006 Biochem Pharmacol 71: 702-710). This suggests the possibility that lower stability regions of the duplex may “breathe” and offer transient single-stranded species available for degradation by RNase A. RNase A inhibitors can be added to serum and improve siRNA longevity and potency (Haupenthal et al., 2007, Int J. Cancer 121: 206-210).

In 21 mers, phosphorothioate or boranophosphate modifications directly stabilize the internucleoside phosphate linkage. Boranophosphate modified RNAs are highly nuclease resistant, potent as silencing agents, and are relatively non-toxic. Boranophosphate modified RNAs cannot be manufactured using standard chemical synthesis methods and instead are made by in vitro transcription (NT) (Hall et al., 2004, Nucleic Acids Res 32: 5991-6000; Hall et al., 2006, Nucleic Acids Res 34: 2773-2781). Phosphorothioate (PS) modifications can be easily placed in the RNA duplex at any desired position and can be made using standard chemical synthesis methods. The PS modification shows dose-dependent toxicity, so most investigators—have recommended limited incorporation in siRNAs, favoring the 3′-ends where protection from nucleases is most important (Harborth et al., 2003, Antisense Nucleic Acid Drug Dev 13: 83-105; Chiu and Rana, 2003, Mol Cell 10: 549-561; Braasch et al., 2003, Biochemistry 42: 7967-7975; Amarzguioui et al., 2003, Nucleic Acids Research 31: 589-595). More extensive PS modification can be compatible with potent RNAi activity; however, use of sugar modifications (such as 2′-O-methyl RNA) may be superior (Choung et al., 2006, Biochem Biophys Res Commun 342: 919-927).

A variety of substitutions can be placed at the 2′-position of the ribose which generally increases duplex stability (T_(m)) and can greatly improve nuclease resistance. 2′-O-methyl RNA is a naturally occurring modification found in mammalian ribosomal RNAs and transfer RNAs. 2′-O-methyl modification in siRNAs is known, but the precise position of modified bases within the duplex is important to retain potency and complete substitution of 2′-O-methyl RNA for RNA will inactivate the siRNA. For example, a pattern that employs alternating 2′-O-methyl bases can have potency equivalent to unmodified RNA and is quite stable in serum (Choung et al., 2006, Biochem Biophys Res Commun 342: 919-927; Czauderna et al., 2003, Nucleic Acids Research 31: 2705-2716).

The 2′-fluoro (2′-F) modification is also compatible with dsRNA (e.g., siRNA and DsiRNA) function; it is most commonly placed at pyrimidine sites (due to reagent cost and availability) and can be combined with 2′-O-methyl modification at purine positions; 2′-F purines are available and can also be used. Heavily modified duplexes of this kind can be potent triggers of RNAi in vitro (Allerson et al., 2005, J Med Chem 48: 901-904; Prakash et al., 2005, J Med Chem 48: 4247-4253; Kraynack and Baker, 2006, RNA 12: 163-176) and can improve performance and extend duration of action when used in vivo (Morrissey et al., 2005, Hepatology 41: 1349-1356; Morrissey et al., 2005, Nat Biotechnol 23: 1002-1007). A highly potent, nuclease stable, blunt 19mer duplex containing alternative 2′-F and 2′-O-Me bases is taught by Allerson. In this design, alternating 2′-O-Me residues are positioned in an identical pattern to that employed by Czauderna, however the remaining RNA residues are converted to 2′-F modified bases. A highly potent, nuclease resistant siRNA employed by Morrissey employed a highly potent, nuclease resistant siRNA in vivo. In addition to 2′-O-Me RNA and 2′-F RNA, this duplex includes DNA, RNA, inverted abasic residues, and a 3′-terminal PS internucleoside linkage. While extensive modification has certain benefits, more limited modification of the duplex can also improve in vivo performance and is both simpler and less costly to manufacture. Soutschek et al. (2004, Nature 432: 173-178) employed a duplex in vivo and was mostly RNA with two 2′-O-Me RNA bases and limited 3′-terminal PS internucleoside linkages.

Locked nucleic acids (LNAs) are a different class of 2′-modification that can be used to stabilize dsRNA (e.g., siRNA and DsiRNA). Patterns of LNA incorporation that retain potency are more restricted than 2′-O-methyl or 2′-F bases, so limited modification is preferred (Braasch et al., 2003, Biochemistry 42: 7967-7975; Grunweller et al., 2003, Nucleic Acids Res 31: 3185-3193; Elmen et al., 2005, Nucleic Acids Res 33: 439-447). Even with limited incorporation, the use of LNA modifications can improve dsRNA performance in vivo and may also alter or improve off target effect profiles (Mook et al., 2007, Mol Cancer Ther 6: 833-843).

Synthetic nucleic acids introduced into cells or live animals can be recognized as “foreign” and trigger an immune response. Immune stimulation constitutes a major class of off-target effects which can dramatically change experimental results and even lead to cell death. The innate immune system includes a collection of receptor molecules that specifically interact with DNA and RNA that mediate these responses, some of which are located in the cytoplasm and some of which reside in endosomes (Marques and Williams, 2005, Nat Biotechnol 23: 1399-1405; Schlee et al., 2006, Mol Ther 14: 463-470). Delivery of siRNAs by cationic lipids or liposomes exposes the siRNA to both cytoplasmic and endosomal compartments, maximizing the risk for triggering a type 1 interferon (IFN) response both in vitro and in vivo (Morrissey et al., 2005, Nat Biotechnol 23: 1002-1007; Sioud and Sorensen, 2003, Biochem Biophys Res Commun 312: 1220-1225; Sioud, 2005, J Mol Biol 348: 1079-1090; Ma et al., 2005, Biochem Biophys Res Commun 330: 755-759). RNAs transcribed within the cell are less immunogenic (Robbins et al., 2006, Nat Biotechnol 24: 566-571) and synthetic RNAs that are immunogenic when delivered using lipid-based methods can evade immune stimulation when introduced unto cells by mechanical means, even in vivo (Heidel et al., 2004, Nat Biotechnol 22: 1579-1582). However, lipid based delivery methods are convenient, effective, and widely used. Some general strategy to prevent immune responses is needed, especially for in vivo application where all cell types are present and the risk of generating an immune response is highest. Use of chemically modified RNAs may solve most or even all of these problems.

In certain embodiments, modifications can be included in the anti-KRAS DsiRNA agents of the present invention so long as the modification does not prevent the DsiRNA agent from possessing KRAS inhibitory activity. In one embodiment, one or more modifications are made that enhance Dicer processing of the DsiRNA agent (an assay for determining Dicer processing of a DsiRNA is described supra). In a second embodiment, one or more modifications are made that result in more effective KRAS inhibition (as described herein, KRAS inhibition/KRAS inhibitory activity of a DsiRNA can be assayed via art-recognized methods for determining RNA levels, or for determining Kras polypeptide levels, should such levels be assessed in lieu of or in addition to assessment of, e.g., KRAS mRNA levels). In a third embodiment, one or more modifications are made that support greater KRAS inhibitory activity (means of determining KRAS inhibitory activity are described supra). In a fourth embodiment, one or more modifications are made that result in greater potency of KRAS inhibitory activity per each DsiRNA agent molecule to be delivered to the cell (potency of KRAS inhibitory activity is described supra). Modifications can be incorporated in the 3′-terminal region, the 5′-terminal region, in both the 3′-terminal and 5′-terminal region or in some instances in various positions within the sequence. With the restrictions noted above in mind, numbers and combinations of modifications can be incorporated into the DsiRNA agent. Where multiple modifications are present, they may be the same or different. Modifications to bases, sugar moieties, the phosphate backbone, and their combinations are contemplated. Either 5′-terminus can be phosphorylated.

Examples of modifications contemplated for the phosphate backbone include phosphonates, including methylphosphonate, phosphorothioate, and phosphotriester modifications such as alkylphosphotriesters, and the like. Examples of modifications contemplated for the sugar moiety include 2′-alkyl pyrimidine, such as 2′-O-methyl, 2′-fluoro, amino, and deoxy modifications and the like (see, e.g., Amarzguioui et al., 2003, Nucleic Acids Research 31: 589-595). Examples of modifications contemplated for the base groups include abasic sugars, 2-O-alkyl modified pyrimidines, 4-thiouracil, 5-bromouracil, 5-iodouracil, and 5-(3-aminoallyl)-uracil and the like. Locked nucleic acids, or LNA's, could also be incorporated. Many other modifications are known and can be used so long as the above criteria are satisfied. Examples of modifications are also disclosed in U.S. Pat. Nos. 5,684,143, 5,858,988 and 6,291,438 and in U.S. published patent application No. 2004/0203145 A1. Other modifications are disclosed in Herdewijn (2000, Antisense Nucleic Acid Drug Dev 10: 297-310), Eckstein (2000, Antisense Nucleic Acid Drug Dev 10: 117-21), Rusckowski et al. (2000, Antisense Nucleic Acid Drug Dev 10: 333-345), Stein et al. (2001, Antisense Nucleic Acid Drug Dev 11: 317-25); Vorobjev et al. (2001, Antisense Nucleic Acid Drug Dev 11: 77-85).

One or more modifications contemplated can be incorporated into either strand. The placement of the modifications in the DsiRNA agent can greatly affect the characteristics of the DsiRNA agent, including conferring greater potency and stability, reducing toxicity, enhance Dicer processing, and minimizing an immune response. In one embodiment, the antisense strand or the sense strand or both strands have one or more 2′-O-methyl modified nucleotides. In another embodiment, the antisense strand contains 2′-O-methyl modified nucleotides. In another embodiment, the antisense stand contains a 3′ overhang that is comprised of 2′-O-methyl modified nucleotides. The antisense strand could also include additional 2′-O-methyl modified nucleotides.

In certain embodiments of the present invention, the anti-KRAS DsiRNA agent has one or more of the following properties: (i) the DsiRNA agent is asymmetric, e.g., has a 3′ overhang on the antisense strand and (ii) the DsiRNA agent has a modified 3′ end on the sense strand to direct orientation of Dicer binding and processing of the dsRNA to an active siRNA. According to this embodiment, the longest strand in the dsRNA comprises 25-35 nucleotides (e.g., 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 nucleotides). In certain such embodiments, the DsiRNA agent is asymmetric such that the sense strand comprises 25-34 nucleotides and the 3′ end of the sense strand forms a blunt end with the 5′ end of the antisense strand while the antisense strand comprises 26-35 nucleotides and forms an overhang on the 3′ end of the antisense strand. In one embodiment, the DsiRNA agent is asymmetric such that the sense strand comprises 25-28 nucleotides and the antisense strand comprises 25-30 nucleotides. Thus, the resulting dsRNA has an overhang on the 3′ end of the antisense strand. The overhang is 1-4 nucleotides, for example 2 nucleotides. The sense strand may also have a 5′ phosphate.

In other embodiments, the sense strand of the DsiRNA agent is modified for Dicer processing by suitable modifiers located at the 3′ end of the sense strand, i.e., the DsiRNA agent is designed to direct orientation of Dicer binding and processing. Suitable modifiers include nucleotides such as deoxyribonucleotides, dideoxyribonucleotides, acyclonucleotides and the like and sterically hindered molecules, such as fluorescent molecules and the like. Acyclonucleotides substitute a 2-hydroxyethoxymethyl group for the 2′-deoxyribofuranosyl sugar normally present in dNMPs. Other nucleotides modifiers could include 3′-deoxyadenosine (cordycepin), 3′-azido-3′-deoxythymidine (AZT), 2′,3′-dideoxyinosine (ddI), 2′,3′-dideoxy-3′-thiacytidine (3TC), 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T) and the monophosphate nucleotides of 3′-azido-3′-deoxythymidine (AZT), 2′,3′-dideoxy-3′-thiacytidine (3TC) and 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T). In one embodiment, deoxynucleotides are used as the modifiers. When nucleotide modifiers are utilized, 1-3 nucleotide modifiers, or 2 nucleotide modifiers are substituted for the ribonucleotides on the 3′ end of the sense strand. When sterically hindered molecules are utilized, they are attached to the ribonucleotide at the 3′ end of the antisense strand. Thus, the length of the strand does not change with the incorporation of the modifiers. In another embodiment, the invention contemplates substituting two DNA bases in the DsiRNA agent to direct the orientation of Dicer processing of the antisense strand. In a further embodiment of the present invention, two terminal DNA bases are substituted for two ribonucleotides on the 3′-end of the sense strand forming a blunt end of the duplex on the 3′ end of the sense strand and the 5′ end of the antisense strand, and a two-nucleotide RNA overhang is located on the 3′-end of the antisense strand. This is an asymmetric composition with DNA on the blunt end and RNA bases on the overhanging end.

The sense and antisense strands of a DsiRNA agent of the instant invention anneal under biological conditions, such as the conditions found in the cytoplasm of a cell. In addition, a region of one of the sequences, particularly of the antisense strand, of the DsiRNA agent has a sequence length of at least 19 nucleotides, wherein these nucleotides are in the 21-nucleotide region adjacent to the 3′ end of the antisense strand and are sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene.

The DsiRNA agent can also have one or more of the following additional properties: (a) the antisense strand has a right shift from the typical 21mer (e.g., the DsiRNA comprises a length of antisense strand nucleotides that extends to the 5′ of a projected Dicer cleavage site within the DsiRNA, with such antisense strand nucleotides base paired with corresponding nucleotides of the sense strand extending 3′ of a projected Dicer cleavage site in the sense strand), (b) the strands may not be completely complementary, i.e., the strands may contain simple mismatched base pairs (in certain embodiments, the DsiRNAs of the invention possess 1, 2, 3, 4 or even 5 or more mismatched base pairs, provided that KRAS inhibitory activity of the DsiRNA possessing mismatched base pairs is retained at sufficient levels (e.g., retains at least 50% KRAS inhibitory activity or more, at least 60% KRAS inhibitory activity or more, at least 70% KRAS inhibitory activity or more, at least 80% KRAS inhibitory activity or more, at least 90% KRAS inhibitory activity or more or at least 95% KRAS inhibitory activity or more as compared to a corresponding DsiRNA not possessing mismatched base pairs. In certain embodiments, mismatched base pairs exist between the antisense and sense strands of a DsiRNA. In some embodiments, mismatched base pairs exist (or are predicted to exist) between the antisense strand and the target RNA. In certain embodiments, the presence of a mismatched base pair(s) between an antisense strand residue and a corresponding residue within the target RNA that is located 3′ in the target RNA sequence of a projected Ago2 cleavage site retains and may even enhance KRAS inhibitory activity of a DsiRNA of the invention) and (c) base modifications such as locked nucleic acid(s) may be included in the 5′ end of the sense strand. A “typical” 21 mer siRNA is designed using conventional techniques. In one technique, a variety of sites are commonly tested in parallel or pools containing several distinct siRNA duplexes specific to the same target with the hope that one of the reagents will be effective (Ji et al., 2003, FEBS Lett 552: 247-252). Other techniques use design rules and algorithms to increase the likelihood of obtaining active RNAi effector molecules (Schwarz et al., 2003, Cell 115: 199-208; Khvorova et al., 2003, Cell 115: 209-216; Ui-Tei et al., 2004, Nucleic Acids Res 32: 936-948; Reynolds et al., 2004, Nat Biotechnol 22: 326-330; Krol et al., 2004, J Biol Chem 279: 42230-42239; Yuan et al., 2004, Nucl Acids Res 32(Webserver issue):W 130-134; Boese et al., 2005, Methods Enzymol 392: 73-96). High throughput selection of siRNA has also been developed (U.S. published patent application No. 2005/0042641 A1). Potential target sites can also be analyzed by secondary structure predictions (Heale et al., 2005, Nucleic Acids Res 33(3): e30). This 21mer is then used to design a right shift to include 3-9 additional nucleotides on the 5′ end of the 21mer. The sequence of these additional nucleotides is not restricted. In one embodiment, the added ribonucleotides are based on the sequence of the target gene. Even in this embodiment, full complementarity between the target sequence and the antisense siRNA is not required.

The first and second oligonucleotides of a DsiRNA agent of the instant invention are not required to be completely complementary. They only need to be sufficiently complementary to anneal under biological conditions and to provide a substrate for Dicer that produces a siRNA sufficiently complementary to the target sequence. Locked nucleic acids, or LNA's, are well known to a skilled artisan (Elmen et al., 2005, Nucleic Acids Res 33: 439-447; Kurreck et al., 2002, Nucleic Acids Res 30: 1911-1918; Crinelli et al., 2002, Nucleic Acids Res 30: 2435-2443; Braasch and Corey, 2001, Chem Biol 8: 1-7; Bondensgaard et al., 2000, Chemistry 6: 2687-2695; Wahlestedt et al., 2000, Proc Natl Acad Sci USA 97: 5633-5638). In one embodiment, an LNA is incorporated at the 5′ terminus of the sense strand. In another embodiment, an LNA is incorporated at the 5′ terminus of the sense strand in duplexes designed to include a 3′ overhang on the antisense strand.

In certain embodiments, the DsiRNA agent of the instant invention has an asymmetric structure, with the sense strand having a 25-base pair length, and the antisense strand having a 27-base pair length with a 2 base 3′-overhang. In other embodiments, this DsiRNA agent having an asymmetric structure further contains 2 deoxynucleotides at the 3′ end of the sense strand in place of two of the ribonucleotides.

Certain DsiRNA agent compositions containing two separate oligonucleotides can be linked by a third structure. The third structure will not block Dicer activity on the DsiRNA agent and will not interfere with the directed destruction of the RNA transcribed from the target gene. In one embodiment, the third structure may be a chemical linking group. Many suitable chemical linking groups are known in the art and can be used. Alternatively, the third structure may be an oligonucleotide that links the two oligonucleotides of the DsiRNA agent in a manner such that a hairpin structure is produced upon annealing of the two oligonucleotides making up the dsRNA composition. The hairpin structure will not block Dicer activity on the DsiRNA agent and will not interfere with the directed destruction of the KRAS RNA.

In certain embodiments, the anti-KRAS DsiRNA agent of the invention has several properties which enhance its processing by Dicer. According to such embodiments; the DsiRNA agent has a length sufficient such that it is processed by Dicer to produce an siRNA and at least one of the following properties: (i) the DsiRNA agent is asymmetric, e.g., has a 3′ overhang on the sense strand and (ii) the DsiRNA agent has a modified 3′ end on the antisense strand to direct orientation of Dicer binding and processing of the dsRNA to an active siRNA. According to these embodiments, the longest strand in the DsiRNA agent comprises 25-30 nucleotides. In one embodiment, the sense strand comprises 25-30 nucleotides and the antisense strand comprises 25-28 nucleotides. Thus, the resulting dsRNA has an overhang on the 3′ end of the sense strand. The overhang is 1-4 nucleotides, such as 2 nucleotides. The antisense strand may also have a 5′ phosphate.

In certain embodiments, the sense strand of a DsiRNA agent is modified for Dicer processing by suitable modifiers located at the 3′ end of the sense strand, i.e., the DsiRNA agent is designed to direct orientation of Dicer binding and processing. Suitable modifiers include nucleotides such as deoxyribonucleotides, dideoxyribonucleotides, acyclonucleotides and the like and sterically hindered molecules, such as fluorescent molecules and the like. Acyclonucleotides substitute a 2-hydroxyethoxymethyl group for the 2′-deoxyribofuranosyl sugar normally present in dNMPs. Other nucleotide modifiers could include 3′-deoxyadenosine (cordycepin), 3′-azido-3′-deoxythymidine (AZT), 2′,3′-dideoxyinosine (ddI), 2′,3′-dideoxy-3′-thiacytidine (3TC), 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T) and the monophosphate nucleotides of 3′-azido-3′-deoxythymidine (AZT), 2′,3′-dideoxy-3′-thiacytidine (3TC) and 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T). In one embodiment, deoxynucleotides are used as the modifiers. When nucleotide modifiers are utilized, 1-3 nucleotide modifiers, or 2 nucleotide modifiers are substituted for the ribonucleotides on the 3′ end of the sense strand. When sterically hindered molecules are utilized, they are attached to the ribonucleotide at the 3′ end of the antisense strand. Thus, the length of the strand does not change with the incorporation of the modifiers. In another embodiment, the invention contemplates substituting two DNA bases in the dsRNA to direct the orientation of Dicer processing. In a further invention, two terminal DNA bases are located on the 3′ end of the sense strand in place of two ribonucleotides forming a blunt end of the duplex on the 5′ end of the antisense strand and the 3′ end of the sense strand, and a two-nucleotide RNA overhang is located on the 3′-end of the antisense strand. This is an asymmetric composition with DNA on the blunt end and RNA bases on the overhanging end.

In certain other embodiments, the antisense strand of a DsiRNA agent is modified for Dicer processing by suitable modifiers located at the 3′ end of the antisense strand, i.e., the DsiRNA agent is designed to direct orientation of Dicer binding and processing. Suitable modifiers include nucleotides such as deoxyribonucleotides, dideoxyribonucleotides, acyclonucleotides and the like and sterically hindered molecules, such as fluorescent molecules and the like. Acyclonucleotides substitute a 2-hydroxyethoxymethyl group for the 2′-deoxyribofuranosyl sugar normally present in dNMPs. Other nucleotide modifiers could include 3′-deoxyadenosine (cordycepin), 3′-azido-3′-deoxythymidine (AZT), 2′,3′-dideoxyinosine (ddI), 2′,3′-dideoxy-3′-thiacytidine (3TC), 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T) and the monophosphate nucleotides of 3′-azido-3′-deoxythymidine (AZT), 2′,3′-dideoxy-3′-thiacytidine (3TC) and 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T). In one embodiment, deoxynucleotides are used as the modifiers. When nucleotide modifiers are utilized, 1-3 nucleotide modifiers, or 2 nucleotide modifiers are substituted for the ribonucleotides on the 3′ end of the antisense strand. When sterically hindered molecules are utilized, they are attached to the ribonucleotide at the 3′ end of the antisense strand. Thus, the length of the strand does not change with the incorporation of the modifiers. In another embodiment, the invention contemplates substituting two DNA bases in the dsRNA to direct the orientation of Dicer processing. In a further invention, two terminal DNA bases are located on the 3′ end of the antisense strand in place of two ribonucleotides forming a blunt end of the duplex on the 5′ end of the sense strand and the 3′ end of the antisense strand, and a two-nucleotide RNA overhang is located on the 3′-end of the sense strand. This is also an asymmetric composition with DNA on the blunt end and RNA bases on the overhanging end.

The sense and antisense strands anneal under biological conditions, such as the conditions found in the cytoplasm of a cell. In addition, a region of one of the sequences, particularly of the antisense strand, of the dsRNA has a sequence length of at least 19 nucleotides, wherein these nucleotides are adjacent to the 3′ end of antisense strand and are sufficiently complementary to a nucleotide sequence of the target KRAS RNA.

Additionally, the DsiRNA agent structure can be optimized to ensure that the oligonucleotide segment generated from Dicer's cleavage will be the portion of the oligonucleotide that is most effective in inhibiting gene expression. For example, in one embodiment of the invention, a 27-bp oligonucleotide of the DsiRNA agent structure is synthesized wherein the anticipated 21 to 22-bp segment that will inhibit gene expression is located on the 3′-end of the antisense strand. The remaining bases located on the 5′-end of the antisense strand will be cleaved by Dicer and will be discarded. This cleaved portion can be homologous (i.e., based on the sequence of the target sequence) or non-homologous and added to extend the nucleic acid strand.

US 2007/0265220 discloses that 27mer DsiRNAs show improved stability in serum over comparable 21mer siRNA compositions, even absent chemical modification. Modifications of DsiRNA agents, such as inclusion of 2′-O-methyl RNA in the antisense strand, in patterns such as detailed above, when coupled with addition of a 5′ Phosphate, can improve stability of DsiRNA agents. Addition of 5′-phosphate to all strands in synthetic RNA duplexes may be an inexpensive and physiological method to confer some limited degree of nuclease stability. The chemical modification patterns of the DsiRNA agents of the instant invention are designed to enhance the efficacy of such agents. Accordingly, such modifications are designed to avoid reducing potency of DsiRNA agents; to avoid interfering with Dicer processing of DsiRNA agents; to improve stability in biological fluids (reduce nuclease sensitivity) of DsiRNA agents; or to block or evade detection by the innate immune system. Such modifications are also designed to avoid being toxic and to avoid increasing the cost or impact the ease of manufacturing the instant DsiRNA agents of the invention.

KRAS Biology and Biochemistry

Transformation is a cumulative process whereby normal control of cell growth and differentiation is interrupted, usually through the accumulation of mutations affecting the expression of genes that regulate cell growth and differentiation.

The platelet derived growth factor (PDGF) system has served as a prototype for identification of substrates of the receptor tyrosine kinases. Certain enzymes become activated by the PDGF receptor kinase, including phospholipase C and phosphatidylinositol 3′ kinase, Ras guanosine triphosphate (GTPase) activating protein (GAP) and src-like tyrosine kinases. GAP regulates the function of the Ras protein by stimulating the GTPase activity of the 21 kD Ras protein. Barbacid, 56 Ann. Rev. Biochem. 779, 1987. Microinjection of oncogenically activated Ras into NIH 3T3 cells has been shown to induce DNA synthesis. Mutations that cause oncogenic activation of Ras lead to accumulation of Ras bound to GTP, the active form of the molecule. These mutations block the ability of GAP to convert Ras to the inactive form. Mutations that impair the interactions of Ras with GAP also block the biological function of Ras.

While a number of Ras alleles exist (N-Ras, KRAS, H-Ras) which have been implicated in carcinogenesis, the type most often associated with colon and pancreatic carcinomas is KRAS. Nucleic acid molecules which are targeted to certain regions of the KRAS allelic mRNAs may also prove inhibitory to the function of the other allelic mRNAs of the N-Ras and H-Ras genes.

The use of DsiRNA agents targeting KRAS therefore provides a class of novel therapeutic agents that can be used in the treatment, alleviation, or prevention of cancer and/or proliferative diseases, conditions, or disorders, alone or in combination with other therapies.

Known human KRAS gene and polypeptide sequences include the following:

Wild-type KRAS sequence (SEQ ID NO: 1; K-Ras4A—transcript variant a; GenBank Accession No. NM_(—)033360.2):

GGCCGCGGCGGCGGAGGCAGCAGCGGCGGCGGCAGTGGCGGCGGCGAAGG TGGCGGCGGCTCGGCCAGTACTCCCGGCCCCCGCCATTTCGGACTGGGAG CGAGCGCGGCGCAGGCACTGAAGGCGGCGGCGGGGCCAGAGGCTCAGCGG CTCCCAGGTGCGGGAGAGAGGCCTGCTGAAAATGACTGAATATAAACTTG TGGTAGTTGGAGCTGGTGGCGTAGGCAAGAGTGCCTTGACGATACAGCTA ATTCAGAATCATTTTGTGGACGAATATGATCCAACAATAGAGGATTCCTA CAGGAAGCAAGTAGTAATTGATGGAGAAACCTGTCTCTTGGATATTCTCG ACACAGCAGGTCA A GAGGAGTACAGTGCAATGAGGGACCAGTACATGAGG ACTGGGGAGGGCTTTCTTTGTGTATTTGCCATAAATAATACTAAATCATT TGAAGATATTCACCATTATAGAGAACAAATTAAAAGAGTTAAGGACTCTG AAGATGTACCTATGGTCCTAGTAGGAAATAAATGTGATTTGCCTTCTAGA ACAGTAGACACAAAACAGGCTCAGGACTTAGCAAGAAGTTATGGAATTCC TTTTATTGAAACATCAGCAAAGACAAGACAGAGAGTGGAGGATGCTTTTT ATACATTGGTGAGGGAGATCCGACAATACAGATTGAAAAAAATCAGCAAA GAAGAAAAGACTCCTGGCTGTGTGAAAATTAAAAAATGCATTATAATGTA ATCTGGGTGTTGATGATGCCTTCTATACATTAGTTCGAGAAATTCGAAAA CATAAAGAAAAGATGAGCAAAGATGGTAAAAAGAAGAAAAAGAAGTCAAA GACAAAGTGTGTAATTATGTAAATACAATTTGTACTTTTTTCTTAAGGCA TACTAGTACAAGTGGTAATTTTTGTACATTACACTAAATTATTTAGCATT TGTTTTAGCATTACCTAATTTTTTTCCTGCTCCATGCAGACTGTTAGCTT TTACCTTAAATGCTTATTTTAAAATGACAGTGGAAGTTTTTTTTTCCTCT AAGTGCCAGTATTCCCAGAGTTTTGGTTTTTGAACTAGCAATGCCTGTGA AAAAGAAACTGAATACCTAAGATTTCTGTCTTGGGGTTTTTGGTGCATGC AGTTGATTACTTCTTATTTTTCTTACCAATTGTGAATGTTGGTGTGAAAC AAATTAATGAAGCTTTTGAATCATCCCTATTCTGTGTTTTATCTAGTCAC ATAAATGGATTAATTACTAATTTCAGTTGAGACCTTCTAATTGGTTTTTA CTGAAACATTGAGGGAACACAAATTTATGGGCTTCCTGATGATGATTCTT CTAGGCATCATGTCCTATAGTTTGTCATCCCTGATGAATGTAAAGTTACA CTGTTCACAAAGGTTTTGTCTCCTTTCCACTGCTATTAGTCATGGTCACT CTCCCCAAAATATTATATTTTTTCTATAAAAAGAAAAAAATGGAAAAAAA TTACAAGGCAATGGAAACTATTATAAGGCCATTTCCTTTTCACATTAGAT AAATTACTATAAAGACTCCTAATAGCTTTTCCTGTTAAGGCAACCCAGTG ATGAAATGGGGATTATTATAGCAACCATTTTGGGGCTATATTTTACATGC TACTAAATTTTTATAATAATTGAAAAGATTTTAACAAGTATAAAAAATTC TCATAGGAATTAAATGTAGTCTCCCTGTGTCAGACTGCTCTTTCATAGTA TAACTTTAAATCTTTTCTTCAACTTGAGTCTTTGAAGATAGTTTTAATTC TGCTTGTGACATTAAAAGATTATTTGGGCCAGTTATAGCTTATTAGGTGT TGAAGAGACCAAGGTTGCAAGGCCAGGCCCTGTGTGAACCTTTGAGCTTT CATAGAGAGTTTCACAGCATGGACTGTGTCCCCACGGTCATCCAGTGTTG TCATGCATTGGTTAGTCAAAATGGGGAGGGACTAGGGCAGTTTGGATAGC TCAACAAGATACAATCTCACTCTGTGGTGGTCCTGCTGACAAATCAAGAG CATTGCTTTTGTTTCTTAAGAAAACAAACTCTTTTTTAAAAATTACTTTT AAATATTAACTCAAAAGTTGAGATTTTGGGGTGGTGGTGTGCCAAGACAT TAATTTTTTTTTTTAAACAATGAAGTGAAAAAGTTTTACAATCTCTAGGT TTGGCTAGTTCTCTTAACACTGGTTAAATTAACATTGCATAAACACTTTT CAAGTCTGATCCATATTTAATAATGCTTTAAAATAAAAATAAAAACAATC CTTTTGATAAATTTAAAATGTTACTTATTTTAAAATAAATGAAGTGAGAT GGCATGGTGAGGTGAAAGTATCACTGGACTAGGAAGAAGGTGACTTAGGT TCTAGATAGGTGTCTTTTAGGACTCTGATTTTGAGGACATCACTTACTAT CCATTTCTTCATGTTAAAAGAAGTCATCTCAAACTCTTAGTTTTTTTTTT TTACAACTATGTAATTTATATTCCATTTTACATAAGGATACACTTATTTG TCAAGCTCAGCACAATCTGTAAATTTTTAACCTATGTTACACCATCTTCA GTGCCAGTCTTGGGCAAAATTGTGCAAGAGGTGAAGTTTATATTTGAATA TCCATTCTCGTTTTAGGACTCTTCTTCCATATTTAGTGTCATCTTGCCTC CCTACCTTCCACATGCCCCATGACTTGATGCAGTTTTAATACTTGTAATT CCCCTAACCATAAGATTTACTGCTGCTGTGGATATCTCCATGAAGTTTTC CCACTGAGTCACATCAGAAATGCCCTACATCTTATTTCCTCAGGGCTCAA GAGAATCTGACAGATACCATAAAGGGATTTGACCTAATCACTAATTTTCA GGTGGTGGCTGATGCTTTGAACATCTCTTTGCTGCCCAATCCATTAGCGA CAGTAGGATTTTTCAAACCTGGTATGAATAGACAGAACCCTATCCAGTGG AAGGAGAATTTAATAAAGATAGTGCTGAAAGAATTCCTTAGGTAATCTAT AACTAGGACTACTCCTGGTAACAGTAATACATTCCATTGTTTTAGTAACC AGAAATCTTCATGCAATGAAAAATACTTTAATTCATGAAGCTTACTTTTT TTTTTTGGTGTCAGAGTCTCGCTCTTGTCACCCAGGCTGGAATGCAGTGG CGCCATCTCAGCTCACTGCAACCTCCATCTCCCAGGTTCAAGCGATTCTC GTGCCTCGGCCTCCTGAGTAGCTGGGATTACAGGCGTGTGCCACTACACT CAACTAATTTTTGTATTTTTAGGAGAGACGGGGTTTCACCCTGTTGGCCA GGCTGGTCTCGAACTCCTGACCTCAAGTGATTCACCCACCTTGGCCTCAT AAACCTGTTTTGCAGAACTCATTTATTCAGCAAATATTTATTGAGTGCCT ACCAGATGCCAGTCACCGCACAAGGCACTGGGTATATGGTATCCCCAAAC AAGAGACATAATCCCGGTCCTTAGGTAGTGCTAGTGTGGTCTGTAATATC TTACTAAGGCCTTTGGTATACGACCCAGAGATAACACGATGCGTATTTTA GTTTTGCAAAGAAGGGGTTTGGTCTCTGTGCCAGCTCTATAATTGTTTTG CTACGATTCCACTGAAACTCTTCGATCAAGCTACTTTATGTAAATCACTT CATTGTTTTAAAGGAATAAACTTGATTATATTGTTTTTTTATTTGGCATA ACTGTGATTCTTTTAGGACAATTACTGTACACATTAAGGTGTATGTCAGA TATTCATATTGACCCAAATGTGTAATATTCCAGTTTTCTCTGCATAAGTA ATTAAAATATACTTAAAAATTAATAGTTTTATCTGGGTACAAATAAACAG GTGCCTGAACTAGTTCACAGACAAGGAAACTTCTATGTAAAAATCACTAT GATTTCTGAATTGCTATGTGAAACTACAGATCTTTGGAACACTGTTTAGG TAGGGTGTTAAGACTTACACAGTACCTCGTTTCTACACAGAGAAAGAAAT GGCCATACTTCAGGAACTGCAGTGCTTATGAGGGGATATTTAGGCCTCTT GAATTTTTGATGTAGATGGGCATTTTTTTAAGGTAGTGGTTAATTACCTT TATGTGAACTTTGAATGGTTTAACAAAAGATTTGTTTTTGTAGAGATTTT AAAGGGGGAGAATTCTAGAAATAAATGTTACCTAATTATTACAGCCTTAA AGACAAAAATCCTTGTTGAAGTTTTTTTAAAAAAAGCTAAATTACATAGA CTTAGGCATTAACATGTTTGTGGAAGAATATAGCAGACGTATATTGTATC ATTTGAGTGAATGTTCCCAAGTAGGCATTCTAGGCTCTATTTAACTGAGT CACACTGCATAGGAATTTAGAACCTAACTTTTATAGGTTATCAAAACTGT TGTCACCATTGCACAATTTTGTCCTAATATATACATAGAAACTTTGTGGG GCATGTTAAGTTACAGTTTGCACAAGTTCATCTCATTTGTATTCCATTGA TTTTTTTTTTCTTCTAAACATTTTTTCTTCAAACAGTATATAACTTTTTT TAGGGGATTTTTTTTTAGACAGCAAAAACTATCTGAAGATTTCCATTTGT CAAAAAGTAATGATTTCTTGATAATTGTGTAGTAATGTTTTTTAGAACCC AGCAGTTACCTTAAAGCTGAATTTATATTTAGTAACTTCTGTGTTAATAC TGGATAGCATGAATTCTGCATTGAGAAACTGAATAGCTGTCATAAAATGA AACTTTCTTTCTAAAGAAAGATACTCACATGAGTTCTTGAAGAATAGTCA TAACTAGATTAAGATCTGTGTTTTAGTTTAATAGTTTGAAGTGCCTGTTT GGGATAATGATAGGTAATTTAGATGAATTTAGGGGAAAAAAAAGTTATCT GCAGATATGTTGAGGGCCCATCTCTCCCCCCACACCCCCACAGAGCTAAC TGGGTTACAGTGTTTTATCCGAAAGTTTCCAATTCCACTGTCTTGTGTTT TCATGTTGAAAATACTTTTGCATTTTTCCTTTGAGTGCCAATTTCTTACT AGTACTATTTCTTAATGTAACATGTTTACCTGGAATGTATTTTAACTATT TTTGTATAGTGTAAACTGAAACATGCACATTTTGTACATTGTGCTTTCTT TTGTGGGACATATGCAGTGTGATCCAGTTGTTTTCCATCATTTGGTTGCG CTGACCTAGGAATGTTGGTCATATCAAACATTAAAAATGACCACTCTTTT AATTGAAATTAACTTTTAAATGTTTATAGGAGTATGTGCTGTGAAGTGAT CTAAAATTTGTAATATTTTTGTCATGAACTGTACTACTCCTAATTATTGT AATGTAATAAAAATAGTTACAGTGACAAAAAAAAAAAAAAA The underlined sequences above correspond to KRAS RNA sequences targeted by exemplified KRAS-355 and KRAS-940 DsiRNA agents of the invention. Known SNPs within the above cDNA sequence include an A/T polymorphism at position 364 (dbSNP Accession No. rs17851045); a T/C polymorphism at position 824 (dbSNP Accession No. rs1137282); and a KRAS G12V mutant G/T polymorphism at position 216, as previously described in US 2005/0176045. These three polymorphic sites are shown in bold italics. Wild-type KRAS Amino Acid Sequence NP_(—)203524.1 (SEQ ID NO: 2; translation of NM_(—)033360):

MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGET CLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQI KRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQ RVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM Wild-type KRAS sequence (SEQ ID NO: 3; K-Ras4b—transcript variant b; GenBank Accession No. NM_(—)004985.3):

GGCCGCGGCGGCGGAGGCAGCAGCGGCGGCGGCAGTGGCGGCGGCGAAGG TGGCGGCGGCTCGGCCAGTACTCCCGGCCCCCGCCATTTCGGACTGGGAG CGAGCGCGGCGCAGGCACTGAAGGCGGCGGCGGGGCCAGAGGCTCAGCGG CTCCCAGGTGCGGGAGAGAGGCCTGCTGAAAATGACTGAATATAAACTTG TGGTAGTTGGAGCTGGTGGCGTAGGCAAGAGTGCCTTGACGATACAGCTA ATTCAGAATCATTTTGTGGACGAATATGATCCAACAATAGAGGATTCCTA CAGGAAGCAAGTAGTAATTGATGGAGAAACCTGTCTCTTGGATATTCTCG ACACAGCAGGTCA A GAGGAGTACAGTGCAATGAGGGACCAGTACATGAGG ACTGGGGAGGGCTTTCTTTGTGTATTTGCCATAAATAATACTAAATCATT TGAAGATATTCACCATTATAGAGAACAAATTAAAAGAGTTAAGGACTCTG AAGATGTACCTATGGTCCTAGTAGGAAATAAATGTGATTTGCCTTCTAGA ACAGTAGACACAAAACAGGCTCAGGACTTAGCAAGAAGTTATGGAATTCC TTTTATTGAAACATCAGCAAAGACAAGACAGGGTGTTGATGATGCCTTCT ATACATTAGTTCGAGAAATTCGAAAACATAAAGAAAAGATGAGCAAAGAT GGTAAAAAGAAGAAAAAGAAGTCAAAGACAAAGTGTGTAATTATGTAAAT ACAATTTGTACTTTTTTCTTAAGGCATACTAGTACAAGTGGTAATTTTTG TACATTACACTAAATTATTAGCATTTGTTTTAGCATTACCTAATTTTTTT CCTGCTCCATGCAGACTGTTAGCTTTTACCTTAAATGCTTATTTTAAAAT GACAGTGGAAGTTTTTTTTTCCTCTAAGTGCCAGTATTCCCAGAGTTTTG GTTTTTGAACTAGCAATGCCTGTGAAAAAGAAACTGAATACCTAAGATTT CTGTCTTGGGGTTTTTGGTGCATGCAGTTGATTACTTCTTATTTTTCTTA CCAATTGTGAATGTTGGTGTGAAACAAATTAATGAAGCTTTTGAATCATC CCTATTCTGTGTTTTATCTAGTCACATAAATGGATTAATTACTAATTTCA GTTGAGACCTTCTAATTGGTTTTTACTGAAACATTGAGGGAACACAAATT TATGGGCTTCCTGATGATGATTCTTCTAGGCATCATGTCCTATAGTTTGT CATCCCTGATGAATGTAAAGTTACACTGTTCACAAAGGTTTTGTCTCCTT TCCACTGCTATTAGTCATGGTCACTCTCCCCAAAATATTATATTTTTTCT ATAAAAAGAAAAAAATGGAAAAAAATTACAAGGCAATGGAAACTATTATA AGGCCATTTCCTTTTCACATTAGATAAATTACTATAAAGACTCCTAATAG CTTTTCCTGTTAAGGCAGACCCAGTATGAAATGGGGATTATTATAGCAAC CATTTTGGGGCTATATTTACATGCTACTAAATTTTTATAATAATTGAAAA GATTTTAACAAGTATAAAAAATTCTCATAGGAATTAAATGTAGTCTCCCT GTGTCAGACTGCTCTTTCATAGTATAACTTTAAATCTTTTCTTCAACTTG AGTCTTTGAAGATAGTTTTAATTCTGCTTGTGACATTAAAAGATTATTTG GGCCAGTTATAGCTTATTAGGTGTTGAAGAGACCAAGGTTGCAAGGCCAG GCCCTGTGTGAACCTTTGAGCTTTCATAGAGAGTTTCACAGCATGGACTG TGTCCCCACGGTCATCCAGTGTTGTCATGCATTGGTTAGTCAAAATGGGG AGGGACTAGGGCAGTTTGGATAGCTCAACAAGATACAATCTCACTCTGTG GTGGTCCTGCTGACAAATCAAGAGCATTGCTTTTGTTTCTTAAGAAAACA AACTCTTTTTTAAAAATTACTTTTAAATATTAACTCAAAAGTTGAGATTT TGGGGTGGTGGTGTGCCAAGACATTAATTTTTTTTTTAAACAATGAAGTG AAAAAGTTTTACAATCTCTAGGTTTGGCTAGTTCTCTTAACACTGGTTAA ATTAACATTGCATAAACACTTTTCAAGTCTGATCCATATTTAATAATGCT TTAAAATAAAAATAAAAACAATCCTTTTGATAAATTTAAAATGTTACTTA TTTTAAAATAAATGAAGTGAGATGGCATGGTGAGGTGAAAGTATCACTGG ACTAGGAAGAAGGTGACTTAGGTTCTAGATAGGTGTCTTTTAGGACTCTG ATTTTGAGGACATCACTTACTATCCATTTCTTCATGTTAAAAGAAGTCAT CTCAAACTCTTAGTTTTTTTTTTTTACAACTATGTAATTTATATTCCATT TACATAAGGATACACTTATTTGTCAAGCTCAGCACAATCTGTAAATTTTT AACCTATGTTACACCATCTTCAGTGCCAGTCTTGGGCAAAATTGTGCAAG AGGTGAAGTTTATATTTGAATATCCATTCTCGTTTTAGGACTCTTCTTCC ATATTAGTGTCATCTTGCCTCCCTACCTTCCACATGCCCCATGACTTGAT GCAGTTTTAATACTTGTAATTCCCCTAACCATAAGATTTACTGCTGCTGT GGATATCTCCATGAAGTTTTCCCACTGAGTCACATCAGAAATGCCCTACA TCTTATTTCCTCAGGGCTCAAGAGAATCTGACAGATACCATAAAGGGATT TGACCTAATCACTAATTTTCAGGTGGTGGCTGATGCTTTGAACATCTCTT TGCTGCCCAATCCATTAGCGAAGTAGGATTTTTCAAACCTGGTATGAATA GACAGAACCCTATCCAGTGGAAGGAGAATTTAATAAAGATAGTGCTGAAA GAATTCCTTAGGTAATCTATAACTAGGACTACTCCTGGTAACAGTAATAC ATTCCATTGTTTTAGTAACCAGAAATCTTCATGCAATGAAAAATACTTTA ATTCATGAAGCTTACTTTTTTTTTTTGGTGTCAGAGTCTCGCTCTTGTCA CCCAGGCTGGAATGCAGTGGCGCCATCTCAGCTCACTGCAACCTCCATCT CCCAGGTTCAAGCGATTCTCGTGCCTCGGCCTCCTGAGTAGCTGGGATTA CAGGCGTGTGCCACTACACTCAACTAATTTTTGTATTTTTAGGAGAGACG GGGTTTCACCCTGTTGGCCAGGCTGGTCTCGAACTCCTGACCTCAAGTGA TTCACCCACCTTGGCCTCATAAACCTGTTTTGCAGAACTCATTTATTCAG CAAATATTTATTGAGTGCCTACCAGATGCCAGTCACCGCACAAGGCACTG GGTATATGGTATCCCCAAACAAGAGACATAATCCCGGTCCTTAGGTAGTG CTAGTGTGGTCTGTAATATCTTACTAAGGCCTTTGGTATACGACCCAGAG ATAACACGATGCGTATTTTAGTTTTGCAAAGAAGGGGTTTGGTCTCTGTG CCAGCTCTATAATTGTTTTGCTACGATTCCACTGAAACTCTTCGATCAAG CTACTTTATGTAAATCACTTCATTGTTTTAAAGGAATAAACTTGATTATA TTGTTTTTTTATTTGGCATAACTGTGATTCTTTTAGGACAATTACTGTAC ACATTAAGGTGTATGTCAGATATTCATATTGACCCAAATGTGTAATATTC CAGTTTTCTCTGCATAAGTAATTAAAATATACTTAAAAATTAATAGTTTT ATCTGGGTACAAATAAACAGGTGCCTGAACTAGTTCACAGACAAGGAAAC TTCTATGTAAAAATCACTATGATTTCTGAATTGCTATGTGAAACTACAGA TCTTTGGAACACTGTTTAGGTAGGGTGTTAAGACTTACACAGTACCTCGT TTCTACACAGAGAAAGAAATGGCCATACTTCAGGAACTGCAGTGCTTATG AGGGGATATTTAGGCCTCTTGAATTTTTGATGTAGATGGGCATTTTTTTA AGGTAGTGGTTAATTACCTTTATGTGAACTTTGAATGGTTTAACAAAAGA TTTGTTTTTGTAGAGATTTTAAAGGGGGAGAATTCTAGAAATAAATGTTA CCTAATTATTACAGCCTTAAAGACAAAAATCCTTGTTGAAGTTTTTTTAA AAAAAGCTAAATTACATAGACTTAGGCATTAACATGTTTGTGGAAGAATA TAGCAGACGTATATTGTATCATTTGAGTGAATGTTCCCAAGTAGGCATTC TAGGCTCTATTTAACTGAGTCACACTGCATAGGAATTTAGAACCTAACTT TTATAGGTTATCAAAACTGTTGTCACCATTGCACAATTTTGTCCTAATAT ATACATAGAAACTTTGTGGGGCATGTTAAGTTACAGTTTGCACAAGTTCA TCTCATTTGTATTCCATTGATTTTTTTTTTCTTCTAAACATTTTTTCTTC AAACAGTATATAACTTTTTTTAGGGGATTTTTTTTTAGACAGCAAAAACT ATCTGAAGATTTCCATTTGTCAAAAAGTAATGATTTCTTGATAATTGTGT AGTAATGTTTTTTAGAACCCAGCAGTTACCTTAAAGCTGAATTTATATTT AGTAACTTCTGTGTTAATACTGGATAGCATGAATTCTGCATTGAGAAACT GAATAGCTGTCATAAAATGAAACTTTCTTTCTAAAGAAAGATACTCACAT GAGTTCTTGAAGAATAGTCATAACTAGATTAAGATCTGTGTTTTAGTTTA ATAGTTTGAAGTGCCTGTTTGGGATAATGATAGGTAATTTAGATGAATTT AGGGGAAAAAAAAGTTATCTGCAGATATGTTGAGGGCCCATCTCTCCCCC CACACCCCCACAGAGCTAACTGGGTTACAGTGTTTTATCCGAAAGTTTCC AATTCCACTGTCTTGTGTTTTCATGTTGAAAATACTTTTGCATTTTTCCT TTGAGTGCCAATTTCTTACTAGTACTATTTCTTAATGTAACATGTTTACC TGGAATGTATTTTAACTATTTTTGTATAGTGTAAACTGAAACATGCACAT TTTGTACATTGTGCTTTCTTTTGTGGGACATATGCAGTGTGATCCAGTTG TTTTCCATCATTTGGTTGCGCTGACCTAGGAATGTTGGTCATATCAAACA TTAAAAATGACCACTCTTTTAATTGAAATTAACTTTTAAATGTTTATAGG AGTATGTGCTGTGAAGTGATCTAAAATTTGTAATATTTTTGTCATGAACT GTACTACTCCTAATTATTGTAATGTAATAAAAATAGTTACAGTGACAAAA AAAAAAAAAAA The underlined sequences above correspond to KRAS RNA sequences targeted by exemplified KRAS-355 and KRAS-940 DsiRNA agents of the invention. Known SNPs within the above cDNA sequence include an A/T polymorphism at position 364 (dbSNP Accession No. rs17851045); a T/C polymorphism at position 700 (dbSNP Accession No. rs1137282); and a KRAS G12V mutant G/T polymorphism at position 216, as previously described in US 2005/0176045. These three polymorphic sites are shown in bold italics. Wild-type KRAS Amino Acid Sequence NP_(—)004976.2 (SEQ ID NO: 4; translation of NM_(—)004985):

MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGET CLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQI KRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQ GVDDAFYTLVREIRKHKEKMSKDGKKKKKKSKTKCVIM

In Vitro Assay to Assess DsiRNA KRAS Inhibitory Activity

An in vitro assay that recapitulates RNAi in a cell-free system can be used to evaluate DsiRNA constructs targeting KRAS RNA sequence(s), and thus to assess KRAS-specific gene inhibitory activity (also referred to herein as KRAS inhibitory activity) of a DsiRNA. The assay comprises the system described by Tuschl et al., 1999, Genes and Development, 13, 3191-3197 and Zamore et al., 2000, Cell, 101, 25-33 adapted for use with DsiRNA agents directed against KRAS RNA. A Drosophila extract derived from syncytial blastoderm is used to reconstitute RNAi activity in vitro. Target RNA is generated via in vitro transcription from an appropriate KRAS expressing plasmid using T7 RNA polymerase or via chemical synthesis. Sense and antisense DsiRNA strands (for example 20 uM each) are annealed by incubation in buffer (such as 100 mM potassium acetate, 30 mM HEPES-KOH, pH 7.4, 2 mM magnesium acetate) for 1 minute at 90° C. followed by 1 hour at 37° C., then diluted in lysis buffer (for example 100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate). Annealing can be monitored by gel electrophoresis on an agarose gel in TBE buffer and stained with ethidium bromide. The Drosophila lysate is prepared using zero to two-hour-old embryos from Oregon R flies collected on yeasted molasses agar that are dechorionated and lysed. The lysate is centrifuged and the supernatant isolated. The assay comprises a reaction mixture containing 50% lysate [vol/vol], RNA (10-50 pM final concentration), and 10% [vol/vol] lysis buffer containing DsiRNA (10 nM final concentration). The reaction mixture also contains 10 mM creatine phosphate, 10 ug/ml creatine phosphokinase, 100 mM GTP, 100 uM UTP, 100 uM CTP, 500 uM ATP, 5 mM DTT, 0.1 U/uL RNasin (Promega), and 100 uM of each amino acid. The final concentration of potassium acetate is adjusted to 100 mM. The reactions are pre-assembled on ice and preincubated at 25° C. for 10 minutes before adding RNA, then incubated at 25° C. for an additional 60 minutes. Reactions are quenched with 4 volumes of 1.25×Passive Lysis Buffer (Promega). Target RNA cleavage is assayed by RT-PCR analysis or other methods known in the art and are compared to control reactions in which DsiRNA is omitted from the reaction.

Alternately, internally-labeled target RNA for the assay is prepared by in vitro transcription in the presence of [alpha-³²P] CTP, passed over a G50 Sephadex column by spin chromatography and used as target RNA without further purification. Optionally, target RNA. is 5′-³²P-end labeled using T4 polynucleotide kinase enzyme. Assays are performed as described above and target RNA and the specific RNA cleavage products generated by RNAi are visualized on an autoradiograph of a gel. The percentage of cleavage is determined by PHOSPHOR IMAGER® (autoradiography) quantitation of bands representing intact control RNA or RNA from control reactions without DsiRNA and the cleavage products generated by the assay.

In one embodiment, this assay is used to determine target sites in the KRAS RNA target for DsiRNA mediated RNAi cleavage, wherein a plurality of DsiRNA constructs are screened for RNAi mediated cleavage of the KRAS RNA target, for example, by analyzing the assay reaction by electrophoresis of labeled target RNA, or by northern blotting, as well as by other methodology well known in the art.

In certain embodiments, a DsiRNA of the invention is deemed to possess KRAS inhibitory activity if, e.g., a 50% reduction in KRAS RNA levels is observed in a system, cell, tissue or organism, relative to a suitable control. Additional metes and bounds for determination of KRAS inhibitory activity of a DsiRNA of the invention are described supra.

Conjugation and Delivery of Anti-KRAS DsiRNA Agents

In certain embodiments the present invention relates to a method for treating a subject having a KRAS-associated disease or disorder, or at risk of developing a KRAS-associated disease or disorder. In such embodiments, the DsiRNA can act as novel therapeutic agents for controlling the KRAS-associated disease or disorder. The method comprises administering a pharmaceutical composition of the invention to the patient (e.g., human), such that the expression, level and/or activity of a KRAS RNA is reduced. The expression, level and/or activity of a polypeptide encoded by a KRAS RNA might also be reduced by a DsiRNA of the instant invention, even where said DsiRNA is directed against a non-coding region of the KRAS transcript (e.g., a targeted 5′ UTR or 3′ UTR sequence). Because of their high specificity, the DsiRNAs of the present invention can specifically target KRAS sequences of cells and tissues, optionally in an allele-specific manner where polymorphic alleles exist within an individual and/or population.

In the treatment of a KRAS-associated disease or disorder, the DsiRNA can be brought into contact with the cells or tissue of a subject, e.g., the cells or tissue of a subject exhibiting disregulation of KRAS and/or otherwise targeted for reduction of KRAS levels. For example, DsiRNA substantially identical to all or part of a KRAS RNA sequence, may be brought into contact with or introduced into such a cell, either in vivo or in vitro. Similarly, DsiRNA substantially identical to all or part of a KRAS RNA sequence may administered directly to a subject having or at risk of developing a KRAS-associated disease or disorder.

Therapeutic use of the DsiRNA agents of the instant invention can involve use of formulations of DsiRNA agents comprising multiple different DsiRNA agent sequences. For example, two or more, three or more, four or more, five or more, etc. of the presently described agents can be combined to produce a formulation that, e.g., targets multiple different regions of the KRAS RNA, or that not only target KRAS RNA but also target, e.g., cellular target genes associated with a KRAS-associated disease or disorder. A DsiRNA agent of the instant invention may also be constructed such that either strand of the DsiRNA agent independently targets two or more regions of KRAS RNA, or such that one of the strands of the DsiRNA agent targets a cellular target gene of KRAS known in the art.

Use of multifunctional DsiRNA molecules that target more then one region of a target nucleic acid molecule can also provide potent inhibition of KRAS RNA levels and expression. For example, a single multifunctional DsiRNA construct of the invention can target both the KRAS-355 and KRAS-940 sites simultaneously; additionally and/or alternatively, single or multifunctional agents of the invention can be designed to selectively target one splice variant of KRAS over another.

Thus, the DsiRNA agents of the instant invention, individually, or in combination or in conjunction with other drugs, can be used to treat, inhibit, reduce, or prevent a KRAS-associated disease or disorder. For example, the DsiRNA molecules can be administered to a subject or can be administered to other appropriate cells evident to those skilled in the art, individually or in combination with one or more drugs under conditions suitable for the treatment.

The DsiRNA molecules also can be used in combination with other known treatments to treat, inhibit, reduce, or prevent a KRAS-associated disease or disorder in a subject or organism. For example, the described molecules could be used in combination with one or more known compounds, treatments, or procedures to treat, inhibit, reduce, or prevent a KRAS-associated disease or disorder in a subject or organism as are known in the art.

A DsiRNA agent of the invention can be conjugated (e.g., at its 5′ or 3′ terminus of its sense or antisense strand) or unconjugated to another moiety (e.g. a non-nucleic acid moiety such as a peptide), an organic compound (e.g., a dye, cholesterol, or the like). Modifying DsiRNA agents in this way may improve cellular uptake or enhance cellular targeting activities of the resulting DsiRNA agent derivative as compared to the corresponding unconjugated DsiRNA agent, are useful for tracing the DsiRNA agent derivative in the cell, or improve the stability of the DsiRNA agent derivative compared to the corresponding unconjugated DsiRNA agent.

Methods of Introducing Nucleic Acids, Vectors, and Host Cells

DsiRNA agents of the invention may be directly introduced into a cell (i.e., intracellularly); or introduced extracellularly into a cavity, interstitial space, into the circulation of an organism, introduced orally, or may be introduced by bathing a cell or organism in a solution containing the nucleic acid. Vascular or extravascular circulation, the blood or lymph system, and the cerebrospinal fluid are sites where the nucleic acid may be introduced.

The DsiRNA agents of the invention can be introduced using nucleic acid delivery methods known in art including injection of a solution containing the nucleic acid, bombardment by particles covered by the nucleic acid, soaking the cell or organism in a solution of the nucleic acid, or electroporation of cell membranes in the presence of the nucleic acid. Other methods known in the art for introducing nucleic acids to cells may be used, such as lipid-mediated carrier transport, chemical-mediated transport, and cationic liposome transfection such as calcium phosphate, and the like. The nucleic acid may be introduced along with other components that perform one or more of the following activities: enhance nucleic acid uptake by the cell or other-wise increase inhibition of the target KRAS RNA.

A cell having a target KRAS RNA may be from the germ line or somatic, totipotent or pluripotent, dividing or non-dividing, parenchyma or epithelium, immortalized or transformed, or the like. The cell may be a stem cell or a differentiated cell. Cell types that are differentiated include adipocytes, fibroblasts, myocytes, cardiomyocytes, endothelium, neurons, glia, blood cells, megakaryocytes, lymphocytes, macrophages, neutrophils, eosinophils, basophils, mast cells, leukocytes, granulocytes, keratinocytes, chondrocytes, osteoblasts, osteoclasts, hepatocytes, and cells of the endocrine or exocrine glands.

Depending on the particular target KRAS RNA sequence and the dose of DsiRNA agent material delivered, this process may provide partial or complete loss of function for the KRAS RNA. A reduction or loss of RNA levels or expression (either KRAS RNA expression or encoded polypeptide expression) in at least 50%, 60%, 70%, 80%, 90%, 95% or 99% or more of targeted cells is exemplary. Inhibition of KRAS RNA levels or expression refers to the absence (or observable decrease) in the level of KRAS RNA or KRAS RNA-encoded protein. Specificity refers to the ability to inhibit the KRAS RNA without manifest effects on other genes of the cell. The consequences of inhibition can be confirmed by examination of the outward properties of the cell or organism or by biochemical techniques such as RNA solution hybridization, nuclease protection, Northern hybridization, reverse transcription, gene expression monitoring with a microarray, antibody binding, enzyme linked immunosorbent assay (ELISA), Western blotting, radioimmunoassay (RIA), other immunoassays, and fluorescence activated cell analysis (FACS). Inhibition of target KRAS RNA sequence(s) by the DsiRNA agents of the invention also can be measured based upon the effect of administration of such DsiRNA agents upon development/progression of a KRAS-associated disease or disorder, e.g., tumor formation, growth, metastasis, etc., either in vivo or in vitro. Treatment and/or reductions in tumor or cancer cell levels can include halting or reduction of growth of tumor or cancer cell levels or reductions of, e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99% or more, and can also be measured in logarithmic terms, e.g., 10-fold, 100-fold, 1000-fold, 10⁵-fold, 10⁶-fold, 10⁷-fold reduction in cancer cell levels could be achieved via administration of the DsiRNA agents of the invention to cells, a tissue, or a subject.

For RNA-mediated inhibition in a cell line or whole organism, expression a reporter or drug resistance gene whose protein product is easily assayed can be measured. Such reporter genes include acetohydroxyacid synthase (AHAS), alkaline phosphatase (AP), beta galactosidase (LacZ), beta glucoronidase (GUS), chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), horseradish peroxidase (HRP), luciferase (Luc), nopaline synthase (NOS), octopine synthase (OCS), and derivatives thereof. Multiple selectable markers are available that confer resistance to ampicillin, bleomycin, chloramphenicol, gentarnycin, hygromycin, kanamycin, lincomycin, methotrexate, phosphinothricin, puromycin, and tetracyclin. Depending on the assay, quantitation of the amount of gene expression allows one to determine a degree of inhibition which is greater than 10%, 33%, 50%, 90%, 95% or 99% as compared to a cell not treated according to the present invention.

Lower doses of injected material and longer times after administration of RNA silencing agent may result in inhibition in a smaller fraction of cells (e.g., at least 10%, 20%, 50%, 75%, 90%, or 95% of targeted cells). Quantitation of gene expression in a cell may show similar amounts of inhibition at the level of accumulation of target KRAS RNA or translation of target protein. As an example, the efficiency of inhibition may be determined by assessing the amount of gene product in the cell; RNA may be detected with a hybridization probe having a nucleotide sequence outside the region used for the inhibitory DsiRNA, or translated polypeptide may be detected with an antibody raised against the polypeptide sequence of that region.

The DsiRNA agent may be introduced in an amount which allows delivery of at least one copy per cell. Higher doses (e.g., at least 5, 10, 100, 500 or 1000 copies per cell) of material may yield more effective inhibition; lower doses may also be useful for specific applications.

Pharmaceutical Compositions

In certain embodiments, the present invention provides for a pharmaceutical composition comprising the DsiRNA agent of the present invention. The DsiRNA agent sample can be suitably formulated and introduced into the environment of the cell by any means that allows for a sufficient portion of the sample to enter the cell to induce gene silencing, if it is to occur. Many formulations for dsRNA are known in the art and can be used so long as the dsRNA gains entry to the target cells so that it can act. See, e.g., U.S. published patent application Nos. 2004/0203145 A1 and 2005/0054598 A1. For example, the DsiRNA agent of the instant invention can be formulated in buffer solutions such as phosphate buffered saline solutions, liposomes, micellar structures, and capsids. Formulations of DsiRNA agent with cationic lipids can be used to facilitate transfection of the DsiRNA agent into cells. For example, cationic lipids, such as lipofectin (U.S. Pat. No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (published PCT International Application WO 97/30731), can be used. Suitable lipids include Oligofectamine, Lipofectamine (Life Technologies), NC388 (Ribozyme Pharmaceuticals, Inc., Boulder, Colo.), or FuGene 6 (Roche) all of which can be used according to the manufacturer's instructions.

Such compositions typically include the nucleic acid molecule and a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. Such methods include those described in U.S. Pat. No. 6,468,798.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

The compounds can also be administered by transfection or infection using methods known in the art, including but not limited to the methods described in McCaffrey et al. (2002), Nature, 418(6893), 38-9 (hydrodynamic transfection); Xia et al. (2002), Nature Biotechnol., 20(10), 1006-10 (viral-mediated delivery); or Putnam (1996), Am. J. Health Syst. Pharm. 53(2), 151-160, erratum at Am. J. Health Syst. Pharm. 53(3), 325 (1996).

The compounds can also be administered by a method suitable for administration of nucleic acid agents, such as a DNA vaccine. These methods include gene guns, bio injectors, and skin patches as well as needle-free methods such as the micro-particle DNA vaccine technology disclosed in U.S. Pat. No. 6,194,389, and the mammalian transdermal needle-free vaccination with powder-form vaccine as disclosed in U.S. Pat. No. 6,168,587. Additionally, intranasal delivery is possible, as described in, inter alia, Hamajima et al. (1998), Clin. Immunol. Immunopathol., 88(2), 205-10. Liposomes (e.g., as described in U.S. Pat. No. 6,472,375) and microencapsulation can also be used. Biodegradable targetable microparticle delivery systems can also be used (e.g., as described in U.S. Pat. No. 6,471,996).

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Such formulations can be prepared using standard techniques. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For a compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

As defined herein, a therapeutically effective amount of a nucleic acid molecule (i.e., an effective dosage) depends on the nucleic acid selected. For instance, if a plasmid encoding a DsiRNA agent is selected, single dose amounts in the range of approximately 1 pg to 1000 mg may be administered; in some embodiments, 10, 30, 100, or 1000 pg, or 10, 30, 100, or 1000 ng, or 10, 30, 100, or 1000 μg, or 10, 30, 100, or 1000 mg may be administered. In some embodiments, 1-5 g of the compositions can be administered. The compositions can be administered one from one or more times per day to one or more times per week; including once every other day. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments.

The nucleic acid molecules of the invention can be inserted into expression constructs, e.g., viral vectors, retroviral vectors, expression cassettes, or plasmid viral vectors, e.g., using methods known in the art, including but not limited to those described in Xia et al., (2002), supra. Expression constructs can be delivered to a subject by, for example, inhalation, orally, intravenous injection, local administration (see U.S. Pat. No. 5,328,470) or by stereotactic injection (see e.g., Chen et al. (1994), Proc. Natl. Acad. Sci. USA, 91, 3054-3057). The pharmaceutical preparation of the delivery vector can include the vector in an acceptable diluent, or can comprise a slow release matrix in which the delivery vehicle is imbedded. Alternatively, where the complete delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The expression constructs may be constructs suitable for use in the appropriate expression system and include, but are not limited to retroviral vectors, linear expression cassettes, plasmids and viral or virally-derived vectors, as known in the art. Such expression constructs may include one or more inducible promoters, RNA Pol III promoter systems such as U6 snRNA promoters or H1 RNA polymerase III promoters, or other promoters known in the art. The constructs can include one or both strands of the siRNA. Expression constructs expressing both strands can also include loop structures linking both strands, or each strand can be separately transcribed from separate promoters within the same construct. Each strand can also be transcribed from a separate expression construct, e.g., Tuschl (2002, Nature Biotechnol 20: 500-505).

It can be appreciated that the method of introducing DsiRNA agents into the environment of the cell will depend on the type of cell and the make up of its environment. For example, when the cells are found within a liquid, one preferable formulation is with a lipid formulation such as in lipofectamine and the DsiRNA agents can be added directly to the liquid environment of the cells. Lipid formulations can also be administered to animals such as by intravenous, intramuscular, or intraperitoneal injection, or orally or by inhalation or other methods as are known in the art. When the formulation is suitable for administration into animals such as mammals and more specifically humans, the formulation is also pharmaceutically acceptable. Pharmaceutically acceptable formulations for administering oligonucleotides are known and can be used. In some instances, it may be preferable to formulate DsiRNA agents in a buffer or saline solution and directly inject the formulated DsiRNA agents into cells, as in studies with oocytes. The direct injection of DsiRNA agents duplexes may also be done. For suitable methods of introducing dsRNA (e.g., DsiRNA agents), see U.S. published patent application No. 2004/0203145 A1.

Suitable amounts of a DsiRNA agent must be introduced and these amounts can be empirically determined using standard methods. Typically, effective concentrations of individual DsiRNA agent species in the environment of a cell will be 50 nanomolar or less, 10 nanomolar or less, or compositions in which concentrations of 1 nanomolar or less can be used.

In another embodiment, methods utilizing a concentration of 200 picomolar or less, 100 picomolar or less, 50 picomolar or less, 20 picomolar or less, and even a concentration of 10 picomolar or less, 5 picomolar or less, 2 picomolar or less or 1 picomolar or less can be used in many circumstances.

The method can be carried out by addition of the DsiRNA agent compositions to an extracellular matrix in which cells can live provided that the DsiRNA agent composition is formulated so that a sufficient amount of the DsiRNA agent can enter the cell to exert its effect. For example, the method is amenable for use with cells present in a liquid such as a liquid culture or cell growth media, in tissue explants, or in whole organisms, including animals, such as mammals and especially humans.

The level or activity of a KRAS RNA can be determined by a suitable method now known in the art or that is later developed. It can be appreciated that the method used to measure a target RNA and/or the expression of a target RNA can depend upon the nature of the target RNA. For example, where the target KRAS RNA sequence encodes a protein, the term “expression” can refer to a protein or the KRAS RNA/transcript derived from the KRAS gene (either genomic or of exogenous origin). In such instances the expression of the target KRAS RNA can be determined by measuring the amount of KRAS RNA/transcript directly or by measuring the amount of KRas protein. Protein can be measured in protein assays such as by staining or immunoblotting or, if the protein catalyzes a reaction that can be measured, by measuring reaction rates. All such methods are known in the art and can be used. Where target KRAS RNA levels are to be measured, art-recognized methods for detecting RNA levels can be used (e.g., RT-PCR, Northern Blotting, etc.). In targeting KRAS RNAs with the DsiRNA agents of the instant invention, it is also anticipated that measurement of the efficacy of a DsiRNA agent in reducing levels of KRAS RNA or protein in a subject, tissue, in cells, either in vitro or in vivo, or in cell extracts can also be used to determine the extent of reduction of KRAS-associated phenotypes (e.g., disease or disorders, e.g., cancer or tumor formation, growth, metastasis, spread, etc.). The above measurements can be made on cells, cell extracts, tissues, tissue extracts or other suitable source material.

The determination of whether the expression of a KRAS RNA has been reduced can be by a suitable method that can reliably detect changes in RNA levels. Typically, the determination is made by introducing into the environment of a cell undigested DsiRNA such that at least a portion of that DsiRNA agent enters the cytoplasm, and then measuring the level of the target RNA. The same measurement is made on identical untreated cells and the results obtained from each measurement are compared.

The DsiRNA agent can be formulated as a pharmaceutical composition which comprises a pharmacologically effective amount of a DsiRNA agent and pharmaceutically acceptable carrier. A pharmacologically or therapeutically effective amount refers to that amount of a DsiRNA agent effective to produce the intended pharmacological, therapeutic or preventive result. The phrases “pharmacologically effective amount” and “therapeutically effective amount” or simply “effective amount” refer to that amount of an RNA effective to produce the intended pharmacological, therapeutic or preventive result. For example, if a given clinical treatment is considered effective when there is at least a 20% reduction in a measurable parameter associated with a disease or disorder, a therapeutically effective amount of a drug for the treatment of that disease or disorder is the amount necessary to effect at least a 20% reduction in that parameter.

Suitably formulated pharmaceutical compositions of this invention can be administered by means known in the art such as by parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration. In some embodiments, the pharmaceutical compositions are administered by intravenous or intraparenteral infusion or injection.

In general, a suitable dosage unit of dsRNA will be in the range of 0.001 to 0.25 milligrams per kilogram body weight of the recipient per day, or in the range of 0.01 to 20 micrograms per kilogram body weight per day, or in the range of 0.01 to 10 micrograms per kilogram body weight per day, or in the range of 0.10 to 5 micrograms per kilogram body weight per day, or in the range of 0.1 to 2.5 micrograms per kilogram body weight per day. Pharmaceutical composition comprising the dsRNA can be administered once daily. However, the therapeutic agent may also be dosed in dosage units containing two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day. In that case, the dsRNA contained in each sub-dose must be correspondingly smaller in order to achieve the total daily dosage unit. The dosage unit can also be compounded for a single dose over several days, e.g., using a conventional sustained release formulation which provides sustained and consistent release of the dsRNA over a several day period. Sustained release formulations are well known in the art. In this embodiment, the dosage unit contains a corresponding multiple of the daily dose. Regardless of the formulation, the pharmaceutical composition must contain dsRNA in a quantity sufficient to inhibit expression of the target gene in the animal or human being treated. The composition can be compounded in such a way that the sum of the multiple units of dsRNA together contain a sufficient dose.

Data can be obtained from cell culture assays and animal studies to formulate a suitable dosage range for humans. The dosage of compositions of the invention lies within a range of circulating concentrations that include the ED₅₀ (as determined by known methods) with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For a compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range of the compound that includes the IC₅₀ (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels of dsRNA in plasma may be measured by standard methods, for example, by high performance liquid chromatography.

The pharmaceutical compositions can be included in a kit, container, pack, or dispenser together with instructions for administration.

Methods of Treatment

The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disease or disorder caused, in whole or in part, by KRAS (e.g., misregulation and/or elevation of KRAS transcript and/or KRas protein levels), or treatable via selective targeting of KRAS.

“Treatment”, or “treating” as used herein, is defined as the application or administration of a therapeutic agent (e.g., a DsiRNA agent or vector or transgene encoding same) to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient, who has the disease or disorder, a symptom of disease or disorder or a predisposition toward a disease or disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease or disorder, the symptoms of the disease or disorder, or the predisposition toward disease.

In one aspect, the invention provides a method for preventing in a subject, a disease or disorder as described above (including, e.g., prevention of the commencement of transforming events within a subject via inhibition of KRAS expression), by administering to the subject a therapeutic agent (e.g., a DsiRNA agent or vector or transgene encoding same). Subjects at risk for the disease can be identified by, for example, one or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the detection of, e.g., cancer in a subject, or the manifestation of symptoms characteristic of the disease or disorder, such that the disease or disorder is prevented or, alternatively, delayed in its progression.

Another aspect of the invention pertains to methods of treating subjects therapeutically, i.e., altering the onset of symptoms of the disease or disorder. These methods can be performed in vitro (e.g., by culturing the cell with the DsiRNA agent) or, alternatively, in vivo (e.g., by administering the DsiRNA agent to a subject).

With regards to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics. “Pharmacogenomics”, as used herein, refers to the application of genomics technologies such as gene sequencing, statistical genetics, and gene expression analysis to drugs in clinical development and on the market. More specifically, the term refers the study of how a patient's genes determine his or her response to a drug (e.g., a patient's “drug response phenotype”, or “drug response genotype”). Thus, another aspect of the invention provides methods for tailoring an individual's prophylactic or therapeutic treatment with either the target KRAS RNA molecules of the present invention or target KRAS RNA modulators according to that individual's drug response genotype. Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to patients who will most benefit from the treatment and to avoid treatment of patients who will experience toxic drug-related side effects.

Therapeutic agents can be tested in an appropriate animal model. For example, a DsiRNA agent (or expression vector or transgene encoding same) as described herein can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with said agent. Alternatively, an agent (e.g., a therapeutic agent) can be used in an animal model to determine the mechanism of action of such an agent.

Models Useful to Evaluate the Down-Regulation of KRAS mRNA Levels and Expression

Cell Culture

Kita et al., 1999, Int. J. Cancer, 80, 553-558, describes the growth inhibition of human pancreatic cancer cell lines by antisense oligonucleotides specific to mutated KRAS genes. Antisense oligonucleotides were transfected to the transformed cells using liposomes. Cellular proliferation, KRAS mRNA expression, and KRas protein synthesis were all evaluated as endpoints. Sato et al., 2000, Cancer Lett., 155, 153-161, describes another human pancreatic cancer cell line, HOR-P1, that is characterized by high angiogenic activity and metastatic potential. Genetic and molecular analysis of this cell line revealed both increased telomerase activity and a mutation in the KRAS oncogene.

The DsiRNA agents of the invention can be tested for cleavage activity in vivo, for example, using the following procedure. The nucleotide sequences within the KRAS cDNA targeted by the DsiRNA agents of the invention are shown in the above KRAS sequences.

The DsiRNA reagents of the invention can be tested in cell culture using HeLa or other mammalian cells to determine the extent of KRAS RNA and KRas protein inhibition. DsiRNA reagents (e.g., see FIGS. 1 and 4, and above-recited structures) are selected against the KRAS target as described herein. KRAS RNA inhibition is measured after delivery of these reagents by a suitable transfection agent to, for example, cultured HeLa cells or other transformed or non-transformed mammalian cells in culture. Relative amounts of target KRAS RNA are measured versus actin or other appropriate control using real-time PCR monitoring of amplification (e.g., ABI 7700 TAQMAN®). A comparison is made to a mixture of oligonucleotide sequences made to unrelated targets or to a randomized DsiRNA control with the same overall length and chemistry, but randomly substituted at each position, or simply to appropriate vehicle-treated or untreated controls. Primary and secondary lead reagents are chosen for the target and optimization performed. After an optimal transfection agent concentration is chosen, a RNA time-course of inhibition is performed with the lead DsiRNA molecule.

TAQMAN® (Real-Time PCR Monitoring of Amplification) and Lightcycler Quantification of mRNA

Total RNA is prepared from cells following DsiRNA delivery, for example, using Ambion Rnaqueous 4-PCR purification kit for large scale extractions, or Ambion Rnaqueous-96 purification kit for 96-well assays. For Taqman analysis, dual-labeled probes are synthesized with, for example, the reporter dyes FAM or VIC covalently linked at the 5′-end and the quencher dye TAMARA conjugated to the 3′-end. One-step RT-PCR amplifications are performed on, for example, an ABI PRISM 7700 Sequence detector using 50 uL reactions consisting of 10 uL total RNA, 100 nM forward primer, 100 mM reverse primer, 100 nM probe, 1×TaqMan PCR reaction buffer (PE-Applied Biosystems), 5.5 mM MgCl₂, 100 uM each dATP, dCTP, dGTP and dTTP, 0.2U RNase Inhibitor (Promega), 0.025U AmpliTaq Gold (PE-Applied Biosystems) and 0.2U M-MLV Reverse Transcriptase (Promega). The thermal cycling conditions can consist of 30 minutes at 48° C., 10 minutes at 95° C., followed by 40 cycles of 15 seconds at 95° C. and 1 minute at 60° C. Quantitation of target KRAS mRNA level is determined relative to standards generated from serially diluted total cellular RNA (300, 100, 30, 10 ng/r×n) and normalizing to, for example, 36B4 mRNA in either parallel or same tube TaqMan reactions.

Western Blotting

Nuclear extracts can be prepared using a standard micro preparation technique (see for example Andrews and Faller, 1991, Nucleic Acids Research, 19, 2499). Protein extracts from supernatants are prepared, for example using TCA precipitation. An equal volume of 20% TCA is added to the cell supernatant, incubated on ice for 1 hour and pelleted by centrifugation for 5 minutes. Pellets are washed in acetone, dried and resuspended in water. Cellular protein extracts are run on a 10% Bis-Tris NuPage (nuclear extracts) or 4-12% Tris-Glycine (supernatant extracts) polyacrylamide gel and transferred onto nitro-cellulose membranes. Non-specific binding can be blocked by incubation, for example, with 5% non-fat milk for 1 hour followed by primary antibody for 16 hours at 4° C. Following washes, the secondary antibody is applied, for example (1:10,000 dilution) for 1 hour at room temperature and the signal detected with SuperSignal reagent (Pierce).

In several cell culture systems, cationic lipids have been shown to enhance the bioavailability of oligonucleotides to cells in culture (Bennet, et al., 1992, Mol. Pharmacology, 41, 1023-1033). In one embodiment, DsiRNA molecules of the invention are complexed with cationic lipids for cell culture experiments. DsiRNA and cationic lipid mixtures are prepared in serum-free DMEM immediately prior to addition to the cells. DMEM plus additives are warmed to room temperature (about 20-25° C.) and cationic lipid is added to the final desired concentration and the solution is vortexed briefly. DsiRNA molecules are added to the final desired concentration and the solution is again vortexed briefly and incubated for 10 minutes at room temperature. In dose response experiments, the RNA/lipid complex is serially diluted into DMEM following the 10 minute incubation.

Animal Models

Evaluating the efficacy of anti-KRAS DsiRNA agents in animal models is an important prerequisite to human clinical trials. Various animal models of cancer and/or proliferative diseases, conditions, or disorders as are known in the art can be adapted for use for pre-clinical evaluation of the efficacy of DsiRNA compositions of the invention in modulating KRAS gene expression toward therapeutic use.

As in cell culture models, the most Ras sensitive mouse tumor xenografts are those derived from cancer cells that express mutant Ras proteins. Nude mice bearing H-Ras transformed bladder cancer cell xenografts were sensitive to an anti-Ras antisense nucleic acid, resulting in an 80% inhibition of tumor growth after a 31 day treatment period (Wickstrom, 2001, Mol. Biotechnol., 18, 35-35). Zhang et al., 2000, Gene Ther., 7, 2041, describes an anti-KRAS ribozyme adenoviral vector (KRbz-ADV) targeting a KRAS mutant (KRAS codon 12 GGT to GTT; H441 and H1725 cells respectively). Non-small cell lung cancer cells (NSCLC H441 and H1725 cells) that express the mutant KRas protein were used in nude mouse xenografts compared to NSCLC H1650 cells that lack the relevant mutation. Pre-treatment with KRbz-ADV completely abrogated engraftment of both H441 and H1725 cells and compared to 100% engraftment and tumor growth in animals that received untreated tumor cells or a control vector. Additional mouse models of KRAS misregulation/mutation have also been described (e.g., in Kim et al. Cell 121: 823-835, which identified a role of KRAS in promoting lung adenocarcinomas). The above studies provide proof that inhibition of Ras expression (e.g., KRAS expression) by anti-Ras agents causes inhibition of tumor growth in animals.

As such, these models can be used in evaluating the efficacy of DsiRNA molecules of the invention in inhibiting KRAS levels, expression, tumor/cancer formation, growth, spread, development of other KRAS-associated phenotypes, diseases or disorders, etc. These models and others can similarly be used to evaluate the safety/toxicity and efficacy of DsiRNA molecules of the invention in a pre-clinical setting.

Specific examples of animal model systems useful for evaluation of the KRAS-targeting DsiRNAs of the instant invention include wild-type mice, orthotopic HCC xenograft tumor model mice (e.g., Hep3B and HepG2) and disseminated melanoma model mice. In an exemplary in vivo experiment, DsiRNAs of the invention are tail vein injected into such mouse models at doses ranging from 1 to 10 mg/kg or, alternatively, repeated doses are administered at single-dose IC₅₀ levels, and organs (e.g., liver, kidney, lung, pancreas, colon, skin, spleen, bone marrow, lymph nodes, mammary fat pad, etc.) are harvested 24 hours after administration of the final dose. Such organs are then evaluated for mouse and/or human KRAS levels, depending upon the model used. Duration of action can also be examined at, e.g., 1, 4, 7, 14, 21 or more days after final DsiRNA administration.

The practice of the present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA, genetics, immunology, cell biology, cell culture and transgenic biology, which are within the skill of the art. See, e.g., Maniatis et al., 1982, Molecular Cloning (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.); Sambrook et al., 1989, Molecular Cloning, 2nd Ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.); Sambrook and Russell, 2001, Molecular Cloning, 3rd Ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.); Ausubel et al., 1992), Current Protocols in Molecular Biology (John Wiley & Sons, including periodic updates); Glover, 1985, DNA Cloning (IRL Press, Oxford); Anand, 1992; Guthrie and Fink, 1991; Harlow and Lane, 1988, Antibodies, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.); Jakoby and Pastan, 1979; Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods In Enzymology, Vols. 154 and 155 (Wu et al. eds.), Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); Riott, Essential Immunology, 6th Edition, Blackwell Scientific Publications, Oxford, 1988; Hogan et al., Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986); Westerfield, M., The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio), (4th Ed., Univ. of Oregon Press, Eugene, 2000).

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

EXAMPLES

The present invention is described by reference to the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner. Standard techniques well known in the art or the techniques specifically described below were utilized.

Example 1 Anti-KRAS DsiRNA Design

Preferred anti-KRAS DsiRNA agents were selected from a pre-screened population of DsiRNAs. Design of DsiRNAs can optionally involve use of predictive scoring algorithms that perform in silico assessments of the projected activity/efficacy of a number of possible DsiRNAs spanning a region of sequence.

Example 2 Preparation of Double-Stranded RNA Oligonucleotides

Oligonucleotide Synthesis and Purification

DsiRNA molecules can be designed to interact with various sites in the RNA message, for example, target sequences within the RNA sequences described herein. In presently exemplified agents, two target KRAS sequences were selected. The sequence of one strand of the DsiRNA molecules were complementary to the target KRAS site sequences described above. The DsiRNA molecules were chemically synthesized using methods described herein. Generally, DsiRNA constructs were synthesized using solid phase oligonucleotide synthesis methods as described for 19-23mer siRNAs (see for example Usman et al., U.S. Pat. Nos. 5,804,683; 5,831,071; 5,998,203; 6,117,657; 6,353,098; 6,362,323; 6,437,117; 6,469,158; Scaringe et al., U.S. Pat. Nos. 6,111,086; 6,008,400; 6,111,086).

Individual RNA strands were synthesized and HPLC purified according to standard methods (Integrated DNA Technologies, Coralville, Iowa). For example, RNA oligonucleotides were synthesized using solid phase phosphoramidite chemistry, deprotected and desalted on NAP-5 columns (Amersham Pharmacia Biotech, Piscataway, N.J.) using standard techniques (Damha and Olgivie, 1993, Methods Mol Biol 20: 81-114; Wincott et al., 1995, Nucleic Acids Res 23: 2677-84). The oligomers were purified using ion-exchange high performance liquid chromatography (IE-HPLC) on an Amersham Source 15Q column (1.0 cm×25 cm; Amersham Pharmacia Biotech, Piscataway, N.J.) using a 15 min step-linear gradient. The gradient varies from 90:10 Buffers A:B to 52:48 Buffers A:B, where Buffer A is 100 mM Tris pH 8.5 and Buffer B is 100 mM Tris pH 8.5, 1 M NaCl. Samples were monitored at 260 nm and peaks corresponding to the full-length oligonucleotide species are collected, pooled, desalted on NAP-5 columns, and lyophilized.

The purity of each oligomer was determined by capillary electrophoresis (CE) on a Beckman PACE 5000 (Beckman Coulter, Inc., Fullerton, Calif.). The CE capillaries had a 100 gm inner diameter and contains ssDNA 100R Gel (Beckman-Coulter). Typically, about 0.6 nmole of oligonucleotide was injected into a capillary, run in an electric field of 444 V/cm and detected by UV absorbance at 260 nm. Denaturing Tris-Borate-7 M-urea running buffer was purchased from Beckman-Coulter. Oligoribonucleotides were obtained that are at least 90% pure as assessed by CE for use in experiments described below. Compound identity was verified by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectroscopy on a Voyager DE™ Biospectometry Work Station (Applied Biosystems, Foster City, Calif.) following the manufacturer's recommended protocol. Relative molecular masses of all oligomers were obtained, often within 0.2% of expected molecular mass.

Preparation of Duplexes

Single-stranded RNA (ssRNA) oligomers were resuspended, e.g., at 100 μM concentration in duplex buffer consisting of 100 mM potassium acetate, 30 mM HEPES, pH 7.5. Complementary sense and antisense strands were mixed in equal molar amounts to yield a final solution of, e.g., 50 μM duplex. Samples were heated to 100° C. for 5′ in RNA buffer (IDT) and allowed to cool to room temperature before use. Double-stranded RNA (dsRNA) oligomers were stored at −20° C. Single-stranded RNA oligomers were stored lyophilized or in nuclease-free water at −80° C.

Nomenclature

For consistency, the following nomenclature has been employed in the instant specification. Names given to duplexes indicate the length of the oligomers and the presence or absence of overhangs. A “25/27” is an asymmetric duplex having a 25 base sense strand and a 27 base antisense strand with a 2-base 3′-overhang. A “27/25” is an asymmetric duplex having a 27 base sense strand and a 25 base antisense strand.

Cell Culture and RNA Transfection

HeLa cells were obtained from ATCC and maintained in Dulbecco's modified Eagle medium (HyClone) supplemented with 10% fetal bovine serum (HyClone) at 37° C. under 5% CO₂. For RNA transfections, HeLa cells were transfected with DsiRNAs as indicated at a final concentration of 1 nM or 0.1 nM using Lipofectamine™ RNAiMAX (Invitrogen) and following manufacturer's instructions. Briefly, 2.5 μL of a 0.2 μM or 0.02 μM stock solution of each DsiRNA were mixed with 46.5 μL of Opti-MEM I (Invitrogen) and 1 μL of Lipofectamine™ RNAiMAX. The resulting 504 mix was added into individual wells of 12 well plates and incubated for 20 min at RT to allow DsiRNA:Lipofectamine™ RNAiMAX complexes to form. Meanwhile, HeLa cells were trypsinized and resuspended in medium at a final concentration of 367 cells/μL. Finally, 450 μL of the cell suspension were added to each well (final volume 500 μL) and plates were placed into the incubator for 24 hours.

Assessment of KRAS Inhibition

KRAS target gene knockdown was determined by qRT-PCR, with values normalized to HPRT expression control treatments, including Lipofectamine™ RNAiMAX alone (Vehicle control) or untreated.

RNA Isolation and Analysis

Cells were washed once with 2 mL of PBS, and total RNA was extracted using RNeasy Mini Kit™ (Qiagen) and eluted in a final volume of 30 μL. 1 μg of total RNA was reverse-transcribed using Transcriptor 1^(st) Strand cDNA Kit™ (Roche) and random hexamers following manufacturer's instructions. One-thirtieth (0.66 μL) of the resulting cDNA was mixed with 5 μL of IQ Multiplex Powermix (Bio-Rad) together with 3.33 μL of H₂O and 1 μL of a 3 μM mix containing primers and probes specific for human genes HPRT-1 (accession number NM_(—)000194) and KRAS target sequences.

Quantitative RT-PCR

A CFX96 Real-time System with a C1000 Thermal cycler (Bio-Rad) was used for the amplification reactions. PCR conditions were: 95° C. for 3 min; and then cycling at 95° C., 10 sec; 55° C., 1 min for 40 cycles. Each sample was tested in triplicate. Relative HPRT mRNA levels were normalized to KRAS mRNA levels and compared with mRNA levels obtained in control samples treated with the transfection reagent alone, or untreated. Data was analyzed using Bio-Rad CFX Manager version 1.0 software.

Example 3 KRAS-355 Targeted DsiRNA Inhibition of KRAS

DsiRNA molecules targeting KRAS were designed and synthesized as described above and tested in HeLa cells for inhibitory efficacy. The ability of DsiRNA agents possessing varying end structures but commonly directed against the same KRAS cDNA target sequence (5′-AGCAGGTCAAGAGGAGTACAGTGCAAT-3′ (SEQ ID NO: 147)) to inhibit KRAS expression was assessed in comparison to corresponding KRAS target sequence-directed 21mer siRNAs (refer to FIG. 1 for anti-KRAS agent structures tested). To perform such experiments, HeLa cells were plated approximately 24 hours before transfection in 96-well plates at 5,000-7,500 cells/well, 100 μl/well, such that at the time of transfection cells were 70-90% confluent. For transfection, annealed DsiRNAs were mixed with the transfection reagent (Lipofectamine™ RNAiMAX, Invitrogen) in a volume of 50 μl/well and incubated for 20 minutes at room temperature. The DsiRNA transfection mixtures were added to cells to give a final DsiRNA concentration of 1 nM (FIG. 2) or 100 μM (FIG. 3) in a volume of 150 μl. Each DsiRNA transfection mixture was added to 3 wells for triplicate DsiRNA treatments. Cells were incubated at 37° C. for 24 hours in the continued presence of the DsiRNA transfection mixture. At 24 hours, RNA was prepared from each well of treated cells. The supernatants with the transfection mixtures were first removed and discarded, then the cells were lysed and RNA prepared from each well. Target KRAS RNA levels following treatment were evaluated by qRT-PCR for the KRAS target gene, with values normalized to those obtained for a vehicle-treated control. Triplicate data was averaged and the standard deviations determined for each treatment. Normalized data were graphed and the fold reduction of target mRNA by active DsiRNAs in comparison to siRNAs and vehicle or untreated controls was determined.

As shown in FIG. 2, the tested 25/27mer DsiRNA agent (DP1148P/DP1151G) showed significantly greater KRAS inhibitory efficacy at 1 nM concentration than an optimized 21 mer siRNA (DP1158P/DP1159G siRNA) directed against the same KRAS target sequence and sharing the same projected Ago2 cleavage site within the target KRAS transcript sequence as all other agents of FIG. 1 that were tested (such Ago2 cleavage site alignment normalizes for variations that might otherwise be attributable to varying levels of RISC activity). Notably, Dicer enzyme cleavage of the tested 25/27mer DsiRNA was projected to generate the exact same “optimized” 21mer siRNA as the “optimized” 21mer tested, with the results obtained emphasizing that DsiRNA agents possess special efficacy/potency advantages over corresponding siRNA agents. Similarly dramatic results at 1 nM concentration were observed for both 27mer blunt/blunt and 27mer blunt/fray DsiRNA agents directed against the KRAS-355 sequence, as compared to 21mer siRNAs possessing blunt/blunt and blunt/fray end structures which were similarly directed against the KRAS-355 sequence. Thus, the 25/27mer and 27mer DsiRNAs tested reproducibly exhibited enhanced inhibitory efficacy against the targeted KRAS transcript as compared to the corresponding 21mer agents concurrently tested. Indeed, all 25/27mer and 27mer DsiRNAs tested at 1 nM concentration surprisingly outperformed all 21mer siRNAs tested at the same concentration.

Robust inhibitory efficacies were also observed for the anti-KRAS-355 DsiRNA agents at 100 pM concentration (FIG. 3). The tested 25/27mer DsiRNA agent (DP1148P/DP1151G) showed significantly greater KRAS inhibitory efficacy at 100 pM concentration than the optimized 21mer siRNA (DP1158P/DP1159G siRNA) directed against the same KRAS-355 target sequence. Similarly dramatic results at 100 pM concentration were observed for 27mer blunt/fray DsiRNA agents directed against the KRAS-355 sequence, as compared to the corresponding 21 mer siRNA possessing blunt/fray end structures. The 27mer blunt/blunt agent was at least equally as effective as the corresponding 21 mer blunt/blunt agent that was tested, even if the apparent enhancement of 27mer blunt/blunt agent efficacy relative to 21 mer blunt/blunt agent efficacy was not statistically significant at 100 pM concentration. Thus, the 25/27mer and 27mer blunt/fray DsiRNAs tested reproducibly exhibited enhanced inhibitory efficacy against the targeted KRAS transcript as compared to the corresponding 21mer siRNA agents concurrently tested at 100 pM.

Example 4 KRAS-940 Targeted DsiRNA Inhibition of KRAS

DsiRNA molecules targeting KRAS were designed and synthesized as described above and tested in HeLa cells for inhibitory efficacy as described in Example 3. The ability of DsiRNA agents possessing varying end structures but commonly directed against the same KRAS cDNA target sequence (5′-TATTAGCATTTTGITTTAGCATTACCTA-3′ (SEQ ID NO: 179)) to inhibit KRAS expression was assessed in comparison to corresponding KRAS target sequence-directed 21mer siRNAs (refer to FIG. 4 for anti-KRAS agent structures tested). As shown in FIG. 5, the tested 25/27mer DsiRNA agent (DP1136P/DP1139G) showed significantly greater KRAS inhibitory efficacy at 1 nM concentration than an optimized 21mer siRNA (DP1146P/DP1147G siRNA) directed against the same KRAS target sequence and sharing the same projected Ago2 cleavage site within the target KRAS transcript sequence as all other agents of FIG. 4 that were tested (such Ago2 cleavage site alignment normalizes for variations that might otherwise be attributable to varying levels of RISC activity). Notably, Dicer enzyme cleavage of the tested 25/27mer DsiRNA was projected to generate the exact same “optimized” 21mer siRNA as the “optimized” 21mer tested, with the results obtained emphasizing that DsiRNA agents possess special efficacy/potency advantages over corresponding siRNA agents. Similarly dramatic results at 1 nM concentration were observed for both 27mer blunt/blunt and 27mer blunt/fray DsiRNA agents directed against the KRAS-940 sequence, as compared to 21mer siRNAs possessing blunt/blunt and blunt/fray end structures which were similarly directed against the KRAS-940 sequence. Thus, the 25/27mer and 27mer DsiRNAs tested reproducibly exhibited enhanced inhibitory efficacy against the targeted KRAS transcript as compared to the corresponding 21mer agents concurrently tested. Indeed, all 25/27mer and 27mer DsiRNAs tested at 1 nM concentration unexpectedly outperformed all 21 mer siRNAs tested at the same concentration.

Robust inhibitory efficacies were also observed for the anti-KRAS-940 DsiRNA agents at 100 pM concentration (FIG. 6). The tested 25/27mer DsiRNA agent (DP1136P/DP1139G) showed significantly greater KRAS inhibitory efficacy at 100 pM concentration than the optimized 21mer siRNA (DP1146P/DP1147G siRNA) directed against the same KRAS-940 target sequence. Similarly dramatic results at 100 pM concentration were observed for 27mer blunt/blunt and blunt/fray DsiRNA agents directed against the KRAS-940 sequence, as compared to the corresponding 21mer siRNAs possessing blunt/blunt and blunt/fray end structures. Thus, the 25/27mer and 27mer blunt/blunt and blunt/fray DsiRNAs tested reproducibly exhibited enhanced inhibitory efficacy against the targeted KRAS transcript as compared to the corresponding 21mer siRNA agents concurrently tested at 100 pM. Indeed, all anti-KRAS-940 25/27mer and 27mer DsiRNAs tested at 100 pM concentration unexpectedly outperformed all 21mer siRNAs which were tested at the same concentration.

Example 5 Further DsiRNA Inhibition of KRAS

The forty DsiRNA molecules shown in Table 3 possessing antisense strand SEQ ID NOs: 11-50 and targeting KRAS wild-type sequences (the DsiRNAs of Table 3 targeting alternative/polymorphic sequences were not tested) were designed and synthesized as described above and tested in HeLa cells for inhibitory efficacy as described in Example 3 above. The ability of these DsiRNA agents to inhibit KRAS expression was assessed in comparison to corresponding KRAS target sequence-directed 21 mer siRNAs (refer to Table 2 for corresponding anti-KRAS 21mer agent antisense strands tested, and to FIG. 7 for a schematic representation of the experiment). All DsiRNA agents showed efficacy as KRAS inhibitors, with 35 of 40 tested DsiRNA agents exhibiting greater than 50% reduction of the KRAS target. As shown in FIG. 8, for four out of every five DsiRNA-cognate siRNA pairs tested, the DsiRNA agent exhibited significantly superior efficacy in decreasing levels of KRAS target than the cognate siRNA agent. The duration of such inhibitory effects was also examined at both 24 hours and 48 hours post-administration, with concentrations of 1 nM and 5 nM tested. For 26 of the 40 DsiRNA-cognate siRNA pairs, the DsiRNA agent showed statistically significant enhanced levels of KRAS target inhibition than the corresponding cognate siRNA agent at all concentrations and durations tested (FIG. 9). This result was in marked contrast to the only 6 of 40 instances in which the cognate siRNA agent outperformed the DsiRNA agent (FIG. 9). Thus, statistically significant distinctions were observed between DsiRNAs and matched cognate siRNAs (possessing aligned projected Agog cleavage sites) across the KRAS target RNA. By a large majority, the DsiRNAs dramatically and unexpectedly outperformed cognate siRNAs. Importantly, these results demonstrated that DsiRNA activity did not directly correlate with siRNA activity, nor did the converse hold. Accordingly, the above results demonstrated that DsiRNAs and siRNAs engage the RNA interference machinery differently, and that DsiRNAs and siRNAs—in spite of both comprising double-stranded RNA—are, in fact, different drugs.

As shown in FIGS. 10 and 11, IC₅₀ values were determined for 29 of these 40 KRAS-targeting asymmetric DsiRNAs. Remarkably, 15 of these 29 asymmetric DsiRNAs exhibited IC₅₀ values below 10 pM, further documenting the remarkable potency of these DsiRNAs.

Example 6 Assay of 243 Selected KRAS-Targeting DsiRNAs for KRAS Inhibition

In this example, 243 asymmetric DsiRNAs (here, as above, tested DsiRNAs possessed a 25/27mer structure) were constructed and tested for KRAS inhibitory efficacy in human HeLa and mouse Hepa 1-6 cells incubated in the presence of such DsiRNAs at a concentration of 1 nM. The 243 asymmetric DsiRNAs tested included a subset of DsiRNAs selected from Tables 2-5 above, as well as a further set of asymmetric DsiRNAs designed to target specific sequences within human KRAS, mouse KRAS, or both. Sequences and structures of these additional 243 asymmetric DsiRNAs are shown in Table 8.

TABLE 8 Additional Anti-KRAS Asymmetric (25/27 mer) DsiRNA  Agent Structures Tested in Human HeLa and Mouse  Hepa 1-6 Cells   5′-GAGGCCUGCUGAAAAUGACUGAAta-3′ (SEQ ID NO: 4650) 3′-CUCUCCGGACGACUUUUACUGACUUAU-5′ (SEQ ID NO: 4407) KRAS-166 Target: 5′-GAGAGGCCTGCTGAAAATGACTGAATA-3′ (SEQ ID NO: 4893)   5′-AGGCCUGCUGAAAAUGACUGAAUat-3′ (SEQ ID NO: 4651) 3′-UCUCCGGACGACUUUUACUGACUUAUA-5′ (SEQ ID NO: 4408) KRAS-167 Target: 5′-AGAGGCCTGCTGAAAATGACTGAATAT-3′ (SEQ ID NO: 4894)   5′-GGCCUGCUGAAAAUGACUGAAUAta-3′ (SEQ ID NO: 4652) 3′-CUCCGGACGACUUUUACUGACUUAUAU-5′ (SEQ ID NO: 4409) KRAS-168 Target: 5′-GAGGCCTGCTGAAAATGACTGAATATA-3′ (SEQ ID NO: 4895)   5′-GCCUGCUGAAAAUGACUGAAUAUaa-3′ (SEQ ID NO: 4653) 3′-UCCGGACGACUUUUACUGACUUAUAUU-5′ (SEQ ID NO: 4410) KRAS-169 Target: 5′-AGGCCTGCTGAAAATGACTGAATATAA-3′ (SEQ ID NO: 4896)   5′-GUUGGAGCUGGUGGCGUAGGCAAga-3′ (SEQ ID NO: 4654) 3′-AUCAACCUCGACCACCGCAUCCGUUCU-5′ (SEQ ID NO: 4411) KRAS-204 Target: 5′-TAGTTGGAGCTGGTGGCGTAGGCAAGA-3′ (SEQ ID NO: 4897)   5′-UUGGAGCUGGUGGCGUAGGCAAGag-3′ (SEQ ID NO: 4655) 3′-UCAACCUCGACCACCGCAUCCGUUCUC-5′ (SEQ ID NO: 4412) KRAS-205 Target: 5′-AGTTGGAGCTGGTGGCGTAGGCAAGAG-3′ (SEQ ID NO: 4898)   5′-UGGAGCUGGUGGCGUAGGCAAGAgt-3′ (SEQ ID NO: 4656) 3′-CAACCUCGACCACCGCAUCCGUUCUCA-5′ (SEQ ID NO: 4413) KRAS-206 Target: 5′-GTTGGAGCTGGTGGCGTAGGCAAGAGT-3′ (SEQ ID NO: 4899)   5′-GGAGCUGGUGGCGUAGGCAAGAGtg-3′ (SEQ ID NO: 4657) 3′-AACCUCGACCACCGCAUCCGUUCUCAC-5′ (SEQ ID NO: 4414) KRAS-207 Target: 5′-TTGGAGCTGGTGGCGTAGGCAAGAGTG-3′ (SEQ ID NO: 4900)   5′-GAGCUGGUGGCGUAGGCAAGAGUgc-3′ (SEQ ID NO: 4658) 3′-ACCUCGACCACCGCAUCCGUUCUCACG-5′ (SEQ ID NO: 4415) KRAS-208 Target: 5′-TGGAGCTGGTGGCGTAGGCAAGAGTGC-3′ (SEQ ID NO: 4901)   5′-AGCUGGUGGCGUAGGCAAGAGUGcc-3′ (SEQ ID NO: 4659) 3′-CCUCGACCACCGCAUCCGUUCUCACGG-5′ (SEQ ID NO: 4416) KRAS-209 Target: 5′-GGAGCTGGTGGCGTAGGCAAGAGTGCC-3′ (SEQ ID NO: 4902)   5′-GCUGGUGGCGUAGGCAAGAGUGCct-3′ (SEQ ID NO: 4660) 3′-CUCGACCACCGCAUCCGUUCUCACGGA-5′ (SEQ ID NO: 4417) KRAS-210 Target: 5′-GAGCTGGTGGCGTAGGCAAGAGTGCCT-3′ (SEQ ID NO: 4903)   5′-UACAGCUAAUUCAGAAUCAUUUUgt-3′ (SEQ ID NO: 4661) 3′-CUAUGUCGAUUAAGUCUUAGUAAAACA-5′ (SEQ ID NO: 4418) KRAS-241 Target: 5′-GATACAGCTAATTCAGAATCATTTTGT-3′ (SEQ ID NO: 4904)   5′-UAAUUGAUGGAGAAACCUGUCUCtt-3′ (SEQ ID NO: 4662) 3′-UCAUUAACUACCUCUUUGGACAGAGAA-5′ (SEQ ID NO: 4419) KRAS-313 Target: 5′-AGTAATTGATGGAGAAACCTGTCTCTT-3′ (SEQ ID NO: 4905)   5′-AAUUGAUGGAGAAACCUGUCUCUtg-3′ (SEQ ID NO: 4663) 3′-CAUUAACUACCUCUUUGGACAGAGAAC-5′ (SEQ ID NO: 4420) KRAS-314 Target: 5′-GTAATTGATGGAGAAACCTGTCTCTTG-3′ (SEQ ID NO: 4906)   5′-GAUGGAGAAACCUGUCUCUUGGAta-3′ (SEQ ID NO: 4664) 3′-AACUACCUCUUUGGACAGAGAACCUAU-5′ (SEQ ID NO: 4421) KRAS-318 Target: 5′-TTGATGGAGAAACCTGTCTCTTGGATA-3′ (SEQ ID NO: 4907)   5′-CCUGUCUCUUGGAUAUUCUCGACac-3′ (SEQ ID NO: 4665) 3′-UUGGACAGAGAACCUAUAAGAGCUGUG-5′ (SEQ ID NO: 4422) KRAS-328 Target: 5′-AACCTGTCTCTTGGATATTCTCGACAC-3′ (SEQ ID NO: 4908)   5′-UGUCUCUUGGAUAUUCUCGACACag-3′ (SEQ ID NO: 4666) 3′-GGACAGAGAACCUAUAAGAGCUGUGUC-5′ (SEQ ID NO: 4423) KRAS-330 Target: 5′-CCTGTCTCTTGGATATTCTCGACACAG-3′ (SEQ ID NO: 4909)   5′-GUCUCUUGGAUAUUCUCGACACAgc-3′ (SEQ ID NO: 4667) 3′-GACAGAGAACCUAUAAGAGCUGUGUCG-5′ (SEQ ID NO: 4424) KRAS-331 Target: 5′-CTGTCTCTTGGATATTCTCGACACAGC-3′ (SEQ ID NO: 4910)   5′-UCUCUUGGAUAUUCUCGACACAGca-3′ (SEQ ID NO: 4668) 3′-ACAGAGAACCUAUAAGAGCUGUGUCGU-5′ (SEQ ID NO: 4425) KRAS-332 Target: 5′-TGTCTCTTGGATATTCTCGACACAGCA-3′ (SEQ ID NO: 4911)   5′-CUCUUGGAUAUUCUCGACACAGCag-3′ (SEQ ID NO: 4669) 3′-CAGAGAACCUAUAAGAGCUGUGUCGUC-5′ (SEQ ID NO: 4426) KRAS-333 Target: 5′-GTCTCTTGGATATTCTCGACACAGCAG-3′ (SEQ ID NO: 4912)   5′-UCUUGGAUAUUCUCGACACAGCAgg-3′ (SEQ ID NO: 4670) 3′-AGAGAACCUAUAAGAGCUGUGUCGUCC-5′ (SEQ ID NO: 4427) KRAS-334 Target: 5′-TCTCTTGGATATTCTCGACACAGCAGG-3′ (SEQ ID NO: 4913)   5′-CUUGGAUAUUCUCGACACAGCAGgt-3′ (SEQ ID NO: 4671) 3′-GAGAACCUAUAAGAGCUGUGUCGUCCA-5′ (SEQ ID NO: 4428) KRAS-335 Target: 5′-CTCTTGGATATTCTCGACACAGCAGGT-3′ (SEQ ID NO: 4914)   5′-UUGGAUAUUCUCGACACAGCAGGtc-3′ (SEQ ID NO: 4672) 3′-AGAACCUAUAAGAGCUGUGUCGUCCAG-5′ (SEQ ID NO: 4429) KRAS-336 Target: 5′-TCTTGGATATTCTCGACACAGCAGGTC-3′ (SEQ ID NO: 4915)   5′-CAGCAGGUCAAGAGGAGUACAGUgc-3′ (SEQ ID NO: 4673) 3′-GUGUCGUCCAGUUCUCCUCAUGUCACG-5′ (SEQ ID NO: 4430) KRAS-352 Target: 5′-CACAGCAGGTCAAGAGGAGTACAGTGC-3′ (SEQ ID NO: 4916)   5′-AGCAGGUCAAGAGGAGUACAGUGca-3′ (SEQ ID NO: 4674) 3′-UGUCGUCCAGUUCUCCUCAUGUCACGU-5′ (SEQ ID NO: 4431) KRAS-353 Target: 5′-ACAGCAGGTCAAGAGGAGTACAGTGCA-3′ (SEQ ID NO: 4917)   5′-GCAGGUCAAGAGGAGUACAGUGCaa-3′ (SEQ ID NO: 4675) 3′-GUCGUCCAGUUCUCCUCAUGUCACGUU-5′ (SEQ ID NO: 4432) KRAS-354 Target: 5′-CAGCAGGTCAAGAGGAGTACAGTGCAA-3′ (SEQ ID NO: 4918)   5′-AGGAGUACAGUGCAAUGAGGGACca-3′ (SEQ ID NO: 4676) 3′-UCUCCUCAUGUCACGUUACUCCCUGGU-5′ (SEQ ID NO: 4433) KRAS-364 Target: 5′-AGAGGAGTACAGTGCAATGAGGGACCA-3′ (SEQ ID NO: 4919)   5′-GGAGUACAGUGCAAUGAGGGACCag-3′ (SEQ ID NO: 4677) 3′-CUCCUCAUGUCACGUUACUCCCUGGUC-5′ (SEQ ID NO: 4434) KRAS-365 Target: 5′-GAGGAGTACAGTGCAATGAGGGACCAG-3′ (SEQ ID NO: 4920)   5′-GAGUACAGUGCAAUGAGGGACCAgt-3′ (SEQ ID NO: 4678) 3′-UCCUCAUGUCACGUUACUCCCUGGUCA-5′ (SEQ ID NO: 4435) KRAS-366 Target: 5′-AGGAGTACAGTGCAATGAGGGACCAGT-3′ (SEQ ID NO: 4921)   5′-AGUACAGUGCAAUGAGGGACCAGta-3′ (SEQ ID NO: 4679) 3′-CCUCAUGUCACGUUACUCCCUGGUCAU-5′ (SEQ ID NO: 4436) KRAS-367 Target: 5′-GGAGTACAGTGCAATGAGGGACCAGTA-3′ (SEQ ID NO: 4922)   5′-GUACAGUGCAAUGAGGGACCAGUac-3′ (SEQ ID NO: 4680) 3′-CUCAUGUCACGUUACUCCCUGGUCAUG-5′ (SEQ ID NO: 4437) KRAS-368 Target: 5′-GAGTACAGTGCAATGAGGGACCAGTAC-3′ (SEQ ID NO: 4923)   5′-UACAGUGCAAUGAGGGACCAGUAca-3′ (SEQ ID NO: 4681) 3′-UCAUGUCACGUUACUCCCUGGUCAUGU-5′ (SEQ ID NO: 4438) KRAS-369 Target: 5′-AGTACAGTGCAATGAGGGACCAGTACA-3′ (SEQ ID NO: 4924)   5′-ACAGUGCAAUGAGGGACCAGUACat-3′ (SEQ ID NO: 4682) 3′-CAUGUCACGUUACUCCCUGGUCAUGUA-5′ (SEQ ID NO: 4439) KRAS-370 Target: 5′-GTACAGTGCAATGAGGGACCAGTACAT-3′ (SEQ ID NO: 4925)   5′-CAGUGCAAUGAGGGACCAGUACAtg-3′ (SEQ ID NO: 4683) 3′-AUGUCACGUUACUCCCUGGUCAUGUAC-5′ (SEQ ID NO: 4440) KRAS-371 Target: 5′-TACAGTGCAATGAGGGACCAGTACATG-3′ (SEQ ID NO: 4926)   5′-AGUGCAAUGAGGGACCAGUACAUga-3′ (SEQ ID NO: 4684) 3′-UGUCACGUUACUCCCUGGUCAUGUACU-5′ (SEQ ID NO: 4441) KRAS-372 Target: 5′-ACAGTGCAATGAGGGACCAGTACATGA-3′ (SEQ ID NO: 4927)   5′-GUAUUUGCCAUAAAUAAUACUAAat-3′ (SEQ ID NO: 4685) 3′-CACAUAAACGGUAUUUAUUAUGAUUUA-5′ (SEQ ID NO: 4442) KRAS-420 Target: 5′-GTGTATTTGCCATAAATAATACTAAAT-3′ (SEQ ID NO: 4928)   5′-UAUUUGCCAUAAAUAAUACUAAAtc-3′ (SEQ ID NO: 4686) 3′-ACAUAAACGGUAUUUAUUAUGAUUUAG-5′ (SEQ ID NO: 4443) KRAS-421 Target: 5′-TGTATTTGCCATAAATAATACTAAATC-3′ (SEQ ID NO: 4929)   5′-AUUUGCCAUAAAUAAUACUAAAUca-3′ (SEQ ID NO: 4687) 3′-CAUAAACGGUAUUUAUUAUGAUUUAGU-5′ (SEQ ID NO: 4444) KRAS-422 Target: 5′-GTATTTGCCATAAATAATACTAAATCA-3′ (SEQ ID NO: 4930)   5′-UUUGCCAUAAAUAAUACUAAAUCat-3′ (SEQ ID NO: 4688) 3′-AUAAACGGUAUUUAUUAUGAUUUAGUA-5′ (SEQ ID NO: 4445) KRAS-423 Target: 5′-TATTTGCCATAAATAATACTAAATCAT-3′ (SEQ ID NO: 4931)   5′-UUGCCAUAAAUAAUACUAAAUCAtt-3′ (SEQ ID NO: 4689) 3′-UAAACGGUAUUUAUUAUGAUUUAGUAA-5′ (SEQ ID NO: 4446) KRAS-424 Target: 5′-ATTTGCCATAAATAATACTAAATCATT-3′ (SEQ ID NO: 4932)   5′-UGCCAUAAAUAAUACUAAAUCAUtt-3′ (SEQ ID NO: 4690) 3′-AAACGGUAUUUAUUAUGAUUUAGUAAA-5′ (SEQ ID NO: 4447) KRAS-425 Target: 5′-TTTGCCATAAATAATACTAAATCATTT-3′ (SEQ ID NO: 4933)   5′-GCCAUAAAUAAUACUAAAUCAUUtg-3′ (SEQ ID NO: 4691) 3′-AACGGUAUUUAUUAUGAUUUAGUAAAC-5′ (SEQ ID NO: 4448) KRAS-426 Target: 5′-TTGCCATAAATAATACTAAATCATTTG-3′ (SEQ ID NO: 4934)   5′-AUACUAAAUCAUUUGAAGAUAUUca-3′ (SEQ ID NO: 4692) 3′-AUUAUGAUUUAGUAAACUUCUAUAAGU-5′ (SEQ ID NO: 4449) KRAS-436 Target: 5′-TAATACTAAATCATTTGAAGATATTCA-3′ (SEQ ID NO: 4935)   5′-UACUAAAUCAUUUGAAGAUAUUCac-3′ (SEQ ID NO: 4693) 3′-UUAUGAUUUAGUAAACUUCUAUAAGUG-5′ (SEQ ID NO: 4450) KRAS-437 Target: 5′-AATACTAAATCATTTGAAGATATTCAC-3′ (SEQ ID NO: 4936)   5′-ACUAAAUCAUUUGAAGAUAUUCAcc-3′ (SEQ ID NO: 4694) 3′-UAUGAUUUAGUAAACUUCUAUAAGUGG-5′ (SEQ ID NO: 4451) KRAS-438 Target: 5′-ATACTAAATCATTTGAAGATATTCACC-3′ (SEQ ID NO: 4937)   5′-CUAAAUCAUUUGAAGAUAUUCACca-3′ (SEQ ID NO: 4695) 3′-AUGAUUUAGUAAACUUCUAUAAGUGGU-5′ (SEQ ID NO: 4452) KRAS-439 Target: 5′-TACTAAATCATTTGAAGATATTCACCA-3′ (SEQ ID NO: 4938)   5′-UAAAUCAUUUGAAGAUAUUCACCat-3′ (SEQ ID NO: 4696) 3′-UGAUUUAGUAAACUUCUAUAAGUGGUA-5′ (SEQ ID NO: 4453) KRAS-440 Target: 5′-ACTAAATCATTTGAAGATATTCACCAT-3′ (SEQ ID NO: 4939)   5′-AAAUCAUUUGAAGAUAUUCACCAtt-3′ (SEQ ID NO: 4697) 3′-GAUUUAGUAAACUUCUAUAAGUGGUAA-5′ (SEQ ID NO: 4454) KRAS-441 Target: 5′-CTAAATCATTTGAAGATATTCACCATT-3′ (SEQ ID NO: 4940)   5′-AAUCAUUUGAAGAUAUUCACCAUta-3′ (SEQ ID NO: 4698) 3′-AUUUAGUAAACUUCUAUAAGUGGUAAU-5′ (SEQ ID NO: 4455) KRAS-442 Target: 5′-TAAATCATTTGAAGATATTCACCATTA-3′ {SEQ ID NO: 4941)   5′-AUCAUUUGAAGAUAUUCACCAUUat-3′ (SEQ ID NO: 4699) 3′-UUUAGUAAACUUCUAUAAGUGGUAAUA-5′ (SEQ ID NO: 4456) KRAS-443 Target: 5′-AAATCATTTGAAGATATTCACCATTAT-3′ (SEQ ID NO: 4942)   5′-UCAUUUGAAGAUAUUCACCAUUAta-3′ (SEQ ID NO: 4700) 3′-UUAGUAAACUUCUAUAAGUGGUAAUAU-5′ (SEQ ID NO: 4457) KRAS-444 Target: 5′-AATCATTTGAAGATATTCACCATTATA-3′ (SEQ ID NO: 4943)   5′-AUAUUCACCAUUAUAGAGAACAAat-3′ (SEQ ID NO: 4701) 3′-UCUAUAAGUGGUAAUAUCUCUUGUUUA-5′ (SEQ ID NO: 4458) KRAS-454 Target: 5′-AGATATTCACCATTATAGAGAACAAAT-3′ (SEQ ID NO: 4944)   5′-UAUUCACCAUUAUAGAGAACAAAtt-3′ (SEQ ID NO: 4702) 3′-CUAUAAGUGGUAAUAUCUCUUGUUUAA-5′ (SEQ ID NO: 4459) KRAS-455 Target: 5′-GATATTCACCATTATAGAGAACAAATT-3′ (SEQ ID NO: 4945)   5′-AUUCACCAUUAUAGAGAACAAAUta-3′ (SEQ ID NO: 4703) 3′-UAUAAGUGGUAAUAUCUCUUGUUUAAU-5′ (SEQ ID NO: 4460) KRAS-456 Target: 5′-ATATTCACCATTATAGAGAACAAATTA-3′ (SEQ ID NO: 4946)   5′-UUCACCAUUAUAGAGAACAAAUUaa-3′ (SEQ ID NO: 4704) 3′-AUAAGUGGUAAUAUCUCUUGUUUAAUU-5′ (SEQ ID NO: 4461) KRAS-457 Target: 5′-TATTCACCATTATAGAGAACAAATTAA-3′ (SEQ ID NO: 4947)   5′-UCACCAUUAUAGAGAACAAAUUAaa-3′ (SEQ ID NO: 4705) 3′-UAAGUGGUAAUAUCUCUUGUUUAAUUU-5′ (SEQ ID NO: 4462) KRAS-458 Target: 5′-ATTCACCATTATAGAGAACAAATTAAA-3′ (SEQ ID NO: 4948)   5′-CACCAUUAUAGAGAACAAAUUAAaa-3′ (SEQ ID NO: 4706) 3′-AAGUGGUAAUAUCUCUUGUUUAAUUUU-5′ (SEQ ID NO: 4463) KRAS-459 Target: 5′-TTCACCATTATAGAGAACAAATTAAAA-3′ (SEQ ID NO: 4949)   5′-ACCAUUAUAGAGAACAAAUUAAAag-3′ (SEQ ID NO: 4707) 3′-AGUGGUAAUAUCUCUUGUUUAAUUUUC-5′ (SEQ ID NO: 4464) KRAS-460 Target: 5′-TCACCATTATAGAGAACAAATTAAAAG-3′ (SEQ ID NO: 4950)   5′-CCAUUAUAGAGAACAAAUUAAAAga-3′ (SEQ ID NO: 4708) 3′-GUGGUAAUAUCUCUUGUUUAAUUUUCU-5′ (SEQ ID NO: 4465) KRAS-461 Target: 5′-CACCATTATAGAGAACAAATTAAAAGA-3′ (SEQ ID NO: 4951)   5′-CAUUAUAGAGAACAAAUUAAAAGag-3′ (SEQ ID NO: 4709) 3′-UGGUAAUAUCUCUUGUUUAAUUUUCUC-5′ (SEQ ID NO: 4466) KRAS-462 Target: 5′-ACCATTATAGAGAACAAATTAAAAGAG-3′ (SEQ ID NO: 4952)   5′-CUAUGGUCCUAGUAGGAAAUAAAtg-3′ (SEQ ID NO: 4710) 3′-UGGAUACCAGGAUCAUCCUUUAUUUAC-5′ (SEQ ID NO: 4467) KRAS-508 Target: 5′-ACCTATGGTCCTAGTAGGAAATAAATG-3′ (SEQ ID NO: 4953)   5′-UGUGAUUUGCCUUCUAGAACAGUag-3′ (SEQ ID NO: 4711) 3′-UUACACUAAACGGAAGAUCUUGUCAUC-5′ (SEQ ID NO: 4468) KRAS-531 Target: 5′-AATGTGATTTGCCTTCTAGAACAGTAG-3′ (SEQ ID NO: 4954)   5′-GUGAUUUGCCUUCUAGAACAGUAga-3′ (SEQ ID NO: 4712) 3′-UACACUAAACGGAAGAUCUUGUCAUCU-5′ (SEQ ID NO: 4469) KRAS-532 Target: 5′-ATGTGATTTGCCTTCTAGAACAGTAGA-3′ (SEQ ID NO: 4955)   5′-GAUUUGCCUUCUAGAACAGUAGAca-3′ (SEQ ID NO: 4713) 3′-CACUAAACGGAAGAUCUUGUCAUCUGU-5′ (SEQ ID NO: 4470) KRAS-534 Target: 5′-GTGATTTGCCTTCTAGAACAGTAGACA-3′ (SEQ ID NO: 4956)   5′-GUUAUGGAAUUCCUUUUAUUGAAac-3′ (SEQ ID NO: 4714) 3′-UUCAAUACCUUAAGGAAAAUAACUUUG-5′ (SEQ ID NO: 4471) KRAS-586 Target: 5′-AAGTTATGGAATTCCTTTTATTGAAAC-3′ (SEQ ID NO: 4957)   5′-UUAUGGAAUUCCUUUUAUUGAAAca-3′ (SEQ ID NO: 4715) 3′-UCAAUACCUUAAGGAAAAUAACUUUGU-5′ (SEQ ID NO: 4472) KRAS-587 Target: 5′-AGTTATGGAATTCCTTTTATTGAAACA-3′ (SEQ ID NO: 4958)   5′-UAUGGAAUUCCUUUUAUUGAAACat-3′ (SEQ ID NO: 4716) 3′-CAAUACCUUAAGGAAAAUAACUUUGUA-5′ (SEQ ID NO: 4473) KRAS-588 Target: 5′-GTTATGGAATTCCTTTTATTGAAACAT-3′ (SEQ ID NO: 4959)   5′-GAUGCCUUCUAUACAUUAGUUCGag-3′ (SEQ ID NO: 4717) 3′-UACUACGGAAGAUAUGUAAUCAAGCUC-5′ (SEQ ID NO: 4474) KRAS-763 Target: 5′-ATGATGCCTTCTATACATTAGTTCGAG-3′ (SEQ ID NO: 4960)   5′-AUGCCUUCUAUACAUUAGUUCGAga-3′ (SEQ ID NO: 4718) 3′-ACUACGGAAGAUAUGUAAUCAAGCUCU-5′ (SEQ ID NO: 4475) KRAS-764 Target: 5′-TGATGCCTTCTATACATTAGTTCGAGA-3′ (SEQ ID NO: 4961)   5′-CGAGAAAUUCGAAAACAUAAAGAaa-3′ (SEQ ID NO: 4719) 3′-AAGCUCUUUAAGCUUUUGUAUUUCUUU-5′ (SEQ ID NO: 4476) KRAS-784 Target: 5′-TTCGAGAAATTCGAAAACATAAAGAAA-3′ (SEQ ID NO: 4962)   5′-GAAAACAUAAAGAAAAGAUGAGCaa-3′ (SEQ ID NO: 4720) 3′-AGCUUUUGUAUUUCUUUUCUACUCGUU-5′ (SEQ ID NO: 4477) KRAS-794 Target: 5′-TCGAAAACATAAAGAAAAGATGAGCAA-3′ (SEQ ID NO: 4963)   5′-AAAACAUAAAGAAAAGAUGAGCAaa-3′ (SEQ ID NO: 4721) 3′-GCUUUUGUAUUUCUUUUCUACUCGUUU-5′ (SEQ ID NO: 4478) KRAS-795 Target: 5′-CGAAAACATAAAGAAAAGATGAGCAAA-3′ (SEQ ID NO: 4964)   5′-AAACAUAAAGAAAAGAUGAGCAAag-3′ (SEQ ID NO: 4722) 3′-CUUUUGUAUUUCUUUUCUACUCGUUUC-5′ (SEQ ID NO: 4479) KRAS-796 Target: 5′-GAAAACATAAAGAAAAGATGAGCAAAG-3′ (SEQ ID NO: 4965)   5′-AACAUAAAGAAAAGAUGAGCAAAga-3′ (SEQ ID NO: 4723) 3′-UUUUGUAUUUCUUUUCUACUCGUUUCU-5′ (SEQ ID NO: 4480) KRAS-797 Target: 5′-AAAACATAAAGAAAAGATGAGCAAAGA-3′ (SEQ ID NO: 4966)   5′-ACAUAAAGAAAAGAUGAGCAAAGat-3′ (SEQ ID NO: 4724) 3′-UUUGUAUUUCUUUUCUACUCGUUUCUA-5′ (SEQ ID NO: 4481) KRAS-798 Target: 5′-AAACATAAAGAAAAGATGAGCAAAGAT-3′ (SEQ ID NO: 4967)   5′-CAUAAAGAAAAGAUGAGCAAAGAtg-3′ (SEQ ID NO: 4725) 3′-UUGUAUUUCUUUUCUACUCGUUUCUAC-5′ (SEQ ID.NO: 4482) KRAS-799 Target: 5′-AACATAAAGAAAAGATGAGCAAAGATG-3′ (SEQ ID NO: 4968)   5′-AUAAAGAAAAGAUGAGCAAAGAUgg-3′ (SEQ ID NO: 4726) 3′-UGUAUUUCUUUUCUACUCGUUUCUACC-5′ (SEQ ID NO: 4483) KRAS-800 Target: 5′-ACATAAAGAAAAGATGAGCAAAGATGG-3′ (SEQ ID NO: 4969)   5′-UAAAGAAAAGAUGAGCAAAGAUGgt-3′ (SEQ ID NO: 4727) 3′-GUAUUUCUUUUCUACUCGUUUCUACCA-5′ (SEQ ID NO: 4484) KRAS-801 Target: 5′-CATAAAGAAAAGATGAGCAAAGATGGT-3′ (SEQ ID NO: 4970)   5′-AAAGAAAAGAUGAGCAAAGAUGGta-3′ (SEQ ID NO: 4728) 3′-UAUUUCUUUUCUACUCGUUUCUACCAU-5′ (SEQ ID NO: 4485) KRAS-802 Target: 5′-ATAAAGAAAAGATGAGCAAAGATGGTA-3′ (SEQ ID NO: 4971)   5′-AAGUGGUAAUUUUUGUACAUUACac-3′ (SEQ ID NO: 4729) 3′-UGUUCACCAUUAAAAACAUGUAAUGUG-5′ (SEQ ID NO: 4486) KRAS-908 Target: 5′-ACAAGTGGTAATTTTTGTACATTACAC-3′ (SEQ ID NO: 4972)   5′-AGUGGUAAUUUUUGUACAUUACAct-3′ (SEQ ID NO: 4730) 3′-GUUCACCAUUAAAAACAUGUAAUGUGA-5′ (SEQ ID NO: 4487) KRAS-909 Target: 5′-CAAGTGGTAATTTTTGTACATTACACT-3′ (SEQ ID NO: 4973)   5′-UUGUACAUUACACUAAAUUAUUAgc-3′ (SEQ ID NO: 4731) 3′-AAAACAUGUAAUGUGAUUUAAUAAUCG-5′ (SEQ ID NO: 4488) KRAS-920 Target: 5′-TTTTGTACATTACACTAAATTATTAGC-3′ (SEQ ID NO: 4974)   5′-UGUACAUUACACUAAAUUAUUAGca-3′ (SEQ ID NO: 4732) 3′-AAACAUGUAAUGUGAUUUAAUAAUCGU-5′ (SEQ ID NO: 4489) KRAS-921 Target: 5′-TTTGTACATTACACTAAATTATTAGCA-3′ (SEQ ID NO: 4975)   5′-GUACAUUACACUAAAUUAUUAGCat-3′ (SEQ ID NO: 4733) 3′-AACAUGUAAUGUGAUUUAAUAAUCGUA-5′ (SEQ ID NO: 4490) KRAS-922 Target: 5′-TTGTACATTACACTAAATTATTAGCAT-3′ (SEQ ID NO: 4976)   5′-UACAUUACACUAAAUUAUUAGCAtt-3′ (SEQ ID NO: 4734) 3′-ACAUGUAAUGUGAUUUAAUAAUCGUAA-5′ (SEQ ID NO: 4491) KRAS-923 Target: 5′-TGTACATTACACTAAATTATTAGCATT-3′ (SEQ ID NO: 4977)   5′-ACAUUACACUAAAUUAUUAGCAUtt-3′ (SEQ ID NO: 4735) 3′-CAUGUAAUGUGAUUUAAUAAUCGUAAA-5′ (SEQ ID NO: 4492) KRAS-924 Target: 5′-GTACATTACACTAAATTATTAGCATTT-3′ (SEQ ID NO: 4978)   5′-CAUUACACUAAAUUAUUAGCAUUtg-3′ (SEQ ID NO: 4736) 3′-AUGUAAUGUGAUUUAAUAAUCGUAAAC-5′ (SEQ ID NO: 4493) KRAS-925 Target: 5′-TACATTACACTAAATTATTAGCATTTG-3′ (SEQ ID NO: 4979)   5′-AUUACACUAAAUUAUUAGCAUUUgt-3′ (SEQ ID NO: 4737) 3′-UGUAAUGUGAUU0AAUAAUCGUAAACA-5′ (SEQ ID NO: 4494) KRAS-926 Target: 5′-ACATTACACTAAATTATTAGCATTTGT-3′ (SEQ ID NO: 4980)   5′-UUACACUAAAUUAUUAGCAUUUGtt-3′ (SEQ ID NO: 4738) 3′-GUAAUGUGAUUUAAUAAUCGUAAACAA-5′ (SEQ ID NO: 4495) KRAS-927 Target: 5′-CATTACACTAAATTATTAGCATTTGTT-3′ (SEQ ID NO: 4981)   5′-UACACUAAAUUAUUAGCAUUUGUtt-3′ (SEQ ID NO: 4739) 3′-UAAUGUGAUUUAAUAAUCGUAAACAAA-5′ (SEQ ID NO: 4496) KRAS-928 Target: 5′-ATTACACTAAATTATTAGCATTTGTTT-3′ (SEQ ID NO: 4982)   5′-UAUUAGCAUUUGUUUUAGCAUUAcc-3′ (SEQ ID NO: 4740) 3′-UAAUAAUCGUAAACAAAAUCGUAAUGG-5′ (SEQ ID NO: 4497) KRAS-938 Target: 5′-ATTATTAGCATTTGTTTTAGCATTACC-3′ (SEQ ID NO: 4983)   5′-AUUAGCAUUUGUUUUAGCAUUACct-3′ (SEQ ID NO: 4741) 3′-AAUAAUCGUAAACAAAAUCGUAAUGGA-5′ (SEQ ID NO: 4498) KRAS-939 Target: 5′-TTATTAGCATTTGTTTTAGCATTACCT-3′ (SEQ ID NO: 4984)   5′-UUAGCAUUUGUUUUAGCAUUACCta-3′ (SEQ ID NO: 4742) 3′-AUAAUCGUAAACAAAAUCGUAAUGGAU-5′ (SEQ ID NO: 4499) KRAS-940 Target: 5′-TATTAGCATTTGTTTTAGCATTACCTA-3′ (SEQ ID NO: 4985)   5′-UAGCAUUUGUUUUAGCAUUACCUaa-3′ (SEQ ID NO: 4743) 3′-UAAUCGUAAACAAAAUCGUAAUGGAUU-5′ (SEQ ID NO: 4500) KRAS-941 Target: 5′-ATTAGCATTTGTTTTAGCATTACCTAA-3′ (SEQ ID NO: 4986)   5′-AGCAUUUGUUUUAGCAUUACCUAat-3′ (SEQ ID NO: 4744) 3′-AAUCGUAAACAAAAUCGUAAUGGAUUA-5′ (SEQ ID NO: 4501) KRAS-942 Target: 5′-TTAGCATTTGTTTTAGCATTACCTAAT-3′ (SEQ ID NO: 4987)   5′-GCAUUUGUUUUAGCAUUACCUAAtt-3′ (SEQ ID NO: 4745) 3′-AUCGUAAACAAAAUCGUAAUGGAUUAA-5′ (SEQ ID NO: 4502) KRAS-943 Target: 5′-TAGCATTTGTTTTAGCATTACCTAATT-3′ (SEQ ID NO: 4988)   5′-CAUUUGUUUUAGCAUUACCUAAUtt-3′ (SEQ ID NO: 4746) 3′-UCGUAAACAAAAUCGUAAUGGAUUAAA-5′ (SEQ ID NO: 4503) KRAS-944 Target: 5′-AGCATTTGTTTTAGCATTACCTAATTT-3′ (SEQ ID NO: 4989)   5′-AUUUGUUUUAGCAUUACCUAAUUtt-3′ (SEQ ID NO: 4747) 3′-CGUAAACAAAAUCGUAAUGGAUUAAAA-5′ (SEQ ID NO: 4504) KRAS-945 Target: 5′-GCATTTGTTTTAGCATTACCTAATTTT-3′ (SEQ ID NO: 4990)   5′-UUUGUUUUAGCAUUACCUAAUUUtt-3′ (SEQ ID NO: 4748) 3′-GUAAACAAAAUCGUAAUGGAUUAAAAA-5′ (SEQ ID NO: 4505) KRAS-946 Target: 5′-CATTTGTTTTAGCATTACCTAATTTTT-3′ (SEQ ID NO: 4991)   5′-CUUAUUUUAAAAUGACAGUGGAAgt-3′ (SEQ ID NO: 4749) 3′-ACGAAUAAAAUUUUACUGUCACCUUCA-5′ (SEQ ID NO: 4506) KRAS-1010 Target: 5′-TGCTTATTTTAAAATGACAGTGGAAGT-3′ (SEQ ID NO: 4992)   5′-UAUUUUAAAAUGACAGUGGAAGUtt-3′ (SEQ ID NO: 4750) 3′-GAAUAAAAUUUUACUGUCACCUUCAAA-5′ (SEQ ID NO: 4507) KRAS-1012 Target: 5′-CTTATTTTAAAATGACAGTGGAAGTTT-3′ (SEQ ID NO: 4993)   5′-UCUAAGUGCCAGUAUUCCCAGAGtt-3′ (SEQ ID NO: 4751) 3′-GGAGAUUCACGGUCAUAAGGGUCUCAA-5′ (SEQ ID NO: 4508) KRAS-1045 Target: 5′-CCTCTAAGTGCCAGTATTCCCAGAGTT-3′ (SEQ ID NO: 4994)   5′-CAAAUUAAUGAAGCUUUUGAAUCat-3′ (SEQ ID NO: 4752) 3′-UUGUUUAAUUACUUCGAAAACUUAGUA-5′ (SEQ ID NO: 4509) KRAS-1197 Target: 5′-AACAAATTAATGAAGCTTTTGAATCAT-3′ (SEQ ID NO: 4995)   5′-AAAUUAAUGAAGCUUUUGAAUCAtc-3′ (SEQ ID NO: 4753) 3′-UGUUUAAUUACUUCGAAAACUUAGUAG-5′ (SEQ ID NO: 4510) KRAS-1198 Target: 5′-ACAAATTAATGAAGCTTTTGAATCATC-3′ (SEQ ID NO: 4996)   5′-UGUGUUUUAUCUAGUCACAUAAAtg-3′ (SEQ ID NO: 4754) 3′-AGACACAAAAUAGAUCAGUGUAUUUAC-5′ (SEQ ID NO: 4511) KRAS-1230 Target: 5′-TCTGTGTTTTATCTAGTCACATAAATG-3′ (SEQ ID NO: 4997)   5′-GUGUUUUAUCUAGUCACAUAAAUgg-3′ (SEQ ID NO: 4755) 3′-GACACAAAAUAGAUCAGUGUAUUUACC-5′ (SEQ ID NO: 4512) KRAS-1231 Target: 5′-CTGTGTTTTATCTAGTCACATAAATGG-3′ (SEQ ID NO: 4998)   5′-UUUUAUCUAGUCACAUAAAUGGAtt-3′ (SEQ ID NO: 4756) 3′-ACAAAAUAGAUCAGUGUAUUUACCUAA-5′ (SEQ ID NO: 4513) KRAS-1234 Target: 5′-TGTTTTATCTAGTCACATAAATGGATT-3′ (SEQ ID NO: 4999)   5′-UAAAUGGAUUAAUUACUAAUUUCag-3′ (SEQ ID NO: 4757) 3′-GUAUUUACCUAAUUAAUGAUUAAAGUC-5′ (SEQ ID NO: 4514) KRAS-1249 Target: 5′-CATAAATGGATTAATTACTAATTTCAG-3′ (SEQ ID NO: 5000)   5′-AAAUGGAUUAAUUACUAAUUUCAgt-3′ (SEQ ID NO: 4758) 3′-UAUUUACCUAAUUAAUGAUUAAAGUCA-5′ (SEQ ID NO: 4515) KRAS-1250 Target: 5′-ATAAATGGATTAATTACTAATTTCAGT-3′ (SEQ ID NO: 5001)   5′-AUUGGUUUUUACUGAAACAUUGAgg-3′ (SEQ ID NO: 4759) 3′-AUUAACCAAAAAUGACUUUGUAACUCC-5′ (SEQ ID NO: 4516) KRAS-1287 Target: 5′-TAATTGGTTTTTACTGAAACATTGAGG-3′ (SEQ ID NO: 5002)   5′-CAUUUCCUUUUCACAUUAGAUAAat-3′ (SEQ ID NO: 4760) 3′-CGGUAAAGGAAAAGUGUAAUCUAUUUA-5′ (SEQ ID NO: 4517) KRAS-1527 Target: 5′-GCCATTTCCTTTTCACATTAGATAAAT-3′ (SEQ ID NO: 5003)   5′-CUUUUCACAUUAGAUAAAUUACUat-3′ (SEQ ID NO: 4761) 3′-AGGAAAAGUGUAAUCUAUUUAAUGAUA-5′ (SEQ ID NO: 4518) KRAS-1533 Target: 5′-TCCTTTTCACATTAGATAAATTACTAT-3′ (SEQ ID NO: 5004)   5′-CAUUAGAUAAAUUACUAUAAAGAct-3′ (SEQ ID NO: 4762) 3′-GUGUAAUCUAUUUAAUGAUAUUUCUGA-5′ (SEQ ID NO: 4519) KRAS-1540 Target: 5′-CACATTAGATAAATTACTATAAAGACT-3′ (SEQ ID NO: 5005)   5′-AUUAGAUAAAUUACUAUAAAGACtc-3′ (SEQ ID NO: 4763) 3′-UGUAAUCUAUUUAAUGAUAUUUCUGAG-5′ (SEQ ID NO: 4520) KRAS-1541 Target: 5′-ACATTAGATAAATTACTATAAAGACTC-3′ (SEQ ID NO: 5006)   5′-UUAGAUAAAUUACUAUAAAGACUcc-3′ (SEQ ID NO: 4764) 3′-GUAAUCUAUUUAAUGAUAUUUCUGAGG-5′ (SEQ ID NO: 4521) KRAS-1542 Target: 5′-CATTAGATAAATTACTATAAAGACTCC-3′ (SEQ ID NO: 5007)   5′-UAAGGCAGACCCAGUAUGAAAUGgg-3′ (SEQ ID NO: 4765) 3′-CAAUUCCGUCUGGGUCAUACUUUACCC-5′ (SEQ ID NO: 4522) KRAS-1583 Target: 5′-GTTAAGGCAGACCCAGTATGAAATGGG-3′ (SEQ ID NO: 5008)   5′-AAGGCAGACCCAGUAUGAAAUGGgg-3′ (SEQ ID NO: 4766) 3′-AAUUCCGUCUGGGUCAUACUUUACCCC-5′ (SEQ ID NO: 4523) KRAS-1584 Target: 5′-TTAAGGCAGACCCAGTATGAAATGGGG-3′ (SEQ ID NO: 5009)   5′-AGGCAGACCCAGUAUGAAAUGGGga-3′ (SEQ ID NO: 4767) 3′-AUUCCGUCUGGGUCAUACUUUACCCCU-5′ (SEQ ID NO: 4524) KRAS-1585 Target: 5′-TAAGGCAGACCCAGTATGAAATGGGGA-3′ (SEQ ID NO: 5010)   5′-GGCAGACCCAGUAUGAAAUGGGGat-3′ (SEQ ID NO: 4768) 3′-UUCCGUCUGGGUCAUACUUUACCCCUA-5′ (SEQ ID NO: 4525) KRAS-1586 Target: 5′-AAGGCAGACCCAGTATGAAATGGGGAT-3′ (SEQ ID NO: 5011)   5′-UAUGAAAUGGGGAUUAUUAUAGCaa-3′ (SEQ ID NO: 4769) 3′-UCAUACUUUACCCCUAAUAAUAUCGUU-5′ (SEQ ID NO: 4526) KRAS-1597 Target: 5′-AGTATGAAATGGGGATTATTATAGCAA-3′ (SEQ ID NO: 5012)   5′-GGGAUUAUUAUAGCAACCAUUUUgg-3′ (SEQ ID NO: 4770) 3′-ACCCCUAAUAAUAUCGUUGGUAAAACC-5′ (SEQ ID NO: 4527) KRAS-1606 Target: 5′-TGGGGATTATTATAGCAACCATTTTGG-3′ (SEQ ID NO: 5013)   5′-GGGCUAUAUUUACAUGCUACUAAat-3′ (SEQ ID NO: 4771) 3′-ACCCCGAUAUAAAUGUACGAUGAUUUA-5′ (SEQ ID NO: 4528) KRAS-1630 Target: 5′-TGGGGCTATATTTACATGCTACTAAAT-3′ (SEQ ID NO: 5014)   5′-GGCUAUAUUUACAUGCUACUAAAtt-3′ (SEQ ID NO: 4772) 3′-CCCCGAUAUAAAUGUACGAUGAUUUAA-5′ (SEQ ID NO: 4529) KRAS-1631 Target: 5′-GGGGCTATATTTACATGCTACTAAATT-3′ (SEQ ID NO: 5015)   5′-GCUAUAUUUACAUGCUACUAAAUtt-3′ (SEQ ID NO: 4773) 3′-CCCGAUAUAAAUGUACGAUGAUUUAAA-5′ (SEQ ID NO: 4530) KRAS-1632 Target: 5′-GGGCTATATTTACATGCTACTAAATTT-3′ (SEQ ID NO: 5016)   5′-CUAUAUUUACAUGCUACUAAAUUtt-3′ (SEQ ID NO: 4774) 3′-CCGAUAUAAAUGUACGAUGAUUUAAAA-5′ (SEQ ID NO: 4531) KRAS-1633 Target: 5′-GGCTATATTTACATGCTACTAAATTTT-3′ (SEQ ID NO: 5017)   5′-UAUAUUUACAUGCUACUAAAUUUtt-3′ (SEQ ID NO: 4775) 3′-CGAUAUAAAUGUACGAUGAUUUAAAAA-5′ (SEQ ID NO: 4532) KRAS-1634 Target: 5′-GCTATATTTACATGCTACTAAATTTTT-3′ (SEQ ID NO: 5018)   5′-AUAUUUACAUGCUACUAAAUUUUta-3′ (SEQ ID NO: 4776) 3′-GAUAUAAAUGUACGAUGAUUUAAAAAU-5′ (SEQ ID NO: 4533) KRAS-1635 Target: 5′-CTATATTTACATGCTACTAAATTTTTA-3′ (SEQ ID NO: 5019)   5′-UAUUUACAUGCUACUAAAUUUUUat-3′ (SEQ ID NO: 4777) 3′-AUAUAAAUGUACGAUGAUUUAAAAAUA-5′ (SEQ ID NO: 4534) KRAS-1636 Target: 5′-TATATTTACATGCTACTAAATTTTTAT-3′ (SEQ ID NO: 5020)   5′-AUUUACAUGCUACUAAAUUUUUAta-3′ (SEQ ID NO: 4778) 3′-UAUAAAUGUACGAUGAUUUAAAAAUAU-5′ (SEQ ID NO: 4535) KRAS-1637 Target: 5′-ATATTTACATGCTACTAAATTTTTATA-3′ (SEQ ID NO: 5021)   5′-UUUACAUGCUACUAAAUUUUUAUaa-3′ (SEQ ID NO: 4779) 3′-AUAAAUGUACGAUGAUUUAAAAAUAUU-5′ (SEQ ID NO: 4536) KRAS-1638 Target: 5′-TATTTACATGCTACTAAATTTTTATAA-3′ (SEQ ID NO: 5022)   5′-UUACAUGCUACUAAAUUUUUAUAat-3′ (SEQ ID NO: 4780) 3′-UAAAUGUACGAUGAUUUAAAAAUAUUA-5′ (SEQ ID NO: 4537) KRAS-1639 Target: 5′-ATTTACATGCTACTAAATTTTTATAAT-3′ (SEQ ID NO: 5023)   5′-UACAUGCUACUAAAUUUUUAUAAta-3′ (SEQ ID NO: 4781) 3′-AAAUGUACGAUGAUUUAAAAAUAUUAU-5′ (SEQ ID NO: 4538) KRAS-1640 Target: 5′-TTTACATGCTACTAAATTTTTATAATA-3′ (SEQ ID NO: 5024)   5′-CUUUCAUAGUAUAACUUUAAAUCtt-3′ (SEQ ID NO: 4782) 3′-GAGAAAGUAUCAUAUUGAAAUUUAGAA-5′ (SEQ ID NO: 4539) KRAS-1736 Target: 5′-CTCTTTCATAGTATAACTTTAAATCTT-3′ (SEQ ID NO: 5025)   5′-AUAGUAUAACUUUAAAUCUUUUCtt-3′ (SEQ ID NO: 4783) 3′-AGUAUCAUAUUGAAAUUUAGAAAAGAA-5′ (SEQ ID NO: 4540) KRAS-1741 Target: 5′-TCATAGTATAACTTTAAATCTTTTCTT-3′ (SEQ ID NO: 5026)   5′-UAGUAUAACUUUAAAUCUUUUCUtc-3′ (SEQ ID NO: 4784) 3′-GUAUCAUAUUGAAAUUUAGAAAAGAAG-5′ (SEQ ID NO: 4541) KRAS-1742 Target: 5′-CATAGTATAACTTTAAATCTTTTCTTC-3′ (SEQ ID NO: 5027)   5′-UAAAUCUUUUCUUCAACUUGAGUct-3′ (SEQ ID NO: 4785) 3′-AAAUUUAGAAAAGAAGUUGAACUCAGA-5′ (SEQ ID NO: 4542) KRAS-1753 Target: 5′-TTTAAATCTTTTCTTCAACTTGAGTCT-3′ (SEQ ID NO: 5028)   5′-AAAUCUUUUCUUCAACUUGAGUCtt-3′ (SEQ ID NO: 4786) 3′-AAUUUAGAAAAGAAGUUGAACUCAGAA-5′ (SEQ ID NO: 4543) KRAS-1754 Target: 5′-TTAAATCTTTTCTTCAACTTGAGTCTT-3′ (SEQ ID NO: 5029)   5′-CUUGAGUCUUUGAAGAUAGUUUUaa-3′ (SEQ ID NO: 4787) 3′-UUGAACUCAGAAACUUCUAUCAAAAUU-5′ (SEQ ID NO: 4544) KRAS-1769 Target: 5′-AACTTGAGTCTTTGAAGATAGTTTTAA-3′ (SEQ ID NO: 5030)   5′-UGAGUCUUUGAAGAUAGUUUUAAtt-3′ (SEQ ID NO: 4788) 3′-GAACUCAGAAACUUCUAUCAAAAUUAA-5′ (SEQ ID NO: 4545) KRAS-1771 Target: 5′-CTTGAGTCTTTGAAGATAGTTTTAATT-3′ (SEQ ID NO: 5031)   5′-GAGUCUUUGAAGAUAGUUUUAAUtc-3′ (SEQ ID NO: 4789) 3′-AACUCAGAAACUUCUAUCAAAAUUAAG-5′ (SEQ ID NO: 4546) KRAS-1772 Target: 5′-TTGAGTCTTTGAAGATAGTTTTAATTC-3′ (SEQ ID NO: 5032)   5′-GAUAGUUUUAAUUCUGCUUGUGAca-3′ (SEQ ID NO: 4790) 3′-UUCUAUCAAAAUUAAGACGAACACUGU-5′ (SEQ ID NO: 4547) KRAS-1783 Target: 5′-AAGATAGTTTTAATTCTGCTTGTGACA-3′ (SEQ ID NO: 5033)   5′-AUAGUUUUAAUUCUGCUUGUGACat-3′ (SEQ ID NO: 4791) 3′-UCUAUCAAAAUUAAGACGAACACUGUA-5′ (SEQ ID NO: 4548) KRAS-1784 Target: 5′-AGATAGTTTTAATTCTGCTTGTGACAT-3′ (SEQ ID NO: 5034)   5′-UAGUUUUAAUUCUGCUUGUGACAtt-3′ (SEQ ID NO: 4792) 3′-CUAUCAAAAUUAAGACGAACACUGUAA-5′ (SEQ ID NO: 4549) KRAS-1785 Target: 5′-GATAGTTTTAATTCTGCTTGTGACATT-3′ (SEQ ID NO: 5035)   5′-CUUGUGACAUUAAAAGAUUAUUUgg-3′ (SEQ ID NO: 4793) 3′-ACGAACACUGUAAUUUUCUAAUAAACC-5′ (SEQ ID NO: 4550) KRAS-1799 Target: 5′-TGCTTGTGACATTAAAAGATTATTTGG-3′ (SEQ ID NO: 5036)   5′-UAUUAACUCAAAAGUUGAGAUUUtg-3′ (SEQ ID NO: 4794) 3′-UUAUAAUUGAGUUUUCAACUCUAAAAC-5′ (SEQ ID NO: 4551) KRAS-2100 Target: 5′-AATATTAACTCAAAAGTTGAGATTTTG-3′ (SEQ ID NO: 5037)   5′-UGUGCCAAGACAUUAAUUUUUUUtt-3′ (SEQ ID NO: 4795) 3′-CCACACGGUUCUGUAAUUAAAAAAAAA-5′ (SEQ ID NO: 4552) KRAS-2134 Target: 5′-GGTGTGCCAAGACATTAATTTTTTTTT-3′ (SEQ ID NO: 5038)   5′-UGGUUAAAUUAACAUUGCAUAAAca-3′ (SEQ ID NO: 4796) 3′-UGACCAAUUUAAUUGUAACGUAUUUGU-5′ (SEQ ID NO: 4553) KRAS-2216 Target: 5′-ACTGGTTAAATTAACATTGCATAAACA-3′ (SEQ ID NO: 5039)   5′-GGUUAAAUUAACAUUGCAUAAACac-3′ (SEQ ID NO: 4797) 3′-GACCAAUUUAAUUGUAACGUAUUUGUG-5′ (SEQ ID NO: 4554) KRAS-2217 Target: 5′-CTGGTTAAATTAACATTGCATAAACAC-3′ (SEQ ID NO: 5040)   5′-GUUAAAUUAACAUUGCAUAAACAct-3′ (SEQ ID NO:.4798) 3′-ACCAAUUUAAUUGUAACGUAUUUGUGA-5′ (SEQ ID NO: 4555) KRAS-2218 Target: 5′-TGGTTAAATTAACATTGCATAAACACT-3′ (SEQ ID NO: 5041)   5′-AUUGCAUAAACACUUUUCAAGUCtg-3′ (SEQ ID NO: 4799) 3′-UGUAACGUAUUUGUGAAAAGUUCAGAC-5′ (SEQ ID NO: 4556) KRAS-2229 Target: 5′-ACATTGCATAAACACTTTTCAAGTCTG-3′ (SEQ ID NO: 5042)   5′-AAGUCUGAUCCAUAUUUAAUAAUgc-3′ (SEQ ID NO: 4800) 3′-AGUUCAGACUAGGUAUAAAUUAUUACG-5′ (SEQ ID NO: 4557) KRAS-2247 Target: 5′-TCAAGTCTGATCCATATTTAATAATGC-3′ (SEQ ID NO: 5043)   5′-UAAAAUAAAUGAAGUGAGAUGGCat-3′ (SEQ ID NO: 4801) 3′-AAAUUUUAUUUACUUCACUCUACCGUA-5′ (SEQ ID NO: 4558) KRAS-2326 Target: 5′-TTTAAAATAAATGAAGTGAGATGGCAT-3′ (SEQ ID NO: 5044)   5′-AAAAUAAAUGAAGUGAGAUGGCAtg-3′ (SEQ ID NO: 4802) 3′-AAUUUUAUUUACUUCACUCUACCGUAC-5′ (SEQ ID NO: 4559) KRAS-2327 Target: 5′-TTAAAATAAATGAAGTGAGATGGCATG-3′ (SEQ ID NO: 5045)   5′-AAGCUCAGCACAAUCUGUAAAUUtt-3′ (SEQ ID NO: 4803) 3′-AGUUCGAGUCGUGUUAGACAUUUAAAA-5′ (SEQ ID NO: 4560) KRAS-2547 Target: 5′-TCAAGCTCAGCACAATCTGTAAATTTT-3′ (SEQ ID NO: 5046)   5′-AGCUCAGCACAAUCUGUAAAUUUtt-3′ (SEQ ID NO: 4804) 3′-GUUCGAGUCGUGUUAGACAUUUAAAAA-5′ (SEQ ID NO: 4561) KRAS-2548 Target: 5′-CAAGCTCAGCACAATCTGTAAATTTTT-3′ (SEQ ID NO: 5047)   5′-AUAACUGUGAUUCUUUUAGGACAat-3′ (SEQ ID NO: 4805) 3′-CGUAUUGACACUAAGAAAAUCCUGUUA-5′ (SEQ ID NO: 4562) KRAS-3741 Target: 5′-GCATAACTGTGATTCTTTTAGGACAAT-3′ (SEQ ID NO: 5048)   5′-UGUGAUUCUUUUAGGACAAUUACtg-3′ (SEQ ID NO: 4806) 3′-UGACACUAAGAAAAUCCUGUUAAUGAC-5′ (SEQ ID NO: 4563) KRAS-3746 Target: 5′-ACTGTGATTCTTTTAGGACAATTACTG-3′ (SEQ ID NO: 5049)   5′-GUGAUUCUUUUAGGACAAUUACUgt-3′ (SEQ ID NO: 4807) 3′-GACACUAAGAAAAUCCUGUUAAUGACA-5′ (SEQ ID NO: 4564) KRAS-3747 Target: 5′-CTGTGATTCTTTTAGGACAATTACTGT-3′ (SEQ ID NO: 5050)   5′-UGUAUGUCAGAUAUUCAUAUUGAcc-3′ (SEQ ID NO: 4808) 3′-CCACAUACAGUCUAUAAGUAUAACUGG-5′ (SEQ ID NO: 4565) KRAS-3783 Target: 5′-GGTGTATGTCAGATATTCATATTGACC-3′ (SEQ ID NO: 5051)   5′-GUAUGUCAGAUAUUCAUAUUGACcc-3′ (SEQ ID NO: 4809) 3′-CACAUACAGUCUAUAAGUAUAACUGGG-5′ (SEQ ID NO: 4566) KRAS-3784 Target: 5′-GTGTATGTCAGATATTCATATTGACCC-3′ (SEQ ID NO: 5052)   5′-AAUGUGUAAUAUUCCAGUUUUCUct-3′ (SEQ ID NO: 4810) 3′-GUUUACACAUUAUAAGGUCAAAAGAGA-5′ (SEQ ID NO: 4567) KRAS-3810 Target: 5′-CAAATGTGTAATATTCCAGTTTTCTCT-3′ (SEQ ID NO: 5053)   5′-CACUGCAUAGGAAUUUAGAACCUaa-3′ (SEQ ID NO: 4811) 3′-GUGUGACGUAUCCUUAAAUCUUGGAUU-5′ (SEQ ID NO: 4568) KRAS-4396 Target: 5′-CACACTGCATAGGAATTTAGAACCTAA-3′ (SEQ ID NO: 5054)   5′-CACCAUUGCACAAUUUUGUCCUAat-3′ (SEQ ID NO: 4812) 3′-CAGUGGUAACGUGUUAAAACAGGAUUA-5′ (SEQ ID NO: 4569) KRAS-4447 Target: 5′-GTCACCATTGCACAATTTTGTCCTAAT-3′ (SEQ ID NO: 5055)   5′-ACCAUUGCACAAUUUUGUCCUAAta-3′ (SEQ ID NO: 4813) 3′-AGUGGUAACGUGUUAAAACAGGAUUAU-5′ (SEQ ID NO: 4570) KRAS-4448 Target: 5′-TCACCATTGCACAATTTTGTCCTAATA-3′ (SEQ ID NO: 5056)   5′-CCAUUGCACAAUUUUGUCCUAAUat-3′ (SEQ ID NO: 4814) 3′-GUGGUAACGUGUUAAAACAGGAUUAUA-5′ (SEQ ID NO: 4571) KRAS-4449 Target: 5′-CACCATTGCACAATTTTGTCCTAATAT-3′ (SEQ ID NO: 5057)   5′-CAUUGCACAAUUUUGUCCUAAUAta-3′ (SEQ ID NO: 4815) 3′-UGGUAACGUGUUAAAACAGGAUUAUAU-5′ (SEQ ID NO: 4572) KRAS-4450 Target: 5′-ACCATTGCACAATTTTGTCCTAATATA-3′ (SEQ ID NO: 5058)   5′-AUUGCACAAUUUUGUCCUAAUAUat-3′ (SEQ ID NO: 4816) 3′-GGUAACGUGUUAAAACAGGAUUAUAUA-5′ (SEQ ID NO: 4573) KRAS-4451 Target: 5′-CCATTGCACAATTTTGTCCTAATATAT-3′ (SEQ ID NO: 5059)   5′-UUGCACAAUUUUGUCCUAAUAUAta-3′ (SEQ ID NO: 4817) 3′-GUAACGUGUUAAAACAGGAUUAUAUAU-5′ (SEQ ID NO: 4574) KRAS-4452 Target: 5′-CATTGCACAATTTTGTCCTAATATATA-3′ (SEQ ID NO: 5060)   5′-UAGCAUGAAUUCUGCAUUGAGAAac-3′ (SEQ ID NO: 4818) 3′-CUAUCGUACUUAAGACGUAACUCUUUG-5′ (SEQ ID NO: 4575) KRAS-4748 Target: 5′-GATAGCATGAATTCTGCATTGAGAAAC-3′ (SEQ ID NO: 5061)   5′-AGCAUGAAUUCUGCAUUGAGAAAct-3′ (SEQ ID NO: 4819) 3′-UAUCGUACUUAAGACGUAACUCUUUGA-5′ (SEQ ID NO: 4576) KRAS-4749 Target: 5′-ATAGCATGAATTCTGCATTGAGAAACT-3′ (SEQ ID NO: 5062)   5′-UUUGAAGUGCCUGUUUGGGAUAAtg-3′ (SEQ ID NO: 4820) 3′-UCAAACUUCACGGACAAACCCUAUUAC-5′ (SEQ ID NO: 4577) KRAS-4878 Target: 5′-AGTTTGAAGTGCCTGTTTGGGATAATG-3′ (SEQ ID NO: 5063)   5′-UUGAAGUGCCUGUUUGGGAUAAUga-3′ (SEQ ID NO: 4821) 3′-CAAACUUCACGGACAAACCCUAUUACU-5′ (SEQ ID NO: 4578) KRAS-4879 Target: 5′-GTTTGAAGTGCCTGTTTGGGATAATGA-3′ (SEQ ID NO: 5064)   5′-UGAAGUGCCUGUUUGGGAUAAUGat-3′ (SEQ ID NO: 4822) 3′-AAACUUCACGGACAAACCCUAUUACUA-5′ (SEQ ID NO: 4579) KRAS-4880 Target: 5′-TTTGAAGTGCCTGTTTGGGATAATGAT-3′ (SEQ ID NO: 5065)   5′-UUUGAGUGCCAAUUUCUUACUAGta-3′ (SEQ ID NO: 4823) 3′-GGAAACUCACGGUUAAAGAAUGAUCAU-5′ (SEQ ID NO: 4580) KRAS-5073 Target: 5′-CCTTTGAGTGCCAATTTCTTACTAGTA-3′ (SEQ ID NO: 5066)   5′-UUGAGUGCCAAUUUCUUACUAGUac-3′ (SEQ ID NO: 4824) 3′-GAAACUCACGGUUAAAGAAUGAUCAUG-5′ (SEQ ID NO: 4581) KRAS-5074 Target: 5′-CTTTGAGTGCCAATTTCTTACTAGTAC-3′ (SEQ ID NO: 5067)   5′-UGAGUGCCAAUUUCUUACUAGUAct-3′ (SEQ ID NO: 4825) 3′-AAACUCACGGUUAAAGAAUGAUCAUGA-5′ (SEQ ID NO: 4582) KRAS-5075 Target: 5′-TTTGAGTGCCAATTTCTTACTAGTACT-3′ (SEQ ID NO: 5068)   5′-GAGUGCCAAUUUCUUACUAGUACta-3′ (SEQ ID NO: 4826) 3′-AACUCACGGUUAAAGAAUGAUCAUGAU-5′ (SEQ ID NO: 4583) KRAS-5076 Target: 5′-TTGAGTGCCAATTTCTTACTAGTACTA-3′ (SEQ ID NO: 5069)   5′-AGUGCCAAUUUCUUACUAGUACUat-3′ (SEQ ID NO: 4827) 3′-ACUCACGGUUAAAGAAUGAUCAUGAUA-5′ (SEQ ID NO: 4584) KRAS-5077 Target: 5′-TGAGTGCCAATTTCTTACTAGTACTAT-3′ (SEQ ID NO: 5070)   5′-GUGCCAAUUUCUUACUAGUACUAtt-3′ (SEQ ID NO: 4828) 3′-CUCACGGUUAAAGAAUGAUCAUGAUAA-5′ (SEQ ID NO: 4585) KRAS-5078 Target: 5′-GAGTGCCAATTTCTTACTAGTACTATT-3′ (SEQ ID NO: 5071)   5′-AUGUAUUUUAACUAUUUUUGUAUag-3′ (SEQ ID NO: 4829) 3′-CUUACAUAAAAUUGAUAAAAACAUAUC-5′ (SEQ ID NO: 4586) KRAS-5128 Target: 5′-GAATGTATTTTAACTATTTTTGTATAG-3′ (SEQ ID NO: 5072)   5′-UGUAUUUUAACUAUUUUUGUAUAgt-3′ (SEQ ID NO: 4830) 3′-UUACAUAAAAUUGAUAAAAACAUAUCA-5′ (SEQ ID NO: 4587) KRAS-5129 Target: 5′-AATGTATTTTAACTATTTTTGTATAGT-3′ (SEQ ID NO: 5073)   5′-ACUAUUUUUGUAUAGUGUAAACUga-3′ (SEQ ID NO: 4831) 3′-AUUGAUAAAAACAUAUCACAUUUGACU-5′ (SEQ ID NO: 4588) KRAS-5138 Target: 5′-TAACTATTTTTGTATAGTGTAAACTGA-3′ (SEQ ID NO: 5074)   5′-CUAUUUUUGUAUAGUGUAAACUGaa-3′ (SEQ ID NO: 4832) 3′-UUGAUAAAAACAUAUCACAUUUGACUU-5′ (SEQ ID NO: 4589) KRAS-5139 Target: 5′-AACTATTTTTGTATAGTGTAAACTGAA-3′ (SEQ ID NO: 5075)   5′-UAUUUUUGUAUAGUGUAAACUGAaa-3′ (SEQ ID NO: 4833) 3′-UGAUAAAAACAUAUCACAUUUGACUUU-5′ (SEQ ID NO: 4590) KRAS-5140 Target: 5′-ACTATTTTTGTATAGTGTAAACTGAAA-3′ (SEQ ID NO: 5076)   5′-AUUUUUGUAUAGUGUAAACUGAAac-3′ (SEQ ID NO: 4834) 3′-GAUAAAAACAUAUCACAUUUGACUUUG-5′ (SEQ ID NO: 4591) KRAS-5141 Target: 5′-CTATTTTTGTATAGTGTAAACTGAAAC-3′ (SEQ ID NO: 5077)   5′-UUUUUGUAUAGUGUAAACUGAAAca-3′ (SEQ ID NO: 4835) 3′-AUAAAAACAUAUCACAUUUGACUUUGU-5′ (SEQ ID NO: 4592) KRAS-5142 Target: 5′-TATTTTTGTATAGTGTAAACTGAAACA-3′ (SEQ ID NO: 5078)   5′-UUUUGUAUAGUGUAAACUGAAACat-3′ (SEQ ID NO: 4836) 3′-UAAAAACAUAUCACAUUUGACUUUGUA-5′ (SEQ ID NO: 4593) KRAS-5143 Target: 5′-ATTTTTGTATAGTGTAAACTGAAACAT-3′ (SEQ ID NO: 5079)   5′-AACAUGCACAUUUUGUACAUUGUgc-3′ (SEQ ID NO: 4837) 3′-CUUUGUACGUGUAAAACAUGUAACACG-5′ (SEQ ID NO: 4594) KRAS-5163 Target: 5′-GAAACATGCACATTTTGTACATTGTGC-3′ (SEQ ID NO: 5080)   5′-ACAUGCACAUUUUGUACAUUGUGct-3′ (SEQ ID NO: 4838) 3′-UUUGUACGUGUAAAACAUGUAACACGA-5′ (SEQ ID NO: 4595) KRAS-5164 Target: 5′-AAACATGCACATTTTGTACATTGTGCT-3′ (SEQ ID NO: 5081)   5′-UGCACAUUUUGUACAUUGUGCUUtc-3′ (SEQ ID NO: 4839) 3′-GUACGUGUAAAACAUGUAACACGAAAG-5′ (SEQ ID NO: 4596) KRAS-5167 Target: 5′-CATGCACATTTTGTACATTGTGCTTTC-3′ (SEQ ID NO: 5082)   5′-GCACAUUUUGUACAUUGUGCUUUct-3′ (SEQ ID NO: 4840) 3′-UACGUGUAAAACAUGUAACACGAAAGA-5′ (SEQ ID NO: 4597) KRAS-5168 Target: 5′-ATGCACATTTTGTACATTGTGCTTTCT-3′ (SEQ ID NO: 5083)   5′-CACAUUUUGUACAUUGUGCUUUCtt-3′ (SEQ ID NO: 4841) 3′-ACGUGUAAAACAUGUAACACGAAAGAA-5′ (SEQ ID NO: 4598) KRAS-5169 Target: 5′-TGCACATTTTGTACATTGTGCTTTCTT-3′ (SEQ ID NO: 5084)   5′-ACAUUUUGUACAUUGUGCUUUCUtt-3′ (SEQ ID NO: 4842) 3′-CGUGUAAAACAUGUAACACGAAAGAAA-5′ (SEQ ID NO: 4599) KRAS-5170 Target: 5′-GCACATTTTGTACATTGTGCTTTCTTT-3′ (SEQ ID NO: 5085)   5′-CAUUUUGUACAUUGUGCUUUCUUtt-3′ (SEQ ID NO: 4843) 3′-GUGUAAAACAUGUAACACGAAAGAAAA-5′ (SEQ ID NO: 4600) KRAS-5171 Target: 5′-CACATTTTGTACATTGTGCTTTCTTTT-3′ (SEQ ID NO: 5086)   5′-AUUUUGUACAUUGUGCUUUCUUUtg-3′ (SEQ ID NO: 4844) 3′-UGUAAAACAUGUAACACGAAAGAAAAC-5′ (SEQ ID NO: 4601) KRAS-5172 Target: 5′-ACATTTTGTACATTGTGCTTTCTTTTG-3′ (SEQ ID NO: 5087)   5′-UUUUGUACAUUGUGCUUUCUUUUgt-3′ (SEQ ID NO: 4845) 3′-GUAAAACAUGUAACACGAAAGAAAACA-5′ (SEQ ID NO: 4602) KRAS-5173 Target: 5′-CATTTTGTACATTGTGCTTTCTTTTGT-3′ (SEQ ID NO: 5088)   5′-UGGGACAUAUGCAGUGUGAUCCAgt-3′ (SEQ ID NO: 4846) 3′-ACACCCUGUAUACGUCACACUAGGUCA-5′ (SEQ ID NO: 4603) KRAS-5197 Target: 5′-TGTGGGACATATGCAGTGTGATCCAGT-3′ (SEQ ID NO: 5089)   5′-GGGACAUAUGCAGUGUGAUCCAGtt-3′ (SEQ ID NO: 4847) 3′-CACCCUGUAUACGUCACACUAGGUCAA-5′ (SEQ ID NO: 4604) KRAS-5198 Target: 5′-GTGGGACATATGCAGTGTGATCCAGTT-3′ (SEQ ID NO: 5090)   5′-GGACAUAUGCAGUGUGAUCCAGUtg-3′ (SEQ ID NO: 4848) 3′-ACCCUGUAUACGUCACACUAGGUCAAC-5′ (SEQ ID NO: 4605) KRAS-5199 Target: 5′-TGGGACATATGCAGTGTGATCCAGTTG-3′ (SEQ ID NO: 5091)   5′-GACAUAUGCAGUGUGAUCCAGUUgt-3′ (SEQ ID NO: 4849) 3′-CCCUGUAUACGUCACACUAGGUCAACA-5′ (SEQ ID NO: 4606) KRAS-5200 Target: 5′-GGGACATATGCAGTGTGATCCAGTTGT-3′ (SEQ ID NO: 5092)   5′-ACAUAUGCAGUGUGAUCCAGUUGtt-3′ (SEQ ID NO: 4850) 3′-CCUGUAUACGUCACACUAGGUCAACAA-5′ (SEQ ID NO: 4607) KRAS-5201 Target: 5′-GGACATATGCAGTGTGATCCAGTTGTT-3′ (SEQ ID NO: 5093)   5′-CAUAUGCAGUGUGAUCCAGUUGUtt-3′ (SEQ ID NO: 4851) 3′-CUGUAUACGUCACACUAGGUCAACAAA-5′ (SEQ ID NO: 4608) KRAS-5202 Target: 5′-GACATATGCAGTGTGATCCAGTTGTTT-3′ (SEQ ID NO: 5094)   5′-AUAUGCAGUGUGAUCCAGUUGUUtt-3′ (SEQ ID NO: 4852) 3′-UGUAUACGUCACACUAGGUCAACAAAA-5′ (SEQ ID NO: 4609) KRAS-5203 Target: 5′-ACATATGCAGTGTGATCCAGTTGTTTT-3′ (SEQ ID NO: 5095)   5′-UAUGCAGUGUGAUCCAGUUGUUUtc-3′ (SEQ ID NO: 4853) 3′-GUAUACGUCACACUAGGUCAACAAAAG-5′ (SEQ ID NO: 4610) KRAS-5204 Target: 5′-CATATGCAGTGTGATCCAGTTGTTTTC-3′ (SEQ ID NO: 5096)   5′-AUGCAGUGUGAUCCAGUUGUUUUcc-3′ (SEQ ID NO: 4854) 3′-UAUACGUCACACUAGGUCAACAAAAGG-5′ (SEQ ID NO: 4611) KRAS-5205 Target: 5′-ATATGCAGTGTGATCCAGTTGTTTTCC-3′ (SEQ ID NO: 5097)   5′-AGUGUGAUCCAGUUGUUUUCCAUca-3′ (SEQ ID NO: 4855) 3′-CGUCACACUAGGUCAACAAAAGGUAGU-5′ (SEQ ID NO: 4612) KRAS-5209 Target: 5′-GCAGTGTGATCCAGTTGTTTTCCATCA-3′ (SEQ ID NO: 5098)   5′-GUGUGAUCCAGUUGUUUUCCAUCat-3′ (SEQ ID NO: 4856) 3′-GUCACACUAGGUCAACAAAAGGUAGUA-5′ (SEQ ID NO: 4613) KRAS-5210 Target: 5′-CAGTGTGATCCAGTTGTTTTCCATCAT-3′ (SEQ ID NO: 5099)   5′-UGUGAUCCAGUUGUUUUCCAUCAtt-3′ (SEQ ID NO: 4857) 3′-UCACACUAGGUCAACAAAAGGUAGUAA-5′ (SEQ ID NO: 4614) KRAS-5211 Target: 5′-AGTGTGATCCAGTTGTTTTCCATCATT-3′ (SEQ ID NO: 5100)   5′-GUGAUCCAGUUGUUUUCCAUCAUtt-3′ (SEQ ID NO: 4858) 3′-CACACUAGGUCAACAAAAGGUAGUAAA-5′ (SEQ ID NO: 4615) KRAS-5212 Target: 5′-GTGTGATCCAGTTGTTTTCCATCATTT-3′ (SEQ ID NO: 5101)   5′-UGAUCCAGUUGUUUUCCAUCAUUtg-3′ (SEQ ID NO: 4859) 3′-ACACUAGGUCAACAAAAGGUAGUAAAC-5′ (SEQ ID NO: 4616) KRAS-5213 Target: 5′-TGTGATCCAGTTGTTTTCCATCATTTG-3′ (SEQ ID NO: 5102)   5′-GAUCCAGUUGUUUUCCAUCAUUUgg-3′ (SEQ ID NO: 4860) 3′-CACUAGGUCAACAAAAGGUAGUAAACC-5′ (SEQ ID NO: 4617) KRAS-5214 Target: 5′-GTGATCCAGTTGTTTTCCATCATTTGG-3′ (SEQ ID NO: 5103)   5′-UUUGGUUGCGCUGACCUAGGAAUgt-3′ (SEQ ID NO: 4861) 3′-GUAAACCAACGCGACUGGAUCCUUACA-5′ (SEQ ID NO: 4618) KRAS-5234 Target: 5′-CATTTGGTTGCGCTGACCTAGGAATGT-3′ (SEQ ID NO: 5104)   5′-UUGGUUGCGCUGACCUAGGAAUGtt-3′ (SEQ ID NO: 4862) 3′-UAAACCAACGCGACUGGAUCCUUACAA-5′ (SEQ ID NO: 4619) KRAS-5235 Target: 5′-ATTTGGTTGCGCTGACCTAGGAATGTT-3′ (SEQ ID NO: 5105)   5′-GGAAUGUUGGUCAUAUCAAACAUta-3′ (SEQ ID NO: 4863) 3′-AUCCUUACAACCAGUAUAGUUUGUAAU-5′ (SEQ ID NO: 4620) KRAS-5252 Target: 5′-TAGGAATGTTGGTCATATCAAACATTA-3′ (SEQ ID NO: 5106)   5′-GAAUGUUGGUCAUAUCAAACAUUaa-3′ (SEQ ID NO: 4864) 3′-UCCUUACAACCAGUAUAGUUUGUAAUU-5′ (SEQ ID NO: 4621) KRAS-5253 Target: 5′-AGGAATGTTGGTCATATCAAACATTAA-3′ (SEQ ID NO: 5107)   5′-AAUGUUGGUCAUAUCAAACAUUAaa-3′ (SEQ ID NO: 4865) 3′-CCUUACAACCAGUAUAGUUUGUAAUUU-5′ (SEQ ID NO: 4622) KRAS-5254 Target: 5′-GGAATGTTGGTCATATCAAACATTAAA-3′ (SEQ ID NO: 5108)   5′-AUGUUGGUCAUAUCAAACAUUAAaa-3′ (SEQ ID NO: 4866) 3′-CUUACAACCAGUAUAGUUUGUAAUUUU-5′ (SEQ ID NO: 4623) KRAS-5255 Target: 5′-GAATGTTGGTCATATCAAACATTAAAA-3′ (SEQ ID NO: 5109)   5′-UGUUGGUCAUAUCAAACAUUAAAaa-3′ (SEQ ID NO: 4867) 3′-UUACAACCAGUAUAGUUUGUAAUUUUU-5′ (SEQ ID NO: 4624) KRAS-5256 Target: 5′-AATGTTGGTCATATCAAACATTAAAAA-3′ (SEQ ID NO: 5110)   5′-GUUGGUCAUAUCAAACAUUAAAAat-3′ (SEQ ID NO: 4868) 3′-UACAACCAGUAUAGUUUGUAAUUUUUA-5′ (SEQ ID NO: 4625) KRAS-5257 Target: 5′-ATGTTGGTCATATCAAACATTAAAAAT-3′ (SEQ ID NO: 5111)   5′-UUGGUCAUAUCAAACAUUAAAAAtg-3′ (SEQ ID NO: 4869) 3′-ACAACCAGUAUAGUUUGUAAUUUUUAC-5′ (SEQ ID NO: 4626) KRAS-5258 Target: 5′-TGTTGGTCATATCAAACATTAAAAATG-3′ (SEQ ID NO: 5112)   5′-UGGUCAUAUCAAACAUUAAAAAUga-3′ (SEQ ID NO: 4870) 3′-CAACCAGUAUAGUUUGUAAUUUUUACU-5′ (SEQ ID NO: 4627) KRAS-5259 Target: 5′-GTTGGTCATATCAAACATTAAAAATGA-3′ (SEQ ID NO: 5113)   5′GGUCAUAUCAAACAUUAAAAAUGac.73′ (SEQ ID NO: 4871) 3′-AACCAGUAUAGUUUGUAAUUUUUACUG-5′ (SEQ ID NO: 4628) KRAS-5260 Target: 5′-TTGGTCATATCAAACATTAAAAATGAC-3′ (SEQ ID NO: 5114)   5′-AAAUUAACUUUUAAAUGUUUAUAgg-3′ (SEQ ID NO: 4872) 3′-ACUUUAAUUGAAAAUUUACAAAUAUCC-5′ (SEQ ID NO: 4629) KRAS-5299 Target: 5′-TGAAATTAACTTTTAAATGTTTATAGG-3′ (SEQ ID NO: 5115)   5′-AAUUAACUUUUAAAUGUUUAUAGga-3′ (SEQ ID NO: 4873) 3′-CUUUAAUUGAAAAUUUACAAAUAUCCU-5′ (SEQ ID NO: 4630) KRAS-5300 Target: 5′-GAAATTAACTTTTAAATGTTTATAGGA-3′ (SEQ ID NO: 5116)   5′-AACUUUUAAAUGUUUAUAGGAGUat-3′ (SEQ ID NO: 4874) 3′-AAUUGAAAAUUUACAAAUAUCCUCAUA-5′ (SEQ ID NO: 4631) KRAS-5304 Target: 5′-TTAACTTTTAAATGTTTATAGGAGTAT-3′ (SEQ ID NO: 5117)   5′-ACUUUUAAAUGUUUAUAGGAGUAtg-3′ (SEQ ID NO: 4875) 3′-AUUGAAAAUUUACAAAUAUCCUCAUAC-5′ (SEQ ID NO: 4632) KRAS-5305 Target: 5′-TAACTTTTAAATGTTTATAGGAGTATG-3′ (SEQ ID NO: 5118)   5′-CUUUUAAAUGUUUAUAGGAGUAUgt-3′ (SEQ ID NO: 4876) 3′-UUGAAAAUUUACAAAUAUCCUCAUACA-5′ (SEQ ID NO: 4633) KRAS-5306 Target: 5′-AACTTTTAAATGTTTATAGGAGTATGT-3′ (SEQ ID NO: 5119)   5′-UUUUAAAUGUUUAUAGGAGUAUGtg-3′ (SEQ ID NO: 4877) 3′-UGAAAAUUUACAAAUAUCCUCAUACAC-5′ (SEQ ID NO: 4634) KRAS-5307 Target: 5′-ACTTTTAAATGTTTATAGGAGTATGTG-3′ (SEQ ID NO: 5120)   5′-UUUAAAUGUUUAUAGGAGUAUGUgc-3′ (SEQ ID NO: 4878) 3′-GAAAAUUUACAAAUAUCCUCAUACACG-5′ (SEQ ID NO: 4635) KRAS-5308 Target: 5′-CTTTTAAATGTTTATAGGAGTATGTGC-3′ (SEQ ID NO: 5121)   5′-UUAAAUGUUUAUAGGAGUAUGUGct-3′ (SEQ ID NO: 4879) 3′-AAAAUUUACAAAUAUCCUCAUACACGA-5′ (SEQ ID NO: 4636) KRAS-5309 Target: 5′-TTTTAAATGTTTATAGGAGTATGTGCT-3′ (SEQ ID NO: 5122)   5′-AAAUUUGUAAUAUUUUUGUCAUGaa-3′ (SEQ ID NO: 4880) 3′-AUUUUAAACAUUAUAAAAACAGUACUU-5′ (SEQ ID NO: 4637) KRAS-5347 Target: 5′-TAAAATTTGTAATATTTTTGTCATGAA-3′ (SEQ ID NO: 5123)   5′-AAUUUGUAAUAUUUUUGUCAUGAac-3′ (SEQ ID NO: 4881) 3′-UUUUAAACAUUAUAAAAACAGUACUUG-5′ (SEQ ID NO: 4638) KRAS-5348 Target: 5′-AAAATTTGTAATATTTTTGTCATGAAC-3′ (SEQ ID NO: 5124)   5′-AUUUGUAAUAUUUUUGUCAUGAAct-3′ (SEQ ID NO: 4882) 3′-UUUAAACAUUAUAAAAACAGUACUUGA-5′ (SEQ ID NO: 4639) KRAS-5349 Target: 5′-AAATTTGTAATATTTTTGTCATGAACT-3′ (SEQ ID NO: 5125)   5′-UUUGUAAUAU6UUUGUCAUGAACtg-3′ (SEQ ID NO: 4883) 3′-UUAAACAUUAUAAAAACAGUACUUGAC-5′ (SEQ ID NO: 4640) KRAS-5350 Target: 5′-AATTTGTAATATTTTTGTCATGAACTG-3′ (SEQ ID NO: 5126)   5′-UUGUAAUAUUUUUGUCAUGAACUgt-3′ (SEQ ID NO: 4884) 3′-UAAACAUUAUAAAAACAGUACUUGACA-5′ (SEQ ID NO: 4641) KRAS-5351 Target: 5′-ATTTGTAATATTTTTGTCATGAACTGT-3′ (SEQ ID NO: 5127)   5′-UGUAAUAUUUUUGUCAUGAACUGta-3′ (SEQ ID NO: 4885) 3′-AAACAUUAUAAAAACAGUACUUGACAU-5′ (SEQ ID NO: 4642) KRAS-5352 Target: 5′-TTTGTAATATTTTTGTCATGAACTGTA-3′ (SEQ ID NO: 5128)   5′-GUAAUAUUUUUGUCAUGAACUGUac-3′ (SEQ ID NO: 4886) 3′-AACAUUAUAAAAACAGUACUUGACAUG-5′ (SEQ ID NO: 4643) KRAS-5353 Target: 5′-TTGTAATATTTTTGTCATGAACTGTAC-3′ (SEQ ID NO: 5129)   5′-UAAUAUUUUUGUCAUGAACUGUAct-3′ (SEQ ID NO: 4887) 3′-ACAUUAUAAAAACAGUACUUGACAUGA-5′ (SEQ ID NO: 4644) KRAS-5354 Target: 5′-TGTAATATTTTTGTCATGAACTGTACT-3′ (SEQ ID NO: 5130)   5′-AUUGUAAUGUAAUAAAAAUAGUUac-3′ (SEQ ID NO: 4888) 3′-AAUAACAUUACAUUAUUUUUAUCAAUG-5′ (SEQ ID NO: 4645) KRAS-5389 Target: 5′-TTATTGTAATGTAATAAAAATAGTTAC-3′ (SEQ ID NO: 5131)   5′-UUGUAAUGUAAUAAAAAUAGUUAca-3′ (SEQ ID NO: 4889) 3′-AUAACAUUACAUUAUUUUUAUCAAUGU-5′ (SEQ ID NO: 4646) KRAS-5390 Target: 5′-TATTGTAATGTAATAAAAATAGTTACA-3′ (SEQ ID NO: 5132)   5′-UGUAAUGUAAUAAAAAUAGUUACag-3′ (SEQ ID NO: 4890) 3′-UAACAUUACAUUAUUUUUAUCAAUGUC-5′ (SEQ ID NO: 4647) KRAS-5391 Target: 5′-ATTGTAATGTAATAAAAATAGTTACAG-3′ (SEQ ID NO: 5133)   5′-GUAAUGUAAUAAAAAUAGUUACAgt-3′ (SEQ ID NO: 4891) 3′-AACAUUACAUUAUUUUUAUCAAUGUCA-5′ (SEQ ID NO: 4648) KRAS-5392 Target: 5′-TTGTAATGTAATAAAAATAGTTACAGT-3′ (SEQ ID NO: 5134)   5′-UAAUGUAAUAAAAAUAGUUACAGtg-3′ (SEQ ID NO: 4892) 3′-ACAUUACAUUAUUUUUAUCAAUGUCAC-5′ (SEQ ID NO: 4649) KRAS-5393 Target: 5′-TGTAATGTAATAAAAATAGTTACAGTG-3′ (SEQ ID NO: 5135)

As in Tables 2-5 above, underlined nucleotide residues of above Table 8 indicate 2′-O-methyl modified residues; ribonucleotide residues are shown as UPPER CASE, while deoxyribonucleotide residues are shown as lower case.

Assay of the above 243 KRAS targeting DsiRNAs in human HeLa and mouse Hepa 1-6 cells at 1 nM revealed the following KRAS inhibitory efficacies, presented in Table 9. KRAS levels were determined using paired qPCR assays positioned at distinct locations within the KRAS transcript (for HeLa cell experiments, qPCR assays are indicated as “Hs KRAS 268-385 (MAX)” and “Hs KRAS 3393-3516 (FAM)”; for Hepa 1-6 cell experiments, such assays are indicated as “Mm KRAS 279-390 (MAX)” and “Mm KRAS1064-1161 (FAM)”).

TABLE 9 KRAS Inhibitory Efficacy of Table 8 DsiRNAs Assayed at 1 nM in Human HeLa and Mouse Hepa 1-6 Cells Human - HeLa Mouse - Hepa 1-6 Normalized HPRT/SFRS9; vs NC1, NC5, NC7 Normalized HPRT/Rpl23; vs NC1, NC5, NC7 Assay: Hs KRAS Assay: Hs KRAS Assay: Mm KRAS Assay: Mm KRAS 268-385 (MAX) 3393-3516 (FAM) 279-390 (MAX) 1064-1161 (FAM) Hs Mm % % % % % % % % Name Loc Loc nM Left Ave Error Left Ave Error Left Ave Error Left Ave Error Hs|NM_033360.2|166 166 179 1 16.9 5.8 18.8 8.6 43.4 1.0 47.5 5.1 Hs|NM_033360.2|167 167 180 1 22.4 6.8 28.5 5.4 54.1 5.0 53.0 2.7 Hs|NM_033360.2|168 168 181 1 12.0 3.0 20.1 4.2 47.9 3.9 43.7 2.6 Hs|NM_033360.2|169 169 182 1 12.4 1.6 21.7 2.6 38.7 3.0 31.5 1.5 Hs|NM_033360.2|204 204 217 1 92.7 11.5 107.2 11.4 109.3 5.4 96.7 13.5 Hs|NM_033360.2|205 205 218 1 105.3 7.7 127.7 5.6 108.2 3.3 94.9 4.5 Hs|NM_033360.2|206 206 219 1 67.1 4.7 80.9 10.9 71.9 1.6 59.3 2.6 Hs|NM_033360.2|207 207 220 1 46.0 N/A 62.7 N/A 63.1 5.9 55.8 5.8 Hs|NM_033360.2|208 208 221 1 54.6 10.4 47.3 14.6 53.4 1.9 59.0 1.9 Hs|NM_033360.2|209 209 222 1 83.2 3.4 90.4 4.2 89.5 6.1 90.8 4.1 Hs|NM_033360.2|210 210 223 1 78.1 5.2 89.9 5.6 96.4 1.3 88.2 2.9 Hs|NM_033360.2|241 241 254 1 14.5 10.8 22.4 4.9 42.6 5.9 36.4 3.8 Hs|NM_033360.2|313 313 326 1 32.2 6.7 51.5 3.7 63.1 5.6 53.8 4.4 Hs|NM_033360.2|314 314 327 1 34.2 6.8 46.6 10.0 66.6 3.3 56.2 3.6 Hs|NM_033360.2|318 318 331 1 10.9 9.2 27.6 6.8 43.0 10.4 30.3 9.0 Hs|NM_033360.2|328 328 341 1 25.1 5.8 28.1 6.8 47.6 6.4 36.2 3.1 Hs|NM_033360.2|330 330 343 1 10.3 5.5 17.2 8.0 26.2 3.5 25.0 6.1 Hs|NM_033360.2|331 331 344 1 15.1 6.2 27.0 7.4 44.0 6.0 37.2 6.0 Hs|NM_033360.2|332 332 345 1 20.8 9.6 40.2 5.8 45.7 11.0 38.0 5.4 Hs|NM_033360.2|333 333 346 1 19.4 3.8 38.6 3.8 47.2 5.9 36.3 3.4 Hs|NM_033360.2|334 334 347 1 7.6 5.2 29.6 3.2 35.6 3.3 28.8 5.8 Hs|NM_033360.2|335 335 348 1 28.0 10.3 41.2 16.6 72.8 6.5 55.2 10.7 Hs|NM_033360.2|336 336 349 1 16.5 9.3 31.9 1.1 57.0 4.0 41.7 2.6 Hs|NM_033360.2|352 352 365 1 15.7 7.0 29.5 2.2 64.9 6.1 43.3 4.6 Hs|NM_033360.2|353 353 366 1 7.2 5.6 26.1 7.0 35.7 10.8 26.3 5.7 Hs|NM_033360.2|354 354 367 1 15.3 3.8 42.4 3.9 57.1 1.6 41.8 2.6 Hs|NM_033360.2|364 364 377 1 31.3 1.8 44.3 6.2 57.1 2.6 47.8 3.9 Hs|NM_033360.2|365 365 378 1 10.0 13.3 23.1 5.8 38.8 2.1 28.3 6.4 Hs|NM_033360.2|366 366 379 1 11.1 8.0 27.1 8.3 44.3 5.4 28.7 2.5 Hs|NM_033360.2|367 367 380 1 14.6 11.3 37.3 8.7 58.4 3.2 34.5 5.2 Hs|NM_033360.2|368 368 381 1 54.4 2.6 81.7 11.4 113.2 9.3 81.6 8.6 Hs|NM_033360.2|369 369 382 1 73.5 N/A 83.8 N/A 104.8 27.8 90.3 9.3 Hs|NM_033360.2|370 370 383 1 56.7 3.8 61.9 5.0 69.0 3.2 66.4 1.8 Hs|NM_033360.2|371 371 384 1 12.7 9.4 22.7 8.8 47.4 2.8 42.2 3.8 Hs|NM_033360.2|372 372 385 1 26.6 7.9 63.7 12.0 75.0 3.0 49.2 4.3 Hs|NM_033360.2|420 420 433 1 11.8 11.9 21.5 10.5 39.9 5.0 31.5 4.1 Hs|NM_033360.2|421 421 434 1 40.7 10.6 55.4 13.0 72.0 8.5 59.6 7.7 Hs|NM_033360.2|422 422 435 1 18.1 13.3 30.2 18.8 41.8 5.8 32.1 11.0 Hs|NM_033360.2|423 423 436 1 18.6 14.2 27.2 13.4 52.3 7.6 40.5 5.0 Hs|NM_033360.2|424 424 437 1 10.8 14.3 24.3 7.7 31.6 12.7 24.4 3.0 Hs|NM_033360.2|425 425 438 1 10.2 6.6 16.7 10.6 26.1 4.5 27.0 4.9 Hs|NM_033360.2|426 426 439 1 10.4 13.1 22.7 10.6 32.0 3.9 28.9 4.5 Hs|NM_033360.2|436 436 449 1 9.6 11.4 19.2 6.5 37.6 5.9 33.4 4.7 Hs|NM_033360.2|437 437 450 1 22.8 5.2 32.9 5.2 53.6 5.4 46.2 5.2 Hs|NM_033360.2|438 438 451 1 11.0 9.4 18.6 3.9 34.5 1.7 26.7 3.8 Hs|NM_033360.2|439 439 452 1 14.0 15.4 18.6 11.3 40.5 4.6 28.6 4.5 Hs|NM_033360.2|440 440 453 1 12.6 2.2 22.8 4.4 43.1 4.5 33.9 5.3 Hs|NM_033360.2|441 441 454 1 10.9 11.6 20.7 8.9 40.1 8.9 28.7 2.7 Hs|NM_033360.2|442 442 455 1 16.8 2.1 23.4 4.0 37.1 5.9 37.3 9.2 Hs|NM_033360.2|443 443 456 1 17.2 8.9 26.9 6.6 47.5 2.4 45.8 3.7 Hs|NM_033360.2|444 444 457 1 13.3 6.7 20.0 1.9 35.1 3.2 32.3 2.7 Hs|NM_033360.2|454 454 467 1 8.4 6.5 18.2 8.4 42.5 4.3 33.7 4.4 Hs|NM_033360.2|455 455 468 1 11.7 7.0 19.9 5.0 44.2 10.4 41.5 3.1 Hs|NM_033360.2|456 456 469 1 13.0 6.4 24.6 1.6 42.8 3.4 30.9 6.4 Hs|NM_033360.2|457 457 470 1 10.8 7.7 21.4 1.3 43.4 8.2 32.7 3.4 Hs|NM_033360.2|458 458 471 1 13.7 3.5 15.2 19.2 37.0 2.9 28.6 8.7 Hs|NM_033360.2|459 459 472 1 11.5 9.3 14.8 2.4 31.8 1.5 32.1 3.0 Hs|NM_033360.2|460 460 473 1 5.0 12.7 11.3 9.3 37.2 0.2 32.7 2.1 Hs|NM_033360.2|461 461 474 1 7.6 9.6 12.7 8.5 31.6 1.5 28.1 2.9 Hs|NM_033360.2|462 462 475 1 6.8 14.3 14.1 7.6 33.3 3.2 27.8 3.2 Hs|NM_033360.2|508 508 h534 1 16.8 6.6 22.8 14.8 102.3 9.0 79.5 8.1 Hs|NM_033360.2|531 531 544 1 31.4 2.1 36.0 5.0 63.9 3.4 62.9 20.1 Hs|NM_033360.2|532 532 545 1 16.2 7.1 22.6 7.5 43.0 4.9 33.2 4.2 Hs|NM_033360.2|534 534 547 1 15.5 3.7 20.7 3.8 44.8 4.4 35.1 8.6 Hs|NM_033360.2|586 586 h612 1 9.4 4.3 11.8 4.9 86.3 7.2 91.3 7.9 Hs|NM_033360.2|587 587 h613 1 20.1 4.6 30.6 4.5 102.6 1.7 103.2 2.4 Hs|NM_033360.2|588 588 h614 1 22.0 9.3 23.9 13.9 104.1 14.0 104.4 9.8 Hs|NM_033360.2|763 763 652 1 16.4 6.0 20.3 4.8 42.6 1.6 37.9 2.1 Hs|NM_033360.2|764 764 653 1 15.9 4.2 21.3 3.4 36.8 6.2 32.9 5.4 Hs|NM_033360.2|784 784 673 1 8.5 2.8 13.3 5.9 31.7 15.4 25.2 17.6 Hs|NM_033360.2|794 794 683 1 11.4 8.4 18.1 7.7 31.9 9.8 24.8 7.9 Hs|NM_033360.2|795 795 684 1 10.4 6.7 13.9 2.5 27.7 7.0 23.2 7.2 Hs|NM_033360.2|796 796 685 1 30.5 2.0 33.2 2.0 25.3 N/A 37.8 N/A Hs|NM_033360.2|797 797 686 1 12.7 2.3 20.9 3.5 23.2 1.8 29.6 2.4 Hs|NM_033360.2|798 798 687 1 11.0 11.3 28.2 9.3 27.5 4.1 35.4 2.2 Hs|NM_033360.2|799 799 688 1 8.7 8.4 16.7 4.7 119.5 1.7 100.7 4.1 Hs|NM_033360.2|800 800 689 1 13.6 7.4 19.3 6.7 144.8 21.8 105.1 7.8 Hs|NM_033360.2|801 801 690 1 28.5 5.8 40.8 5.8 37.0 5.3 40.8 4.9 Hs|NM_033360.2|802 802 691 1 13.9 4.6 37.2 2.0 152.1 2.9 124.7 6.4 Hs|NM_033360.2|908 908 h810 1 21.4 12.6 17.4 13.1 130.7 7.5 117.6 5.3 Hs|NM_033360.2|909 909 h811 1 11.6 2.0 9.0 7.7 90.4 2.6 100.0 2.6 Hs|NM_033360.2|920 920 807 1 15.9 7.1 14.1 11.6 110.8 4.6 107.1 4.4 Hs|NM_033360.2|921 921 808 1 15.5 9.3 18.4 11.9 118.2 11.7 108.9 9.8 Hs|NM_033360.2|922 922 809 1 14.3 8.5 13.2 6.5 135.9 4.6 110.9 6.5 Hs|NM_033360.2|923 923 810 1 17.3 8.7 12.6 12.0 129.0 2.2 106.2 5.2 Hs|NM_033360.2|924 924 811 1 19.6 3.1 20.7 8.8 111.5 8.5 100.9 7.4 Hs|NM_033360.2|925 925 812 1 22.2 6.0 28.8 8.6 115.3 3.2 99.8 1.7 Hs|NM_033360.2|926 926 813 1 21.2 23.3 27.7 8.6 114.7 18.4 124.1 5.8 Hs|NM_033360.2|927 927 814 1 15.6 10.3 10.7 1.7 99.2 7.3 103.9 6.7 Hs|NM_033360.2|928 928 815 1 26.1 4.7 21.6 3.0 118.0 4.4 111.7 5.3 Hs|NM_033360.2|938 938 825 1 26.0 7.2 22.1 17.7 106.2 9.8 107.7 6.9 Hs|NM_033360.2|939 939 826 1 13.9 3.9 13.9 11.1 30.9 8.9 32.2 10.9 Hs|NM_033360.2|940 940 827 1 19.7 6.4 22.2 8.2 28.0 7.0 34.2 4.8 Hs|NM_033360.2|941 941 828 1 13.8 9.7 15.0 12.2 26.0 17.1 29.5 15.2 Hs|NM_033360.2|942 942 829 1 15.9 2.8 18.3 7.0 50.1 5.8 48.2 2.3 Hs|NM_033360.2|943 943 830 1 22.8 N/A 25.1 N/A 128.1 3.3 113.3 7.6 Hs|NM_033360.2|944 944 831 1 22.1 11.4 15.7 7.2 45.5 3.8 44.1 2.3 Hs|NM_033360.2|945 945 832 1 15.6 8.3 12.7 8.1 32.7 2.2 29.4 2.8 Hs|NM_033360.2|946 946 833 1 13.7 7.4 12.9 2.5 29.7 2.3 25.8 4.4 Hs|NM_033360.2|1010 1010 h912 1 20.6 3.6 22.6 1.6 22.8 4.5 17.2 3.7 Hs|NM_033360.2|1012 1012 h914 1 24.4 N/A 28.3 N/A 29.9 8.6 23.3 9.1 Hs|NM_033360.2|1045 1045 936 1 18.3 10.7 19.3 6.7 52.5 4.3 42.0 3.1 Hs|NM_033360.2|1197 1197 h1099 1 12.2 8.9 11.6 8.4 30.4 6.3 24.5 3.1 Hs|NM_033360.2|1198 1198 h1100 1 17.3 12.1 12.8 5.8 138.8 11.4 114.9 18.5 Hs|NM_033360.2|1230 1230 h1132 1 18.4 12.0 11.6 12.5 75.1 1.5 83.5 1.2 Hs|NM_033360.2|1231 1231 h1133 1 16.7 7.1 12.7 5.0 20.5 8.2 26.0 6.3 Hs|NM_033360.2|1234 1234 h1136 1 21.9 4.0 16.4 3.0 24.3 8.6 26.6 10.3 Hs|NM_033360.2|1249 1249 h1151 1 20.1 1.5 12.0 1.8 20.9 3.9 22.9 6.1 Hs|NM_033360.2|1250 1250 h1152 1 26.2 6.7 21.0 7.3 27.4 5.8 30.8 7.0 Hs|NM_033360.2|1287 1287 h1189 1 44.3 6.8 40.1 4.3 30.1 6.5 31.2 6.6 Hs|NM_033360.2|1527 1527 h1429 1 34.0 2.7 17.3 5.7 40.8 4.1 41.0 3.5 Hs|NM_033360.2|1533 1533 h1435 1 25.6 17.6 15.4 4.8 33.7 8.8 49.1 21.9 Hs|NM_033360.2|1540 1540 h1442 1 25.6 6.2 11.4 5.6 18.3 15.2 26.9 11.0 Hs|NM_033360.2|1541 1541 h1443 1 25.2 4.7 9.8 6.2 40.3 9.4 48.6 6.5 Hs|NM_033360.2|1542 1542 h1444 1 41.4 5.6 32.1 7.2 32.0 7.8 34.4 15.7 Hs|NM_033360.2|1583 1583 1435 1 22.5 4.3 13.3 2.1 23.3 9.6 25.1 9.6 Hs|NM_033360.2|1584 1584 1436 1 32.7 2.0 24.5 3.1 28.1 4.1 29.0 4.1 Hs|NM_033360.2|1585 1585 1437 1 32.9 7.8 22.2 9.7 16.6 10.1 18.5 11.7 Hs|NM_033360.2|1586 1586 1438 1 52.5 2.5 36.2 6.1 23.8 7.2 26.0 3.6 Hs|NM_033360.2|1597 1597 h1499 1 38.2 N/A 36.1 N/A 29.3 7.6 31.1 3.9 Hs|NM_033360.2|1606 1606 h1508 1 45.4 5.0 28.5 4.2 110.9 2.9 119.3 2.0 Hs|NM_033360.2|1630 1630 1471 1 23.2 8.0 16.5 8.1 26.8 7.3 34.7 4.8 Hs|NM_033360.2|1631 1631 1472 1 35.4 5.2 23.6 5.7 37.1 4.6 44.0 4.2 Hs|NM_033360.2|1632 1632 1473 1 26.9 2.3 20.0 1.6 29.8 4.3 32.8 1.8 Hs|NM_033360.2|1633 1633 1474 1 25.4 5.8 24.4 13.4 31.6 3.4 38.9 7.6 Hs|NM_033360.2|1634 1634 1475 1 27.8 3.5 20.3 3.6 28.5 5.9 31.6 5.3 Hs|NM_033360.2|1635 1635 1476 1 29.8 0.4 23.2 3.4 37.4 4.9 38.7 4.7 Hs|NM_033360.2|1636 1636 1477 1 51.0 22.3 38.9 11.1 63.5 11.6 65.0 6.7 Hs|NM_033360.2|1637 1637 1478 1 31.5 7.4 14.0 11.9 28.2 6.0 37.3 6.0 Hs|NM_033360.2|1638 1638 1479 1 31.1 1.4 27.4 2.5 44.1 8.9 51.8 3.0 Hs|NM_033360.2|1639 1639 1480 1 47.7 4.9 26.0 7.7 57.0 3.2 60.9 2.6 Hs|NM_033360.2|1640 1640 1481 1 35.1 3.7 17.7 4.2 62.1 2.6 59.9 3.7 Hs|NM_033360.2|1736 1736 h1638 1 30.9 3.9 20.2 7.0 133.0 2.5 110.1 1.7 Hs|NM_033360.2|1741 1741 h1643 1 25.2 9.1 12.4 7.0 126.6 0.8 111.7 4.0 Hs|NM_033360.2|1742 1742 h1644 1 18.5 4.4 11.5 6.7 130.1 4.7 106.9 4.9 Hs|NM_033360.2|1753 1753 h1655 1 33.4 15.2 29.9 5.2 130.3 3.4 105.4 2.0 Hs|NM_033360.2|1754 1754 h1656 1 31.3 5.8 14.6 16.3 93.9 4.7 100.7 4.6 Hs|NM_033360.2|1769 1769 h1671 1 25.7 4.9 18.4 11.5 107.6 4.2 129.9 14.3 Hs|NM_033360.2|1771 1771 h1673 1 31.4 3.1 13.9 9.0 106.8 12.2 100.8 8.5 Hs|NM_033360.2|1772 1772 h1674 1 24.5 3.5 13.2 5.0 111.3 1.0 95.3 2.4 Hs|NM_033360.2|1783 1783 h1685 1 31.3 2.2 27.9 11.1 126.6 4.0 109.3 5.4 Hs|NM_033360.2|1784 1784 h1686 1 33.6 16.9 22.0 20.9 121.4 15.0 98.0 15.2 Hs|NM_033360.2|1785 1785 h1687 1 28.2 4.9 19.9 5.0 124.1 2.2 105.5 5.3 Hs|NM_033360.2|1799 1799 h1701 1 23.0 6.1 15.1 8.4 128.6 1.8 106.8 2.8 Hs|NM_033360.2|2100 2100 h2002 1 49.7 19.4 34.1 12.1 106.3 5.6 111.4 2.7 Hs|NM_033360.2|2134 2134 h2036 1 51.2 N/A 35.0 N/A 130.2 3.6 119.6 4.9 Hs|NM_033360.2|2216 2216 h2118 1 28.4 4.6 13.2 6.6 113.2 2.8 114.0 2.6 Hs|NM_033360.2|2217 2217 h2119 1 23.6 6.9 11.2 12.2 127.0 1.7 111.9 1.8 Hs|NM_033360.2|2218 2218 h2120 1 30.7 13.0 16.3 11.9 119.3 2.4 106.3 7.2 Hs|NM_033360.2|2229 2229 h2131 1 34.4 6.7 16.0 6.5 118.3 3.9 110.1 8.9 Hs|NM_033360.2|2247 2247 h2149 1 31.2 6.8 18.1 10.6 129.1 6.1 117.7 6.2 Hs|NM_033360.2|2326 2326 h2228 1 85.1 24.0 118.0 25.0 170.9 9.9 151.3 16.5 Hs|NM_033360.2|2327 2327 h2229 1 105.3 4.8 76.9 2.9 106.7 1.1 108.6 6.0 Hs|NM_033360.2|2547 2547 2285 1 68.5 3.8 41.4 1.8 98.3 6.3 102.5 2.4 Hs|NM_033360.2|2548 2548 2286 1 50.0 6.7 30.2 12.6 85.8 3.2 80.3 3.1 Hs|NM_033360.2|3741 3741 h3643 1 51.3 21.2 51.4 10.6 110.0 2.5 97.0 2.8 Hs|NM_033360.2|3746 3746 h3648 1 49.6 10.5 41.6 11.3 129.2 8.7 116.8 9.0 Hs|NM_033360.2|3747 3747 h3649 1 42.3 3.9 39.2 3.2 115.5 1.5 105.8 1.7 Hs|NM_033360.2|3783 3783 h3685 1 36.2 4.3 31.1 4.7 119.2 2.3 108.7 1.3 Hs|NM_033360.2|3784 3784 h3686 1 78.0 20.4 42.2 11.3 141.2 6.9 125.0 1.4 Hs|NM_033360.2|3810 3810 h3712 1 56.0 18.6 39.7 19.3 91.2 1.6 102.4 2.5 Hs|NM_033360.2|4396 4396 3584 1 58.6 2.6 48.2 2.0 88.8 3.1 94.0 2.2 Hs|NM_033360.2|4447 4447 3633 1 65.1 3.6 49.0 1.9 78.4 9.3 76.4 9.6 Hs|NM_033360.2|4448 4448 3634 1 41.7 3.1 31.5 8.6 98.3 4.5 86.0 4.2 Hs|NM_033360.2|4449 4449 3635 1 57.3 11.0 54.8 10.9 108.2 7.1 92.5 5.0 Hs|NM_033360.2|4450 4450 3636 1 55.8 7.5 54.7 6.3 87.6 7.5 75.0 9.4 Hs|NM_033360.2|4451 4451 3637 1 76.7 3.5 74.5 3.8 106.1 1.1 88.3 2.3 Hs|NM_033360.2|4452 4452 3638 1 56.1 2.1 50.0 4.1 109.4 4.5 94.8 5.9 Hs|NM_033360.2|4748 4748 3940 1 54.7 13.7 41.7 10.8 89.1 0.9 97.6 1.0 Hs|NM_033360.2|4749 4749 3941 1 52.3 13.5 41.0 9.5 109.1 5.4 109.6 4.0 Hs|NM_033360.2|4878 4878 4082 1 63.9 4.5 63.1 5.1 116.7 7.2 104.9 7.1 Hs|NM_033360.2|4879 4879 4083 1 43.5 4.1 41.3 2.3 117.8 4.3 102.2 4.2 Hs|NM_033360.2|4880 4880 4084 1 64.1 10.5 75.7 12.4 119.1 3.4 100.4 5.1 Hs|NM_033360.2|5073 5073 4259 1 36.8 4.0 36.1 7.2 116.2 2.9 106.8 5.9 Hs|NM_033360.2|5074 5074 4260 1 45.0 3.6 58.5 3.0 148.1 7.0 129.1 6.9 Hs|NM_033360.2|5075 5075 4261 1 48.5 2.6 53.1 6.6 Hs|NM_033360.2|5076 5076 4262 1 38.4 9.2 29.4 10.6 83.3 N/A 90.7 N/A Hs|NM_033360.2|5077 5077 4263 1 32.9 6.0 29.1 4.0 91.5 4.8 91.2 3.5 Hs|NM_033360.2|5078 5078 4264 1 29.7 7.8 28.6 6.7 99.1 2.6 95.2 1.1 Hs|NM_033360.2|5128 5128 4314 1 56.7 4.6 62.4 5.3 108.3 3.9 91.6 4.6 Hs|NM_033360.2|5129 5129 4315 1 54.7 5.3 61.6 6.4 110.3 9.6 91.4 9.8 Hs|NM_033360.2|5138 5138 4324 1 38.2 6.5 42.1 5.6 102.6 6.7 96.3 7.8 Hs|NM_033360.2|5139 5139 4325 1 31.5 7.1 35.6 9.6 101.4 0.9 89.0 2.7 Hs|NM_033360.2|5140 5140 4326 1 47.1 21.2 40.8 15.3 114.9 2.9 96.7 5.7 Hs|NM_033360.2|5141 5141 4327 1 48.6 4.8 41.9 5.7 76.3 2.9 82.6 3.1 Hs|NM_033360.2|5142 5142 4328 1 60.3 16.7 54.1 17.5 95.4 1.1 90.9 1.4 Hs|NM_033360.2|5143 5143 4329 1 42.2 7.7 42.5 10.0 89.2 7.9 84.5 4.0 Hs|NM_033360.2|5163 5163 4349 1 109.7 2.4 94.3 2.1 Hs|NM_033360.2|5164 5164 4350 1 34.5 6.4 37.5 6.1 94.7 3.6 79.5 5.3 Hs|NM_033360.2|5167 5167 4353 1 49.4 9.8 54.7 11.0 89.9 12.2 76.5 14.1 Hs|NM_033360.2|5168 5168 4354 1 46.9 2.4 54.3 5.4 111.9 3.8 95.9 1.5 Hs|NM_033360.2|5169 5169 4355 1 52.8 3.3 52.1 4.9 113.7 3.1 99.7 2.8 Hs|NM_033360.2|5170 5170 4356 1 42.2 3.2 38.2 1.6 82.6 5.5 84.1 3.1 Hs|NM_033360.2|5171 5171 4357 1 51.6 5.7 49.4 4.5 86.4 0.6 92.6 1.4 Hs|NM_033360.2|5172 5172 4358 1 56.4 6.2 58.8 4.5 81.0 4.0 79.6 3.7 Hs|NM_033360.2|5173 5173 4359 1 44.8 8.5 51.5 8.1 89.8 4.2 87.9 5.7 Hs|NM_033360.2|5197 5197 4435 1 63.9 19.5 64.1 10.2 90.5 3.8 94.4 5.1 Hs|NM_033360.2|5198 5198 4436 1 47.3 5.7 58.2 6.4 91.9 3.3 92.9 6.0 Hs|NM_033360.2|5199 5199 4437 1 50.0 4.8 52.7 4.8 114.0 4.9 95.5 3.9 Hs|NM_033360.2|5200 5200 4438 1 65.4 N/A 69.3 N/A 98.1 4.0 88.1 1.8 Hs|NM_033360.2|5201 5201 4439 1 54.0 4.4 42.2 5.7 89.1 10.4 79.4 6.4 Hs|NM_033360.2|5202 5202 4440 1 45.3 4.6 41.8 5.9 109.5 1.8 92.8 3.7 Hs|NM_033360.2|5203 5203 4441 1 35.7 5.7 34.5 3.1 102.3 2.7 87.3 2.3 Hs|NM_033360.2|5204 5204 4442 1 51.9 5.3 55.8 3.3 107.5 8.5 90.1 8.9 Hs|NM_033360.2|5205 5205 4443 1 57.7 24.4 67.9 34.1 105.0 6.0 90.4 4.0 Hs|NM_033360.2|5209 5209 4447 1 55.1 7.8 58.9 7.2 121.2 7.6 102.1 6.1 Hs|NM_033360.2|5210 5210 4448 1 46.9 8.9 45.0 9.1 106.8 5.0 94.1 3.1 Hs|NM_033360.2|5211 5211 4449 1 54.4 11.7 54.8 11.5 107.4 4.8 94.8 6.4 Hs|NM_033360.2|5212 5212 4450 1 41.3 7.5 33.3 6.6 101.2 6.8 83.0 8.4 Hs|NM_033360.2|5213 5213 4451 1 47.6 3.6 42.6 5.1 84.6 6.4 66.6 8.0 Hs|NM_033360.2|5214 5214 4452 1 43.5 5.2 42.7 9.1 106.3 1.7 82.9 2.2 Hs|NM_033360.2|5234 5234 4472 1 45.0 3.8 47.3 5.0 103.1 4.9 83.9 4.0 Hs|NM_033360.2|5235 5235 4473 1 39.8 9.1 41.1 7.7 86.6 13.1 71.4 10.3 Hs|NM_033360.2|5252 5252 4491 1 34.4 17.6 39.8 17.3 139.6 6.9 127.6 9.9 Hs|NM_033360.2|5253 5253 4492 1 24.2 12.4 23.9 11.2 Hs|NM_033360.2|5254 5254 4493 1 35.3 7.6 36.8 7.9 102.0 1.2 84.1 1.6 Hs|NM_033360.2|5255 5255 4494 1 38.1 7.3 32.2 4.5 71.0 3.3 86.8 1.7 Hs|NM_033360.2|5256 5256 4497 1 52.5 5.8 48.3 7.2 89.4 2.2 93.8 4.1 Hs|NM_033360.2|5257 5257 4542 1 40.0 7.6 36.6 8.8 90.3 5.7 79.7 4.6 Hs|NM_033360.2|5258 5258 4548 1 27.1 8.7 21.1 6.4 90.8 3.0 86.0 4.0 Hs|NM_033360.2|5259 5259 4551 1 44.7 20.6 50.5 24.9 124.7 4.2 102.6 3.0 Hs|NM_033360.2|5260 5260 4591 1 48.0 2.0 50.1 2.8 110.2 3.6 108.4 3.3 Hs|NM_033360.2|5299 5299 4594 1 58.7 3.4 64.4 3.3 148.0 7.0 131.7 9.8 Hs|NM_033360.2|5300 5300 4597 1 87.6 9.8 93.5 6.4 127.6 11.6 136.8 10.6 Hs|NM_033360.2|5304 5304 4495 1 116.3 7.7 91.4 8.9 91.2 2.0 107.3 2.7 Hs|NM_033360.2|5305 5305 4498 1 107.0 6.1 109.6 6.2 117.0 5.4 126.7 4.5 Hs|NM_033360.2|5306 5306 4543 1 97.6 1.4 110.9 1.7 99.0 8.4 95.3 7.2 Hs|NM_033360.2|5307 5307 4549 1 98.3 5.2 113.5 1.6 116.9 2.1 112.7 1.8 Hs|NM_033360.2|5308 5308 4552 1 147.8 11.0 180.2 11.4 143.6 10.3 124.2 7.3 Hs|NM_033360.2|5309 5309 4592 1 129.4 8.9 152.9 11.7 118.2 5.2 115.1 6.7 Hs|NM_033360.2|5347 5347 4595 1 41.5 2.4 45.4 3.9 105.0 9.6 90.0 7.1 Hs|NM_033360.2|5348 5348 4632 1 75.8 8.9 88.4 6.6 119.6 8.6 105.3 12.9 Hs|NM_033360.2|5349 5349 4496 1 78.2 2.7 65.1 3.0 95.2 3.2 111.7 1.9 Hs|NM_033360.2|5350 5350 4499 1 92.3 2.7 94.9 2.5 114.7 3.0 125.1 2.7 Hs|NM_033360.2|5351 5351 4547 1 61.8 13.7 67.0 16.6 96.1 5.2 81.8 9.0 Hs|NM_033360.2|5352 5352 4550 1 54.8 11.2 58.5 6.0 97.8 6.1 93.4 6.1 Hs|NM_033360.2|5353 5353 4590 1 75.5 8.8 89.7 9.5 124.3 9.8 108.1 8.3 Hs|NM_033360.2|5354 5354 4593 1 52.7 16.3 63.2 16.3 90.4 4.4 85.8 6.9 Hs|NM_033360.2|5389 5389 4596 1 44.4 3.1 52.5 4.7 110.6 5.2 98.3 2.7 Hs|NM_033360.2|5390 5390 4633 1 36.7 5.0 36.1 6.3 97.8 2.4 90.8 2.8 Hs|NM_033360.2|5391 5391 4634 1 29.0 5.7 26.4 5.9 62.7 3.5 67.1 5.6 Hs|NM_033360.2|5392 5392 4635 1 45.8 5.2 44.9 4.5 98.7 6.7 95.3 8.4 Hs|NM_033360.2|5393 5393 4636 1 51.3 3.6 52.7 4.1 110.4 2.3 101.9 1.9 As shown in Table 9, 103 of 243 asymmetric DsiRNAs examined showed greater than 70% reduction of human KRAS levels in HeLa cells at 1 nM, in both qPCR assays used to determine human KRAS levels. Of these 103 DsiRNAs, 37 exhibited greater than 80% reduction of human KRAS levels in HeLa cells at 1 nM in both qPCR assays used to determine human KRAS levels. A number of asymmetric DsiRNAs also capable of inhibiting mouse KRAS levels in mouse Hepa 1-6 cells at 1 nM in the environment of a cell were also identified in such assays.

120 asymmetric DsiRNAs of the above experiment were then examined in a secondary assay (“Phase 2”), with results of such assays presented in histogram form in FIGS. 12-31. Specifically, the 120 asymmetric DsiRNAs selected from the 243 tested above were assessed for inhibition of human KRAS at 1 nM, 0.1 nM and 0.1 nM (0.1 nM was performed in duplicate, independent assays for each KRAS-targeting asymmetric DsiRNA) in the environment of human HeLa cells (FIGS. 12-21). These 120 asymmetric DsiRNAs were also assessed for inhibition of mouse KRAS at 1 nM, 0.1 nM and 0.1 nM (again, 0.1 nM was performed in duplicate, independent assays for each KRAS-targeting asymmetric DsiRNA) in the environment of mouse Hepa 1-6 cells (FIGS. 22-31). As shown in FIGS. 12-21, a remarkable number of asymmetric DsiRNAs reproducibly exhibited robust human KRAS inhibitory efficacies at 100 pM when assayed in the environment of HeLa cells. In addition, as shown in FIGS. 22-31, a number of these asymmetric DsiRNAs also showed robust mouse KRAS inhibitory efficacies at 1 nM and 100 pM when assayed in the environment of mouse Hepa 1-6 cells. (Meanwhile, human KRAS-specific inhibitory asymmetric DsiRNAs were also identified.)

Example 7 Inhibition of KRAS by Additional Preferred DsiRNAs

The remaining DsiRNA molecules shown in Tables 4-5 possessing sense and antisense strand sequences as shown and targeting KRAS wild-type sequences (and variant sequences where applicable) are designed and synthesized as described above and tested in HeLa cells (and, optionally, in mouse Hepa 1-6 cells) for inhibitory efficacy as described in Examples 3 and 6 above. The ability of these DsiRNA agents to inhibit KRAS expression is optionally assessed in comparison to corresponding KRAS target sequence-directed 21mer siRNAs (21mer siRNA identification methods identical to those used to populate the siRNA sequences of Table 2 can be applied to the DsiRNAs of Tables 4-6). The remaining selected DsiRNA agents of Tables 4-6 are expected to show efficacy as KRAS inhibitors, with a significant number of tested DsiRNA agents anticipated to exhibit greater than 50% reduction of the KRAS target at 1 nM and at 100 pM. As seen for the DsiRNA agents of Tables 2-3, a significant majority of DsiRNAs are anticipated to outperform cognate siRNA pairs, as determined via measurement of efficacy in decreasing levels of KRAS target relative to the cognate siRNA agent. The duration of such inhibitory effects is also examined at both 24 hours and 48 hours post-administration, with concentrations of 0.1 nM, 1 nM and 5 nM tested. As above, a significant majority of DsiRNAs is anticipated to outperform its cognate siRNA pair, as determined via measurement of potency and duration of effect.

Example 8 Indications

The present body of knowledge in KRAS research indicates the need for methods to assay KRAS activity and for compounds that can regulate KRAS expression for research, diagnostic, and therapeutic use. As described herein, the nucleic acid molecules of the present invention can be used in assays to diagnose disease state related to KRAS levels. In addition, the nucleic acid molecules can be used to treat disease state related to KRAS misregulation, levels, etc.

Particular disorders and disease states that can be associated with KRAS expression modulation include, but are not limited to cancer and/or proliferative diseases, conditions, or disorders and other diseases, conditions or disorders that are related to or will respond to the levels of KRAS in a cell or tissue, alone or in combination with other therapies. Particular degenerative and disease states that are associated with KRAS expression modulation include but are not limited to, for example lung cancer, colorectal cancer, bladder cancer, pancreatic cancer, breast cancer, and prostate cancer.

Gemcytabine and cyclophosphamide are non-limiting examples of chemotherapeutic agents that can be combined with or used in conjunction with the nucleic acid molecules (e.g. DsiRNA molecules) of the instant invention. Those skilled in the art will recognize that other drugs such as anti-cancer compounds and therapies can be similarly be readily combined with the nucleic acid molecules of the instant invention (e.g. DsiRNA molecules) and are hence within the scope of the instant invention. Such compounds and therapies are well known in the art (see for example Cancer: Principles and Practice of Oncology, Volumes 1 and 2, eds Devita, V. T., Hellman, S., and Rosenberg, S. A., J. B. Lippincott Company, Philadelphia, USA) and include, without limitations, antifolates; fluoropyrimidines; cytarabine; purine analogs; adenosine analogs; amsacrine; topoisomerase I inhibitors; anthrapyrazoles; retinoids; antibiotics such as bleomycin, anthacyclins, mitomycin C, dactinomycin, and mithramycin; hexamethylmelamine; dacarbazine; 1-asperginase; platinum analogs; alkylating agents such as nitrogen mustard, melphalan, chlorambucil, busulfan, ifosfamide, 4-hydroperoxycyclophosphamide, nitrosoureas, thiotepa; plant derived compounds such as vinca alkaloids, epipodophyllotoxins, taxol; Tamoxifen; radiation therapy; surgery; nutritional supplements; gene therapy; radiotherapy such as 3D-CRT; immunotoxin therapy such as ricin, monoclonal antibodies Herceptin; and the like. For combination therapy, the nucleic acids of the invention are prepared in one of two ways. First, the agents are physically combined in a preparation of nucleic acid and chemotherapeutic agent, such as a mixture of a nucleic acid of the invention encapsulated in liposomes and ifosfamide in a solution for intravenous administration, wherein both agents are present in a therapeutically effective concentration (e.g., ifosfamide in solution to deliver 1000-1250 mg/m2/day and liposome-associated nucleic acid of the invention in the same solution to deliver 0.1-100 mg/kg/day). Alternatively, the agents are administered separately but simultaneously in their respective effective doses (e.g., 1000-1250 mg/m2/d ifosfamide and 0.1 to 100 mg/kg/day nucleic acid of the invention).

Those skilled in the art will recognize that other compounds and therapies used to treat the diseases and conditions described herein can similarly be combined with the nucleic acid molecules of the instant invention (e.g. siNA molecules) and are hence within the scope of the instant invention.

Example 9 Serum Stability for DsiRNAs

Serum stability of DsiRNA agents is assessed via incubation of DsiRNA agents in 50% fetal bovine serum for various periods of time (up to 24 h) at 37° C. Serum is extracted and the nucleic acids are separated on a 20% non-denaturing PAGE and visualized with Gelstar stain. Relative levels of protection from nuclease degradation are assessed for DsiRNAs (optionally with and without modifications).

Example 10 Use of Additional Cell Culture Models to Evaluate the Down-Regulation of KRAS Gene Expression

A variety of endpoints have been used in cell culture models to look at Ras-mediated effects after treatment with anti-Ras agents. Phenotypic endpoints include inhibition of cell proliferation, RNA expression, and reduction of Ras protein expression. Because KRAS oncogene mutations are directly associated with increased proliferation of certain tumor cells, a proliferation endpoint for cell culture assays is preferably used as the primary screen. There are several methods by which this endpoint can be measured. Following treatment of cells with DsiRNA, cells are allowed to grow (typically 5 days), after which the cell viability, the incorporation of [³H] thymidine into cellular DNA and/or the cell density are measured. The assay of cell density can be done in a 96-well format using commercially available fluorescent nucleic acid stains (such as Syto® 13 or CyQuant®). As a secondary, confirmatory endpoint, a DsiRNA-mediated decrease in the level of KRas protein expression can be evaluated using a KRas-specific ELISA.

Example 11 Evaluation of Anti-KRAS DsiRNA Efficacy in a Mouse Model of KRAS Misregulation

Anti-KRAS DsiRNA chosen from in vitro assays can be further tested in mouse models, including, e.g., xenograft and other animal models as recited above. In one example, mice possessing misregulated (e.g., elevated) KRAS levels are administered a DsiRNA agent of the present invention via hydrodynamic tail vein injection. 3-4 mice per group (divided based upon specific DsiRNA agent tested) are injected with 50 μg or 200 μg of DsiRNA. Levels of KRAS RNA are evaluated using RT-qPCR. Additionally or alternatively, levels of KRas (e.g., KRas protein levels and/or cancer cell/tumor formation, growth or spread) can be evaluated using an art-recognized method, or phenotypes associated with misregulation of KRAS (e.g., tumor formation, growth, metastasis, etc.) are monitored (optionally as a proxy for measurement of KRAS transcript or KRas protein levels). Active DsiRNA in such animal models can also be subsequently tested in combination with standard chemotherapies.

Example 12 Diagnostic Uses

The DsiRNA molecules of the invention can be used in a variety of diagnostic applications, such as in the identification of molecular targets (e.g., RNA) in a variety of applications, for example, in clinical, industrial, environmental, agricultural and/or research settings. Such diagnostic use of DsiRNA molecules involves utilizing reconstituted RNAi systems, for example, using cellular lysates or partially purified cellular lysates. DsiRNA molecules of this invention can be used as diagnostic tools to examine genetic drift and mutations within diseased cells. The close relationship between DsiRNA activity and the structure of the target KRAS RNA allows the detection of mutations in a region of the KRAS molecule, which alters the base-pairing and three-dimensional structure of the target KRAS RNA. By using multiple DsiRNA molecules described in this invention, one can map nucleotide changes, which are important to RNA structure and function in vitro, as well as in cells and tissues. Cleavage of target KRAS RNAs with DsiRNA molecules can be used to inhibit gene expression and define the role of specified gene products in the progression of a KRAS-associated disease or disorder. In this manner, other genetic targets can be defined as important mediators of the disease. These experiments will lead to better treatment of the disease progression by affording the possibility of combination therapies (e.g., multiple DsiRNA molecules targeted to different genes, DsiRNA molecules coupled with known small molecule inhibitors, or intermittent treatment with combinations of DsiRNA molecules and/or other chemical or biological molecules). Other in vitro uses of DsiRNA molecules of this invention are well known in the art, and include detection of the presence of RNAs associated with a disease or related condition. Such RNA is detected by determining the presence of a cleavage product after treatment with a DsiRNA using standard methodologies, for example, fluorescence resonance emission transfer (FRET).

In a specific example, DsiRNA molecules that cleave only wild-type or mutant or polymorphic forms of the target KRAS RNA are used for the assay. The first DsiRNA molecules (i.e., those that cleave only wild-type forms of target KRAS RNA) are used to identify wild-type KRAS RNA present in the sample and the second DsiRNA molecules (i.e., those that cleave only mutant or polymorphic forms of target RNA) are used to identify mutant or polymorphic KRAS RNA in the sample. As reaction controls, synthetic substrates of both wild-type and mutant or polymorphic KRAS RNA are cleaved by both DsiRNA molecules to demonstrate the relative DsiRNA efficiencies in the reactions and the absence of cleavage of the “non-targeted” KRAS RNA species. The cleavage products from the synthetic substrates also serve to generate size markers for the analysis of wild-type and mutant KRAS RNAs in the sample population. Thus, each analysis requires two DsiRNA molecules, two substrates and one unknown sample, which is combined into six reactions. The presence of cleavage products is determined using an RNase protection assay so that full-length and cleavage fragments of each KRAS RNA can be analyzed in one lane of a polyacrylamide gel. It is not absolutely required to quantify the results to gain insight into the expression of mutant or polymorphic KRAS RNAs and putative risk of KRAS-associated phenotypic changes in target cells. The expression of KRAS mRNA whose protein product is implicated in the development of the phenotype (i.e., disease related/associated) is adequate to establish risk. If probes of comparable specific activity are used for both transcripts, then a qualitative comparison of KRAS RNA levels is adequate and decreases the cost of the initial diagnosis. Higher mutant or polymorphic form to wild-type ratios are correlated with higher risk whether KRAS RNA levels are compared qualitatively or quantitatively.

All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. All references cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually.

One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims.

It will be readily apparent to one skilled in the art that varying substitutions and modifications can be made to the invention disclosed herein without departing from the scope and spirit of the invention. Thus, such additional embodiments are within the scope of the present invention and the following claims. The present invention teaches one skilled in the art to test various combinations and/or substitutions of chemical modifications described herein toward generating nucleic acid constructs with improved activity for mediating RNAi activity. Such improved activity can comprise improved stability, improved bioavailability, and/or improved activation of cellular responses mediating RNAi. Therefore, the specific embodiments described herein are not limiting and one skilled in the art can readily appreciate that specific combinations of the modifications described herein can be tested without undue experimentation toward identifying DsiRNA molecules with improved RNAi activity.

The invention illustratively described herein suitably can be practiced in the absence of any element or elements, limitation or limitations that are not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of”, and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims.

In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.

The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

Embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description.

The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

LENGTHY TABLES The patent application contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20110021604A1). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3). 

1. An isolated double stranded ribonucleic acid (dsRNA) comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein said second strand of said dsRNA comprises 1-5 single-stranded nucleotides at its 3′ terminus, wherein said second oligonucleotide strand is sufficiently complementary to a target KRAS cDNA sequence selected from the group consisting of SEQ ID NOs: 141-186 along at least 19 nucleotides and at most 35 nucleotides of said second oligonucleotide strand length to reduce KRAS target gene expression when said double stranded nucleic acid is introduced into a mammalian cell.
 2. The isolated dsRNA of claim 1, wherein starting from the first nucleotide (position 1) at the 3′ terminus of the first oligonucleotide strand, position 1, 2 and/or 3 is substituted with a modified nucleotide.
 3. The isolated dsRNA of claim 1, wherein said 3′ terminus of said first strand and said 5′ terminus of said second strand form a blunt end.
 4. The isolated dsRNA of claim 1, wherein said first strand is 25 nucleotides in length and said second strand is 27 nucleotides in length.
 5. The isolated dsRNA of claim 1, wherein said second strand comprises a sequence selected from the group consisting of SEQ ID NOs: 11-50 and 135-140.
 6. The isolated dsRNA of claim 1, wherein said first strand comprises a sequence selected from the group consisting of SEQ ID NOs: 5, 8 and 91-134.
 7. The isolated dsRNA of claim 1 comprising a pair of first strand/second strand sequences selected from the group consisting of SEQ ID NO: 5/SEQ ID NO: 14, SEQ ID NO: 8/SEQ ID NO: 43, SEQ ID NO: 132/SEQ ID NO: 138, SEQ ID NO: 91/SEQ ID NO: 11, SEQ ID NO: 129/SEQ ID NO: 135, SEQ ID NO: 92/SEQ ID NO: 12, SEQ ID NO: 130/SEQ ID NO: 136, SEQ ID NO: 93/SEQ ID NO: 13, SEQ ID NO: 131/SEQ ID NO: 137, SEQ ID NO: 94/SEQ ID NO: 15, SEQ ID NO: 133/SEQ ID NO: 139, SEQ ID NO: 95/SEQ ID NO: 16, SEQ ID NO: 96/SEQ ID NO: 17, SEQ ID NO: 97/SEQ ID NO: 18, SEQ ID NO: 98/SEQ ID NO: 19, SEQ ID NO: 99/SEQ ID NO: 20, SEQ ID NO: 100/SEQ ID NO: 21, SEQ ID NO: 101/SEQ ID NO: 22, SEQ ID NO: 102/SEQ ID NO: 23, SEQ ID NO: 103/SEQ ID NO: 24, SEQ ID NO: 104/SEQ ID NO: 25, SEQ ID NO: 105/SEQ ID NO: 26, SEQ ID NO: 106/SEQ ID NO: 27, SEQ ID NO: 107/SEQ ID NO: 28, SEQ ID NO: 108/SEQ ID NO: 29, SEQ ID NO: 109/SEQ ID NO: 30, SEQ ID NO: 110/SEQ ID NO: 31, SEQ ID NO: 111/SEQ ID NO: 32, SEQ ID NO: 112/SEQ ID NO: 33, SEQ ID NO: 113/SEQ ID NO: 34, SEQ ID NO: 114/SEQ ID NO: 35, SEQ ID NO: 115/SEQ ID NO: 36, SEQ ID NO: 116/SEQ ID NO: 37, SEQ ID NO: 117/SEQ ID NO: 38, SEQ ID NO: 118/SEQ ID NO: 39, SEQ ID NO: 119/SEQ ID NO: 40, SEQ ID NO: 134/SEQ ID NO: 140, SEQ ID NO: 120/SEQ ID NO: 41, SEQ ID NO: 121/SEQ ID NO: 42, SEQ ID NO: 122/SEQ ID NO: 44, SEQ ID NO: 123/SEQ ID NO: 45, SEQ ID NO: 124/SEQ ID NO: 46, SEQ ID NO: 125/SEQ ID NO: 47, SEQ ID NO: 126/SEQ ID NO: 48, SEQ ID NO: 127/SEQ ID NO: 49 and SEQ ID NO: 128/SEQ ID NO:
 50. 8. The isolated dsRNA of claim 1, wherein each of said first and said second strands has a length which is at least 26 nucleotides.
 9. The isolated dsRNA of claim 2, wherein said modified nucleotide residue of said 3′ terminus of said first strand is selected from the group consisting of a deoxyribonucleotide, an acyclonucleotide and a fluorescent molecule.
 10. The isolated dsRNA of claim 2, wherein position 1 of said 3′ terminus of the first oligonucleotide strand is a deoxyribonucleotide.
 11. The isolated dsRNA of claim 1, wherein said nucleotides of said 3′ overhang comprise a modified nucleotide.
 12. The isolated dsRNA of claim 11, wherein said modified nucleotide of said 3′ overhang is a 2′-O-methyl ribonucleotide.
 13. The isolated dsRNA of claim 1, wherein all nucleotides of said 3′ overhang are modified nucleotides.
 14. The isolated dsRNA of claim 1, wherein one or both of the first and second oligonucleotide strands comprises a 5′ phosphate.
 15. The isolated dsRNA of claim 1 wherein said modified nucleotide residues are selected from the group consisting of 2′-O-methyl, 2′-methoxyethoxy, 2′-fluoro, 2′-allyl, 2′-O-[2-(methylamino)-2-oxoethyl], 4′-thio, 4′-CH2-O-2′-bridge, 4′-(CH2)2-O-2′-bridge, 2′-LNA, 2′-amino and 2′-O-(N-methlycarbamate).
 16. The isolated dsRNA of claim 1, wherein said 3′ overhang is 1-3 nucleotides in length.
 17. The isolated dsRNA of claim 1, wherein said 3′ overhang is 1-2 nucleotides in length.
 18. The isolated dsRNA of claim 1, wherein said 3′ overhang is two nucleotides in length and wherein said modified nucleotide of said 3′ overhang is a 2′-O-methyl modified ribonucleotide.
 19. The isolated dsRNA of claim 1, wherein said second oligonucleotide strand, starting from the nucleotide residue of said second strand that is complementary to the 5′ terminal nucleotide residue of said first oligonucleotide strand, comprises alternating modified and unmodified nucleotide residues.
 20. The isolated dsRNA of claim 1, wherein said second oligonucleotide strand, starting from the nucleotide residue of said second strand that is complementary to the 5′ terminal nucleotide residue of said first oligonucleotide strand, comprises unmodified nucleotide residues at all positions from position 18 to the 5′ terminus of said second oligonucleotide strand.
 21. The isolated dsRNA of claim 1, wherein each of said first and said second strands has a length which is at least 26 and at most 30 nucleotides.
 22. The isolated dsRNA of claim 1, wherein said dsRNA is cleaved endogenously in said cell by Dicer.
 23. The isolated dsRNA of claim 1, wherein the amount of said isolated double stranded nucleic acid sufficient to reduce expression of the target gene is selected from the group consisting of 1 nanomolar or less, 200 picomolar or less, 100 picomolar or less, 50 picomolar or less, 20 picomolar or less, 10 picomolar or less, 5 picomolar or less, 2, picomolar or less and 1 picomolar or less in the environment of said cell.
 24. The isolated dsRNA of claim 1, wherein said isolated dsRNA possesses greater potency than isolated 21mer siRNAs directed to the identical at least 19 nucleotides of said target KRAS cDNA in reducing target KRAS gene expression when assayed in vitro in a mammalian cell at an effective concentration in the environment of a cell of 1 nanomolar or less.
 25. The isolated dsRNA of claim 1, wherein said isolated dsRNA possesses greater potency than isolated 21mer siRNAs directed to the identical at least 19 nucleotides of said target KRAS cDNA in reducing target KRAS gene expression when assayed in vitro in a mammalian cell at an effective concentration in the environment of a cell selected from the group consisting of 200 picomolar or less, 100 picomolar or less, 50 picomolar or less, 20 picomolar or less, 10 picomolar or less, 5 picomolar or less, 2, picomolar or less and 1 picomolar or less in the environment of said cell.
 26. The isolated dsRNA of claim 1, wherein said isolated dsRNA is sufficiently complementary to the target KRAS cDNA sequence to reduce KRAS target gene expression by an amount (expressed by %) selected from the group consisting of at least 10%, at least 50%, at least 80-90%, at least 95%, at least 98%, and at least 99% when said double stranded nucleic acid is introduced into a mammalian cell.
 27. The isolated dsRNA of claim 1, wherein the first and second strands are joined by a chemical linker.
 28. The isolated double stranded nucleic acid of claim 1, wherein said 3′ terminus of said first strand and said 5′ terminus of said second strand are joined by a chemical linker.
 29. The isolated double stranded nucleic acid of claim 1, wherein a nucleotide of said second or first strand is substituted with a modified nucleotide that directs the orientation of Dicer cleavage.
 30. The isolated double stranded nucleic acid of claim 1 comprising a modified nucleotide selected from the group consisting of a deoxyribonucleotide, a dideoxyribonucleotide, an acyclonucleotide, a 3′-deoxyadenosine (cordycepin), a 3′-azido-3′-deoxythymidine (AZT), a 2′,3′-dideoxyinosine (ddI), a 2′,3′-dideoxy-3′-thiacytidine (3TC), a 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), a monophosphate nucleotide of 3′-azido-3′-deoxythymidine (AZT), a 2′,3′-dideoxy-3′-thiacytidine (3TC) and a monophosphate nucleotide of 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), a 4-thiouracil, a 5-bromouracil, a 5-iodouracil, a 5-(3-aminoallyl)-uracil, a 2′-O-alkyl ribonucleotide, a 2′-O-methyl ribonucleotide, a 2′-amino ribonucleotide, a 2′-fluoro ribonucleotide, and a locked nucleic acid.
 31. The isolated double stranded nucleic acid of claim 1 comprising a phosphate backbone modification selected from the group consisting of a phosphonate, a phosphorothioate and a phosphotriester.
 32. A method for reducing expression of a target KRAS gene in a mammalian cell comprising contacting a mammalian cell in vitro with an isolated dsRNA of claim 1 in an amount sufficient to reduce expression of a target KRAS gene in said cell.
 33. The method of claim 32, wherein target KRAS gene expression is reduced by an amount (expressed by %) selected from the group consisting of at least 10%, at least 50% and at least 80-90%.
 34. The method of claim 32, wherein KRAS mRNA levels are reduced by an amount (expressed by %) of at least 90% at least 8 days after said cell is contacted with said dsRNA.
 35. The method of claim 32, wherein KRAS mRNA levels are reduced by an amount (expressed by %) of at least 70% at least 10 days after said cell is contacted with said dsRNA.
 36. A method for reducing expression of a target KRAS gene in a mammal comprising administering an isolated dsRNA of claim 1 to a mammal in an amount sufficient to reduce expression of a target KRAS gene in the mammal.
 37. The method of claim 36, wherein said isolated dsRNA is administered at a dosage selected from the group consisting of 1 microgram to 5 milligrams per kilogram of said mammal per day, 100 micrograms to 0.5 milligrams per kilogram, 0.001 to 0.25 milligrams per kilogram, 0.01 to 20 micrograms per kilogram, 0.01 to 10 micrograms per kilogram, 0.10 to 5 micrograms per kilogram, and 0.1 to 2.5 micrograms per kilogram.
 38. The method of claim 36, wherein said isolated dsRNA possesses greater potency than isolated 21mer siRNAs directed to the identical at least 19 nucleotides of said target KRAS cDNA in reducing target KRAS gene expression when assayed in vitro in a mammalian cell at an effective concentration in the environment of a cell of 1 nanomolar or less.
 39. The method of claim 36, wherein said administering step comprises a mode selected from the group consisting of intravenous injection, intramuscular injection, intraperitoneal injection, infusion, subcutaneous injection, transdermal, aerosol, rectal, vaginal, topical, oral and inhaled delivery.
 40. A method for selectively inhibiting the growth of a cell comprising contacting a cell with an amount of an isolated dsRNA of claim 1 sufficient to inhibit the growth of the cell.
 41. The method of claim 40, wherein said cell is a tumor cell of a subject.
 42. The method of claim 40, wherein said cell is a tumor cell in vitro.
 43. The method of claim 40, wherein said cell is a human cell.
 44. A formulation comprising the isolated dsRNA of claim 1, wherein said dsRNA is present in an amount effective to reduce target KRAS RNA levels when said dsRNA is introduced into a mammalian cell in vitro by an amount (expressed by %) selected from the group consisting of at least 10%, at least 50% and at least 80-90%, and wherein said dsRNA possesses greater potency than isolated 21mer siRNAs directed to the identical at least 19 nucleotides of said target KRAS cDNA in reducing target KRAS RNA levels when assayed in vitro in a mammalian cell at an effective concentration in the environment of a cell of 1 nanomolar or less.
 45. The formulation of claim 44, wherein said effective amount is selected from the group consisting of 1 nanomolar or less, 200 picomolar or less, 100 picomolar or less, 50 picomolar or less, 20 picomolar or less, 10 picomolar or less, 5 picomolar or less, 2, picomolar or less and 1 picomolar or less in the environment of said cell.
 46. A formulation comprising the isolated dsRNA of claim 1, wherein said dsRNA is present in an amount effective to reduce target RNA levels when said dsRNA is introduced into a cell of a mammalian subject by an amount (expressed by %) selected from the group consisting of at least 10%, at least 50% and at least 80-90%, and wherein said dsRNA possesses greater potency than isolated 21mer siRNAs directed to the identical at least 19 nucleotides of said target KRAS cDNA in reducing target KRAS RNA levels when assayed in vitro in a mammalian cell at an effective concentration in the environment of a cell of 1 nanomolar or less.
 47. The formulation of claim 46, wherein said effective amount is a dosage selected from the group consisting of 1 microgram to 5 milligrams per kilogram of said subject per day, 100 micrograms to 0.5 milligrams per kilogram, 0.001 to 0.25 milligrams per kilogram, 0.01 to 20 micrograms per kilogram, 0.01 to 10 micrograms per kilogram, 0.10 to 5 micrograms per kilogram, and 0.1 to 2.5 micrograms per kilogram.
 48. A mammalian cell containing the isolated dsRNA of claim
 1. 49. A pharmaceutical composition comprising the isolated dsRNA of claim 1 and a pharmaceutically acceptable carrier.
 50. A kit comprising the isolated dsRNA of claim 1 and instructions for its use.
 51. A composition possessing KRAS inhibitory activity consisting essentially of an isolated double stranded ribonucleic acid (dsRNA) comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein said second strand of said dsRNA comprises 1-5 single-stranded nucleotides at its 3′ terminus, wherein said second oligonucleotide strand is sufficiently complementary to a target KRAS cDNA sequence selected from the group consisting of SEQ ID NOs: 141-186 along at least 19 nucleotides and at most 35 nucleotides of said second oligonucleotide strand length to reduce KRAS target gene expression when said double stranded nucleic acid is introduced into a mammalian cell.
 52. An isolated double stranded ribonucleic acid (dsRNA) comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein said second strand of said dsRNA comprises 1-5 single-stranded nucleotides at its 3′ terminus, wherein said second oligonucleotide strand is sufficiently complementary to a target KRAS cDNA sequence selected from the group consisting of SEQ ID NOs: 1595-2297 and 3704-4406 along at least 19 nucleotides and at most 35 nucleotides of said second oligonucleotide strand length to reduce KRAS target gene expression when said double stranded nucleic acid is introduced into a mammalian cell.
 53. The isolated dsRNA of claim 52, wherein starting from the first nucleotide (position 1) at the 3′ terminus of the first oligonucleotide strand, position 1, 2 and/or 3 is substituted with a modified nucleotide.
 54. The isolated dsRNA of claim 52, wherein said 3′ terminus of said first strand and said 5′ terminus of said second strand form a blunt end.
 55. The isolated dsRNA of claim 52, wherein said first strand is 25 nucleotides in length and said second strand is 27 nucleotides in length.
 56. The isolated dsRNA of claim 52, wherein said second strand comprises a sequence selected from the group consisting of SEQ ID NOs: 189-891 and 2298-3000.
 57. The isolated dsRNA of claim 52, wherein said first strand comprises a sequence selected from the group consisting of SEQ ID NOs: 892-1594 and 3001-3703.
 58. The isolated dsRNA of claim 52 comprising a pair of first strand/second strand sequences selected from the group consisting of DsiRNA agents shown in Tables 4-5.
 59. The isolated dsRNA of claim 52, wherein each of said first and said second strands has a length which is at least 26 nucleotides.
 60. The isolated dsRNA of claim 53, wherein said modified nucleotide residue of said 3′ terminus of said first strand is selected from the group consisting of a deoxyribonucleotide, an acyclonucleotide and a fluorescent molecule.
 61. The isolated dsRNA of claim 53, wherein position 1 of said 3′ terminus of the first oligonucleotide strand is a deoxyribonucleotide.
 62. The isolated dsRNA of claim 52, wherein said nucleotides of said 3′ overhang comprise a modified nucleotide.
 63. The isolated dsRNA of claim 62, wherein said modified nucleotide of said 3′ overhang is a 2′-O-methyl ribonucleotide.
 64. The isolated dsRNA of claim 52, wherein all nucleotides of said 3′ overhang are modified nucleotides.
 65. The isolated dsRNA of claim 52, wherein one or both of the first and second oligonucleotide strands comprises a 5′ phosphate.
 66. The isolated dsRNA of claim 52 wherein said modified nucleotide residues are selected from the group consisting of 2′-O-methyl, 2′-methoxyethoxy, 2′-fluoro, 2′-allyl, 2′-O-[2-(methylamino)-2-oxoethyl], 4′-thio, 4′-CH2-O-2′-bridge, 4′-(CH2)₂-O-2′-bridge, 2′-LNA, 2′-amino and 2′-O-(N-methlycarbamate).
 67. The isolated dsRNA of claim 52, wherein said 3′ overhang is 1-3 nucleotides in length.
 68. The isolated dsRNA of claim 52, wherein said 3′ overhang is 1-2 nucleotides in length.
 69. The isolated dsRNA of claim 52, wherein said 3′ overhang is two nucleotides in length and wherein said modified nucleotide of said 3′ overhang is a 2′-O-methyl modified ribonucleotide.
 70. The isolated dsRNA of claim 52, wherein said second oligonucleotide strand, starting from the nucleotide residue of said second strand that is complementary to the 5′ terminal nucleotide residue of said first oligonucleotide strand, comprises alternating modified and unmodified nucleotide residues.
 71. The isolated dsRNA of claim 52, wherein said second oligonucleotide strand, starting from the nucleotide residue of said second strand that is complementary to the 5′ terminal nucleotide residue of said first oligonucleotide strand, comprises unmodified nucleotide residues at all positions from position 18 to the 5′ terminus of said second oligonucleotide strand.
 72. The isolated dsRNA of claim 52, wherein each of said first and said second strands has a length which is at least 26 and at most 30 nucleotides.
 73. The isolated dsRNA of claim 52, wherein said dsRNA is cleaved endogenously in said cell by Dicer.
 74. The isolated dsRNA of claim 52, wherein the amount of said isolated double stranded nucleic acid sufficient to reduce expression of the target gene is selected from the group consisting of 1 nanomolar or less, 200 picomolar or less, 100 picomolar or less, 50 picomolar or less, 20 picomolar or less, 10 picomolar or less, 5 picomolar or less, 2, picomolar or less and 1 picomolar or less in the environment of said cell.
 75. The isolated dsRNA of claim 52, wherein said isolated dsRNA possesses greater potency than isolated 21mer siRNAs directed to the identical at least 19 nucleotides of said target KRAS cDNA in reducing target KRAS gene expression when assayed in vitro in a mammalian cell at an effective concentration in the environment of a cell of 1 nanomolar or less.
 76. The isolated dsRNA of claim 52, wherein said isolated dsRNA possesses greater potency than isolated 21mer siRNAs directed to the identical at least 19 nucleotides of said target KRAS cDNA in reducing target KRAS gene expression when assayed in vitro in a mammalian cell at an effective concentration in the environment of a cell selected from the group consisting of 200 picomolar or less, 100 picomolar or less, 50 picomolar or less, 20 picomolar or less, 10 picomolar or less, 5 picomolar or less, 2, picomolar or less and 1 picomolar or less in the environment of said cell.
 77. The isolated dsRNA of claim 52, wherein said isolated dsRNA is sufficiently complementary to the target KRAS cDNA sequence to reduce KRAS target gene expression by an amount (expressed by %) selected from the group consisting of at least 10%, at least 50%, at least 80-90%, at least 95%, at least 98%, and at least 99% when said double stranded nucleic acid is introduced into a mammalian cell.
 78. The isolated dsRNA of claim 52, wherein the first and second strands are joined by a chemical linker.
 79. The isolated double stranded nucleic acid of claim 52, wherein said 3′ terminus of said first strand and said 5′ terminus of said second strand are joined by a chemical linker.
 80. The isolated double stranded nucleic acid of claim 52, wherein a nucleotide of said second or first strand is substituted with a modified nucleotide that directs the orientation of Dicer cleavage.
 81. The isolated double stranded nucleic acid of claim 52 comprising a modified nucleotide selected from the group consisting of a deoxyribonucleotide, a dideoxyribonucleotide, an acyclonucleotide, a 3′-deoxyadenosine (cordycepin), a 3′-azido-3′-deoxythymidine (AZT), a 2′,3′-dideoxyinosine (ddI), a 2′,3′-dideoxy-3′-thiacytidine (3TC), a 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), a monophosphate nucleotide of 3′-azido-3′-deoxythymidine (AZT), a 2′,3′-dideoxy-3′-thiacytidine (3TC) and a monophosphate nucleotide of 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), a 4-thiouracil, a 5-bromouracil, a 5-iodouracil, a 5-(3-aminoallyl)-uracil, a 2′-O-alkyl ribonucleotide, a 2′-O-methyl ribonucleotide, a 2′-amino ribonucleotide, a 2′-fluoro ribonucleotide, and a locked nucleic acid.
 82. The isolated double stranded nucleic acid of claim 52 comprising a phosphate backbone modification selected from the group consisting of a phosphonate, a phosphorothioate and a phosphotriester.
 83. A method for reducing expression of a target KRAS gene in a mammalian cell comprising contacting a mammalian cell in vitro with an isolated dsRNA of claim 1 in an amount sufficient to reduce expression of a target KRAS gene in said cell.
 84. The method of claim 83, wherein target KRAS gene expression is reduced by an amount (expressed by %) selected from the group consisting of at least 10%, at least 50% and at least 80-90%.
 85. The method of claim 83, wherein KRAS mRNA levels are reduced by an amount (expressed by %) of at least 90% at least 8 days after said cell is contacted with said dsRNA.
 86. The method of claim 83, wherein KRAS mRNA levels are reduced by an amount (expressed by %) of at least 70% at least 10 days after said cell is contacted with said dsRNA.
 87. A method for reducing expression of a target KRAS gene in a mammal comprising administering an isolated dsRNA of claim 52 to a mammal in an amount sufficient to reduce expression of a target KRAS gene in the mammal.
 88. The method of claim 87, wherein said isolated dsRNA is administered at a dosage selected from the group consisting of 1 microgram to 5 milligrams per kilogram of said mammal per day, 100 micrograms to 0.5 milligrams per kilogram, 0.001 to 0.25 milligrams per kilogram, 0.01 to 20 micrograms per kilogram, 0.01 to 10 micrograms per kilogram, 0.10 to 5 micrograms per kilogram, and 0.1 to 2.5 micrograms per kilogram.
 89. The method of claim 87, wherein said isolated dsRNA possesses greater potency than isolated 21mer siRNAs directed to the identical at least 19 nucleotides of said target KRAS cDNA in reducing target KRAS gene expression when assayed in vitro in a mammalian cell at an effective concentration in the environment of a cell of 1 nanomolar or less.
 90. The method of claim 87, wherein said administering step comprises a mode selected from the group consisting of intravenous injection, intramuscular injection, intraperitoneal injection, infusion, subcutaneous injection, transdermal, aerosol, rectal, vaginal, topical, oral and inhaled delivery.
 91. A method for selectively inhibiting the growth of a cell comprising contacting a cell with an amount of an isolated dsRNA of claim 52 sufficient to inhibit the growth of the cell.
 92. The method of claim 91, wherein said cell is a tumor cell of a subject.
 93. The method of claim 91, wherein said cell is a tumor cell in vitro.
 94. The method of claim 91, wherein said cell is a human cell.
 95. A formulation comprising the isolated dsRNA of claim 52, wherein said dsRNA is present in an amount effective to reduce target KRAS RNA levels when said dsRNA is introduced into a mammalian cell in vitro by an amount (expressed by %) selected from the group consisting of at least 10%, at least 50% and at least 80-90%, and wherein said dsRNA possesses greater potency than isolated 21mer siRNAs directed to the identical at least 19 nucleotides of said target KRAS cDNA in reducing target KRAS RNA levels when assayed in vitro in a mammalian cell at an effective concentration in the environment of a cell of 1 nanomolar or less.
 96. The formulation of claim 95, wherein said effective amount is selected from the group consisting of 1 nanomolar or less, 200 picomolar or less, 100 picomolar or less, 50 picomolar or less, 20 picomolar or less, 10 picomolar or less, 5 picomolar or less, 2, picomolar or less and 1 picomolar or less in the environment of said cell.
 97. A formulation comprising the isolated dsRNA of claim 52, wherein said dsRNA is present in an amount effective to reduce target RNA levels when said dsRNA is introduced into a cell of a mammalian subject by an amount (expressed by %) selected from the group consisting of at least 10%, at least 50% and at least 80-90%, and wherein said dsRNA possesses greater potency than isolated 21mer siRNAs directed to the identical at least 19 nucleotides of said target KRAS cDNA in reducing target KRAS RNA levels when assayed in vitro in a mammalian cell at an effective concentration in the environment of a cell of 1 nanomolar or less.
 98. The formulation of claim 97, wherein said effective amount is a dosage selected from the group consisting of 1 microgram to 5 milligrams per kilogram of said subject per day, 100 micrograms to 0.5 milligrams per kilogram, 0.001 to 0.25 milligrams per kilogram, 0.01 to 20 micrograms per kilogram, 0.01 to 10 micrograms per kilogram, 0.10 to 5 micrograms per kilogram, and 0.1 to 2.5 micrograms per kilogram.
 99. A mammalian cell containing the isolated dsRNA of claim
 52. 100. A pharmaceutical composition comprising the isolated dsRNA of claim 52 and a pharmaceutically acceptable carrier.
 101. A kit comprising the isolated dsRNA of claim 52 and instructions for its use.
 102. A composition possessing KRAS inhibitory activity consisting essentially of an isolated double stranded ribonucleic acid (dsRNA) comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein said second strand of said dsRNA comprises 1-5 single-stranded nucleotides at its 3′ terminus, wherein said second oligonucleotide strand is sufficiently complementary to a target KRAS cDNA sequence selected from the group consisting of SEQ ID NOs: 1595-2297 and 3704-4406 along at least 19 nucleotides and at most 35 nucleotides of said second oligonucleotide strand length to reduce KRAS target gene expression when said double stranded nucleic acid is introduced into a mammalian cell. 